An investigation of genome-wide promoter region cytosine-phosphate-guanine (CpG) Island methylation profiles in patients with chronic hepatitis B virus infection by Kgatle, Mankgopo Magdeline
AN INVESTIGATION OF GENOME-WIDE PROMOTER 
REGION CYTOSINE-PHOSPHATE-GUANINE (CpG) ISLAND 
METHYLATION PROFILES IN PATIENTS WITH CHRONIC 
HEPATITIS B VIRUS INFECTION 
 
MANKGOPO MAGDELINE KGATLE 
BSc, BSc(Med)Hons, MSc(Med) 
KGTMAN001 
 
 
 
 
Thesis Presented for the Degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
In the Department of Medicine and Division of Human Genetics 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
October 2013 
 
 
 
 
Principal Investigator: Dr Henry Hairwadzi 
Co –supervisor: Prof Raj Ramesar 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
i 
Declaration 
DECLARATION OF CANDIDATE 
 
I, Mankgopo Magdeline Kgatle, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements 
indicate otherwise) and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or 
any portion of the contents in any manner whatsoever. 
 
Signature: ………………………………… 
 
Date:   ……………………………………. 
 
 
 
ii 
Dedication 
DEDICATION 
 
 
I dedicate this thesis to my parents,  
Martha Mokgadi Kgatle and Jacob Malesela Monyepao.  
I thank thee Almighty God for giving me life through you.  
I am really honoured and proud to call you Mma and Papa. 
I love you both dearly. 
 
 
 
I also dedicate this thesis to my hero the late  
Tata Nelson Rolihlahla Mandela. 
 
 
  
iii 
Acknowledgements 
ACKNOWLEDGEMENTS 
 
Firstly, I would like to thank thee God Almighty for being by my side at all times, and 
enabling me to see this thesis through to completion.  
I would like to express my deepest gratitude to my supervisor, Dr. Henry Hairwadzi, for 
accepting me as his Ph.D student, and for the huge amount of time he has invested in me. I 
am indebted to him for his excellent supervision, wonderful support and encouragement, 
particularly in those tough times.   
I am grateful to Prof. Raj Ramesar in the Department of Human Genetics for his support and 
guidance. Many thanks to HumGen family including colleagues and office mates for all the 
smiles, support and kindness.  
Special thanks are given to Prof Perumal Vivekananadan, who afforded me the opportunity 
of visiting his laboratory in the School of Biological Sciences at the Indian Institute of 
Technology, New Delhi, India.  An expert in the field of Hepatitis B virus and epigenetics, 
he supervised and funded the microarray work that would not have been easily afforded in 
my institution.  
Dr Paras Yadav and Ashish Shukla from Affymetrix trained me in microarray work and data 
analysis, for which I am deeply grateful. I would also like to express my gratitude to Prof 
Vivekanandan’s students Manish Kandpal, Jasmin Samal and Mohita Uphadyay for all the 
support and help in the laboratory, and ensuring that my stay in India was both productive 
and memorable.   
I would like to thank Dr Anne Corrigall in the Department of Medicine for all the assistance 
in the laboratory, and wonderful cakes to celebrate any good results obtained. In addition, I 
wish to thank Prof Wendy Spearman, Dr Mark Sonderup, Prof Wainwright and all the staff 
members in C8 Vascular and Interventional Radiology, including radiologists (Dr Khumalo, 
Dr Somhlahlo, Dr Clark, Dr Morkel, Dr Mabusela), radiographers (Yanda Ncanywa, Cherral 
Bourne, Bongiwe Nonkongolo and Mathew Swart) and Sisters (Sr Nel, Sr Willson, Sr 
Beyers, Sr Williams and Sr Jafta) for greatly assisting me in the collection of liver biopsies. 
Cherral Bourne, Yanda Ncanywa and Rashida Hoosain, I appreciated all your calls and 
messages in informing me whenever you had patients for liver biopsy. 
Thanks to the postgraduate administration staff  including Salega Tape, Adri Winckler, 
Dianna Pryce, Lorraine McDonald, Charmaine Chalkley-Peters, Taryn-Lee Safers, Vuyiseka 
Mgoqi, Jackie Cogill and Thobeka Ncgazafor their kind love, support and encouragement.  
iv 
Acknowledgements 
I would like to acknowledge the National Research Foundation, Poliomyelitis Research 
Foundation and University of Cape Town Scholarships for financial assistance.  
Special thanks to my friends Femke Akkermans, Annemarie Meiberg, Karien Huisman, 
Gemma Lemmens, Patty Dekker, Maria Disselhorst, Christa van Bunderen, Janna de Boer, 
Floris Lansen, Joost Hooimeӯer, Sanne Kooyman, Lianne Verhaar, Maggie Moshitwa and 
others for the generous funding that enabled me to come to University of Cape Town. I am 
truly grateful for your love and support. 
Finally, I am greatly indebted to my mom, siblings (Punkie, Tebogo, Sinah, Kgopotšo, 
Maite, Ouma and Kgothatso Kgatle), nephew (Karabo Kgatle), nieces (Katlego and 
Mankgopo Kgatle), cousin (Lucas Morerwa), Getrude Kgatle and her family. They form the 
backbone and origin of my happiness. Their constant love and support have enabled me to 
get where I am today. I owe my every achievement to all of them.  
 v 
Table of Contents 
TABLE OF CONTENTS 
 
 
Title Page 
  
Declaration i 
Dedication ii 
Acknowledgements  iii 
Table of Contents v 
List of Figures and Tables xi 
Abbreviations xvi 
Abstract xxiv 
 
Chapter 1: Introduction and Literature Review 
 
Section  Page 
1. History of epigenetics 1 
2. Modern concepts of epigenetics 2  
2.1 Epigenetic regulation of gene transcription 3  
2.2 Role of epigenetic changes in normal cells  5  
2.2.1 Genomic imprinting 5 
2.2.2 Inactivation of X-chromosome 7 
2.3 DNA methylation changes in the human genome 9  
2.4 Physiological activities of DNA methyltransferases 10 
2.5 DNA methylation and cancer development  13  
3. Oncogenic viruses and DNA Methylation  16 
3.1 Epstein- Barr virus and DNA methylation 16  
3.2 Human Papillomavirus and DNA methylation 18  
3.3 Hepatitis B virus and DNA methylation 19 
3.3.1 Transmission of HBV 21 
3.3.2 Global epidemic of HBV infection 22 
3.3.3 Epidemic of HBV infection in Africa 23 
 vi 
Table of Contents 
3.3.4 HBV genotypes, mutations and genomic DNA methylation 23  
3.3.5 Prevention and treatment 25 
3.3.6 HBV virion structure, genomic organisation and functions 27  
3.3.7 Life-cycle of HBV 29  
4. HBV-induced HCC and DNA methylation 31  
4.1 Adaptive immune responses and liver damage  33 
4.2 Integration of HBV DNA into the human genome 36  
4.3 Hepatitis B virus x gene or protein and its carcinogenic effects 37  
4.3.1 HBx protein as a transcriptional activator 38 
4.3.2 HBx protein, proliferation and apoptosis 39 
4.3.3 HBx protein and DNA methylation 40 
5. Summary 42 
6. References 44 
 
Chapter 2: Study Hypothesis, Clinical Setting and Aims  
  
Section Page 
2.1 Hypothesis of the study 86 
2.2 Clinical setting of the study 86 
2.3 Aims of the study 87 
2.4 Studies reported in this thesis 88 
2.5 References 90 
 
Chapter 3: Investigation of Genome-Wide Promoter Region CpG Island 
Methylation Profiles in Patients with Chronic HBV Infection 
 
  
Section  Page 
3.  Introduction 91 
3.1 Study aims 93 
3.2 Materials 94 
3.2.1 Fresh liver biopsy samples 94 
3.2.2 Formalin-fixed paraffin embedded liver biopsy samples  94 
3.3 Methods for sample preparation and microarray analysis 94 
 vii 
Table of Contents 
3.3.1 Nucleic acids extraction from fresh liver biopsy samples 94 
3.3.2 Nucleic acids extraction from formalin-fixed paraffin embedded 
liver tissue samples 
95 
3.3.3 Generation of double stranded DNA targets 96 
3.3.4 Fragmentation and labelling of double stranded DNA targets 98 
3.3.5 Hybridization, washing, staining and scanning of microarray chips 99 
3.4 Statistical methods and microarray data analysis 101 
3.4.1 Data importation, normalisation and background correction 102 
3.4.2 Statistical analysis by disease categories 102 
3.4.3 Detection of methylated regions 103 
3.4.4 Pathway analysis 105 
3.4.5 Cohort analysis 105 
3.5 Results 106 
3.5.1 Sample patient cohort profile 106 
3.5.2 Generation of dsDNA targets, DNA fragmentation and labelling  106 
3.5.3 Principal component analysis of microarray data 108 
3.5.4 Profile of  promoter region CpG islands methylation within 100bp of 
the TSS in the cohort  
109 
3.5.5 Methylation profiles of promoter CpG islands in HBV infection 111 
3.6 Discussion 121 
3.6.1 Cyclin-dependent kinases 122 
3.6.2 Growth factors 124 
3.6.3 Metabolic regulators 125 
3.6.4 Tumour suppressor genes 127 
3.6.5 Transcription Regulators 135 
3.6.6 Regulation of RNA splicing 136 
3.6.7 Vitamin D receptor regulated genes 139 
3.6.8 Genes encoding ubiquitin proteins 141 
3.6.9 Pseudogenes 144 
3.6.10 Genes that interact with HIV-1 proteins 145 
3.7 Conclusions 147 
3.8 References 149 
   
 viii 
Table of Contents 
Chapter 4: Validation of Microarray Data Findings using Bisulfite DNA 
Sequencing 
 
  
Section  Page 
4. Introduction 173 
4.1 Aims 174 
4.2 Methods 174 
4.2.1 Sample Materials 174 
4.2.2 Isolation of DNA from blood samples  174 
4.2.3 Designing of bisulfite DNA sequencing primers 175 
4.2.4 Bisulfite conversion of genomic DNA 177 
4.2.5 Cloning of  amplified bisulfite converted DNA into the vector 178 
4.2.6 Screening of positive clones with vector plus insert 180 
4.2.7 Sequencing of positive clones with vector plus insert 180 
4.3 Statistical methods and data analysis 181 
4.4 Results 182 
4.4.1 Visualising successful bisulfite DNA conversion 182 
4.4.2 Analysis of PCR amplified bisulfite converted genomic DNA 183 
4.4.3 Screening of positive clones with vector plus insert by colony PCR 184 
4.4.4 Methylation pattern of the gene promoter CpG island regions of 
selected candidate genes 
185 
4.4.5 Methylation profile of Cyclin D3 gene in HBV e antigen positive 
and negative patients 
194 
4.5 Discussion 197 
4.5.1 Visualizing successful bisulfite DNA conversion 197 
4.5.2 Validation of methylation profiles obtained through microarray data 
analysis  
197 
4.5.3 Methylation of CCND3 gene promoter region compared by HBV e 
antigen status 
200 
4.6 Conclusion 202 
4.7 References 203 
 
 
 
  
 ix 
Table of Contents 
Chapter 5: Discussion and Conclusions 
 
Sections  Page 
5. Introduction 210 
5.1 DNA methylation and liver disease 211 
5.2 Hypothesis and study outline 212 
5.3 HBV induced hepatic inflammation and fibrosis 213 
5.3.1 Transforming growth factor beta signalling pathway 213 
5.3.2 MAPK/ERK/PKC signalling pathway 214 
5.3.3 NF-кB signalling pathway 215 
5.4 Hepatitis B viral infection and malignancy 215 
5.4.1 Cell cycle and apoptosis 215 
5.4.2 Calcium signalling pathway 216 
5.4.3 Alteration of mRNA splicing 217 
5.4.4 Protein ubiquitination 218 
5.4.5 Suppression of tumour suppressor genes 219 
5.5  Clinical correlation of HBV with metabolism 219 
5.6  Association of HBV and HIV infection 220 
5.7 A unifying hypothesis based on the literature and thesis research 
findings 
221 
5.8 Study limitations 223 
5.9 Future work 224 
5.10 Conclusions 226 
5.11 References 227 
 
Appendices Used in the Study 
 
1 Nucleic acids extraction from fresh liver biopsies  240 
2 Nucleic acids extraction from Formalin fixed paraffin embedded 
liver tissues  
243 
3 Kits, products, equipments and other consumable used for DNA 
microarray work 
244 
4 Restriction digest of DNA with MseI enzyme 248 
 x 
Table of Contents 
5 Purification of DNA from PCR product/s 250 
6 Annealing of universal linkers 251 
7 Ligation of DNA with universal linkers 252 
8 PCR amplification of ligated produc/ts  253 
9 Restriction digestion of purified PCR products with BstuI and HhaI 
enzymes 
254 
10 Fragmentation of PCR amplified and purified DNA target/s 255 
11 Labelling of fragmented dsDNA target/s 256 
12 Hybridization of labelled dsDNA target/s 257 
13 Preparation of GeneChip
®
 Fluidics Station 450/250 258 
14 Staining and washing of the probe arrays using GeneChip
®
 Fluidics 
Station 450/250 
260 
15 Scanning of the probe arrays protocol 262 
16 Commercial kits, reagents and other consumables used for isolation 
of DNA from blood and bisulfite sequencing work 
264 
17 Isolation of genomic DNA from blood using Wizard® Genomic 
DNA Purification Kit 
266 
18 Restriction digests of genomic DNA with BamHI enzyme 268 
19 Bisulfite conversion of digested DNA using EZ DNA Methylation-
Gold
TM
 Kit 
269 
20 PCR amplification of bisulfite converted DNA 270 
21 Purification of excised gel product/s using QIAquick Gel Extraction 
Kit
® 
271 
22 Cloning of purified DNA into pGEM-T
®
 Easy Vector System II 272 
23 Preparation of media, plates and transformation of ligated products 273 
24 Screening transformants for inserts using colony PCR 275 
25 DNA sequencing of colony PCR products 277 
26 Pathway analysis charts 279 
27 Ethics approval letter 295 
28 Patient consent form used in the study 296 
 
 
 
xi 
List of Figures and Tables 
 
LIST OF FIGURES AND TABLES 
 
 
Chapter 1 
Figures Page 
1.1 The effects of epigenetic changes on gene transcription 4 
1.2 DNA Methylation at the carbon 5 position of cytosine 9 
1.3 The structure of DNA methyltransferase enzymes 11 
1.4 DNA methylation in normal and cancer cells 14 
1.5 Chronic HBV infection, cirrhosis and HCC development 21 
1.6 Global geographical distribution of chronic hepatitis B infection 22 
1.7 An electron micrograph image of hepatitis B virion and surface 
antigen components 
27 
1.8 The structure of the HBV genome 28 
1.9 The life-cycle of HBV infection 30 
1.10 Model of chronic HBV infection and DNA methylation 33 
1.11 Adaptive immune response and liver damage in chronic HBV 
infection 
34 
Tables 
1.1 Molecular changes and biological effects caused by post-
translational histone modifications  
3 
1.2 Genes methylated in human cancers and their role in tumour 
development 
15 
1.3 The global geographic distribution of HBV genotypes, mutations 
and associated CpG promoter DNA methylation  
24 
1.4 Examples of Chromosomal Fragile Sites associated with HBV 
insertions and their roles in tumour development 
37 
   
   
 
 
 
 
xii 
List of Figures and Tables 
 
Chapter 2 
 
Figures Page 
2.1 The overall research plan employed in the study 88 
   
Chapter 3 
Figures Page 
3.1 Schematic outline for generating the DNA targets 97 
3.2 Outline of protocol for fragmentation and labelling of DNA targets 99 
3.3 Outline of protocol for hybridization, washing, staining and 
scanning   
100 
3.4 Outline of the workflow used to analyse the microarray data 101 
3.5 Typical structure of eukaryotic gene illustrating region analysed 103 
3.6 Illustration of gene overlap annotation 104 
3.7 Agarose gel confirmation of successful dsDNA targets  generation 
and fragmentation  
107 
3.8 Principal component analysis of microarray data samples 108 
3.9 Profile by chromosome of hypermethylated gene promoter regions 
within 100bp of TSS in the microarray cohort 
109 
3.10 Profile by chromosome of hypermethylated gene promoter regions 
within 100bp of TSS in the HBV infected patients compared to 
controls  
110 
Tables 
3.1 Characteristics of microarray patient cohort 106 
3.2 Cohort characteristics by diagnosis 111 
3.3 Methylation profile of gene promoter CpG islands in HBV Patients 
compared to normal controls 
112 
3.4 Methylation profile of gene promoter CpG islands in HBV 
compared to AIH patients 
113 
3.5 Methylation profile of gene promoter CpG islands in HBV  
compared to HCC Patients 
113 
3.6 Methylation profile of gene CpG islands in HCC tissues compared 
to corresponding tissues with no HCC 
114 
xiii 
List of Figures and Tables 
 
3.7 Methylation profile of gene promoter CpG islands in Patients who 
are HBeAg positive compared to normal controls  
115 
3.8 Methylation profile of  gene promoter CpG islands in cirrhotic HBV 
compared to non-cirrhotic HBV patients 
116 
3.9 Methylation profile of gene promoter CpG islands in cirrhotic HBV 
patients compared to normal controls 
117 
3.10 Methylation profile of gene promoter CpG islands in HBV patients 
with inflammation compared to normal controls 
118 
3.11 Methylation profile of gene promoter CpG islands in HBV patients 
older than 40 years compared to normal controls 
119 
3.12 Summary of genes with Promoter Region CpG Island 
Hypermethylation and their Clinical Significance in HBV Infection 
120 
   
Chapter 4 
Figures Page 
4.1 Primer design algorithm 176 
4.2 Bisulfite conversion of genomic DNA 178 
4.3 Sequence map and multi-cloning site of pGEM
®
-T Easy vector map 179 
4.4 Agarose gel analysis of DNA products after bisulfite treatment 182 
4.5 Gel analysis of PCR amplified bisulfite converted DNA 183 
4.6 Agarose gel analysis of cloned bisulfite converted PCR products 
into pGEM
®
 T-Easy vector 
184 
4.7 Methylation Profile of a selected section of CCND3 promoter CpG 
island using bisulfite DNA sequencing 
186 
4.8 Methylation Profile of a selected section of FGFRL1 promoter CpG 
island using bisulfite DNA sequencing 
187 
4.9 Methylation Profile of a selected section of NACC2 promoter CpG 
sites using bisulfite DNA sequencing 
188 
4.10 Methylation Profile of a selected section of PA2G4 promoter CpG 
sites using bisulfite DNA sequencing 
189 
4.11 Methylation Profile of a selected section of THRAP3 promoter CpG 
island using bisulfite DNA sequencing 
190 
4.12 Methylation Profile of a selected section of TUBA4A promoter CpG 191 
xiv 
List of Figures and Tables 
 
island using bisulfite DNA sequencing 
4.13 Methylation Profile of a selected section of GABPB2 promoter CpG 
island using bisulfite DNA sequencing 
192 
4.14 Methylation Profile of a selected section of EXOSC3 promoter CpG 
island using bisulfite DNA sequencing 
193 
4.15 Methylation profile in a selected section of the CCND3 promoter 
region in HBV patients and controls 
195 
Tables 
4.1 Promoter region primers used for bisulfite DNA sequencing work 177 
4.2 The DNA methylation profiles of the gene promoter CpG sequences 
used for validation 
185 
4.3 Profile of patient cohort used to investigate CCND3 gene  194 
4.4 Demographic and methylation profile of the CCND3 gene promoter 
in HBV infected cohort 
196 
4.5 Cohorts HBV genotype and CCND3 gene promoter methylation 
profiles 
196 
 
Chapter 5 
Figures Page 
5.1 Proposed model in which HBV induced genetic alterations 
contributes to liver disease. 
211 
5.2 An integrated review of the identified genes and their possible role 
in causing liver disease 
221 
 
Appendix 26 
A HBV Infection and HCC Calcium Signalling Pathway 280 
B HBV Infection and TGF Beta Pathway 281 
C HBV Infection and TB Pathway 282 
D HBV Infection and Cancer Pathway 283 
E HBV Infection and Cell Adhesion Pathway 284 
F HBV Infection Pathway 285 
G HBV Infection and Tight Junction Pathway 286 
H HBV Infection and mRNA Surveillance Pathway 287 
xv 
List of Figures and Tables 
 
I HBV Infection and MAP Kinase Pathway 288 
J HBV Infection and the Cell Cycle Pathway 289 
K HBV Infection and Viral Carcinogenesis Pathway 290 
L HBV Infection and PPAR Gamma Signalling Pathway 291 
M HBV Infection and Type 2 Diabetes Mellitus Signalling Pathway 292 
N HBV Infection and Apoptosis Pathway 293 
O HBV Infection and HTLV-1 Infection Pathway 294 
 
 
 
xvi 
Abbreviations 
 
ABBREVIATIONS 
 
 
 
α : Alpha 
ß : Beta 
γ : Gamma 
°C : Degrees Celsius 
% : Percentage 
- : Negative 
+ : Positive 
µl : Microlitres 
µg : Microgram 
ABHD1 : Abhydrolase domain containing 1  
ADP : Adenosine diphosphate 
AGCC : Affymetrix GeneChipR Command Console  
AIB1 : Amplified in breast cancer 1  
AIH : Autoimmune hepatitis 
ALAS1 : Aminolevulinate, delta, synthase 1 
ALT : Alanine aminotransferase 
ANOVA : Analysis of variance  
APE1 : Human apurinic/apyrimidinic endonuclease I 
APC : Adenomatous polyposis coli  
AP : Activating protein 
AP2B1 : Adaptor-related protein complex 2, beta 1 subunit 
ARF : Auxin response factors 
ArfGAP : Auxin response factors -GTPase activating protein  
ASPP : Ankyrin-repeat containing and proline-rich region-containing proteins 
ATP : Adenosine triphosphate 
ATP5S1 : ATP synthase H+ transporting mitochondrial Fo complex subunit S 
ATRX : Alpha-thalassemia/mental retardation, x-linked  
BARD1 : BRCA1-associated RING domain protein 1 
BCAR3 : Breast cancer anti-oestrogen resistance 2 
Bcl : B-cell CLL/ lymphoma  
BDS : Bisulfite DNA sequencing 
BIRC3 : Baculoviral IAP repeat-containing 3 
bp : Base pairs 
BRCA1 : Breast cancer 1  
C6orf97 : Chromosome 6 open reading frame 97 
Cp : BamHI C promoter  
cAMP : Cyclic adenosine monophosphate  
CARHSP1 : Calcium regulated heat stable protein 1 
CASPR3 : Contactin-associated protein-like 3 
CBLC : Cbl proto-oncogene E3 ubiquitin protein ligase C 
CBX8 : Chromobox homolog 8 
cccDNA : Covalently closed circular super-coiled DNA 
CCND3 : Cyclin D3 
CCDC56 : Coiled-coil domain containing 56 (pseudogene) 
CCDC144B : Coiled-coil domain containing 144B (pseudogene) 
CCDC127 : Coiled-coil domain containing 127 
CD4+ : Cluster of differentiation 4+ T-helper  
xvii 
Abbreviations 
 
CDK : Cyclin-dependent kinase 
CDKN1C : Cyclin dependent kinase inhibitor 1C  
CDKN2A : Cyclin dependent kinase inhibitor 2A  
CDH13 : E-cadherin 13 
CD21/CR21 : Complement receptor type 21  
CFS : Chromosomal fragile sites 
CGB8 : Chorionic gonadotropin, beta polypeptide 8 
CHML : Choroideremia-like gene 
COBRA : Combined bisulfite restriction analysis 
COX-2 : Cyclooxygenase 2 
CpA : Cytosine-phosphate-Adenine 
CpG : Cytosine-phosphate-Guanine 
CpT : Cytosine-phosphate-Thymine 
CREB : cAMP response element binding protein 
CTL : Cytotoxic T lymphocytes 
CXorf57 : Chromosome X open reading frame 57 
CYB5D1 : Cytochrome b5 domain containing 1   
DDB1 : DNA binding protein 1  
DEFB109P1 : Defensin beta 109 pseudogene 1 
DEFT1P : Defensin theta 1 pseudogene 
DGCR11 : Di-George syndrome critical region gene 11 
DHBV : Duck hepatitis B virus 
DILI : Drug induced liver injury 
DLEC1 : Deleted in lung and oesophageal cancer 1  
DLR : DNA labelling reagent 
DNA : Deoxyribonucleic acid 
DNAJC14 : DNAJ (Hsp40) homolog, subfamily C, member 14 
DNMTs : DNA methyltransferases 
DNaseI : Deoxyribonuclease I 
DNASE2B : Deoxyribonuclease II beta 
DPC4 : Deleted in pancreatic cancer 4 
DPEP3 : Dipeptidase 3 
DR1 : Direct repeat 1  
DRF : DNA replication foci  
DILI  : Drug induced liver injury 
dsDNA : Double-stranded DNA 
DYRK4 : Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 
E2F : E2 promoter binding factor 
E6-AP : E6 associated protein  
EBV : Epstein-Barr virus  
EBERs : EBV-encoded small RNAs  
EBNAs : EBV nuclear antigens  
EBP1 : V-erb-b2 erythroblastic leukemia viral oncogene homolog 3-binding protein 1  
ECM : Extracellular matrix  
EGFs : Epidermal growth factors  
EGFR : Epidermal growth factor receptor  
EMILIN2 : Elastin microfibril interfacer 2   
EMX2 : Empty spiracle homeobox 2 
EPHB6 : EPH receptor B6  
ErbB3 : V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
ERRC2 : Excision repair cross-complementing rodent-repair deficiency group 2  
xviii 
Abbreviations 
 
EXOSC3 : Exosome component 3 
FAM106C : Family with sequence similarity 106, member C 
FAM173A : Family with sequence similarity 173, member A 
FANCE : Fanconi anaemia complementation group E 
FXR : Farnesoid x receptor 
FasL : Fas ligand  
FBXO39 : F-box protein 39 
FFPE : Formalin-fixed paraffin-embedded  
FGF : Fibroblast growth factor  
FGF4 : Fibroblast growth factor 4 
FGFRL1 : Fibroblast growth factor receptor-like 1 
FRA : Fragile 
g : Gram 
G : Guanine 
GABPB2 : GA binding protein transcription factor beta subunit 2 
GCOS : GeneChipR Operating Software  
GO : Gene ontology 
GK : Lysine and glycine 
GRASP : General receptor for phosphoinositides  
GSN : Gelsolin 
GSHV : Ground squirrel hepatitis virus 
GSTP1 : Glutathione S-transferase pi 1  
GTPBP5 : GTP binding protein 5 (putative) 
HATs : Histone acetylases 
HBc : Hepatitis B core 
HBcAg : Hepatitis B c antigen 
HBeAg : Hepatitis B e antigen 
HBs : Hepatitis B surface 
HBsAg : Hepatitis B surface antigen  
HBx : Hepatitis B x  
HBxAg : Hepatitis B x antigen 
HBV : Hepatitis B virus  
HC : Hepatic cirrhosis  
HCC : Hepatocellular carcinoma  
HCV : Hepatitis C virus 
HDACs : Histone deacetylases 
HIST1H4F : Histone cluster 1 H4F  
HIV-1 : Human immunodeficiency virus type 1 
HLA : Human leukocyte antigen  
hMLH1 : Human mutL homolog 1 
HPGD : Hydroxyprostaglandin dehydrogenase 15 – (NAD) 
HPV : Human xviiiazalxviiiomavirus  
HSPA1A : Heat shock 70kDa protein 1A 
hTERT : human telomerase reverse transcriptase 
HTN3 : Histatin 3 
HTR3B : 5-Hydroxytryptamine (serotonin) receptor 3B, ionotropic 
Htt : Huntingtin  
HSC : Hepatic stellate cells 
HYAL3 : Hyaluronoglucosaminidase 3 
ICF : Immunodeficiency centromere instability and facial anomalies syndrome  
ICR2 : Imprinting center 2 
xix 
Abbreviations 
 
IFIT1B : Interferon induced protein with tetratricopeptide repeats 1B 
IFNγ : Interferon gamma  
IGFII : Insulin-like growth factor II 
IGJBP-3 : Tumour promoter insulin-like growth factor binding 3  
IgG : Immunoglobulin G 
IITD : Indian Institute of Technology, New Delhi 
IKBKB : Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
IKZF3 : IKAROS family zinc finger 3 
IL : Interleukin   
IL11RA : Interleukin 11 receptor, alpha 
IL15RA  : Interleukin-15 receptor alpha  
IMP-2 : Insulin-like growth factor II mRNA binding protein 2 
INR : International normalised ratio 
IQR : Inter –quantile range 
IRAK2 : Interleukin-1 receptor associated kinase 2 
GRID2IP : Glutamate receptor ionotropic delta 2 interacting protein 
JAK1 : Janus kinase 1 
JNK : c-Jun N-terminal kinase 
Kb : Kilobase 
KCNK2 : Potassium inwardly- rectifying channel subfamily k, member 2 
KCNJ15 : Potassium inwardly- rectifying channel subfamily J, member 15 
kDa : Kilo-dalton 
KLF1 : Krueppel-like factor 1 
KRBA2 : KRAB-A domain containing 2 
KRT77 : Keratin 77 
KRT42P : Keratin 42 pseudogene 
L : Large 
LCR : Long control region 
LENG1 : Leukocyte receptor cluster member 1  
LINE-1 : Long interspersed nuclear element-1  
LMP : Latent membrane protein  
LNX2 : Ligand of numb-protein X 2 
LOC285441 : Uncharacterised 
LOC650368 : Asparagine-linked glycosylation 1-like pseudogene 
LOC151534 : Ladybird homeobox 2 
LOC100189589 : DICTN1antisense RNA 1 
LOC401010 : Nucleolar complex associated 2 homolog  
LOC729080 : Glycine cleavage system protein H (aminimethyl carrier) pseudogene 
LOH : Loss of heterozygocity 
LRRC28 : Leucine rich repeat containing 28 
LSD : Lysine-specific demethylase  
LYPD5 : LY6/PLAUR domain containing 3 
M : Middle 
MALDI : Matrix assisted laser desorption/ionization 
MAT : Model-based analysis of tiling-arrays 
MAPK : Mitogen-activated protein kinase  
MBP : Methyl-CpG binding protein  
MDGA2 : MAM domain containing glycosylphosphatidylinositol anchor 2  
MeCPs : Methyl-CpG binding proteins 
MeDIP : DNA immunoprecipitation 
MEPE : 6kDa matrix extracellular phosphoglycoprotein 
xx 
Abbreviations 
 
mg : Milligram 
MGMT : O-6-methylguanine-DNA methyltransferase  
Mill2 : Major histocompatibility complex I like leukocyte 2 
pMol : Pico molar 
ml : Millilitre 
mRNA : Messenger RNA 
miRNAs : Micro RNAs  
MIR644 : MicroRNA 644 
MIR138-2 : MicroRNA 138-2 
MIR1293 : MicroRNA 1293 
MIR573 : MicroRNA-573 
MIR527 : MicroRNA-527 
MIR4267 : MicroRNA-4267 
MS4A13 : Membrane-spanning 4-domains, subfamily A, member 13 
MS-SNuPE : Methylation-sensitive single nucleotide primer extension 
MSP : Methylation-specific PCR  
MTA1 : Metastasis associated 1 
mTOR : Mammalian target of rapamycin  
MTUS1 : Microtubule associated tumour suppressor 1 
ng : Nanogram 
N : Number  
NAD : Nicotinamide adenine dinucleotides 
NADH : Nicotinamide adenine dinucleotides hydrate  
NAIF1 : Nuclear apoptosis inducing factor 1 
NACC : Nuclear accumbens 
NACC2 : Nucleus accumbens associated 2 
NAFLD : Non-alcoholic fatty liver disease 
NaOH : Sodium hydroxide 
NAT6 : N-acetyltransferase 6 
NBPF1 : Neuroblastoma breakpoint family member 1 
NCBI : National Center for Biotechnology Information 
NCF1 : Neutrophil cytosolic factor 1 
NCRNA00085 : Non-protein coding RNA 85 
NF-κB : Nuclear factor-kappaB  
nm : Nanometre 
NLS : Nuclear localization signal  
NSMAF : Neutral sphingomyelinase activation associated factor 
NTCP : Sodium taurocholate cotransporting polypeptide  
NTSR1 : Neurotensin receptor type 1 
NUDT13 : Nucleoside diphosphate linked moiety X type motif 13  
OR52I1 : Olfactory receptor, family 52, subfamily I, member 1 
OR5AU1 : Olfactory receptor, family 5, subfamily AU, member 1 
ORFs : Open reading frames 
OR6C6 : Olfactory receptor family 6, subfamily C, member 6 
OR8B4 : Olfactory receptor, family 8, subfamily B, member 4 
OR8B8 : Olfactory receptor family 8 subfamily member 8 
OR11H2 : Olfactory receptor, family 11, subfamily H, member 2 
PA2G4 : Proliferation associated 2G4 
PAOX : Polyamine oxidase (exo-N4-amino) 
PARD6A : Par-6 partitioning defective 6 homolog alpha 
PATE3 : Prostate and testis expressed 3 
xxi 
Abbreviations 
 
PAX1 : Paired box1 
pCBPAF : P300/ CREB-binding protein-associated factor  
PCDHA1 : Protocadherin alpha -1 
PCR : Polymerase chain reaction 
PDGFRβ : Platelet derived growth factor receptor beta 
P4HTM : Prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) 
PGRF1 : Polycomb group ring finger 1 
PGSS : Partek genomic suite software®  
PHD : Polybromo-1 homology domain 
PI3K : Phophatidylinositol 3–kinase  
PLAC8 : Placenta specific 8 
PODNL1 : Podocan-like 1 
POLA2 : Polymerase (DNA directed) alpha 2 
Poly (A) : Polyadenylation 
PPAR : Peroxisome proliferator-activated receptor  
PPARγ : Peroxisome proliferator-activated receptor gamma 
PPP1R8 : Protein phosphatise 1 regulatory subunit 8 
PRAME : Preferentially expressed antigen in melanoma 
PRAMEF20 : PRAME family member 20 
PRMT1 : Protein arginine N-methyltransferase 1 
PRSS53 : Protease serine 53 
PRSS41 : Protease serine 41 
POU5F1P3 : POU class 5 homeobox 1 pseudogene 3 
PTEN : Phosphatise and tensin homologue  
PTGR2 : Prostaglandin reductase 2 
PTOV1 : Prostate tumour overexpressed gene 1 
PWWP : Proline-tryptophan-tryptophan proline  
RAR-β2 : Retinoic acid receptor-beta2  
RASSF1α : Ras association domain family 1 alpha 
RASSF1 : Ras association domain family 1  
REC8 : Rec8 homolog  
RECQL : RecQ protein-like DNA helicase Q1-like 
RGS14 : Regulator of G protein signalling 14 
RING-1 : Really interesting new gene domain 1 
RMA : Robust multichip averaging algorithm  
RNA : Ribonucleic acid 
RNA pols : RNA polymerases 
ROS : Reactivation oxygen species  
RP1 : Retinitis pigmentosa 1 (autosomal dominant) 
RRN3P3 : RNA polymerase transcription factor homolog pseudogene 3 
RXR : Retinoid x receptor 
rtN236T : Asparagines-to-threonine  
rTdT : Terminal deoxynucleotidyl transferase, recombinant 
SA : South Africa 
SAH : S-adenosylhomocysteine  
SAM : S-adenosylmethionine 
SAPE : Streptavidin-phycoerythrin 
Sat-2 : Satellite 2  
SCARF2 : Scavenger receptor class F member 2   
SCARB2 : Scavenger receptor class B, member 2 
SDHA : Succinate dehydrogenase complex, subunit A, flavoprotein 
xxii 
Abbreviations 
 
SLC34A1 : Solute carrier family 34 (sodium phosphate) member 1 
SNORA7B : Small nucleolar RNA, H/ACA box 7B 
SNORA52 : Small nucleolar RNA, H/ACA box 52 
SNX11 : Sorting nexin 11 
SOC : Stimulate store operated calcium  
SPIK : Serine protease inhibitor Kazal  
ssDNA : Single-stranded DNA 
SSTR1 : Somatostatin receptor 1  
STAT : Signal transducers and activators of transcription  
SUMO-1 : Small ubiquitin-related modifier-1 
TAD : Transcriptional activation domain  
Tat : Transactivator of transcription 
TBC1D17 : TBC1 domain family, member 17 
TBP : TATA binding protein 
TBS : Tris-buffered saline 
TCEA : Transcription elongation factor A 
TF : Transcription factors 
TFIIH : Transcription factor II H 
TGF-β1 : Transforming growth factor beta 1 
THRAP3 : Thyroid hormone receptor associated protein 3 
TIRAP : Toll-interleukin 1 receptor domain containing adaptor protein  
TLX3 : T-cell leukaemia homeobox 3  
TMS1 : Target of methylation-induced silencing  
TMEM25 : Transmembrane protein 25 
TMEM80 : Transmembrane protein 80 
TMEM95 : Transmembrane protein 95 
TM6SF1 : Transmembrane 6 superfamily member 1  
TNFα : Tumour necrosis factor alpha  
TRIM58 : Tripartite motif-containing 58  
TRIM77 : Tripartite motif-containing 77 
TRIP12 : Thyroid hormone receptor interactor 12 
TRPV5 : Transient receptor potential cation channel subfamily v member 5 
TSS : Transcription start site 
TUBA4A : Tubulin alpha 4a 
TUBGCP5 : Tubulin, gamma complex associated protein 5 
UBB : Ubiquitin B 
UBC : Ubiquitin carrier protein  
UBXN1 : UBX domain protein 1 
UCT : University of Cape Town 
UDG : Uracil-DNA glycosylase  
URR : Upstream regulatory region  
USA : United State of America 
UTR : Untranslated region  
XCI : X-chromosome inactivation 
Xic : X-inactivation center 
Xist : X-inactive-specific transcript  
XKR8 : XK, Kell blood group complex subunit-related family member 8 
XPB : Xanthoma pigmentosa B  
VDRE : Vitamin-D responsive elements 
VHL : von Hippel Landau  
JAK1 : Janus kinase 1 
xxiii 
Abbreviations 
 
YDMM : Tyrosine-methionine-aspartate-aspartate  
WBV : Woodchuck B virus  
WNK2 : Wnk lysine deficient protein kinase 2  
Wnt : Wingless type 
Wp : BamHI W promoter  
ZMYND12 : Zinc finger, MYND-type containing 12 
 
 xxiv 
Abstract 
ABSTRACT 
 
Hepatitis B virus (HBV) is oncogenic and a major cause of hepatocellular carcinoma 
(HCC) in the developing world. It integrates parts of its genome such as the HBx 
gene, core and surface antigens into the human genome. The integrated viral DNA 
disrupts gene function resulting in physiological changes that cause liver disease. 
The viral inserts are inactivated through methylation. This is a protective innate 
response driven by human DNA methyltransferases triggered by the presence of viral 
DNA inserts. 
This thesis investigates the hypothesis that during the innate response to methylate 
integrated HBV DNA, there is unintended methylation of genomic DNA around the 
intercalated viral DNA that could be adjacent host promoter Cytosine-phosphate-
Guanine (CpG) islands. This would activate or silence genes including tumour 
suppressors and result in the clinical disease phenotypes of hepatic inflammation, 
fibrosis and HCC that characterise chronic HBV infection. 
Genome-wide microarray analysis was used to investigate for the presence of 
promoter CpG island methylation in a cohort of patients with liver disease due to 
HBV infection, HCC, autoimmune hepatitis which is a non-viral liver disease and 
normal cases with no liver disease. The study identified hypermethylation in 
promoter regions, transcription start sites, gene exons and introns. Only sites in the 
promoter region and within 100bp upstream of a transcription start site were 
analysed for this thesis presentation. Using an extended cohort of patients with 
chronic HBV infection and normal controls, bisulfite DNA sequencing was used to 
validate and confirm the presence of DNA methylation in a selection of some of 
genes identified.  
HBV infected patients were shown to have hypermethylation in the promoter CpG 
island regions of several genes that regulate hepatic metabolism, tumour suppression, 
ribonucleic acid splicing, vitamin D receptor binding, protein ubiquitination and the 
cell cycle. Many of these genes have transcriptional binding factors that are known to 
be affected by the transcriptional transactivator HBx protein, suggesting that HBx 
protein is important in the pathogenesis of liver disease. 
 xxv 
Abstract 
Amongst the most hypermethylated core promoter regions identified were those for 
cyclin kinases genes such as Cyclin D3 (CCND3). CCND3 gene is important in liver 
regeneration and wound healing and its abnormal function has been linked to the 
development of liver fibrosis and HCC. Increased methylation of CCND3 gene was 
associated with HBV e antigen positive status and genotype D, supporting the 
hypothesis that increased methylation is associated with host and viral factors.  
Methylation induced alteration in the function of the identified gene promoters would 
affect cellular signalling with effects on cell growth, differentiation, proliferation and 
apoptosis. These changes would explain the development of hepatic inflammation, 
apoptosis, fibrosis and malignant transformation seen in chronic HBV infection. 
Further investigation of these genes will provide new insights on mechanisms of 
HBV induced liver disease and the development of new molecular diagnostic tools or 
therapeutic interventions. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW  
 
1. HISTORY OF EPIGENETICS  
In the 16
th
 century, the popular theory of preformation implied that a human body 
developed through the enlargement of a homunculus, which is a diminutive fully 
formed human being that was thought to exist in the germ cells and merely enlarged 
into an adult form
 1 - 4
. Later in the 17
th
 century, the term “epigenesis” was coined and 
discredited the theory of preformation. Epigenesis opposed the idea of preformation 
by suggesting that an embryo develops from successive differentiation of an 
originally unstructured egg that has been fertilized. In the theory of epigenesis, the 
formation of all tissues and organs that form a human body proceeded through 
successive gradual change 
3, 5
.  
The process of epigenesis was thought to be driven by environmental dependent gene 
expression that differentiated various cell types into functional organs. Conrad Hal 
Waddington integrated the theory of epigenesis with genetics to propose the term 
epigenetics. Epigenetics literally means “beyond genetics”. The term was used to 
describe the manner in which the genes interact with their environment to produce a 
phenotype 
6 - 7
. 
Waddington was a leading geneticist and embryologist of his time who proposed 
various conceptual models which laid the foundation of the new field of epigenetics. 
In 1942, he published the book Principles of Embryology, in which he presented the 
term “epigenetics” for the first time in the form of the conceptual model of 
“epigenetic landscape”. He used the metaphor of an epigenetic landscape to describe 
a surface on which a cell in a developing embryo was represented by a marble. He 
hypothesised that the development of a cell was influenced by various environmental 
factors and mutations much like a marble rolling down a series of hills and valleys on 
the surface or landscape. Consequently, these various environmental factors and 
mutations would affect the manner in which cells differentiate and develop 
6
. 
The definition of the term epigenetics has been developed further. Currently, 
2 
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epigenetics is defined as the study of mitotic inheritance and post-translational 
modification of gene expression, which is not due to any changes in the 
deoxyribonucleic acid (DNA) coding sequence 
8 - 11
. This emphasises alterations that 
occur during transcription rather than what Waddington described as the “epigenetic 
landscape”.  
 
2.  MODERN CONCEPTS OF EPIGENETICS   
Epigenetic changes occur largely in multi-cellular eukaryotic organisms and less so 
in prokaryotes. Prokaryotes are relatively simple and have one single looped 
chromosome. In contrast, eukaryotes are complicated and have a well-defined 
nucleus with large quantities of genes and DNA spread across multiple chromosomes 
12
.  
In eukaryotes, DNA is packaged into chromatin within the chromosomes 
13, 14
. This 
protects the DNA from deoxyribonuclease I (DNase1) attack and also ensures that 
the correct gene is transcribed during transcription. Chromatin consists of DNA 
structural histone and non-histone proteins 
14 - 16
. Within the chromatin, the repeating 
unit is the nucleosome. Nucleosomes are made-up of 146 base pairs (bp) of two 
super-helical turns of DNA wrapped around a core containing two copies, each of the 
histone molecules H2A, H2B, H3 and H4 
16, 13, 17
. Histone molecules are key targets 
in epigenetics 
17
. They have extensive lysine-rich amino terminal tails that protrude 
from nucleosomes, which make them prone to post-translational modifications
 18 - 20
.  
Eukaryotic histone protein modifications may include acetylation, methylation, 
phosphorylation, ubiquitination, SUMOylation by small ubiquitin-related modifier-1 
(SUMO-1) and adenosine diphosphate (ADP)-ribosylation 
15, 21, 22
. These 
modifications maintain the shape and structure of chromatin, and also affect the 
availability of transcription factors that are important for gene transcription 
15, 18, 23 - 
25
. They are catalysed by the activation of several enzymes including DNA 
methyltransferases (DNMTs), histone acetylases (HATs) and histone deacetylases 
(HDACs) 
21, 24, 26
. Abnormal post-translational histone modifications can cause 
human diseases through mutations and some of these diseases are summarised in 
Table 1.1. 
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Table 1.1: Molecular Changes and Biological Effects Caused by Post-Translational 
Histone Modifications 
27 -  40
 
 
 
2.1 Epigenetic Regulation of Gene Transcription  
DNA methylation and histone protein modifications are important epigenetic events 
that occur in eukaryotes 
41 - 43
. These epigenetic processes affect gene regulation by 
changing DNA conformation in eukaryotic organisms 
12, 43, 44
. Epigenetic changes 
may influence the expression of several genes during embryonic development 
9
. 
Gene transcription is influenced by cis-regulatory elements located within the core 
promoter, transcriptional factors, methylated DNA sequences and lysine residues 
within histone proteins 
24, 43
. 
Epigenetic changes determine whether a gene is transcribed or repressed. They are 
also essential in instructing different cell types in the living organism how and when 
to read the DNA blueprint. For instance, in the antibody secreting plasma B cells of 
the immune system, antibody genes are transcriptionally active, but are silenced 
elsewhere in the body 
43
.  
There are two major ways through which gene transcription can be regulated through 
epigenetic changes. One way of regulating gene transcription is directly through 
DNA methylation (see Figure 1.1). This involves the addition of a methyl group into 
DNA sequence. Methyl groups are carbon and hydrogen molecules which bind to the 
genome through the action of methyl cytosine-phosphate-guanine (CpG) binding 
 Histone Modification 
 
Acetylation  
 
 
ADP-ribosylation 
 
 
 
Methylation  
 
 
 
Phosphorylation  
 
 
SUMOylation  
 
 
Ubiquitination 
 
  
 
 
 
 
Molecular Change 
 
Introduction of acetyl group into an 
organic molecule 
 
Transfer of the ADP-ribose moiety 
from NAD+ onto chromatin protein 
e.g. arginine, aspartic acid 
 
Addition of methyl group to the 
nucleotide sequence  
 
 
Addition of phosphate group to a 
protein 
 
Tagging of SUMO-1 to substrate 
proteins 
 
Transfer of ubiquitin molecule via 
trans (thiol) esterification reaction 
 
 
 
Some Known Biological Effect 
 
Lysine acetylation leads to toxicity of Htt protein and 
accelerated Huntington’s disease 
 
Loss of poly ADP-ribosylation causes progressive 
neurodegeneration in Drosophila Melanogaster 
 
 
Loss of X-linked MeCP2 results in Rett syndrome 
Mutations in the DNMT3B cause autoimmune disease ICF 
syndrome via hypomethylation. 
 
Abnormal protein phosphorylation may cause diabetes, arthritis 
and Alzheimer’s disease 
 
Mutations in SUMO-1 site cause familial dilated 
cardiomyopathy by reducing lamin A sumoylation 
 
Disruption of ubiquitin E3 ligase in von-Hippel Lindau (VHL) 
tumour suppressor gene causes VHL syndrome  
 
 
 
 
Abbreviations: ADP - Adenosine diphosphate, DNMT - DNA methyltransferase, Htt - Huntingtin, ICF - Immunodeficiency 
centromere instability and facial anomalies, NAD - Nicotinamide adenine dinucleotides, MeCP2 - Methyl-CpG binding protein 2, 
SUMO-1 - Small ubiquitin-related modifier-1, VHL - Von Hippel Lindau. 
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proteins (MeCPs), DNMTs and HDACs, which inactivate gene transcription 
45
. 
Other transcription repressors including nuclear factor kappa B (NF-κB), c-myc/c-
myn, activator protein (AP)-2, E2 promoter binding factor (E2F) and the cyclic 
adenosine monophosphate (cAMP)-response element binding protein (CREB) may 
also be activated by methyl groups to inhibit gene transcription 
20, 46, 47
.  
 
 
Figure 1.1: The Effects of Epigenetic Changes on Gene Transcription 
41- 43
.  
Chromatin exists in two forms: open - relaxed and closed - folded forms. In an open - relaxed form, 
the DNA is loose around the histone proteins (open lollipops with green oval circles) and this allows 
transcription factors to bind the DNA and activate gene transcription (black arrow without a star). 
Deacetylation of histone molecules (blue oval circles) causes closed-folded form of chromatin (closed 
lollipops with green oval circles) associated with transcriptional repression (black arrow with a red 
star).  
Abbreviations: DNA - Deoxyribonucleic acid, DNMTs - DNA methyltransferases, HAT - Histone 
acetylase, HDACs - Histone deacetylases, MeCPs – Methyl CpG binding proteins, RNA - 
Ribonucleic acid, RNA Pols - RNA polymerases, TF - Transcription factors. 
 
In addition to DNA methylation, epigenetics can also be regulated by histone protein 
modifications 
18, 45
. Histone protein modifications may be caused by over-expression 
or aberrant recruitment of HDACs that remodel the chromatin shape and structure 
(see Figure 1.1). The two basic mechanisms responsible for chromatin remodelling 
are histone acetylation and deacetylation 
14, 18, 25, 48, 49
. These mechanisms are 
controlled by the enzyme activity of HATs and HDACs, respectively 
18, 25
.  
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Acetylation of histone proteins is generally acknowledged as playing a key role in 
gene regulation 
18
. For a gene to be transcribed it must become physically accessible 
to the transcriptional machinery 
18, 26 , 25
. Acetylation by HATs substitute the positive 
charges on the amino terminal tails of histone proteins with an acetyl group derived 
from acetyl coenzyme A, causing uncoiling of the DNA and euchromatin into an 
open-relaxed form of chromatin 
18, 25
. Consequently, this makes genes accessible to 
several binding factors such as RNA polymerase  II and transcriptional factors, 
allowing gene expression to occur and proteins to be made (see Figure 1.1) 
18, 20, 26, 
50
.  
Deacetylation of histone proteins by HDACs results in the tight coiling of the DNA 
and closed-form of chromatin regions known as heterochromatin 
25, 26, 45
. This 
prevents the interaction between DNA and transcription factors leading to 
suppression of gene transcription 
18
. In some cancer cells, there is increased 
expression or aberrant recruitment of HDACs and decreased expression of HATs. 
This results in the hypoacetylation of histone proteins and therefore a condensed or 
closed chromatin structure 
18, 26
.  
 
2.2 Role of Epigenetic Changes in Normal Cells 
Epigenetic changes are thought to play a critical role during early embryonic 
development 
24, 43, 51
. They maintain the transcriptional repression of inserted viral 
sequences, non-coding regions, repeat and transposable elements which exist within 
the genome 
52, 53
. Epigenetic changes are also known to either repress or activate 
certain genes via genomic imprinting and X-chromosome inactivation, although, 
these mechanisms are regulated differently 
54 - 56
. 
 
2.2.1 Genomic Imprinting 
The seminal work of Surani et al
57
 hypothesised that both paternal and maternal 
genomes are required for normal embryonic development. To test this theory, nuclear 
transplantation experiments were performed in mice. In these experiments, either the 
paternal or maternal pronucleus was removed from the fertilized egg and replaced by 
the opposite sex pronucleus. The obtained uniparental zygote was transferred back to 
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the mother and the embryo’s development was monitored. The results showed that 
the embryo failed to develop. As a control for these experiments, either maternal or 
paternal pronuclei were removed and replaced by the same sex pronucleus and this 
produced a normal embryo. On the basis of their observations, they concluded that 
both parental contributions are important in producing a healthy normal embryo 
during development.  
Although both parents contribute equally to the normal embryonic development and 
the genetic content of their off-spring as shown in mice, the genes inherited from 
each are not equally expressed. This is believed to be due to genomic imprinting. 
Genomic imprinting is therefore defined as the normal form of epigenetic 
phenomena that either activates or represses transcription of certain genes based on 
the parental origin of the DNA. This means that maternally or paternally inherited 
alleles of a gene are imprinted or marked so that they are monoallelicly expressed 
58 - 
59
. 
Surani et al
57
 also showed that there were imprinted genes expressed either in 
maternally or paternally inherited chromosomes which were important for early 
embryonic development. Three well known classical examples of imprinting in 
humans are H19, cyclin dependent kinase inhibitor 1C (CDKN1C) and insulin-like 
growth factor II (IGFII) alleles 
60 - 63
. H19 which is a long non-coding RNA and 
CDKN1C are transcribed only from the maternally inherited allele 
61
. The main 
function of the H19 maternal allele is to regulate the expression of IGFII protein that 
is expressed from the paternally inherited allele 
62, 63
. The expression of both H19 
and IGFII proteins is controlled by imprinting regulatory elements called imprinting 
center 2 (ICR2) and differentially methylated regions (DMR) 
58,  63
. 
Genomic imprinting is thought to occur through DNA methylation tags and is 
important in gene regulation by controlling the level of allelic activity required for 
normal embryonic development in mammals 
59
. The process of imprinting is 
sustained throughout somatic cells
 
as they differentiate into the various cells and 
organs of an organism. Due to genomic imprinting, the genomes of both parents are 
distinctively marked with methyl groups that alter the DNA structure as they pass 
through the germ lines 
44, 64
. In turn, germ cells acquire the original biparental 
epigenetic state based on the sex of transmitting parent 
44, 58
. 
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Genomic imprinting occurs in three stages. During the first stage, the imprint from 
previous generations on both parental genomes is erased in the male and female germ 
lines, in order to be differentially established once more in the genome of egg and 
sperm cells 
58
. The second stage occurs during gametogenesis and results in the 
establishment of a new imprint that matches the sex of the transmitting parent. In the 
final stage, parental imprints are inherited and maintained throughout development 
58, 
65, 62
. 
The disruption of genomic imprinting during oocyte growth and development can be 
detrimental and results in an individual having two active or inactive copies of alleles 
leading to various human genetic diseases 
66 - 69
. Diseases caused by disruption of 
genomic imprinting include Angelman, Beckwith - Wiedemann, Prada - Willie and 
Russel - Silver syndromes 
66, 67, 69
. Beckwith - Wiedemann and Russel - Silver 
syndromes arise from mutations of CDKN1C, IGFII and H19 genes, which are 
associated with poor growth of some parts of the body and digestive system 
abnormalities 
69, 70
. Several cancers including cervical carcinoma, hepatoblastoma, 
human glioma, renal cell carcinoma, colorectal and uterine small-cell cancers have 
been shown to occur due to abnormal genomic imprinting 
69
.  
 
2.2.2 Inactivation of X-Chromosome 
In 1959, Ohno et al 
71
 showed that the two female X-chromosomes were different. 
One chromosome was found to be euchromatic with sparsely packed DNA and 
active transcription, whereas the other one was heterochromatic, tightly packed and 
transcriptionally repressed. These observations prompted Mary Lyon in 1962 to 
hypothesise that one chromosome undergoes inactivation to achieve equal expression 
levels of X-chromosome linked genes in both males and female 
71 - 73
.  
X-chromosome inactivation (XCI), also known as Lyonisation named after Mary 
Lyon, results in a monoallelic expression profile whereby one of the two X-
chromosomes in females is inactivated. Mary Lyon was intrigued by the fact that 
female but not male mice had the calico or tortoiseshell coat colour. She performed 
breeding experiments that demonstrated the inheritance of these colours. An 
important element of Lyon’s hypothesis was the random nature of the inactivation 
8 
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process, which could therefore affect the maternally inherited or paternally inherited 
X-chromosomes. This is the reason why male mice could only have one X-
chromosome. Lyon’s analysis in humans and other species showed that XCI occurs 
in mammals 
54, 55, 73
.  
XCI occurs at an early stage of development, being initiated at the late blastula stage 
in mice, and most likely also in humans 
73 - 75
. It occurs only in female mammals 
whereby one of the two copies of X-chromosomes is silenced or activated through 
DNA methylation. The silenced chromosome turns into a Barr body, which is the 
process of Lyonization. In addition, the silenced X-chromosome becomes condensely 
packaged and therefore results in traits like calico or tortoiseshell colour in female 
cats. A similar process cannot occur in male mammals because they have only one 
X-chromosome that is required for their survival 
73
. 
The process of XCI occurs through three distinct phases of initiation, spreading and 
maintenance. Initiation occurs during the early stage of embryonic development 
72
. 
When one of the two chromosomes is randomly activated, the other one remains 
silenced. Spreading is the process of compacting and inactivating the X-chromosome 
by a non-coding RNA gene designated X-inactive specific transcript (Xist) 
72, 76,  77
. 
Xist gene binds in the X-inactivation center (Xic) and spreads around the entire X-
chromosome in cis, resulting in transcriptional repression of one of the two X-
chromosomes in the female through epigenetic marking 
77
. The repressed 
chromosome then turns into a Barr body. After the Barr body is formed, maintenance 
begins and continues throughout adult life. The Barr body remains highly compacted 
and is essentially inactive through the entire life.  
The chromatin state of Xist gene is controlled by Tsix gene, which acts as an 
antisense partner of Xist 
78
. Tsix gene is transcribed on the opposite strand and 
maintains the Xist-mediated chromosome silencing by controlling its expression 
79 - 
81
. 
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2.3  DNA Methylation Changes in the Human Genome  
DNA methylation is an important feature of the mammalian genome. It is defined as 
the attachment of a methyl group (CH3) to the carbon-5 position of the cytosine ring 
in the nucleotide sequence (see Figure 1.2) 
24, 82 - 84
.  
 
Figure 1.2: DNA Methylation at the Carbon 5
 
Position of Cytosine (Adapted from 
Bestor 
86
).  
The DNA methyltransferase enzyme transfers the methyl group (CH3) of a SAM to C5 cytosine, 
yielding 5-methylcytosine and SAH, respectively. 
Abbreviations: C5 - Carbon 5, CH3 - Methyl group, N - Nitrogen, NH - Nitrogen hydrogen, O - 
Oxygen, SAH - S adenosylhomocysteine (SAH), SAM - S adenosylmethionine.   
 
Eukaryotic DNA methylation changes are established and maintained throughout life 
by DNA methyltransferases (DNMTs) 
85
. DNMT enzymes catalyse the transfer of a 
methyl group under the influence of a methyl donor S-adenosylmethionine (SAM) 
leading to the formation of 5-methylcytosine and S-adenosylhomocysteine (SAH, see 
Figure 1.2) 
21
. DNA methylation patterns are inherited from the parent strand to the 
newly synthesized daughter strand during cell divisions 
24, 84
.  
DNA methylation occurs primarily in the context of cytosine-phosphate-guanine 
(CpG) dinucleotides that are located in CpG islands which are 500 to 5000 bp long. 
The CpG to guanine -phosphate-cytosine (GpC) dinucleotides are present with the 
observed-to-expected ratio of 0.65 and G+C content of more than 60%. This is  
10 
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calculated using the formula (Number of CpG)/ (Number of C x Number of G) x 
(Total number of nucleotides in the sequence) 
24, 84
.There are more than 29 000 CpG 
islands in the human genome 
83, 84, 87,  88
. The CpG dinucleotides that are not 
associated with these islands are highly methylated with 80% being located within 
the coding region of a gene 
83, 84
. 
In the DNA promoter regions of normal cells, the CpG dinucleotides are protected 
from DNA methylation regardless of the transcriptional state of genes 
89, 90
. 
However, in cancer cells, the CpG dinucleotides in CpG islands of the gene promoter 
regions are highly methylated and this correlates with the transcriptional inactivation 
of genes including genes that are critical for tumorigenesis 
89
. In somatic cells, 
cytosine methylation has also been observed within Cytosine-phosphate-Adenine 
(CpA) and Cytosine-phosphate-Thymine (CpT) dinucleotides and this methylation 
also affects embryonic development but to a lesser extent compared to CpG islands 
methylation 
91
. 
 
2.4  Physiological Activities of DNA Methyltransferases  
DNA methylation profiles are established during early embryonic development by 
the action of DNMTs 
23, 24
. DNMTs have two parts, a diversified amino terminal 
region and a relatively conserved carboxy terminal region. They have distinctly 
different methyltransferase activities which are used to categorise them as 
maintenance DNMTs or de novo DNMTs (see Figure 1.3) 
24, 84
.  
Maintenance methyltransferase, DNMT1, was identified first in the eukaryotes. It 
was classified as a maintenance methyltransferase enzyme because it has a 5 to 30 
fold preference for hemi-methylated dsDNA over unmethylated dsDNA in in vitro 
24, 
84
. It is responsible for maintaining DNA methylation patterns that de novo 
methyltransferases establish from parental strands to newly synthesised daughter 
strands throughout cell replication 
92
. DNMT1 consists of an amino terminal 
regulatory and carboxy terminal catalytic domains (see Figure 1.3). These domains 
are connected by a lysine and glycine rich (GK) repeat sequence and mediate 
protein-protein interaction during chromatin regulation. 
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Figure 1.3: The Structure of DNA Methyltransferase Enzymes (Adapted from 
Robertson and Wolffer
98
).  
DNMT1 does maintenance methylation and DNMT3A, 3B do de novo methylation. They have amino 
terminal regulatory and carboxyl terminal catalytic domains. The regulatory domain of DNMT1 is 
longer than that of DNMT3A and 3B. Regulatory domain of DNMT1 has NLS, DNA replication foci, 
zinc binding cysteine-rich domain and GK-repeat region. In the sequences of DNMT3A, 3B and 3L 
are PWWP, PHD-like ATRX with a cys-rich region and catalytic domain. In contrast, DNMTL lacks 
catalytic activity and PWWP, but has PHD-like ATRX region. 
Abbreviations: ATRX - Alpha-thalassemia/mental retardation, x-linked, DNMTs - DNA 
methyltransferases,  GK - Glycine lysine, NLS - Nnuclear localization signal, N terminal - Amino 
terminal, PHD - Polybromo -1 homology domain, PWWP - Proline tryptophan tryptophan proline.   
 
The amino terminal regulatory domain has a nuclear localization signal (NLS), DNA 
replication foci (DRF) and cysteine-rich region which binds to zinc ions 
93
. The NLS 
sequence is responsible for DNMT1 localization in the nucleus where it is recruited 
to DRF during the S phase of the cell cycle and preferentially methylates hemi-
methylated cytosines 
93
. This occurs through interaction between DNMT1, ubiquitin-
like containing polybromo-1 homology domain (PHD) and really interesting new 
gene finger domain 1 (RING-1) 
93, 94
. RING-1 finger domain 1 is a protein structural 
domain that binds one or more zinc ions in the DNA sequence. It plays an important 
role in chromatin remodelling and gene transcription 
95, 96
. Disruption of interaction 
between DNMT1, PHD and RING-1 promotes the development of tumour in human 
and glial cells 
97
. 
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In contrast to maintenance DNMT1, the regulatory domain amino terminal regions of 
de novo methyltransferase enzymes are poorly conserved and smaller, but their 
catalytic domains are well conserved 
21, 49
. In the centre between regulatory and 
catalytic domains of de novo methyltransferase enzymes are proline-tryptophan-
tryptophan-proline (PWWP) and PHD-like alpha-thalassemia/mental retardation, x-
linked (ATRX) cysteine-rich regions (see Figure 1.3). The ATRX gene is located on 
the X-chromosome and regulates adenosine triphosphate (ATP)-dependent chromatin 
remodelling. Mutations in the gene cause X-linked mental retardation syndrome that 
occurs mainly in males due to X-linked recessive inheritance 
21, 49
.  
DNMT3A and 3B are de novo methylatransferases 
85
. They establish the DNA 
methylation patterns of dsDNA during embryonic development 
64
. They were 
mapped on chromosomes 2p23 and 20q11.2, respectively 
99, 100
. The DNMT3L 
enzyme is located on chromosome 21q22.3. Its methyltransferase enzyme structure is 
similar to that of DNMT3A and 3B, but its biological catalytic activity remains 
unknown. DNMT3L increases the ability of DNMT3A and 3B to bind to DNA and 
stimulates their de novo methyltransferase activities. It interacts directly with 
DNMT3A and 3B to establish maternal de novo methylation during genomic 
imprinting 
24, 84, 85
.  
The biological effects of both maintenance and de novo methylations have been 
characterised 
101
. The DNMT1 is highly expressed in sperm, suggesting a role during 
spermatogenesis 
51
. In early embryogenesis, DNMT1 enzyme maintains the 
methylation patterns of genomic imprinted genes and its absence or over-expression 
is associated with embryonic lethality. DNMT3B is highly expressed in bone 
marrow, thyroid and testicular tissues, but less so in brain, skeletal muscle and 
peripheral blood mononuclear cell 
100 - 102
. Mutations in the DNMT3B gene are 
associated with increased chromosomal rearrangements in methylated centromeric 
regions that may lead to the development of immunodeficiency centromere 
instability and facial anomalies syndrome (ICF) 
28, 29, 42
 . These mutations can also 
impair the regulation of DNMT3B by DNMT3L 
41
. 
DNMT enzymes can be targeted by tissue-specific micro RNAs (miRNAs) which are 
small ribonucleic acids of 18 to 25 nucleotides in length 
103
. In human cancers, 
various miRNAs are lined up with the untranslated region (UTR) that binds to 
13 
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DNMTs and induce translation repression and degradation of messenger RNA 
(mRNA). MiRNA-148 down-regulates DNMT1 leading to over-expression of 
methylation-sensitive genes in cluster of differentiation 4
+
 T-helper (CD4
+
)  cells and 
silences the ras association domain family 1 alpha (RASSF1α) gene in human 
cholangiocarcinoma xenografts 
104, 105
. Interaction of miRNA-29 family members 
with 3ꞌUTR of DNMT3A and DNMT3B genes has been shown to result in global 
DNA hypomethylation in lung cancer cells 
103, 104
.   
 
2.5 DNA Methylation and Cancer Development   
Cancer develops as a result of germline mutations and aberrant DNA methylation 
106
. 
Cancer is associated with the activation and silencing of proto-oncogenes and tumour 
suppressor genes, respectively 
48. According to Knudson’s two-hit hypothesis, the 
functions of both alleles in the tumour suppressor gene must be altered in order for 
the gene to lose its function completely and result in cell transformation. Germline 
mutations can silence tumour suppressor genes, resulting in the loss of normal gene 
function. Therefore, promoter hypermethylation could be considered as a second hit 
after germline mutation 
107, 108
.  
Cancer cells usually have significant aberrant DNA methylation changes that affect 
genes involved in the prevention of carcinogenesis. Tumour suppressor genes and 
oncogenes play a vital role in controlling cell proliferation, programmed cell death 
and the repair of damaged DNA 
41,  42
. Any disruption of their functions may result in 
malignant transformation leading to cancer 
41, 109
. 
Cancer associated DNA methylation may be global hypo- or hypermethylation (see 
Figure 1.4). Global DNA hypomethylation was the first epigenetic abnormality 
identified in cancer by methylation-sensitive restriction enzymes 
41, 47
. 
Hypomethylation involves a decrease in the methylation of CpG dinucleotides in 
DNA and causes increased mutation rates 
92
. It may contribute to carcinogenesis by 
causing loss of genomic imprinting, X-chromosome inactivation and induction of 
genomic instability through transcriptional controls.   
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Figure 1.4: DNA Methylation in Normal and Cancer Cells (Adapted from Perret
112
).  
Most CpG sites within the genome of the normal cell become stably methylated (as shown by closed 
lollipop) for normal embryonic development. Simultaneously, some CpG sites within the promoter 
regions are also unmethylated (as shown by open lollipop) and this is associated with normal active 
transcription of tumour suppressor genes important to prevent the development of cancer. In cancer 
cells, the CpG sites outside the CpG islands become hypomethylated, while the CpG dinucleotides 
within the promoter regions of tumour suppressor genes which are usually not methylated in normal 
cells are associated with hypermethylation leading to silencing of gene transcription.   
Abbreviations: CpG - Cytosine-phosphate-Guanine, GSTP1 - Glutathione S-transferase pi 1 gene, 
TSG - Tumour suppressor gene. 
 
Hypomethylation of DNA may also target the transposons, the repeated DNA 
elements and introns in which they activate the encoded genes, preferably proto-
oncogenes, which are normally transcriptionally repressed in normal cells 
41, 42, 109
. 
This abnormality is observed in a wide variety of cancers and is seen in neoplastic 
nodules. For example, Long interspersed nuclear element 1 (LINE-1) repeats, 
epidermal growth factor receptor (EGFR), fos, raf, myc, ras, and wnt genes are 
hypomethylated and down-regulated in hepatocellular carcinoma (HCC), breast, 
colorectal, colon, gastric and many more cancers  
41, 47, 110, 111
.  
Hypermethylation appears in the early and late stages of carcinogenesis 
42, 48
. CpG 
sites that are usually unmethylated in normal cells become hypermethylated, 
resulting in the transcriptional repression of the encoding tumour suppressor genes 
15 
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and the development of cancer 
112
 (see Figure 1.4). It is not known why some CpG 
sites are hypermethylated while others are not. Genes usually known to be 
hypermethylated in human cancers generally play important roles in cell-cycle 
regulation, cell adherence, metastasis, apoptosis, repair and protection of DNA 
19, 113, 
117
. Table 1.2 illustrates a list of genes that are usually hyper- or hypomethylated in 
various tumours. 
 
Table 1.2: Genes Methylated in Human Cancers and Their Role in Tumour 
Development  
32, 47, 48, 110, 111, 113, 114, 117, 119 -126, 128  - 134, 442 -443
 
 
 
 
Abbreviations: β – Beta, APC -adenomatous polyposis coli, BRCA1 - Breast cancer 1, CDKN2A - Cyclin dependent kinase 
inhibitor 2A, CHD13- coronary heart disease 13, DAPK - Death associated protein kinase,  DLEC1- Deleted in lung and 
oesophageal cancer 1, DNA - Deoxyribonucleic acid, EGFR - Epidermal growth factor receptor, ERα - Estrogen receptor-
alpha, GSTP1 - Glutathione S-transferase pi 1, HCC - Hepatocellular carcinoma, hMLH1 - Human mutL homolog 1, LINE-
1 - Long interspersed nuclear elements, MGMT - O-6-methylguanine DNA methyltransferase, RASSF1- Ras association 
domain family 1, pRb - Retinoblastoma protein,  RARα - Retinoic acid receptor alpha, VHL - Von Hippel Landau, Wnt - 
Wingless type. 
Role in Tumour Development 
 
 
Wnt signaling 
 
Cell-cycle regulation 
 
 
 
 
 
Apoptosis and DNA damage 
 
 
Cell-cycle regulation 
 
 
 
 
 
 
 
 
 
 
Repair and protection of DNA 
 
 
 
 
Apoptosis 
 
Cell adherence and metastasis 
 
Hormone resistance 
 
 
 
 
Gene  
 
Hypomethylated  
β-catenin 
 
EGFR 
Myc 
Fos 
Ras 
Raf  
 
LINE-1 
 
Hypermethylated 
APC 
CDKN2A 
DLEC1 
pRb 
p16INK4α 
p15INK4 
p14ARF 
RASSF1 
RARβ 
VHL 
 
BRCA1 
GSTP1 
hMLH1 
MGMT 
 
DAPK 
 
E-cadherin (CDH13) 
 
ERα 
 
Tumour Type 
 
 
HCC, Parathyroid carcinoma, Colorectal and Breast cancers 
 
HCC, Breast, Lung, Anal cancers  
Breast, Cervical, Colon and Lung cancers 
Breast, Thyroid and Ovarian cancers 
Adenocarcinoma, Thyroid, Lung and Colon cancers 
Gastric, Leukaemia, Thyroid and Prostate cancers 
 
HCC, Colon, Bladder, Familial and Sporadic cancers 
 
 
Prostate, Colorectal, Breast and Esophageal cancers 
Lung, Colorectal, Head and Neck cancers 
HCC, Breast, Lung and Esophageal cancers 
Colon, Oligodendroglioma, Retinoblastoma cancers 
Gastric, Breast, Head and Neck, Colorectal, and Lung cancers 
Gastric, Leukaemia, Lymphoma, Liver and Lung cancers 
Gastric, Prostate, Bladder 
Prostate, Colorectal, Ovarian and Nasopharyngeal cancers 
HCC, Esophageal carcinoma and Prostate cancer 
Renal cell cancer and Esophageal carcinoma 
 
Breast and Ovarian cancers 
Gastric, Prostate HCC and Breast cancers  
Gastric, Colon and Ovarian cancers 
Gastric, Head and Neck, Colorectal and Brain cancers  
 
Lung, Brain, Head and Neck cancers 
 
HCC, Breast, Prostate, Cervical, Head and Neck cancers 
 
Breast, Colon and Prostate cancers 
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3. ONCOGENIC VIRUSES AND DNA METHYLATION 
Worldwide, 20% of human cancers are linked to infection with oncogenic viruses 
135, 
136
. Three well-studied viruses associated with malignant transformation are human 
papillomavirus (HPV), hepatitis B virus (HBV) and Epstein-Barr virus (EBV). These 
hepadnaviruses are capable of establishing persistent infection which in a small 
minority of those infected may give rise to cancer 
137 - 139
.  
The EBV, HPV and HBV infections are associated with gastric or nasopharyngeal, 
cervical and liver cancers respectively 
139
. The various mechanisms by which these 
viruses cause malignancy are still under investigation, but hypermethylation has been 
shown to be one such mechanism. The cellular methylation systems that are activated 
during chronic viral infections methylate the viral genome inserted in the human 
genome as an innate protective mechanism to stop viral replication 
135, 140, 141
. 
However, the same methylation system may also methylate and suppress important 
tumour suppressor genes and oncogenes, resulting in malignant transformation that 
may lead to the development of cancer 
142
. 
 
3.1  Epstein - Barr Virus and DNA Methylation 
EBV or human herpesvirus 4 is a DNA virus that was first described in Burkitt’s 
lymphoma B-cells by British pathologists Michael Anthony Epstein and Yvonne 
Barr 
143
. It was the first oncovirus to be identified and is also known to be associated 
with Hodgkin’s lymphomas, gastric and nasopharyngeal carcinomas 116, 142, 144 - 150. It 
is classified into EBV-1 and EBV-2, which differ in the sequence of the genes that 
code for the viral genome 
150 , 151
. 
About 90% of the adult population worldwide is infected with EBV. The infection 
occurs mostly during childhood without showing any evidence of symptoms. EBV is 
transmitted from one individual to another through intimate contact with saliva from 
an EBV infected person. It infects the B-cells which express solely complement 
receptor type 21 (CD21/CR21) 
147, 152, 153
. However, it may also infect 
nasopharyngeal epithelial cells 
144
.  
The primary infection of EBV in vitro begins through interactions of envelope 
glycoproteins gp350/220 with CD21 receptor and gp21 with human leukocyte 
17 
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antigen (HLA) class II co-receptor 
152 - 154
. These interactions trigger fusion and 
internalization of the virus membrane with the cell membrane. Following 
endocytosis of the virus into the host cell, the EBV genome circularises to exist in an 
episomal form. Episomes replicate simultaneously with the cellular DNA replication 
and establish latent infection 
153, 155
. During latent infection, various EBV genes 
including EBV nuclear antigens (EBNAs), the latent membrane proteins (LMPs) and 
the EBV-encoded small RNAs (EBERs) are expressed 
156, 158
.  
EBV is a gammaherpesvirus of the Lymphocryptovirus genus. It is composed of a 
toroid-shaped protein. It has 0.5kb terminal direct repeats at both ends of a linear 
genome that divide the genome into short and long sequence domains. Its genome 
contains linear, double-stranded DNA (dsDNA) of 172 kilobases (kb) in length
159
. It 
also has various open reading frames (ORFs), which encode various EBV genes that 
are located on the BamHI restriction fragment. The BamHI restriction fragment is 
made-up of four viral promoters including BamHI W promoter which play an 
important role in the transcription of viral gene expression 
152, 153
.   
The BamHI W promoter of EBV is susceptible to DNA methylation and this alters 
the expression of EBNA proteins 
115, 147, 152, 153, 160
. Methylation of the EBV genome 
induces aberrant methylation that suppresses the transcription of important host 
tumour suppressor genes and leads to uncontrolled cell growth 
161
. The activation of 
oncogene latent membrane protein (LMP) 1, one of the LMP proteins, enhances 
upregulation of DNMT1, which is associated with hypermethylation of retinoic acid 
receptor-beta2 (RAR-β2) and E-cadherin 13 (CDH13) genes in EBV-associated 
nasopharyngeal cancer 
121, 157
.  
The activation of DNMT1 by LMP2 causes the suppression of LMP2 gene 
expression that results in the hypermethylation of the phosphatase and tensin 
homolog (PTEN) promoter in EBV-related gastric cancer. EBV-negative gastric 
cancer does not have such hypermethylation changes 
162
.  
EBV-induced gastric adenocarcinoma is associated with promoter methylation of 
p14, p16 and adenomatous polyposis coli (APC) genes 
115
. Other EBV-driven 
aberrant CpG islands promoter hypermethylation in human gastric cancer include 
EPH receptor B6 (EPHB6), MAM domain containing glycosylphosphatidylinositol 
anchor 2 (MDGA2), interleukin-15 receptor alpha (IL15RA), scavenger receptor 
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class F member 2 (SCARF2), somatostatin receptor 1 (SSTR1) and Rec8 homolog 
(REC8) 
163
.  
 
3.2  Human Papillomavirus and DNA Methylation 
Worldwide, cervical cancer is the second most common cancer affecting women. 
Approximately 500 000 women are diagnosed each year with cervical cancer and 
almost 300 000 die from the disease 
164, 165
. Nearly all cases of cervical cancers are 
caused by HPV, with about 630 million people infected worldwide 
138, 166 - 169
.  
More than hundred types of HPV have been characterised and are classified into low- 
or high-risk HPV types 
168
. HPV -1, -6 and -11 are low-risk types that cause foot and 
genital warts. They are found mostly in benign and low grade squamous 
intraepithelial lesions 
138, 168, 169
. High-risk HPV types 16, 18, 31 and 45 cause 
cervical cancer, and are found in high grade squamous intraepithelial lesions 
168, 170 - 
174
. The best described types are HPV-16 which is associated with squamous cell 
carcinoma and HPV-18 associated with adenocarcinoma 
168, 175
.  
The transmission of HPV occurs mainly through direct skin-to-skin contacts such as 
during anal and vaginal intercourse. The life cycle of HPV begins with infection of 
epithelial basal cells. Following infection and uncoating of the viral capsids, the viral 
genome is transcribed into the nucleus. In the nucleus, the HPV genome exists as an 
episome, which replicates in order to establish persistent infection 
169, 176 - 178
. 
HPV is a non-enveloped dsDNA virus of the genus Alpha-Papillomavirus in the 
Papillomaviridae family 
173, 175, 176
. HPV genome is approximately 8 kb in length and 
contains eight ORFs which encode E1-E7 and Late (L) proteins L1 and L2 
178 - 181
. 
An upstream regulatory region (URR) of HPV genome is 850bp long control region 
(LCR) of HPV genome. The URR contains a TATA box and Sp1-binding sites and is 
therefore important for initiating replication and gene transcription regulation 
182, 183
. 
Infection with high-risk HPV types is associated with integration of viral DNA into 
host DNA. HPV integration in the human genome has been linked to disruption of 
viral E2 ORF that results in the loss of E2 protein 
181
. E2 protein regulates the 
expression of E6 and E7 oncogenes 
180
. The loss of E2 protein may result in the 
transcriptional repression of E6 and E7 proteins 
182, 184
.  
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In some HPV infected cells, ORF E2 over-expresses early viral proteins E6 and E7, 
which extend the cells’ life span 179, 185. These cells retain the capacity to proliferate a 
process known as immortalization 
186
. During cell immortalisation caused by HPV, 
normal cellular mechanisms that protect cells from mutations are disabled and 
selective tumour suppressor genes are inactivated. As mutations accumulate, the cells 
undergo morphologic or epigenetic changes that lead to the development of 
precancerous cells and cancers of the cervix, vagina or vulva 
161, 172, 186, 187
.  
Epigenetic changes in HPV occur through the interaction of viral proteins with host 
epigenetic machinery proteins such as DNMT and HAT 
184, 188
. For instance, HPV-16 
E7 protein binds to DNMT1 and P300/ CREB-binding protein-associated factor 
(pCBPAF) acetyltransferase and regulates their enzymatic activities 
93, 189
. HPV-16 
E6 protein interacts with transcriptional activator pCBPAF or p53 and inhibits HAT 
activity. Interaction of ORF E6 protein with p53 promotes cell cycle progression and 
therefore enhances viral replication 
161, 184
. HPV type 16 and 18 E6 proteins also bind 
and inactivate human telomerase reverse transcriptase (hTERT) protein through 
proteasomal degradation by ubiquitin ligase E6 associated protein (E6-AP) 
186, 187, 190
. 
DNA methylation also occurs in HPV -16 and -18 infections 
191 - 194
. In HPV-16 
related invasive cervical cancer, LCR and E2 binding sites at the URR are 
hypermethylated 
137, 193
. The methylation of these binding sites disrupts the function 
of E2 protein resulting in the upregulation of E6 and E7 oncogenes  
192, 193, 195, 196
. 
Similar patterns of methylation were observed in immortalised cells from foreskin 
keratinocytes and primary cell carcinomas transfected with HPV-18 
188, 191, 194, 197
.  
 
3.3 Hepatitis B Virus and DNA Methylation 
HBV was first identified in the 1960s and was the first human hepatitis virus to be 
well characterised at a molecular level 
198
. HBV is classified as an 
Orthohepadnavirus which belongs to the family Hepadnaeviridae. Contained in this 
family, are other viruses such as the hepatic viruses of woodchucks, ducks, herons, 
ground and tree squirrels. These viruses were classified as Hepadnaeviridae due to 
their structure and genomic organization being similar to that of HBV. They replicate 
via reverse transcription of RNA intermediates, the step in which the DNA is 
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packaged into hepadnaviral infectious particles 
199 - 204
. 
HBV infection may be acute or chronic. Acute infection occurs shortly after the 
initial exposure and it may take up to 8 weeks for symptoms to show 
205 , 206
. Chronic 
infection is defined as the presence of hepatitis B surface antigen (HBsAg) in the 
blood more than 6 months following initial infection. It results in the development of 
liver cirrhosis and hepatocellular carcinoma (HCC) 
205, 207 - 209
. 
Epidemiological studies show that chronic HBV infection is a major cause of liver 
cirrhosis and HCC 
210 - 213
. HCC, also known as malignant hepatoma, primary liver 
cell carcinoma or hepatocarcinoma, is the third leading cause of global cancer-related 
deaths after colon and lung cancer 
210, 214
.  
The link between HBV and HCC was identified a decade after the discovery of HBV 
infection by Sherlock, who noticed a high prevalence of chronic HBV infection in 
HCC cases 
215
. HCC occurs in individuals who have chronic HBV infection. 
Progression from acute to chronic HBV infection is common in infants and children 
with an estimated rate of 70 – 95 % due to an immature immune system while only 
about 3 – 5 % of acutely HBV infected adults may develop chronic infection  210, 216 , 
217
.   
The progression of HBV infection to HCC occurs in a series of steps generally 
following a sequence of chronic HBV infection, fibrosis or cirrhosis, dysplastic 
nodule formation and HCC development 
218 - 220
 as illustrated in Figure 1.5. It is 
thought that during this sequence progression, mutations and epigenetic alterations 
accumulate and lead to the development of malignant transformation in the HBV 
infected liver 
207, 221, 222
. It has been reported that 10 to 20 % of chronic HBV infected 
patients may develop cirrhosis within a period of 3 to 5 years 
218
. The average period 
of HBV infection progression to cancer is about 20 to 30 years and 8 to 10 years after 
the development of cirrhosis 
207, 216
.  
Aberrant DNA methylation of promoter CpG islands is the primary epigenetic 
change seen during the course of HBV infection as it progresses to cirrhosis and 
HCC. Such methylation is detected at higher rates in HCC cells and less so in 
hepatocytes at the stage of chronic HBV infection, fibrosis and cirrhosis. This 
suggests the important role of epigenetic-related alteration in liver disease. 
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Figure 1.5: Chronic HBV Infection, Cirrhosis and HCC Development. 
About 70 - 95 % of children and 3 - 5 % adults infected with HBV may progress to chronic 
HBV infection associated with chronic inflammation and fibrosis.  
Abbreviations: HBV - Hepatitis B virus, HCC - Hepatocellular carcinoma. 
 
3.3.1 Transmission of HBV 
HBV can be stable for seven days or more on dry environmental surfaces. The two 
major routes of HBV transmission are horizontal and perinatal or vertical 
transmission. The efficient modes of transmission are blood and sexual contact with 
an infected person 
223 - 225
. 
The virus is horizontally transmissible during child to child physical contact or 
through contact with blood or infected toys 
224, 226 - 229
. Horizontal transmission can 
also occur through body fluids such as semen and vaginal secretions 
223, 224, 230
.  
Perinatal or vertical transmission of HBV occurs through blood or secretions from an 
infected mother to the newborn baby during delivery 
225, 229, 231, 232 
. Perinatal 
transmission is high in mothers who are hepatitis B e antigen (HBeAg) positive at 85 
– 90 % and lower in those who are negative for HBeAg where the rate is 5 – 20 % 
231, 233 - 235
.  
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3.3.2 Global Epidemic of HBV Infection 
Worldwide, it is estimated that more than 350 million people are currently living 
with chronic HBV infection, contributing to more than one million deaths annually 
208, 236
. The prevalence of HBV infection is determined by the seroprevalence of 
HBsAg 
237
. HBV is highly endemic in Asia and sub-Saharan Africa with HBsAg 
seroprevalence rates exceeding 8% (see Figure 1.6).  
 
 
Figure 1.6: Global Geographical Distribution of Chronic Hepatitis B Infection 
(Adapted from Stannard
407
). 
Abbreviations: HBsAg - Hepatitis B surface antigen, USA - United States of America. 
 
In these regions, the infection is typically acquired at birth or in early childhood 
207
. 
Progression to chronic HBV infection is common in these regions and is associated 
with prevalence rates of 30% for hepatic cirrhosis and 53% for HCC 
209, 238, 239
 .  
Annually, approximately one million people are diagnosed with HCC worldwide and 
more than half of these people die within a year of diagnosis. Studies show that the 
highest HCC incidence rates of 70 – 80 % occur in Southeast Asia and sub-Saharan 
Africa, the regions with a high prevalence of chronic HBV infection 
211, 212
. This is 
due to various factors that include the late presentation of patients with large 
tumours, failure to recognise those at risk, high prevalence of risk factors in the 
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population, lack of medical facilities for early diagnosis and limited access to 
effective treatment after diagnosis 
212
. 
An intermediate HBsAg seroprevalence of 2 – 7 % is seen in some parts of Asia, 
Europe, America and Russia. The prevalence of HBV infection is low in Western 
Europe, Australia and United States where HBsAg seroprevalence is less than two 
percent 
240
.  
 
3.3.3 Epidemic of HBV Infection in Africa 
There are 65 million individuals infected with chronic HBV in Africa and 250 000 of 
these people die annually due to HBV related diseases. The prevalence of chronic 
HBV infection in Africa varies by geographic region. It is high in sub-Saharan 
Africa, with HBsAg seroprevalence rates of more than 8%. In Kenya, Sierra Leone, 
Zambia, Senegal and Liberia, the prevalence of HBV infection is intermediate with 
HBsAg seroprevalence rates ranging from 2% to 8%. North African countries 
including Morocco, Egypt, Algeria and Tunisia have low prevalence rates of less 
than 2% 
241, 242
.  
In South Africa and other African countries, the prevalence of HBV infection is 
much higher in rural compared to urban areas 
230, 243
. Low socio-economic status, 
infected household contact, unsafe sexual intercourse, sharing of partially eaten 
sweets or chewing gum, dental work and bathing towels may be some of the 
contributing factors for the high prevalence of HBV infection in rural areas 
223, 229, 241, 
244
.  
 
3.3.4 HBV Genotypes, Mutations and Genomic DNA Methylation 
HBV is classified into eight genotypes (A - H) with four major serotypes (adw, adr, 
ayw and ayr) 
245 - 249
. HBV genotypes are differentiated by more than 8% sequence 
divergence in the entire genome and more than 4% at the level of S gene 
250, 251
. They 
have distinct geographical distribution as illustrated in Table 1.3. Genotype A is 
predominant in sub-Saharan Africa, north-west Europe and North America 
252 - 254
. 
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Table 1.3: The Global Geographic Distribution of HBV Genotypes, Mutations and 
Associated CpG Promoter DNA Methylation
 245, 248 - 252, 255 -  258 
 
 
 
Genotype A has four subgenotypes. Subgenotype 1A is common in South Africa, 
Malawi, Tanzania, Uganda, Somalia, Yemen, India, Nepal, Brazil and the 
Philippines. There are three CpG islands within HBV genotype A, which are 
associated with methylation of the promoter of Deleted in Lung and Esophageal 
Cancer 1 (DLEC) gene and down-regulation of its expression in HBV-induced HCC 
255, 259
. DLEC is a tumour suppressor gene and has been reported to be down-
regulated in ovarian, liver, lung and EBV-related cancers 
116, 255, 259
. 
Genotypes B and C are more prevalent in Asia, Indonesia and Vietnam 
236, 247, 261, 445
. 
Genotype D is commonly found in the Mediterranean region and Middle East 
252 -254
. 
The hepatitis B x (HBx) protein is associated with hypermethylation and down-
regulation of the GSTP1 gene which plays an important role in the development of 
cancer. Genotype E is found mainly in Africa. Genotype F is found in Europe and the 
United States, and genotype G in France and America 
249, 251
. Genotype H is 
predominant in Central America, California and Mexico 
258
. 
HBV has a mutation rate of 10%, which is relatively high compared to other viruses. 
It replicates via reverse transcription of RNA intermediates that result in random 
mismatched base errors during genomic replication. HBV DNA polymerase lacks the 
ability to proofread these errors and this predisposes HBV to mutations 
262, 273
. HBV 
develops four major mutations which are the precore, basic core promoter, tyrosine-
 
Abbreviations: A - Adenine , CpG - Cytosine-phosphate-Guanine, DLEC1 - Deleted in Lung and Esophageal 
cancer 1, G - Guanine, GSTP1 - Glutathione S transferase pi 1, HBV - Hepatitis B virus, T - Thymine. 
 
Genotype 
 
A  
 
 
 
B 
C 
 
D  
 
E 
F 
G 
H 
Geographic Distribution 
 
North America, sub-Saharan Africa, 
north-west Europe  
 
 
Indonesia, China, Vietnam  
East Asia, Korea, China, Japan, 
Polynesia, Vietnam 
Mediterranean area, Middle East 
 
Africa 
Central and South America, Polynesia 
France, America  
Central America, California, Mexico  
Mutation 
 
G1888A 
1762T1764A 
G1862T  
 
Unknown 
Unknown  
 
G1896A                 
 
Unknown 
Unknown 
Unknown 
Unknown 
Host CpG Promoter Methylation 
 
Induces hypomethylation and down-
regulation of DLEC1 gene 
 
 
Unknown 
Unknown 
 
Induces hypermethylation and down-
regulation of GSTP1 gene 
Unknown 
Unknown 
Unknown 
Unknown 
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methionine-aspartate-aspartate (YMDD) and asparagines-to-threonine (rtN236T) 
mutations. The precore mutants were the first to be identified and are characterised 
by a nonsense G1896A mutation 
264, 265
. The G1896A mutation is responsible for 
HBeAg negativity in chronic HBV carriers and induces the down-regulation of HLA 
class II molecules in hepatocytes 
266
. This mutation is common in individuals 
infected with HBV genotype D 
234, 267
. The basic core promoter mutations include 
A1762T and G1764A and were identified after the precore mutations 
235, 265
. Similar 
to the precore mutations, the basic core promoter mutations are found in HBeAg-
negative individuals where they prevent HBeAg expression 
265, 268
. 
 
3.3.5 Prevention and Treatment 
HBV infection can be prevented by avoiding direct contact with any HBV 
contaminated fluids and materials. Immunization with recombinant hepatitis B 
vaccines is recommended for all infants at birth 
416
 and in individuals who are at high 
risk of acquiring the infection. Passive immunoprophylaxis with hepatitis B 
immunoglobulin derived from sera of positive HBV individuals is used to prevent 
mother-to-child HBV transmission at birth, after liver transplantation for HBV 
infection, needle-stick injuries and sexual intercourse 
247, 417, 418
. 
Acute HBV infection does not require treatment as it usually resolves spontaneously 
205, 206
. Two major classes of drugs available for treating chronic HBV infection 
include the injectable standard interferon-α and pegylated interferon-α2, and the oral 
nucleos(t)ide analogues. Nucleoside analogues are lamivudine, entecavir telbivudine, 
while nucleotide analoques are adefovir dipivoxil and tenofovir 
343, 440, 419 – 425
. The 
main aims of treatment are to improve long-term survival by reducing the risk of 
developing cirrhosis and HCC 
421, 423
.  
Treatment with oral nucleos(t)ide analogues is associated with the development of 
mutations  
269, 270
. Lamivudine induces point mutations in the YMDD motif of the 
HBV polymerase and these include rtM204V and rtM204I mutations 
271, 272
. The 
viral replication rate increases in the presence of lamivudine resistance and when 
lamivudine treatment is stopped, the wild-type virus re-establishes itself 
 272, 273
. 
Lamuvidine resistance mutations are responsible for the development of resistance in 
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entecavir that is also associated with similar mutations and more including rtI169T, 
rtT184G, rtS202I and rtM250V 
118, 127, 260
. Telbivudine has a high antiviral potency 
and relatively low resistance than lamuvidine and entecavir. It is associated with 
mutations at rtL80I/V, rtL180M, rtA181T/V, rtM204I and rtL229W/V 
441
. 
Telbivudine results in myoparthy and neuropathy when used simultaneously with 
pegylated interferon-α2 and therefore combination of these two agents is avoided 120.  
Adevovir treatment causes mutations that are associated with the emergence of 
resistant strains such as the rtN236T mutation which is downstream to the YMDD 
motif 
269,
 
270
. The use of adevovir treatment is now rare as it is associated with severe 
kidney injury, which may be a consequence of mitochondrial DNA depletion and 
activity of multidrug resistance-associated protein 4 
438, 439
.  
Despite the availability of treatment for chronic HBV infection, many patients will 
develop cancer and this remains a major medical problem worldwide. This may be 
attributed to HCC-associated risk factors such as the HBV genotype, alanine 
aminotransferase (ALT), HBV load and HBV surface antigen level, which may 
influence the response to chronic HBV treatment 
426, 430, 431
. The response to 
interferon is significantly higher in patients infected with HBV genotype A compared 
to D and in patients with lower levels of HBV DNA and higher levels of ALT 
357, 426 
– 431, 435
.  
Aberrant methylation of promoter CpG islands is the primary epigenetic change seen 
during the course of HBV infection as it progresses to cirrhosis and HCC
 207
. Such 
methylation is detected at higher rates in HCC tissues compared to liver cirrhosis 
without cancer 
207, 221, 222
. In a recent large cohort study report by Tseng et al, high 
HBV surface antigen levels are associated with a risk of developing HCC even in the 
presence of low HBV DNA levels 
435
. This finding may be due to a higher degree of 
viral HBV surface antigen integration into the host genome that would result in 
mutations and epigenetic alteration particularly DNA methylation, causing chronic 
liver damage, malignant transformation and HCC 
432, 433, 435 - 437
.  
The association of DNA methylation with chronic HBV treatment was first observed 
during telbivudine treatment 
434
. Telbuvidine is a thymidine agent that interacts with 
protein kinases to form telbivudine 5'–triphosphate via phosphorylation. Telbivudine  
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5'–triphosphate competes with thymidine 5'–triphosphate, leading to the suppression 
of HBV DNA polymerase and reduced viral replication 
434
. Interestingly, telbuvidine 
was recently reported to correct HBV-induced histone methylation in HBV infected 
hepatocytes 
434
. 
 
3.3.6 HBV Virion Structure, Genomic Organisation and Functions 
HBV virions are infectious double-shelled particles of approximately 40 to 42 
nanometre (nm) in diameter (see Figure 1.7). They consist of a nucleocapsid core of 
27 nm in diameter, which forms the inner part of enveloped virions known as Dane 
particles 
274
. The nucleocapsid core is surrounded by an outer surface antigen coat of 
~4 nm thickness. It contains HBsAg and hepatitis B core antigen (HBcAg), which 
are detected in the sera of HBV-infected individuals in the form of spherical and 
filamentous particles 
274 -277
.  
 
 
Figure 1.7: An Electron Micrograph Image of Hepatitis B Virion and Surface 
Antigen Components (Adapted from Otto et al
408
).  
HBV is circular and partially double-stranded DNA virus of 40 to 42 nm in diameter. It has a 
nucleocapsid core of 27 nm in diameter, surrounded by an outer coat containing hepatitis B surface 
antigen of nearly 4nm thick that can be in the form of spherical and filamentous particles in the blood 
of HBV infected individuals. 
Abbreviation: DNA - Deoxyribonucleic acid, HBV- Hepatitis B virus, nm - Nanometre. 
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HBV genome is a small and relaxed circular molecule of 3.2 kb in size (see Figure 
1.8). It contains two strands of different length, a long minus strand and a short plus 
strand 
276
. The minus strand is terminally redundant and contains a second copy of 
direct repeat 1 (DR1), ɛ signal and poly A tail. It serves as a template for reverse 
transcription of a plus strand and also as a transcript for the translation of viral 
proteins including polymerase, HBcAg and HBeAg 
267. The 5ʹ end of a minus strand 
is covalently linked to the viral reverse transcriptase and polymerase through a 
phosphor-tyrosine bond. The plus strand overlaps part of the minus strand whilst its 
5ʹ end bears the oligoribonucleotides 276. 
 
 
Figure 1.8: The Structure of the HBV Genome (Adapted from Ganem and 
Prince
206
).  
The inner circles represent two DNA strands, the full-length minus and the incomplete plus strands. 
The thin black lines represent four viral RNA transcripts of different length. The outermost coloured 
lines indicate HBV surface glycoproteins (Large, Middle and Small), Polymerase, HBx and 
precore/core proteins.  
Abbreviations: (-) - Negative, (+) - Positive, DR - Direct repeat,  HBs - Hepatitis B surface, HBx - 
Hepatitis B x antigen, HBV - Hepatitis B virus, L - Large, M - Middle, Poly (A) - Polyadenylation, 
RNA - Ribonucleic acid, S - Small. 
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The HBV genome contains four ORFs, which have the same orientation and partially 
overlap 
278
. These ORFs encode the viral envelope pre-S/S, a pre-core/core, a 
polymerase and X proteins. The viral envelope also encodes three surface 
glycoproteins, which are the Large (L), Middle (M), and Small (S) glycoproteins 
279, 
280
. These surface glycoproteins are synthesised by the initial transcription of pre-S/S. 
The L surface glycoprotein is important for viral assembly and infectivity, while the 
function of M surface glycoprotein is unknown 
281
.  
The longest open reading frame encodes the viral polymerase which serves as a 
reverse transcriptase and DNA polymerase 
282
. The pre-S/S envelope open reading 
frame overlaps the precore/core and X open reading frames, and encodes HBsAg 
208
. 
The precore/core open reading frame produces HBeAg and HBcAg through cleavage 
by cellular proteases. HBcAg is the nucleocapsid and encloses the viral DNA 
267, 278
.  
HBx protein is a transactivating protein that alters the expression of some genes via 
DNA methylation leading to tumorigenesis 
283 - 286
. It consists of 154 amino acid 
residues with a molecular weight of 27kD and is encoded by the smallest ORF 
287
. It 
stimulates viral replication either by activating viral transcription or by enhancing the 
reverse transcription of the viral polymerase 
213, 283, 288
. In hepatoma cell lines, HBx 
protein enhances viral replication by interacting with DNA binding protein 1 which 
interferes with cell growth and viability. In mice infected with wild-type HBV, viral 
replication is stimulated by HBx protein, suggesting that HBx protein is required for 
viral replication in normal hepatocyte cells 
287, 289
.  
 
3.3.7 Life-Cycle of HBV 
Due to the lack of efficient in vitro infection systems and animal models in which to 
study the life cycle of HBV infection, a lot of data is from the duck model infected 
with duck hepatitis B virus (DHBV) 
277, 290
. HBV life-cycle begins through the 
interaction of HBsAg with cellular receptor/s at the surface of hepatocytes (see 
Figure 1.9).  
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Figure 1.9: The Life-Cycle of HBV Infection (Adapted from Ganem and Prince
206
).  
During the entry of HBV into hepatocytes, the genome moves to the nucleus where is converted into 
cccDNA. The cccDNA is transcribed and moves to the cytoplasm. The viral polymerase uses reverse 
transcription to form pregenomic RNA and viral transcripts, which are then translated to form viral 
proteins. Molecular mechanisms that occur during HBV infection and may explain the transition of 
chronic HBV infection to HCC are shown in green colour and highlighted with yellow arrows. 
Abbreviations: cccDNA - Covalently closed circular deoxyribonucleic acid, HBV - Hepatitis B virus, 
HBx - Hepatitis B x protein, HCC - Hepatocellular carcinoma, RNA - Ribonucleic acid. 
 
A number of potential cellular receptors that interact with HBsAg during HBV 
infection have been previously identified, but the mechanisms of action still remain 
controversial as none of them has been proved to be functional to HBV. These 
receptors include retinoid X receptor (RXR), peroxisome proliferator-activated 
receptor (PPAR) and farnesoid X receptor (FXR) 
291, 292
.  
Recently, sodium taurocholate cotransporting polypeptide (NTCP) was discovered as 
the potential receptor for HBV infection 
414
. NTCP is abundantly expressed in the 
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liver and is involved in the transportation and clearance of bile acids from portal 
blood into hepatocytes
 415
. Yan et al
414  
have shown by using near zero distance 
photo-cross-linking, tandem affinity purification and mass spectrophotometry that 
the pre-S/S envelope domain, a key determinant for receptor/s binding, selectively 
interacts with NTCP to facilitate HBV infection. Knockdown of the NTCP 
expression in duck primary hepatocytes infected with DHBV significantly decreased 
HBV infection, suggesting that NTCP is actually required for HBV infection 
414
.    
HBV requires DNA polymerase and reverse transcriptase to replicate through RNA 
intermediates known as pregenomic RNA 
293
. Following the interaction of surfaces 
antigen with cellular receptor, the viral nucleocapsid enters the host cell’s nucleus to 
deliver dsDNA. In the nucleus, the dsDNA gets repaired and converted to covalently 
closed circular super-coiled DNA (cccDNA) by DNA polymerase 
263, 294
. The 
cccDNA molecule serves as a template for the transcription of four viral RNA 
transcripts 3.5, 2.4, 2.1 and 0.4 kb in size, pregenomic RNA and RNA intermediate 
for viral replication before moving to the cytoplasm 
293, 295, 296
. The mRNA 
transcripts are then translated to produce the envelope (pre-S/S), precore/core, viral 
polymerase and X proteins. The 3.5 RNA transcript is reverse-transcribed into viral 
dsDNA 
293, 294
. Some of the resulting viral DNA and polymerase containing capsids 
are enveloped via budding into the endoplasmic reticulum (ER). The rest of the viral 
DNA is recycled or is migrated back to the nucleus where it produces new 
generations of cccDNA which maintains persistent HBV infection 
297
.  
 
4. HBV-INDUCED HCC AND DNA METHYLATION  
Three CpG islands are identified in episomal HBV DNA. These are island 1 located 
on nucleotide positions 55-286, island 2 on 1224-1667 and island 3 on 2257-2443 
298, 
299
. Methylation of CpG islands in the human genome is known to regulate gene 
transcription. This prompted Vivekanandan et al 
300
 to hypothesise that methylation 
of CpG islands in HBV DNA may regulate viral gene expression. To test this 
hypothesis, in vitro methylation of the transfected HBV DNA was done and this 
resulted in decreased expression of HBV mRNA and proteins in the cells. In 
addition, the effect of viral cccDNA methylation in the liver tissue of patients with  
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chronic HBV infection was investigated and found to be associated with reduced 
HBV replication 
300
. These findings support the work of Pollicino et al
 301
 who 
showed that HBV replication is regulated by the acetylation of HBV cccDNA bound 
H3 and H4 histone proteins. Although, this data suggest that HBV DNA methylation 
is a novel mechanism that influences the regulation of viral gene expression, the 
mechanisms of action are still not known.  
Previous human studies have shown that DNA viruses integrate into the host genome 
and that the expression levels of DNMTs increase in response to active viral 
replication 
136, 140, 141,191, 302, 303
.  Vivekanandan et al 
303
 hypothesised that the 
upregulation of DNMTs give infected cells the ability to methylate viral DNA and 
therefore control viral replication. To investigate this, the expression of DNMTs was 
measured in cell lines exposed to HBV DNA using two experimental systems, one of 
temporary transfection of cells and another that mimicked natural chronic infection. 
High levels expression of DNMT1, 2 and 3 were observed in response to persistent 
HBV infection. This correlated with suppressed viral replication associated with 
methylation of HBV DNA and increased methylation of host CpG islands 
303
.   
The seminal work of Vivekanandan et al
303
 allows for the development of a model 
that explains the development of liver injury and HCC in chronic HBV infection (see 
Figure 1.10). In this model, infected host cells respond to HBV infection by 
upregulating the expression of DNMTs. Upregulation of DNMTs can also result 
from interaction with HBx transcriptional activator protein 
303
. Once activated, 
DNMTs methylate HBV DNA and switch off the expression of viral mRNA and 
proteins, thereby reducing viral replication 
303
. The methylation of integrated HBV 
DNA may be detrimental to the host genome through the inappropriate methylation 
of the neighbouring host genome, particularly if the promoter CpG islands regions of 
the gene are affected. A consequence of this effect would be the transcriptional 
repression of host immunoregulatory and tumour suppressor genes that prevent the 
development of cancer 
303
. 
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Figure 1.10: Model of Chronic HBV Infection and DNA Methylation.  
HBV integrates into the host genome and promotes viral persistence. Infected cells increase the 
expression of DNMTs in response to viral replication. This causes methylation of HBV cccDNA and 
reduces viral replication. The same methylation system methylates the adjacent host tumour 
suppressor and immunoregulatory genes leading to hepatocarcinogenesis. 
Abbreviations: cccDNA - Covalently closed circular deoxyribonucleic acid, CTL - CD8
+
 cytotoxic T 
lymphocytes, HBV - Hepatitis B virus, HBx - Hepatitis B x protein. 
 
4.1 Adaptive Immune Responses and Liver Damage 
During acute HBV infection, some individuals successfully clear the virus without 
any evidence of liver disease 
304 - 306
 (see Figure 1.11). However, HBV can be 
detected in blood several years after clinical recovery from an acute infection 
307
. The 
continuous presence of HBV DNA stimulates an active immune response that over 
time can cause liver damage 
216, 308 - 310
. The chronic inflammatory and regenerative 
processes are susceptible to develop mutagenic changes 
311, 312
. In turn, mutagenesis 
damages the DNA thereby increasing the chances of malignant transformation 
313, 314
.  
The CD4
+
 cells are important component in the adaptive immune response in acute 
HBV infection 
311, 315 - 317
. When activated, they produce CD8
+
 cytotoxic T-
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lymphocytes (CTL) that helps in controlling and eliminating virus by killing infected 
cells 
318, 319
. HBV specific CTL responses are stronger in acute compared to chronic 
HBV infection 
320
. They can persist for decades following viral clearance and 
recovery from acute HBV infection (see Figure 1.11).  
 
 
Figure 1.11: Adaptive Immune Response and Liver Damage in Chronic HBV 
Infection. 
In acute HBV infection, individuals with strong immune responses clear the virus. Patients with weak 
immune responses fail to clear the virus and develop chronic HBV infection. 
Abbreviations: HBV - Hepatitis B virus, HCC - Hepatocellular carcinoma, IFNγ - Interferon 
gamma, TNFα - Tumour necrosis factor alpha.  
 
During interaction with infected hepatocytes, CTL activate the caspase-3 dependent 
pathway and express serine protease granzymes A and B 
321, 322
. Granzymes A and B 
induce apoptosis and inflammation via interleukin-1β 323 - 325. They are controlled by 
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perforin molecules and increase reactive oxygen species (ROS) by cleaving 
mitochondrial complex I protein and nicotinamide adenine dinucleotides hydrate 
dehydrogenase (NADH) Fe-S protein 3 
326 - 328
. This causes single- or double-
stranded nicks in the DNA thereby killing HBV-infected cells 
329, 330
.  
Serine protease inhibitor Kazal (SPIK) is an inflammatory protein that is abundantly 
expressed in response to high HBV and hepatitis C virus (HCV) replication 
331, 332
. In 
chronic HBV infection, activation of SPIK causes uncontrolled HBV replication by 
inhibiting granule enzyme A mediated apoptosis. High level of SPIK expression 
suppresses serine protease granzymes-dependent cell apoptosis, resulting in the 
induction of epigenetic alterations that can cause HBV-induced HCC 
325, 333, 334
.  
In chronic HBV infection, the HBV DNA enhances immune responses cause 
apoptosis and cell proliferation and may lead to hepatocarcinogenesis 
335, 336
. The 
CTL responses are robust, polyclonal, multispecific and target HBV-encoded 
antigens. Studies show that during chronic HBV infection with active viral 
replication and weak or pharmacologically suppressed CTL, there is minimal liver 
damage or injury 
337, 338
. HBV is therefore noncytopathic and damage to the liver is 
due to activation of CTL responses that keep viral replication under control 
319
.  
Cytokines such as tumour necrosis factor alpha (TNFα) and interferon gamma 
(IFNγ) inhibit HBV replication and activate macrophages that cause liver damage 
and contribute to hepatic inflammation 
314, 335
. In a HBV transgenic mouse model, 
TNFα and IFNγ eliminate the circulating virus in a proteasome- and kinase- 
dependent manner 
313, 316
. Persistent production of TNFα and IFNγ in response to 
viral replication may cause genetic mutations that lead to HCC in in vivo models of 
HBV 
310, 314, 335, 339
.  
Individuals who fail to eradicate the virus due to deficient or weak immune responses 
develop chronic HBV infection that is often associated with active viral replication 
and minimal liver injury 
306, 340
 (see Figure 1.11). Weak or deficient immune 
responses are thought to be due to poor CTL production, deletion or exhaustion
 306, 
341, 342
. Such patients are more likely to remain asymptomatic with little progression 
of their liver disease. However, about 10 – 30 % may develop liver cirrhosis with the 
risk of liver cancer 
306, 343
.  
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4.2 Integration of HBV DNA into the Human Genome 
Deficient CTL immune responses lead to chronic HBV infection which enables viral 
integration into the host genome and epigenetic alteration of host tumour suppressor 
genes. These events may lead to the development of HBV-induced HCC 
303
.  
HBV integration was first discovered in 1980 using Southern blot hybridization. It 
was associated with genomic instability such as loss of heterozygocity (LOH), 
resulting in the rearrangements, deletions, duplications and inversions of the host and 
viral genomic sequences 
210
. Viral integration results in the insertion of HBV DNA 
sequences such as HBx gene in the host genome and enables viral persistence 
344
.  
Integration of HBV in the host genome also occurs in woodchucks and other animal 
models 
344 - 346
. In woodchucks and California ground squirrels (Spermophilus 
beecheyi), HBV genome integrates close to ras and myc family oncogenes including 
c-myc, N-myc1 and N-myc2 
347 - 349
. Modulation of myc and ras family oncogenes 
through cis-activation enhances cell proliferation and transformation. These events 
occur via transactivation action of HBx protein and favour the development of cancer 
350
.  
The occurrence of integrated HBV DNA at preferential sites in the human 
chromosomes has been identified using Alu-PCR based-technique. The preferential 
sites are known as chromosomal fragile sites (CFS) and are non-random 
344
. HBV 
DNA integrates into the human genome soon after the repair and conversion of HBV 
DNA to cccDNA 
199, 298, 300, 351
. The HBV genome integrates within the coding 
sequence or close to an array of key regulatory cellular genes that can deregulate 
proto-oncogenes and tumour suppressor genes. Activation or inactivation of such 
genes promotes genomic chromosomal instability by altering various cellular 
signalling pathways, triggering genetic mutations and epigenetic alteration 
344, 352, 353
. 
Mutagenesis and epigenetic alteration result in the abnormal regulation of the 
targeted genes. This promotes malignant transformation by altering the control of 
cell growth, differentiation, proliferation and apoptosis 
344, 351, 354, 355
. The integration 
of HBV at or within cyclin A and RARβ genes is associated with increased protein 
activities and hepatocellular growth in HBV-induced HCC, suggesting that HBV 
integration contributes to hepatocytes transformation 
350
. Examples of known active 
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CFS targeted by HBV integration are outlined in Table 1.4. The  60s Ribosomal 
protein, hTERT, major histocompatibility complex I like leukocyte (Mill), platelet 
derived growth factor receptor (PDGFR) and calcium signalling related genes are 
also common sites or targets of HBV integration. These genes are important in 
cellular signalling pathways that control DNA damage, oxidation stress and cell 
growth, and their alteration is associated with development and progression of cancer 
350, 356, 357
. 
 
Table 1.4: Examples of Chromosomal Fragile Sites Associated with HBV Insertions 
and Their Roles in Tumour Development 
344, 350, 356, 357
 
 
 
4.3 Hepatitis B Virus X Gene or Protein and Its Carcinogenic Effects 
HBx protein is a transcriptional transactivator that HBV uses to integrate into the 
host cellular DNA and is associated with malignant transformation in hepatocytes 
288, 
289, 357 - 359
. It interacts with nuclear transcription factors such as NF-κB, AP1, CREB, 
TATA-binding protein (TBP), peroxisome proliferator-activated receptor γ (PPARγ) 
and transcription factor II H (TFIIH) 
360, 406
. Interaction of HBx protein with these 
transcription factors disrupts multiple cellular signalling pathways that include janus 
kinase 1 (JAK1)-signal transducer activator of transcription (STAT), mitogen-
 Chromosomal Fragile Sites 
 
FRA1A (1p36)     
FRA2C (1q) 
FRA4E (4p) 
FRA3D (3q25.3) 
FRA5C (5p31.1) 
FRA7 (7p) 
FRA9 (9q) 
FRA10A (10q)         
FRA11A (11q13) 
FRA12A (12q24)                     
FRA13A (13q32) 
FRA18 (18q) 
FRA19A (19q13) 
FRA20 (20P12.3) 
 
 
 
 
 
 
 
 
Target Gene  
                          
TCEA; RAR; CHML  
EMX2-like gene 
Cyclin A 
IRAK2 
PDGFRβ  
SERCA 1; NCF1 
KLF1; CASPR3               
PTEN; PI3K                    
EMS1, FGF4; BIRC3   
ErbB3; Mill2              
CTGF; CCNL; IMP-2 
DCC; DPC4 
Cyclin E 
hTERT 
Role in Tumor Development    
                                                           
Alters gene expression and Promote cell survival 
Modulates β-catenin signaling pathway and cell survival 
Stimulate cell-cycle and anti-apoptotic effect 
Promotes Apoptosis and tumor progression 
Regulates DNA synthesis and fibrotic genes                       
β-catenin activation 
Promote cell growth; Regulates DNA methylation 
Promotes metastasis                                                                                
Promotes cell cycle progression     
Modulates β-catenin signaling pathway; Alters cell fate 
Promotes tumor progression 
Tumor suppression 
Regulates methyl-CpG- binding proteins 
Delay DNA synthesis; Promotes immortalization  
Abbreviations: BIRC3 - Baculoviral IAP repeat containing 3, CASPR3 - Contactin-associated protein-like 3, CCNL - Cyclin 
L1, CHML - Choroideremia-like gene, CTGF - Connective tissue growth factor, DCC - Deleted in colorectal cancer, DPC4 - 
Deleted in pancreatic cancer 4, EMSL - EMSL, EMX2 - Empty spiracle homeobox 2, ErbB3 - V-erb-b2 erythroblastic 
leukemia viral oncogene homolog 3, FGF4 - Fibroblast growth factor 4, FRA -  Fragile site, hTERT - Human telomerase 
reverse transcriptase, IMP-2 - Insulin-like growth factor II mRNA binding protein 2, IRAK2 -  Interleukin-1 receptor associated 
kinase 2, KLF1 - Krueppel-like factor 1, Mill2 - Major histocompatibility complex I like leukocyte 2, NCF1 - Neutrophil 
cytosolic factor 1, PDGFRβ - Platelet derived growth factor receptor beta, PI3K - Phosphatidylinositol 3 kinase, PTEN - 
Phosphatise and tension homolog, RAR - Retinoic acid receptor, SERCA - Sarco/endoplasmic reticulum calcium transport 
ATPase, TCEA - Transcription elongation factor A. 
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activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and p53 
signalling pathways 
361 - 364
. Cellular signalling pathways are important in regulating 
DNA repair, cell growth, differentiation, adhesion, proliferation and apoptosis 
359, 362, 
365 -367
. Although the precise mechanisms of action are still being elucidated, HBx 
protein has also been shown to induce methylation of important tumour suppressor 
genes critical in HBV-induced hepatocarcinogenesis by modulating DNMTs 
289, 368, 
369
. 
 
4.3.1 HBx Protein as a Transcriptional Activator 
The transcriptional transactivation role of HBx protein on the transforming growth 
factor beta 1 (TGF-β1) protein may be important in explaining liver inflammation 
and fibrosis 
329, 370
. TGF-β1, encoded by TGF-β1 gene, is a cytokine that is produced 
in response to liver injury by activated hepatocytes, platelets and Kupffer cells 
371
. It 
triggers apoptosis, cell growth and differentiation in human hepatocytes, hepatoma 
cell lines and transgenic mice 
152, 370, 372 - 374
. It promotes the development of fibrosis 
and cirrhosis in chronic HBV infection and other liver-related diseases 
372, 375
.  
HBx protein induces the expression of TGF-β1 through the transactivation of TGF-
β1 gene, the down-regulation of α2-macroglobulin and the induction of TGF-β1 
mediator Smad4 
376, 377
. High levels of TGF-β1 protein are observed in the sera of 
chronic HBV-induced HCC patients and correlate with the mutation and loss of 
mannose-6-phosphate/IGF-II receptor that mediates TGF-β1 signalling 373, 378 - 379. In 
addition, HBx protein alters the signalling pathway of TGF-β1 from being tumour 
suppressive to oncogenic in early chronic HBV infection. This occurs via the 
activation of c-Jun N-terminal kinase (JNK) which shifts epithelial tumour 
suppressive pSmad3C signal to mesenchymal oncogenic pSmadL signal pathway 
380
.  
Studies show that in HBx transgenic mice and hepatoma cell lines, HBx protein can 
transactivate the NF-κB, MAPK/ERK, STAT3 and PI3K/ Akt cellular signalling 
pathways by inducing the production of ROS 
329, 353, 381 - 383
. Accumulation of ROS in 
human cancers is associated with anti-apoptotic activity, DNA damage and mutations 
which promote malignant transformation 
328, 329, 382
. HBx-induced ROS and 8-
oxoguanine alter the expression of PTEN protein by oxidising cysteine residues 
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within the promoter region encoding PTEN gene, which activate Akt pathway and 
contributes to hepatocarcinogenesis 
329, 365, 383
.  
 
4.3.2 HBx Protein, Proliferation and Apoptosis 
Apoptosis is an important process in normal development and viruses like HBV that 
are associated with tumorigenesis 
78
. Damage to cellular DNA induced by a variety 
of stimuli such as HBV infection and toxins often triggers localised apoptotic-related 
signals resulting in tissue necrosis. This process enables the elimination of damaged, 
unwanted and redundant hepatocytes that may otherwise lead to uncontrolled cell 
growth, proliferation and liver disease 
79, 80
. Abnormal regulation of cell proliferation 
and apoptosis has been identified as the repercussion of inappropriate inactivation or 
activation of gene transcription in many diseases. These same processes are the 
central mechanisms which link chronic HBV infection to HCC development 
8, 9
.  
HBx protein is mainly found in the cytoplasm, mitochondria and nucleus in which it 
has emerged as the central factor that stirs up the entire cellular signalling machinery 
to establish and maintain viral replication following infection both in vivo and in 
vitro 
10 - 15
. It exerts its transcriptional transactivation activities by altering various 
functions of cellular genes and related signalling pathways 
15
. Some of these 
pathways include p53, cyclooxygenase-2 (COX-2), myloid leukemia cell 
differentiation 1 (Mcl-1), phosphatydylinositol 3 kinase (PI3k) and NF-кB apoptotic-
related pathways which when disrupted inhibits or induce abnormal apoptosis.  
The tumour suppressor gene p53 interacts with DNA and activates the transcription 
of reporter genes located on the downstream binding site of p53. It induces cell-cycle 
arrest in the G1 phase and apoptosis in response to DNA damage. Normal regulation 
of apoptosis by p53 occurs through its interaction with cytoplasmic transcription 
factors. These transcription factors include ankyrin-repeat containing and proline-
rich region-containing proteins (ASPP), fatty acid synthase, p21
CIPWARF1
, xanthoma 
pigmentosa B (XPB) and repair cross-complementing rodent-repair deficiency group 
2 (ERCC2). They are involved in the p53-mediated nucleotide excision repair and 
enhance the binding of p53 gene to proapoptotic stimuli 
15, 16, 385, 399, 402, 406
.   
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HBx protein inhibits apoptosis by forming a complex with p53 protein and blocking 
its transcriptional transactivating properties and protein to protein interaction with 
transcription factors 
358, 386
.  For instance, HBx protein suppresses the p53-mediated 
DNA sequence-specific transcriptional activity by binding to its TFIIH promoter. 
This abolishes the role of p53 in nucleotide excision repair, cell cycle and apoptosis, 
resulting in an increased susceptibility of infected cells to p53 carcinogen-induced 
mutations 
404, 405
. Inhibition of p53 protein-mediated apoptosis also occurs through 
the activation of COX-2-prostaglandin E2 and McI-1 anti-apoptotic pathways.  
HBx protein can also prevent apoptosis via the inhibition of caspase cascade 3 and 
the transactivation of NF-кB and PI3K signal transduction pathways but the 
mechanisms underlying these processes are still unknown 
387 -389
.  
Induction of apoptosis was observed after interaction of HBV x-associated protein 
(XAP3) with protein kinase C (PKC) that switches on the transcription factor NF-кB 
through activation by HBx protein 
75, 76
. HBx protein also induces apoptosis by 
reducing the cellular FLICE like inhibitory protein activity and increasing the 
activities of JNK, caspases 3 and 9 pro-apoptotic pathways which mediate apoptosis 
409, 410
. Being localised in the cytoplasm also gives the HBx protein the ability to 
sensitize HBV infected cells towards these pathways and induce apoptosis 
409
.  
 
4.3.3 HBx Protein and DNA Methylation 
HBx protein has been labelled an epigenetic deregulating agent.  It uses its oncogenic 
ability to induce promoter hypermethylation of some cellular tumour suppressor 
genes that contribute to the development of liver cancer 
384
. By modulating the 
transcriptional activation of DNMTs, HBx protein induces the hypermethylation of 
tumour suppressor gene promoters and silences their expression 
391,398,400, 401
.  
HBx protein induces the hypermethylation of RARβ2 gene by upregulating DNMT1 
and 3A activities and down-regulating the expression of RARβ2 protein 384, 390. 
RARβ2 binds to and inactivates the E2F1 transcription factor, which is essential for 
cell cycle progression 
358, 391. Downregulation of RARβ2 protein expression is 
associated with activation of E2F1 transcription factor, which abolishes the ability of 
retinoic acid to regulate expression of G1 checkpoint regulators, leading to 
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upregulation of p16, p21 and p27 proteins. The activation of E2F1 transcription 
factor is associated with uncontrolled cell proliferation which contributes to 
carcinogenesis 
390
.  
Insulin-like growth factor binding 3 (IGJBP-3) is another potential tumour 
suppressor gene which is both hyper- and hypomethylated in HBV induced HCC 
289
. 
Hypermethylation of IGJBP-3 gene is mediated by DNMT 1 and 3A which are 
upregulated via the transcriptional activities of HBx protein, and this is associated 
with loss of IGJBP-3 gene expression. In contrast, HBx protein reduces the 
transcriptional activities of DNMT 3B, leading to hypomethylation and upregulation 
of the IGJBP-3 gene 
289
.   
DLEC1 is a functional tumour suppressor gene silenced by promoter methylation in 
lung, gastric, colon and nasopharyngeal cancers 
116, 117, 255, 411, 412
. Similar methylation 
has also been observed in HCC where it is associated with induction of G1 cell cycle 
arrest and loss of gene expression 
259
. Silencing of DLEC 1 gene expression is 
mediated by both DNA hypermethylation and histone acetylation 
411, 412
. HBx protein 
encoded by HBV genotype A enhances the transcription of DLEC 1 gene by 
increasing the level of histone acetylation through activation of HATs, leading to 
suppression of tumour progression 
255
. Through the activation of DNMT1 expression 
mediated by the pRB-E2F pathway, HBx protein induces DNA hypermethylation of 
DLEC1 gene and suppresses its transcriptional activities 
255
.  
Caveolin- 1, encoded by caveolin-1 gene, is an integral membrane protein 
abundantly expressed in adipose, fibrous and endothelial tissue 
396
. High level 
expression of Caveolin-1 protein disrupts growth factor signalling pathways, which 
in turn alters cell growth, proliferation and differentiation 
396, 413
.  HCC cells 
expressing high levels of Caveolin-1 are associated with uncontrolled cell growth, 
motility, in vivo tumour aggressiveness and metastasis 
413
. Conversely, HBx-induced 
methylation of Caveolin-1 gene promoter region suppresses its transcriptional 
activities and this correlates with reduced tumour aggressiveness and metastasis, 
indicating a role of DNA methylation in HBV related HCC 
396
.  
Hypermethylation of p16
ink4a
 gene is a frequent event in several malignancies 
including HBV induced HCC 
110, 116, 130, 391, 392, 395, 398
. HBx protein silences the 
expression of p16
ink4a
 gene through the activation of DNA methyltransferase 1 and 
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the cyclin D1-CDK 4/6-pRb-E2F1 pathway 
396
. Methylation of p16
ink4a
 gene is 
associated with increased viral replication, integration and loss of protein expression 
398
. 
HBx protein induced DNA hypermethylation has also been connected with loss of 
expression and normal function of LINE-1, pRB, ASPP, E-cadherin, GSTP1 and 
hTERT tumour suppressor genes 
111, 113 - 116, 256, 302, 394, 397 - 399, 400 - 402
. This methylation 
is associated with increased upregulation of DNMTs with DNMT1being the most 
active one. Aberrant methylation of these genes is associated with perturbed cellular 
signalling pathways such as ubiquitination, DNA repair, transcription, proliferation 
and apoptosis, which may lead to the development of HBV related HCC 
255, 259,289, 393. 
 
HCV is an RNA virus and unlike HBV, is unable to integrate into the human 
genome. However, it is able to cause epigenetic changes that favour its own 
replication and are associated with the development of liver cancer. Apolipoprotein 
E, which is required for the replication and infectivity of HCV is known to be 
hypermethylated in chronic HCV infection. This is associated with increased viral 
replication and an increased risk of developing malignancy
446 - 448
. 
 
5. SUMMARY 
Studies show that there is an association between the methylation of CpG islands and 
transcriptional changes in gene promoter regions. Transcriptional alterations within 
gene promoter regions interfere with the normal function of a wide spectrum of 
cellular genes including tumour suppressor genes which are potential inducers of 
malignancies 
41, 42, 48, 112
.  
Oncogenic viruses integrate themselves into the human genome and alter gene 
transcription through DNA methylation 
137 - 139
. During HBV infection, the 
expression levels of DNMTs are elevated in response to viral replication as viral 
genes are methylated to suppress viral replication. This may result in inappropriate 
random methylation of neighbouring host cellular genes, including tumour 
suppressor genes. This would cause malignant transformation and ultimately liver 
cancer 
303
. In addition, other genes affected by methylation may contribute to the 
development of liver inflammation, fibrosis and cirrhosis. 
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As a multifunctional viral transactivator, the HBx protein may be the driving force 
behind the activation of DNMTs, causing gene promoter hypermethylation and gene 
silencing. The epigenetic alteration of genes may affect cellular signalling pathways 
and favour uncontrolled hepatocyte proliferation and HBV-induced inflammation, 
fibrosis and cancer 
288, 289, 362-370, 376, 377, 380, 384, 390 - 402
.  
Data on HBV induced DNA methylation has been obtained largely through the 
analysis of single genes using methods with variable levels of sensitivity to detect 
methylation such as bisulfite DNA sequencing and methylation specific PCR (MSP). 
These assays target only known methylated CpG promoter regions and therefore 
leave other potential CpG sites unidentified 
403
.  There is therefore value in 
investigating genome-wide methylation of promoter region CpG islands in patients 
with chronic HBV infection. Such studies may provide information that will 
contribute to the further understanding of HBV induced liver injury and cancer.   
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CHAPTER 2 
STUDY HYPOTHESIS, CLINICAL SETTING AND AIMS 
 
2.1 HYPOTHESIS OF THE STUDY 
The literature review discussed in Chapter 1 demonstrated that methylation of HBV 
DNA integrated into the host genome is associated with transcriptional alteration and 
silencing of host genes. These changes result in several biological effects including 
the development of cancer 
1 - 5
. 
Given these observations, we hypothesised that HBV DNA methylation may result in 
the unintended and inappropriate methylation of adjacent host CpG islands. 
Methylation of CpG islands within gene promoter regions could alter the 
transcriptional activation of genes resulting in biological changes that are responsible 
for the clinical manifestation of liver disease and cancer development seen in chronic 
HBV infection.  
Genome-wide analysis of host CpG island methylation in patients with chronic HBV 
infection may identify hypermethylated genes whose abnormal function may help in 
understanding how chronic HBV infection causes chronic liver inflammation, 
fibrosis and cancer.  
 
2.2 CLINICAL SETTING OF THE STUDY 
This study was conducted at the Liver clinic and research laboratory, Department of 
Medicine, Groote Schuur Hospital, University of Cape Town (UCT) between 
February 2010 and August 2013. Groote Schuur Hospital is a tertiary academic 
institution of UCT. It is a 940 bedded hospital and the clinical service of the Division 
of Hepatology attends to over 3000 outpatient visits annually with 200 -300 hospital 
admissions. About 40 – 55 % of these admissions are for procedures such as liver 
biopsy.   
Following informed and signed consent (see Appendix 28), liver tissue samples 
were collected from patients undergoing liver biopsies as part of their routine clinical 
management at the hospital. The primary cohort was of patients with chronic HBV 
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genotypes A and D infection and control cases with autoimmune hepatitis, non-
alcoholic fatty liver disease, drug induced liver injury and hepatitis C virus (HCV). 
The HBV infection was confirmed by serological detection of HBV antigens as well 
as the detection of HBV DNA in all cases (National Health Laboratory Sciences, 
Groote Schuur Hospital, UCT, South Africa).  
Each sample was split into two parts. One half was put into RNAlater
®
  RNA 
stabilization reagent (Sigma, SA) for use in DNA, RNA and protein isolation and the 
other half was put into gluteraldehyde for future electron microscopy work. All the 
samples were immediately stored at -80°C until isolation. In addition, HCC tissue 
samples were obtained from formalin-fixed paraffin-embedded (FFPE) liver 
biopsies from the archives of the National Health Laboratory Sciences, Groote 
Schuur Hospital, UCT, South Africa. Permission for collection of liver tissue 
samples for research purposes was obtained from the Health Sciences Research 
Ethics Committee of the UCT, South Africa (Ethics Approval Number: 247/2010, 
see  Appendix 27). 
DNA, RNA and protein extraction was done at the Liver Research Laboratories, 
Groote Schuur Hospital, UCT (see Appendix 1). Samples for the thesis microarray 
work were analysed at the Kusuma School of Biological Science, Indian Institute of 
Technology, New Delhi (IITD), India. Only FFPE liver tissue derived DNA was 
used for microarray work. This work was done as part of a postgraduate research 
exchange visit funded by the UCT Baron Hartley Scholarship, National Research 
Foundation and The Academy of Sciences for the Developing World fellowship 
programme for postgraduate research and advanced training. The bisulfite DNA 
sequencing work was done in the Liver Research Laboratory, Department of 
Medicine, Groote Schuur Hospital, UCT. The bisulfite DNA sequencing was done 
using DNA extracted from peripheral blood. 
 
2.3 AIMS OF THE STUDY 
The main aim of the study was to investigate for the presence of genome-wide 
promoter region CpG island methylation profiles in patients with chronic HBV 
infection and validate these with clinical disease and outcomes. 
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The specific objectives of the study were to: 
1) Investigate for the presence of promoter region CpG island methylation 
profiles in patients with chronic HBV infection.  
2) Correlate the methylated genes identified with known clinical features of liver 
disease due to chronic HBV infection.  
3) Validate the obtained microarray data analysis using bisulfite DNA 
sequencing on an extended cohort of patients with chronic HBV infection and 
normal controls.  
 
2.4 STUDIES REPORTED IN THIS THESIS 
The overall research plan was divided into two sections that involved investigating 
for the presence of promoter region CpG islands methylation in patients with chronic 
HBV infection and validating the findings using bisulfite DNA sequencing (see 
Figure 2.1). 
 
  
 
 
 
 
 
 
 
Figure 2.1: The Overall Research Plan Employed in the Study. 
The overall research plan was divided into two sections that involved investigating for the presence of 
promoter methylation across the genome of patients with chronic HBV infection and validation of 
these findings with bisulfite DNA sequencing work. 
Abbreviations: AIH - Autoimmune hepatitis, DILI - Drug induced liver injury, DNA - 
Deoxyribonucleic acid, HBV - Hepatitis B virus, HCC - Hepatocellular carcinoma, HCV - Hepatitis 
C virus, MALDI - Matrix assisted laser desorption/ionization, N - Number.  
 Sample Source Formalin Fixed Paraffin Embedded 
February to December 2010 
Fresh Liver Biopsy 
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Genome DNA from 
Blood 
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Bisulfite DNA Sequencing, Microarray, Proteomics and MALDI 
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Chapter 3 describes the genome-wide promoter methylation array work on FFPE 
tissues from a cohort of patients with chronic HBV infection. FFPE tissues from 
patients with AIH, HCC and tissues adjacent to resected HCC were used as disease 
controls. FFPE tissues from patients with no evidence of liver disease were used as 
normal controls. For microarray analysis, 32 tissue samples were used for the thesis 
work.  
Chapter 4 describes the validation of the promoter microarray data using bisulfite 
DNA sequencing in the DNA extracted from the blood samples. A validation cohort 
of HBV patients and normal controls was used for this work in which eleven 
different genes were investigated. Separately, a highly methylated gene, Cyclin D3 
was used for further validation work in a cohort of chronic HBV infected patients 
and normal controls. 
Chapter 5 discusses and integrates the study findings with the published literature. A 
hypothesis that integrates the study findings and how they could explain many of the 
known features of hepatic inflammation, fibrosis, abnormal cell proliferation and 
cancer seen in chronic liver injury due to HBV infection is presented. 
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CHAPTER 3 
INVESTIGATION OF GENOME-WIDE PROMOTER REGION 
CPG ISLAND METHYLATION PROFILES IN PATIENTS WITH 
CHRONIC HBV INFECTION 
 
3. INTRODUCTION 
DNA-methylation analysis assays such as Southern blot, bisulfite DNA sequencing, 
combined bisulfite restriction analysis (COBRA), methylation specific PCR (MSP), 
methylation-sensitive single nucleotide primer extension (MS-SNuPE) and 
electrochemistry have been useful in investigating the presence of epigenetic 
alterations in human disease.  However, they are low-throughput, labour intensive 
and expensive. The major weakness of these technologies is that they are gene-
specific and analyse genes individually at a single-base resolution of the methylome 
rather than at multiple CpG dinucleotides 
1 - 6
. This makes it difficult for researchers 
to have a full understanding of global epigenetic alterations, which have an important 
role in influencing human disease progression and cancer development. 
Advanced high-throughput microarray-based platforms that are capable of detecting 
and mapping DNA methylation profiles across the entire genome are continually 
being developed and improved. Microarray-based platforms are more sensitive and 
have a high resolution which makes them able to interrogate methylation profiles of 
multiple genes at a genome-wide scale. They also provide large DNA sequences 
reads, which makes the data easier to annotate and interpret biologically using 
various software programmes 
7
.  Examples of microarray platforms that are available 
include the Roche Nimblegen
®
, Affymetrix
®
, Agilent
®
 and Illumina arrays
®
 
7, 8
. 
These arrays involve coupling of bisulfite conversion, digestion with methylation-
sensitive restriction enzymes and immunoprecipitation of methylcytosine or methyl 
binding domain proteins procedures with hybridization prior to microarray analysis. 
The most commonly used standard procedure is differential methylation 
hybridization 
9
.  
Differential methylation hybridization involves the use of a frequent cutter MseI and 
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a combination of methylation sensitive enzymes such as BstUI, HhaI and HpaI. The 
digested products are PCR-amplified to generate DNA targets that can be used to 
investigate methylation profiles on a microarray platform 
9 - 11
.  
The ability of high throughput technologies to analyse methylation profiles at a 
genome-wide scale was illustrated recently in various methylation analysis studies 
which discovered the presence of differentially methylated targets in the human 
genome 
13 - 17, 210
. Recently, Zhao et al
12
 used the Agilent Custom Human Microarray 
platform to analyse genome-wide CpG islands promoter methylation profiles in 
gastric cancer cells. They found novel methylated CpG sites in the gene promoter 
regions which have not been previously described. Studies using the Illumina 
Infinium Human Methylation27 BeadChip
®
, Roche NimbleGen HD2
®
 and Agillent
®
 
arrays also found several new patterns of DNA methylation in different diseases and 
cancers 
13 - 17
. These studies illustrate that the microarray platforms can be used as a 
high-throughput tool to enable more accurate detection of differentially methylated 
regions across the entire human genome.  
GeneChip® Human Promoter 1.0R array is another example of high-throughput 
technologies and this platform was employed in the work reported in this thesis. It is 
a high resolution and sensitive tilling array with probes reproducing all known non-
repetetive DNA sequences 
18, 19
. It interrogates promoter region CpG island 
methylation profiles, histone proteins interaction and transcription factor binding 
sites across the entire human genome 
218
. It has more than 4.6 million probes per 
array tilled through over 25,500 human promoter regions. Each promoter region is 
located within approximately 7.5kb upstream and 2.45kb downstream from the 
transcription start site (TSS)
 218
. The promoter region covered by probes was 
expanded to include an additional 10kb upstream and 2.5kb downstream of the TSS 
to include an additional 1300 cancer-associated genes. The probes are 25bp long 
tilled at a resolution of 35bp intervals with10bp gaps between the oligonucleotides. 
The promoter regions were annotated by the University of California, Santa Cruz in 
the National Center for Biotechnology Information (NCBI) human genome assembly 
(Build 34) using sequence information from Ensembl genes (version21_34d May 14, 
2004), RefSeq mRNAs (NCBI GenBank® February 7, 2004) and complete-coding 
sequence mRNA (NCBI GenBank® December 15, 2003). The arrays contain control 
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probe sets for both hybridization (e.g bioA, bioB, bioC, cre and dap) and tilling 
mRNA transcripts (dap, lys, phe, thr, LTP4, LTP6, CAB, RBCL, RCA, RCP1, 
XCP2, NAC1, PRKASE and TIM) 
218
. 
DNA methylation studies have largely relied on high-quality DNA extracted from 
unprocessed tissue samples. The difficulty in obtaining unprocessed tissue samples 
limits the ability to do large studies, particularly of population based-epidemiology. 
Until recently, the use of formalin fixed paraffin embedded (FFPE) tissues in 
downstream analyses of methylation and gene expression profiles was not 
recommended due to heavy degradation and modification of nucleic acids that are 
cross-linked in amino acid molecules 
20, 21
. When using current commercial kits with 
appropriate protease digestion steps, it is possible to release huge and usable amounts 
of nucleic acids from FFPE tissues despite degradation 
22
. Complete 
deparaffinisation followed by a series of ethanol washes and proteinase K digestion 
to reverse formalin fixation and facilitate the release of DNA from the cross-linked 
protein are some of the techniques used to improve the quality of DNA and RNA 
recovered from FFPE tissue samples 
23
. 
Human Promoter 1.0R microarray platform allows analysis of DNA extracted from 
FFPE material, providing many opportunities for large retrospective studies in tissue 
samples 
24, 26
.  In this study, some FFPE tissues were successfully used for 
microarray work. This was attributed to the use of restriction enzymes and PCR 
amplification which enabled the generation of high quality dsDNA targets for 
hybridization and microarray. 
 
3.1 STUDY AIMS 
The aim of this study was to investigate for the presence of genome-wide promoter 
region CpG islands methylation in patients with chronic HBV infection. 
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3.2 MATERIALS  
3.2.1 Fresh Liver Biopsy Samples 
Sixty-two fresh liver biopsies were collected from patients undergoing liver biopsies 
as part of their routine clinical management at Groote Schuur Hospital, University of 
Cape Town (UCT), South Africa. Following informed and signed consent (see 
Appendix 28), a 1 - 2 mm piece of fresh liver biopsy was cut from obtained liver 
biopsy specimen and split into two parts. One half was put into RNAlater RNA 
stabilization reagent for use in DNA, RNA and protein isolation and the other half 
was put into gluteraldehyde for future electron microscopy work. All the samples 
were immediately stored at -80°C until isolation. 
 
3.2.2 Formalin-Fixed Paraffin Embedded Liver Biopsy Samples 
FFPE liver biopsy samples were used to obtain HCC tissues taken at surgical 
resection as this was extremely difficult to access from fresh liver biopsies. Two of 
these samples had biopsies of adjacent liver tissue with no HCC, which were used as 
controls in the microarray experiment. FFPE liver biopsy samples were also used to 
obtain liver tissue samples of two cases that were known to have no evidence of liver 
disease.  
One hundred and twelve FFPE tissue samples were retrieved from the archives of the 
National Health Laboratory Service, Groote Schuur Hospital, UCT, South Africa. 
These specimens were from patients undergoing routine liver biopsies as part of their 
clinical mamangement at Groote Schuur Hospital, Cape Town during the period of 
2008 - 2010. The study was approved by Health Sciences Research Ethics 
Committee of UCT, South Africa (Ethics Approval Number: 247/2010, see 
Appendix 27). Based on the samples size calculation, study costs and efficiency, 
DNA from 32 FFPE samples was used for the microarray work (see also Chapter 2, 
Figure 2.1). 
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3.3 METHODS FOR SAMPLE PREPARATION AND 
MICROARRAY ANALYSIS 
3.3.1 Nucleic Acids Extraction from Fresh Liver Biopsy Samples 
Total genomic DNA, RNA and protein were simultaneously extracted from fresh 
liver biopsies using TRI-reagent (Sigma Aldrich) according to the manufacturer’s 
protocol (see Appendix 1). Briefly, 1mm of liver biopsy tissues was homogenised in 
TRI-reagent solution. After addition of 1-Bromo-3-chloropropane to the 
homogenised mixture and centrifugation, the mixture was separated into three phases 
containing DNA, RNA and protein respectively. The phases were transferred 
individually into fresh tubes and used to extract DNA, RNA and protein as outlined 
in Appendix 1. The quality of recovered products was quantified using a Nanodrop 
ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, USA). 
  
3.3.2 Nucleic Acids Extraction from Formalin-Fixed Paraffin Embedded Liver 
Tissue Samples  
In this study, the AllPrep
®
 DNA/RNA FFPE extraction kit (Qiagen, Valencia, CA; 
Hilden, Germany) was used for simultaneous isolation of both DNA and RNA 
according to the manufacturer’s protocol (see Appendix 2). Briefly four 5 μm-thick 
sections of FFPE tissue per sample were used. The FFPE sections were 
deparaffinised in heptane-methanol solutions, rehydrated with ethanol and then 
centrifuged to obtain pellets for nucleic acids isolation. Xylene can also be used for 
deparaffinisation; but heptane has been shown to be more convenient and efficient 
than xylene as it provides a compact sample pellets with good nucleic acids 
extraction.  
Total genomic DNA and RNA was then isolated from the pellets obtained. Samples 
were lysed, followed by proteinase K digestion and centrifugation at 12000 x g for 
10 minutes at 4°C (Eppendorf 5417C Centrifuge, Germany) to obtain a DNA-
containing pellet and RNA-containing supernatant. RNA was extracted from the 
supernatant and kept in storage at -80°C for future use. The DNA-containing pellets 
were digested again with proteinase K and incubated at 90ºC. After centrifugation, 
the sample was bound onto a QIAamp MinElute
®
 spin column membrane, washed 
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and eluted. The eluted DNA sample was stored in aliquots at -80°C. The quality of 
the DNA samples was determined by agarose gel electrophoresis and quantified 
using a Nanodrop ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, USA) 
with absorbance of the DNA read at a wavelength of 260nm (A260) and 280nm 
(A280). 
 
3.3.3 Generation of Double Stranded DNA Targets 
Differential methylation hybridization of DNA was performed based on the 
technique developed by Huang and Perry for genome-wide DNA methylation 
analysis in the human genome 
27
. The preparation process of DNA targets is 
illustrated in Figure 3.1. The sources of reagents and the protocols employed are 
outlined in Appendices 3 - 9. 
Briefly, genomic DNA derived from FFPE tissues was restricted to completion with 
four-base TTAA cutter, MseI restriction enzyme from New England Biolabs, USA 
(see Appendices 3 and 4). The MseI enzyme restricts bulk DNA into smaller 
fragments (<200bp), but leaves larger GC-rich CpG islands fragments relatively 
intact. The digested DNA is run on 1.5% agarose gel to check the efficiency of 
digestion. A uniform smear indicates complete digestion. The cleaved ends of the 
digests were purified using the QIAquick PCR Purification Kit
®
 (Qiagen, USA, 
Appendix 3) according to the manufacturer’s instruction as outlined in Appendix 5.  
The purified cleaved ends of the DNA were ligated to the annealed universal linkers 
that are meant to enable the subsequent amplification of methylated fragments (Yan 
et al, 2002). The linkers were prepared by adding H-12 oligonucleotide 5′-TAA TCC 
CTC GGA- 3′ and H-24 oligonucleotide 5′-AGG CAA CTG TGC TAT CCG AGG 
GAT-3′ (see Appendix 6).  After ligation of the digested DNA to the linkers, PCR 
amplification was performed to check for successful linker ligation. The PCR 
product was checked on a 1.5% agarose gel and the smear was visualized using 
ethidium bromide (10mg/ml). A uniform smear of 100 - 2000 bp in size indicated 
successful MseI digestion and linker ligation. The PCR product was purified using 
the QIAquick PCR Purification Kit
®
 (Qiagen, USA) as described in Appendix 5.  
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Figure 3.1: Schematic Outline for Generating the DNA Targets. 
DNA sample is first digested with a four-base cutter, MseI (TTAA), an enzyme that restricts bulk DNA 
into small fragments (<200bp), but preserves larger GC-rich CpG island fragments. These GC-rich 
fragments are ligated to H12/H24 linkers and sequentially digested with two methylation-sensitive 
endonucleases, BstUI (CGCG) and HhaI (GCGC). Only unmethylated DNA fragments are digested 
by these enzymes, whereas methylated DNA fragments remain intact and are then amplified by PCR 
using H24-primer.  
Abbreviations: C - Cytosine, G - Guanine, T - Thymine, A - Adenine, DNA – Deoxyribonucleic 
acid, bp - Base pairs, PCR - Polymerase chain reaction, M - Methylation. 
 
The purified products were digested with the methylation sensitive endonuclease 
BstU1 (New England Biolabs, USA), after which they were digested with the 
methylation sensitive endonuclease HhaI from New England Biolabs, USA. Only 
genomic DNA fragments containing unmethylated BstUl (CGCG) or HhaI (GCGC) 
sites are cut whereas the fragments containing methylated BstUl (mCGCG) or HhaI 
(GmCGC) sites remained unaffected from the digestion such that they can be 
amplified subsequently by PCR 
217
. After digestion, the DNA was purified and PCR 
amplification was carried out. The dUTP was incorporated into the PCR mix for 
replacement of dTTP during amplification, to enable DNA fragmentation with 
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Uracil-DNA glycosylase (UDG). The protocols for ligation, PCR amplification and 
digestion are outlined in Appendices 7 - 9. 
 
3.3.4 Fragmentation and Labelling of Double Stranded DNA Targets 
After PCR amplification, 7.5 microgram (µg) of the amplified DNA was fragmented 
and labelled using the Affymetrix
®
 chromatin immunoprecipitation assay protocol 
242
. The purpose of fragmentation is to reduce the size of dsDNA fragments to less 
than 200bp fragments. This facilitates the subsequent step of hybridization onto the 
microarray chip. The amplified DNA targets were treated with UDG (Affymetrix, 
Santa Clara California) which breaks down the dsDNA into smaller fragments by 
removing dUTP residues. Human apurinic/apyrimidinic endonuclease I (APE1) from 
Affymetrix, Santa Clara, California was used to create a nick in the phosphodiester 
backbone of the apurinic/apyrimidinic site created by UDG treatment. This enables 
the labelling of the fragments with biotin. The protocol used for fragmentation and 
labelling is outlined in Figure 3.2 and detailed in Appendix 10 and 11. 
After fragmentation, each fragmented DNA sample was run on 4% agarose gel and 
bands between 100 - 200 bp were considered proper fragmentation. The fragmented 
samples were treated with terminal deoxynucleotidyl transferase, recombinant (rTdT) 
from Affymetrix, Santa Clara, California and labelled with DNA labelling reagent 
(DLR) also from Affymetrix. This process labelled the 3ʹ end of the dsDNA 
fragments with DLR containing the Biotin-11-dXTP Analog that binds to a 
fluorescent molecule during staining.  
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Figure 3.2: Outline of Protocol for Fragmentation and Labelling of DNA Targets. 
Amplified DNA was fragmented by treatment with UDG and APE 1 enzymes that remove the dUTP 
residues and leave the dsDNA in smaller fragments. The resulting DNA fragments were labelled with 
biotin molecules. 
Abbreviations: dsDNA - Double stranded deoxyribonucleic acid, UDG - Uracil DNA glycosylase, 
APE1 - Human apurinic/apyrimidinic endonuclease I.  
 
3.3.5 Hybridization, Washing, Staining and Scanning of Microarray Chips  
The biotinylated dsDNA targets were hybridized to the GeneChip
®
 Human Promoter 
1.0R array (Affymetrix, Santa Clara, California). This array is a high resolution and 
sensitivity tilling array with probes reproducing all known non-repetitive DNA 
sequences. The procedure for hybridization, staining and washing is depicted in 
Figure 3.3. Hybridization was done according to the manufacturer’s protocol (see 
Appendix 12). It was performed for 16 hours at 45°C in the Genechip
®
 
Hybridization Oven 640 (Affymetrix, Santa Clara, California) rotating at 60 rpm. 
The hybridised probe arrays were stained, washed and scanned. Prior to the staining 
and washing cycles, the arrays were first registered on the Affymetrix GeneChip 
Command Console
®
 (AGCC) installed on the computer connected to the microarray 
platform workstation using AGCC Fluidics Control Software
®
 (Affymetrix, Santa 
Clara, CA, USA). 
The arrays were stained and washed on the Genechip
®
 Fluidics Station 450 
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(Affymetrix, Santa Clara, CA, USA). The staining reagents had stain 1 containing 
the fluorescent molecule streptavidin-phycoerythrin (SAPE), which binds to biotin. 
During a series of staining and washing cycles with anti-SAPE IgG (goat) and 
biotynylated anti-streptavidin antibody reagents, additional newly deposited biotins 
bind to SAPE and provides amplified flour that emits light when scanning of arrays. 
 
Figure 3.3: Outline of Protocol for Hybridization, Washing, Staining and Scanning.   
The chips were hybridized in the Genechip
®
 hybridization oven 640 for 16 hours. The arrays were 
then stained with reagents containing SAPE molecules with biotin and washed using the Genechip
® 
Fluidics Station 450. The chips were scanned with Genechip
®
 Scanner 3000 7G and the array BitMap 
images and data files generated were used for data analysis. 
Abbreviations: dsDNA - Double stranded deoxyribonucleic acid, SAPE – Streptavidin 
phycoerythrin, IgG - Immunoglobulin G. 
 
The microarray chips were then scanned with the Genechip
®
 Scanner 3000 7G 
(Affymetrix, Santa Clara, CA, USA). The scanner contains a confocal laser beam 
that records the distribution of signals in the arrays. Array BitMap images and raw 
data files were generated for use in data analysis. The protocols followed for 
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registering, staining, washing and scanning the probe arrays are described in 
Appendices 13 -15. 
 
3.4 STATISTICAL METHODS AND MICROARRAY DATA 
ANALYSIS 
The algorithm used for data analysis is outlined in Figure 3.4. The main stages of 
analysis were raw data importation into an a microarray data analysis programme, 
microarray data statistical analysis by sampling groups, determination of methylated 
sites and biological pathway analysis using gene ontology (GO) terms. The data 
analysis was performed using the Partek Genomic Suite Software
®
 (PGSS) 6.0 
(Partek Incorporated, North America). The PGSS is an advanced microarray data 
bioinformatics programme that integrates the statistical analysis of microarray data, 
sampling groups, demographics and GO terms of small or large data sets on an 
interactive, fast and efficient platform. 
 
Figure 3.4: Outline of the Workflow used to Analyse the Microarray Data. 
Abbreviations: ANOVA – Analysis of variance, AIH – Autoimmune hepatitis, CpG – Cytosine-
phosphate-Guanine, GO – Gene ontology, HBV – Hepatitis B virus, HBV>40yrs – Infected HBV 
patients older than 40 years, HBV_Cirrhosis – HBV infection with cirrhosis, HBV_No_Cirrhosis – 
HBV infection without cirrhosis, HBV_inflammation- HBV infection with inflammation, HCC – 
Hepatocellular carcinoma, PGSS – Partek Genomic Suite Software®. 
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3.4.1 Data Importation, Normalisation and Background Correction 
Raw array data files (CEL files) with methylation measurements generated by 
GeneChip
®
 Operating Software (GCOS) were imported into PGSS 6.0 and analysed 
using the PGSS Affymetrix Tilling workflow interface. The human genome 
GRCh37/hg19 (hg19) assembly was used to analyse the probe data
 243
. Hg19 data 
was used to extract 600bp sequences centred at each probe start position. The 
imported data were processed using the Robust Multichip Averaging (RMA) 
algorithm which performs log2 transformation, background correction and quantile 
normalization to remove any technical biological batch effects. Principal component 
analysis (PCA) was done as part of quality control and to identify potential outliers 
that could significantly affect the data analysis.  
The Model-based Analysis of Tilling-arrays (MAT) algorithm in PGSS 6.0 was used 
to analyse the probe signals for significant differences that could have biological 
effects 
18
. The MAT algorithm performs a robust trimmed mean of t-values that 
removes outliers and noisy effects across all normalised probe intensities in a 
window of 600bp in length. It scores regions for chromatin immunoprecipitation 
enrichment which allows for the calculation of robust p-value cut-off values and 
false discovery rate calculations. Positive MAT scores would represent 
hypermethylation in for example, HBV tissues relative to another group being 
compared to them whereas negative MAT scores would represent hypomethylation 
relative to the comparison group. 
 
3.4.2 Statistical Analysis by Disease Categories 
To compare enriched regions in different groups, an Analysis of Variance (ANOVA) 
for the different diagnoses of HBV infection, AIH, HCC and normal controls was 
created by applying the t-test and fold change calculated at log2-scale. The ANOVA 
spreadsheet generated contained p-values, fold change and T-statistic values. A p-
value of ≤ 0.05 was considered significant. A positive T-statistic value when 
comparing HBV cases to another group, meaning that HBV cases have a higher 
average intensity than the comparison group. When it is negative, HBV cases have a 
lower average intensity than the comparison cases. The ANOVA results were used to 
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identify the enriched regions that are differentially methylated between different 
groups. 
The MAT algorithm was used to asses methylation quantified by the MAT score 
using the default or corrected probe on a 600bp window with at least 10 probes. The 
analysis generated a spreadsheet of an enriched regions list with MAT scores 
appearing as either positive or negative. Positive MAT scores when comparing HBV 
cases to normal controls mean that the identified region in HBV cases is 
hypermethylated compared to normal controls. 
 
3.4.3 Detection of Methylated Regions 
To detect differentially methylated regions, the enriched regions were annotated to 
their corresponding overlapping regions using the PGSS gene annotation tool against 
hg19 transcripts (Affymetrix U133_Plus_2_na24.hg19.-transcript.csv file 
246
). In 
addition, methylated genes and cytobands (chromosomal locations) located 7kb 
upstream and 2.45kb downstream from transcription start site (TSS) were also 
annotated. For purposes of this thesis, the analysis of significantly differentially 
methylated genes was focused on the region 100bp upstream from TSS, with high 
MAT scores and cut-off p-values of ≤ 0.05 (see Figure 3.5). 
 
Figure 3.5: Typical Structure of Eukaryotic Gene Illustrating Region Analysed.   
The core promoter is located upstream of a gene and has a TATA sequence that is required to properly 
initiate gene transcription. In this thesis work only data on methylated CpG island regions in the 
promoter region starting within 100bp of the transcription start site were analysed. If methylated, this 
region would affect gene transcription the most. 
Abbreviations: bp – base pairs, TSS – Transcription start site. 
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Methylation of promoter CpG island regions of various cellular genes when 
comparing HBV to AIH, HCC or normal controls was analysed. The distance 
between a region of interest to the TSS and the overlap percentage of the region with 
nearest genes were reported. The length of overlap divided by the length of the 
transcript was also calculated and this represented the percentage of overlap with a 
region or gene (see Figure 3.6). The percentage overlap with a gene of the 
methylated CpG islands that were analysed were all zero (see Figure 3.6A), meaning 
that the methylated region did not overlap with a gene and was entirely within the 
promoter region upstream to TSS. 
Only methylated CpG islands located as illustrated in Figure 3.6A, B and starting 
within 100bp of TSS were analysed for this thesis presentation. For example, the 
methylated sequence that was used for the CCND3 gene was located and started 
100bp upstream from the TSS as illustrated in Figure 3.6B and was 573 base pairs 
in size. Another sequence that was 13121bp downstream from the TSS as illustrated 
in Figure 3.6D and 676bp in size was not used as this was located within the gene 
region. 
 
Figure 3.6: Illustration of the Gene Overlap Annotation.   
A and B: Percentage overlap with a gene is 0%, meaning that the methylated region does not overlap 
with a gene and is entirely within the promoter region upstream of TSS. C and D: The methylated 
region overlap with the nearest gene is 50% and is located entirely downstream of TSS. E: The 
methylated region overlap is 20% with the nearest gene while the rest is located upstream of TSS 
(within promoter region). 
Abbreviations: TSS – Transcription start site. 
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3.4.4 Pathway Analysis 
Pathway analysis using GO terms was used to determine the biological significance 
of the identified genes. Genes were tested using Fisher’s exact test and analysis was 
restricted to pathways with more than 2 genes. The p-value of less than 0.01 was 
used to filter methylated gene promoter CpG island regions to increase the 
significance. Significant pathways with high enrichment scores and significant p 
values less than 0.01 were reported.  
 
3.4.5 Cohort Analysis 
The histology of the samples was scored using the histological activity index of Ishak 
et al
220
.  Samples were categorised as cirrhotic if the fibrosis score was ≥5/6 and 
assessed as having significant hepatic inflammation if the inflammation grade score 
was ≥7/18.  
The demographic and clinical patient variables were analysed using STATA 13 
(College Station, Texas, USA). Categorical binary data were summarised as counts 
and percentages while categorical ordinal data was summarised as medians and inter-
quartile values. Ordinal numerical data was summarised as medians and inter-
quartile values and continuous numerical data as means and standard deviations. 
The investigation of possible associations between categorical variables was 
performed using the Pearson Chi-squared test and Fishers’ exact test where 
appropriate. A two-sided p value of ˂0.05 was considered significant. 
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3.5 RESULTS 
3.5.1 Sample Patient Cohort Profile 
The characteristics of the microarray patient cohort are described in Table 3.1. 
56.25% of the cohort was of mixed ancestry race, 62.5% were male and 40.62% 
were cirrhotic. The mean age at sampling was 36.8 years. Most of the samples were 
from HBV infected patients and 18.75% were HCC tissues. 
 
Table 3.1: Characteristics of Microarray Patient Cohort 
 
 
3.5.2 Generation of dsDNA Targets, DNA Fragmentation and Labelling  
Analysis with 1.5% agarose gel was used to confirm the presence of successful 
digestion, DNA linker-ligation, PCR amplification of methylated sites and generation 
of dsDNA fragments of less than 200bp for use in microarray analysis (see Figure 
3.7). The successful digestion of genomic DNA with MseI restriction enzyme is 
shown in Figure 3.7A. A uniform smear pattern of between 50 – 2000 bp indicates 
successful and complete digestion.  
 
Abbreviations: % - Percentage, ALT - Alanine aminotransferase,  
HAI - Histology Activity Index, HCC - Hepatocellular carcinoma,  
IQR - Inter-quantile range, u/L –  International unit per litre  
SD – Standard deviation. 
Cohort Characterisation 
 
 
 
Age (years) 
 
ALT (0 – 40 u/L) 
 
 
Male 
Race  
Caucasian 
Mixed race 
Indian 
Black African 
Diagnosis  
Normal 
Hepatitis B virus 
Autoimmune Hepatitis  
Hepatocellular Carcinoma  
Corresponding HCC Control 
Histology  
Liver Cirrhosis (HAI Score ≥ 5/6) 
Liver Inflammation (HAI Grade ≥ 7/18) 
 
  
 
 
 
 
Number = 32 
 
 
Mean (SD) 
36.8 (15.4) 
Median (IQR) 
115.5 (30.5-202.5) 
 
Number (%) 
20 (62.5) 
 
4 (12.5) 
18 (56.25) 
3 (9.38) 
7 (21.88) 
 
2 (6.25) 
18 (56.25) 
4 (12.5) 
6 (18.75) 
2 (6.25) 
 
13 (40.62) 
7 (21.88) 
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Figure 3.7: Agarose Gel Confirmation of Successful dsDNA Targets Generation and 
Fragmentation.  
DNA aliquots were run on 1.5% agarose gel. A: DNA after MseI digestion, B: DNA after ligation 
with linkers and PCR amplification, C: DNA after digestion with methylation sensitive endonucleases 
BstUI and HhaI and PCR amplification, D: dsDNA targets after fragmentation for confirmation of 
successful fragmentation.  
Lane 1: Molecular weight marker, Lane 2: Sample ID_62, Lane 3: Sample ID_66, Lane 4: Sample 
ID_68, Lane 5: Sample ID_69, Lane 6: Sample ID_71, Lane 7: Sample ID_72, Lane 8: Sample 
ID_73 and Lane 9:  Sample ID_74. 
Abbreviations: dsDNA - Double-stranded deoxyribonucleotides, PCR - Polymerase chain reaction.  
 
The agarose gel in Figure 3.7B shows successful DNA-linker ligation. This is 
confirmed by the presence of a smear pattern between 100 - 2000 bp. Figure 3.7C 
shows successful PCR amplification of fragments with methylated BstUI and HhaI 
sites. Successful fragmentation of dsDNA into smaller fragments by the removal of 
dNTP residues is shown in Figure 3.7D gel with the expected DNA fragments of 
smear patter being less than 200bp in size. 
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3.5.3 Principal Component Analysis of Microarray Data 
Principal component analysis (PCA) after background correction for the differences 
in probe signal intensities and DNA methylation profiles showed clustering of the 
samples by diagnosis (see Figure 3.8B). There was one significant outlier of a HBV 
sample. 
 
Figure 3.8: Principal Component Analysis of Microarray Data Samples. 
The data for each sample type is represented by different colours in circles. HBV tissue samples are 
presented in purple, AIH in red, HCC in orange, corresponding HCC controls in green and normal 
controls in blue. A represents PCA analysis before background correction and B represents PCA 
analysis after background correction.  
Abbreviations: AIH - Autoimmune hepatitis, HBV - Hepatitis B virus, HCC - Hepatocellular 
carcinoma, PCA - Principal Component Analysis. 
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The data for each sample type is represented by different colours in circles. HBV 
tissue samples are presented in purple, AIH in red, HCC in orange, corresponding 
HCC controls in green and normal controls in blue. Figure 3.8A shows clustering of 
HCC tissue samples from HBV, AIH, Control-HCC and Normal tissue samples 
which are closely clustered and have less variation across individual samples. After 
background correction, PCA shows more close clustering of tissue samples across 
various groups with one HBV samples still straying away from the HBV samples 
(see Figure 3.8B). 
 
3.5.4 Profile of Promoter Region CpG Islands Methylation Within 100bp of the 
TSS in the Cohort  
The methylation profile of promoter regions within 100bp upstream of the 
transcription start site in the cohort used for microarray is shown in Figure 3.9. 
There were no hypermethylated core promoter regions within 100bp upstream of the 
TSS in chromosomes X and Y while chromosomes 11 and 19 had the highest 
number of hypermethylated genes at 6 genes each. 
 
Figure 3.9: Profile by Chromosome of Hypermethylated Gene Promoter Regions 
within 100bp of TSS in the Microarray Cohort  
Abbreviations:  bp – Base pair, TSS – Transcription Start Site. 
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The chromosomes with promoter region hypermethylation in the different 
comparison groups of chronic HBV infected patients are shown in Figure 3.10 and 
compared to the profile of the whole microarray cohort shown in Figure 3.10.A. 
When all the patients with chronic HBV infection were compared to normal controls, 
there was hypermethylation across the genome with most of it occurring in 
chromosome 9 (see Figure 3.10.B). In HBV infected patients older than 40 years, 
there was a slight increase in gene hypermethylation in chromosome 19 when 
compared to normal controls (see Figure 3.10.C). 
 
Figure 3.10: Profile by Chromosome of Hypermethylated Gene Promoter Regions 
within 100bp of TSS in the HBV Infected Patients Compared to Controls  
Abbreviations:  AIH - Autoimmune hepatitis, bp - Base pair, HBV - Hepatitis B virus, HBVeag - 
Hepatitis B Virus e antigen, HCC - Hepatocellular Carcinoma, TSS - Cytosine Transcription Start 
Site 
 
In HBV e antigen positive patients compared to normal controls, most of the gene 
hypermethylation was in chromosomes 2, 3 and 9 (see Table 3.8D), HBV patients 
compared to autoimmune hepatitis patients had hypermethylation in a varied number 
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of chromosomes (see Table 3.8.E) but when compared to hepatocellular carcinoma 
cases, most of the gene hypermethylation was in chromosome 17 (see Table 3.8.F). 
 
3.5.5 Methylation Profiles of Promoter CpG Islands in HBV Infection 
The age at diagnosis was not significantly different between the diagnostic groups 
(see Table 3.2). There were significantly more male patients with HBV infection 
compared to HCC patients (p = 0.02). There were no male patients with AIH. The 
prevalence of cirrhosis was similar in all the groups and only 27.8% of the HBV 
patients were HBV e antigen positive. AIH has significantly higher ALT levels (p = 
0.03) compared to HCC patients. In the HBV infected cohort, 55% were genotype A 
and 45% genotype D. There were no cases of genotype B, C or E documented. 
 
Table 3.2: Cohort Characteristics by Diagnosis 
 
 
The results of promoter CpG island methylated sites less than 100bp upstream of the 
TSS are summarised in Tables 3.3 - 3.11. A positive MAT score in a group 
represents hypermethylation relative to the comparison group, while negative MAT 
score denotes relative hypomethylation.  
In all the HBV infected patients, 13 genes were hypermethylated within 100bp 
upstream of the TSS in the core promoter region while 17 hypomethylated relative to 
normal controls (see Table 3.3). The most hypermethylated promoter CpG islands  
were olfactory receptor family 8 subfamily B member 1 (OR8B4), GA binding 
protein transcription factor beta subunit 2 (GABPB2), interleukin 11 receptor alpha 
 
   
 
  
 Age (years) 
 ALT (0 – 40 u/L) 
 αFP (0 – 7 u/L) 
 Log10 viral DNA  
  
 
Male  
 Liver cirrhosis (HAI ≥ 5/6) 
 All HBV cases  
 HBeAg positive 
 
 
  
 
 
 
HBV 
 
Median (IQR) 
34.2 (13.1) 
103 (30 - 317) 
3 (2.2 – 4) 
3.75 (2.3 – 6) 
 
Number (%) 
13 (72.2) 
8 (44.4) 
18 (100) 
5 (27.8) 
 
 
HCC 
 
Median (IQR) 
43.5 (19.9) 
51.5 (26 - 124) 
2.8 (1 – 3.2) 
0 
 
Number (%) 
4 (66.7) 
2 (33.3) 
1 (16.7) 
0 
 
 
AIH 
 
Median (IQR) 
37.5 (9.9) 
331.5 (212 – 377.5) 
2.6 (1.7 – 3.45) 
N/A 
 
Number (%) 
0 
2 (50) 
N/A 
N/A 
 
 
 
P value 
 
 
N/S 
0.03K
 
N/S 
N/A 
 
 
0.02
P
 
N/S 
N/A 
N/A 
 
 
 
 
Abbreviation: αFP - Alpha fetoprotein, AIH - Autoimmune hepatitis, DNA - Deoxyribonucleic acid, HAI – Histology activity 
index, HBeAg – Hepatitis B virus e antigen, HBV - Hepatitis B virus, HCC – Hepatocellular carcinoma, IQR - Inter-quantile range, 
N – Number, N/A - Not applicable, N/S – Not significant, P = 0.03
k
 - AIH compared to HCC, P = 0.02 
p - AIH compared to HBV 
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(IL11RA), par-6 partitioning defective 6 homolog alpha (PARD6A) and cyclin D3 
(CCND3) genes. 
 
Table 3.3: Methylation Profile of Gene Promoter CpG Islands in HBV Patients 
Compared to Normal Controls 
 
 
When compared to AIH, only 7 gene promoter CpG islands were hypermethylated 
within 100bp upstream of TSS in HBV infected patients while 9 genes were 
hypomethylated (see Table 3.4).  Some of these were pseudogenes including RNA 
polymerase transcription factor homolog pseudogene 3 (RRN3P3). Amongst 3 gene 
promoter CpG islands hypermethylated in this category were nuclear apoptosis 
inducing factor 1 (NAIF1), exosome component 3 (EXOSC3) and interleukin 11 
receptor, alpha (IL11RA) which are located in chromosome 9 (see Table 3.4). 
Chromosome 9 was shown to be highly methylated in HBV infected patients as 
compared to normal controls (see Figure 3.10B).  
 
Abbreviation: HBV - Hepatitis B virus, MAT – Model based analysis of tilling array, TSS - Transcription start site  
 
Distance to TSS 
 
 
 
-9 
-21 
-26 
-30 
-57 
-60 
-60 
-65 
-71 
-84 
-86 
-91 
-100 
 
 
 
-7 
-10 
-22 
-23 
-27 
-31 
-32 
-45 
-59 
-63 
-63 
-65 
-73 
-73 
-77 
-83 
-100 
 
P-value 
 
 
 
0.00136 
0.00737 
0.00959 
0.00684 
0.00615 
0.00899 
0.00986 
0.00689 
0.00679 
0.00777 
0.00291 
0.00532 
0.00730 
 
 
 
0.0056 
0.00045 
˂0.0001 
0.00881 
0.00961 
0.00573 
˂0.0001 
0.00104 
0.00859 
0.00711 
0.00836 
0.00954 
0.00687 
0.00133 
0.00039 
0.00402 
0.00687 
Gene Name 
 
 
 
Olfactory receptor, family 8, subfamily B, member 1 
Ligand of numb-protein X 2 
Nuclear apoptosis inducing factor 1 
Defensin theta 1 pseudogene 
GA binding protein transcription factor beta subunit 2 
Prostaglandin reductase 2 
Tubulin alpha 4a 
6kDa matrix extracellular phosphoglycoprotein 
Non-protein coding RNA 85 
Exosome component 3 
Interleukin 11 receptor, alpha 
Par-6 partitioning defective 6 homolog alpha 
Cyclin D3 
 
 
 
Paired box1 
LY6/PLAUR domain containing 3 
Neuroblastoma breakpoint family member 1 
MicroRNA 644 
Abhydrolase domain containing 1  
MicroRNA 138-2 
DICTN1antisense RNA 1 
Placenta specific 8 
Protease serine 53 
Olfactory receptor, family 52, subfamily I, member 1 
Neutral sphingomyelinase activation associated factor 
Transmembrane protein 80 
N-acetyltransferase 6 
Gelsolin 
Calcium regulated heat stable protein 1 
Ubiquitin B 
Hyaluronoglucosaminidase 3 
 
Gene Title 
 
 
 
OR8B4 
LNX2 
NAIF1 
DEFT1P 
GABPB2 
PTGR2 
TUBA4A 
MEPE 
NCRNA00085 
EXOSC3 
IL11RA 
PARD6A 
CCND3 
 
 
 
PAX1 
LYPD5 
NBPF1 
MIR644 
ABHD1 
MIR138-2 
LOC100189589 
PLAC8 
PRSS53 
OR52I1 
NSMAF 
TMEM80 
NAT6 
GSN 
CARHSP1 
UBB 
HYAL3 
 
Cytoband 
 
 
 
11q24.2 
13q12.2 
9q34.11 
8p23.1 
1q21.3 
14q24.3 
2q35 
4q22.1 
19q13.41 
9p13.2 
9p13.3 
16q22.1 
6p21.1 
 
 
 
20p11.22 
19q13.31 
1p36.13 
20q11.22 
2p23.3 
16q13 
2p13.1 
4q21.22 
16p11.2 
11p15.4 
8q12.1 
11p15.5 
3p21.31 
9q33.22 
16p13.2 
17p11.2 
3p21.31 
 
MAT-score 
  
 
 
2.6209 
2.2629 
2.2016 
2.2772 
2.3022 
2.2185 
2.1953 
2.2753 
2.2795 
2.2505 
2.4618 
2.3311 
2.2651 
 
 
 
-2.5454 
-3.3904 
-4.0944 
-2.3635 
-2.3305 
-2.5429 
-5.0814 
-3.1406 
-2.3770 
-2.4615 
-2.3890 
-2.3328 
-2.4788 
-3.0574 
-3.4419 
-2.6742 
-2.4788 
 
Transcript ID 
 
 
 
NM_001005196 
NM_153371 
NM_197956 
NR_036686.1 
NM_144618 
NM_152444 
NM_024463 
NM_001184694 
NM_024463 
NM_016042 
NM_001142784 
NM_016948 
NM_001136126 
 
 
 
NM_006192 
NM_001031749 
NM_017940 
NR_030374 
NM_032604 
NR_029680 
NM_032604 
NM_032604 
NR_029680 
NR_024463 
NM_001130716 
NM_001039503 
NM_001200018 
NM_00114477 
NM_174940 
NM_018955 
NM_001200029 
 
 
Hypermethylated in HBV relative to Normal (Hypomethylated in Normal) 
 
 
Hypomethylated in HBV relative to Normal (Hypermethylated in Normal) 
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Table 3.4: Methylation Profile of Gene Promoter CpG Islands in HBV Compared to 
AIH Patients 
 
 
Compared to HCC cases, there were 5 genes hypermethylated in HBV patients, some 
of which were pseudogenes. These include coiled-coil domain containing 144B 
(CCDC144B) and keratin 42 (KRT42P) pseudogenes.  Nine genes were 
hypomethylated in HBV relative to HCC patients (see Table 3.5). 
 
Table 3.5: Methylation Profile of Gene Promoter CpG Islands in HBV Compared to 
HCC Patients 
 
 
Abbreviation: AIH - Autoimmune hepatitis, HBV - Hepatitis B virus, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
 
Distance to TSS 
 
 
 
-23 
-29 
-31 
-41 
-51 
-54 
-67 
 
 
 
-3 
-4 
-38 
-16 
-27 
-38 
-38 
-51 
-58 
 
Gene Title 
 
 
 
NUDT13 
KRT77 
RRN3P3 
PTOV1 
TRIM77 
TRIP12 
TRPV5 
 
 
 
OR8B8 
IFIT1B 
PRAME 
PRAMEF20 
LOC729080 
C6orf97 
DPEP3 
CXorf57 
TUBGCP5 
 
P-value  
 
 
 
0.0030 
0.0021 
0.0023 
0.0014 
0.0057 
0.0034 
0.0035 
 
 
 
0.0039 
˂0.0001 
0.0081 
0.0024 
0.0059 
0.0082 
0.0039 
0.0003 
0.0051 
 
Gene Name 
 
 
 
Nucleoside diphosphate linked moiety X type motif 13 
Keratin 77 
RNA polymerase transcription factor homolog pseudogene 3 
Prostate tumour overexpressed gene 1 
Tripartite motif-containing 77 
Thyroid hormone receptor interactor 12 
Transient receptor potential cation channel subfamily v member 5 
 
 
 
Olfactory receptor family 8 subfamily member 1 
Interferon induced protein with tetratricopeptide repeats 1B 
Preferentially expressed antigen in melanoma  
PRAME family member 20 
Glycine cleavage system protein H (aminimethyl carrier) pseudogene 
Chromosome 6 open reading frame 97 
Dipeptidase 3 
Chromosome X open reading frame 57 
Tubulin, gamma complex associated protein 5 
 
Cytoband 
 
 
 
10q22.1 
12q13.13 
16p12.2 
19q13.33 
11q14.3 
2q36.3 
7q34 
 
 
 
11q24.2 
10q23.31 
22q11.22 
1p36.21 
5q31.3 
6q25.1 
16q22.1 
Xq22.3 
15q11.2 
 
 
MAT-score 
 
 
 
3.04796 
3.14933 
3.12476 
3.22968 
2.85175 
3.00349 
2.99707 
 
 
 
-3.12636 
-4.96107 
-2.84555 
-3.30101 
-2.96886 
-2.83998 
-3.11647 
-4.07695 
-3.02184 
 
Transcript ID 
 
 
 
NM_015901 
NM_175078 
NM_027460 
NM_017432 
NM_001146162 
NM_004238 
NM_019841 
 
 
 
NM_012378 
NM_001010987 
NM_206955 
NM_001099852 
NM_033244 
NM_025059 
NM_022357 
NM_018015 
NM_052903 
 
Hypermethylated in HBV relative to AIH (Hypomethylated in AIH) 
 
 
Hypomethylated in HBV relative to AIH (Hypermethylated in AIH) 
 
 
 Distance to TSS 
 
 
 
-11 
-17 
-35 
-43 
-44 
 
 
 
-1 
-2 
-10 
-17 
-34 
-44 
-51 
-51 
-56 
 
 
P-value  
 
 
 
0.0066 
0.0002 
0.0033 
0.0031 
0.0076 
 
 
 
0.0012 
0.0049 
0.0070 
0.0037 
0.0063 
0.0082 
0.0064 
0.0099 
0.0081 
Gene Name 
 
 
 
Family with sequence similarity 106, member C 
Protease serine 41 
Coiled-coil domain containing 144B (pseudogene) 
Keratin 42 pseudogene 
Membrane-spanning 4-domains, subfamily A, member 13 
 
 
 
Heat shock 70kDa protein 1A 
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 
Di-George syndrome critical region gene 11 
Polyamine oxidase (exo-N4-amino) 
MicroRNA 293 
Prostate and testis expressed 3 
Zinc finger, MYND-type containing 12 
5-Hydroxytryptamine (serotonin) receptor 3B, ionotropic 
Family with sequence similarity 173, member A 
 
 
Gene Title 
 
 
 
FAM106C 
PRSS41 
CCDC144B 
KRT42P 
MS4A13 
 
 
 
HSPA1A 
DYRK4 
DGCR11 
PAOX 
MIR1293 
PATE3 
ZMYND12 
HTR3B 
FAM173A 
 
Cytoband 
 
 
 
17p11.2 
16p13.3 
17p11.2 
17q21.2 
11q12.2 
 
 
 
6p21.33 
12p13.32 
22q11.21 
10q26.3 
12q13.12 
11q24.2 
1p34.2 
11q23.2 
16P13.3 
 
 
MAT-score  
 
 
 
3.02086 
4.31789 
3.2606 
3.29559 
2.97 
 
 
 
-3.78691 
-3.21856 
-3.07763 
-3.32986 
-3.11781 
-3.01747 
--3.11473 
-2.94263 
-3.02223 
 
Transcript ID 
 
 
 
NR_026810 
NM_001135086 
NR_036647 
NM_033415 
NM_001012417 
 
 
 
NM_005345 
NM_003845 
NR_024157 
NM_207127 
NR_031625 
NM_001129883 
NM_032257 
NM_006028 
NM_023933 
 
 
Hypermethylated in HBV relative to HCC (Hypomethylated in HCC) 
 
 
Abbreviation: HBV - Hepatitis B virus, HCC - Hepatocellular carcinoma, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
 
Hypomethylated in HBV relative to HCC (Hypermethylated in HCC) 
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When HCC tissues were compared to their neighbouring liver tissues, 
hypermethylation was present in the promoter CpG islands of 6 genes within 100bp 
upstream of TSS (see Table 3.6).  The most hypermethylated were retintis 
pigmentosa 1 (RP1), prolyl 4-hydroxylase transmembrane (P4HTM) and prostate 
and testis expressed 3 (PATE3). The neighbouring tissues had 6 genes 
hypermethylated. 
 
Table 3.6: Methylation Profile of Gene Promoter CpG Islands in HCC Tissues 
Compared to Corresponding Tissues with no HCC 
 
 
HBV e antigen positive patients cases had 10 genes with promoter CpG islands 
hypermethylation compared to normal controls (see Table 3.7).  The most 
methylated were Fibroblast growth factor receptor-like 1 (FGFRL1), NACC family 
member 2, BEN and BOP (POZ) domain containing (NACC2), Non-protein coding 
RNA 85 (NCRNA00085), Deoxyribosnucleic II beta (DNASE2B), Polycomb group 
ring finger 1 (PCGF1), Nuclear apoptosis inducing factor 1 (NAIF1) and Tubulin 
alpha 4 A (TUBA4A). 
 
 
 
 
 Distance to TSS 
 
  
 
-21 
-26 
-30 
-33 
-44 
-51 
 
 
 
-13 
-15 
-29 
-41 
-47 
-69 
 
P-value  
 
 
 
0.0033 
0.0078 
0.0078 
0.0014 
0.0017 
0.0098 
 
 
 
0.0086 
0.0022 
0.0011 
0.0031 
0.0029 
0.0090 
Gene Name 
 
 
 
Retinitis pigmentosa 1 (autosomal dominant) 
Aminolevulinate, delta-, synthase 1 
KRAB-A domain containing 2 
Prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) 
Prostate and testis expressed 3 
Scavenger receptor class B, member 2 
 
 
 
F-box protein 39 
Sorting nexin 11 
Olfactory receptor, family 11, subfamily H, member 2 
DNAJ (Hsp40) homolog, subfamily C, member 14 
Family with sequence similarity 106, member C, pseudogene 
Ladybird homeobox 2 
 
Gene Title 
 
 
 
RP1 
ALAS1 
KRBA2 
P4HTM 
PATE3 
SCARB2 
 
 
 
FBXO39 
SNX11 
OR11H2 
DNAJC14 
FAM106C 
LOC151534 
 
Cytoband 
 
 
 
8q12.1 
3p21.2 
17p13.1 
3p21.31 
11q24.2 
4q21.1 
 
 
 
17p13.1 
17q21.32 
14q11.2 
12q13.2 
17p11.2 
2p13.1 
 
 
MAT-score  
 
 
 
3.00403 
2.75559 
2.75367 
3.23248 
3.18627 
2.68891 
 
 
 
-2.6544 
-3.05614 
-3.43835 
-3.04642 
-3.05614 
-2.63247 
 
Transcript ID 
 
 
 
NM_006269 
NM_000688 
NM_213597 
NM_177938 
NM_001129883 
NM_001204255 
 
 
 
NM_153230 
NM_013323 
NM_001197287 
NM_032364 
NM_026810 
NM_024606 
 
Hypermethylated in HCC relative to Control HCC (Hypomethylated in Control HCC) 
 
 
Abbreviation: HBV - Hepatitis B virus, HCC – Hepatocellular carcinoma, MAT - Model-based analysis of tilling array, TSS - Transcription start site 
 
Hypomethylated in HCC relative to Control HCC (Hypermethylated in Control HCC) 
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Table 3.7: Methylation Profile of Gene Promoter CpG Islands in Patients who are 
HBV e Antigen Positive Compared to Normal Controls 
 
 
Cirrhotic HBV infected patients had 6 genes hypermethylated compared to those 
without cirrhosis (see Table 3.8). The most methylated were Small nuclear RNA C/D 
box 48 (SNORD48), Small Cajal body-specific RNA 10 (SCARNA10) and 
Transmembrane protein 41A (TMEM41A). The non-cirrhotic HBV cases had 19 
genes with promoter CpG islands hypermethylation. 
 
 
 
 
 
 Distance to TSS 
 
 
 
-15 
-25 
-35 
-42 
-53 
-55 
-71 
-84 
-96 
-102 
 
  
 
-7 
-8 
-10 
-21 
-22 
-23 
-34 
-37 
-41 
-52 
-59 
-60 
-63 
-64 
-68 
-72 
-77 
-81 
-81 
-85 
-92 
-94 
-97 
 
 
 
P-value  
 
 
 
0.0093 
0.0066 
0.0071 
0.0079 
0.0089 
0.0044 
0.0074 
0.0086 
0.0082 
0.0093 
 
 
 
0.0008 
0.0093 
0.0003 
0.0082 
0.0004 
0.0074 
0.0094 
0.0079 
˂0.0001 
˂0.0001 
0.0037 
0.0098 
0.0081 
0.0093 
0.0099 
0.0059 
0.0089 
0.0044 
0.0062 
0.0022 
0.0047 
0.0083 
0.0087 
Gene Name 
 
 
 
Small necleolar RNA, H/ACA box 7B 
NACC family member 2, BEN and BTP (POZ) domain containing 
Deoxyribonuclease II beta 
Polycomb group ring finger 1 
Proliferation associated 2G4 
Fibroblast growth factor receptor-like 1 
Non-protein coding RNA 85 
Nuclear apoptosis inducing factor 1 
Tubulin alpha 4A 
Small nucleolar RNA, H/ACA box 7B 
 
 
 
Paired-box 1 
Olfactory receptor family 6, subfamily C, member 6 
LY6/PLAUR domain containing 5 
MicroRNA 573 
Neuroblastoma breakpoint family member 1 
MicroRNA 644 
ATP synthase H+ transporting mitochondrial Fo complex subunit  
Succinate dehydrogenase complex, subunit A, flavoprotein 
Calcium regulated heat stable protein 1 
POU class 5 homeobox 1 pseudogene 3 
Protease serine 53 
Neurotensin receptor type 1 
Neutral sphingomyelinase activation associated factor 
Podocan-like 1 
Defensin beta 109 pseudogene 1 
Microtubule associated tumour suppressor 1 
Glutamate receptor ionotropic delta 2 interacting protein 
Protocadherin alpha -9 
Solute carrier family 34 (sodium phosphate) member 1 
XK, Kell blood group complex subunit-related family member 8 
Chorionic gonadotropin beta polypeptide 8 
IKAROS family zinc finger 3 
Cytochrome b5 domain containing 1   
 
 
 
Gene Title 
 
 
 
SNORA7B 
NACC2 
DNASE2B 
PCGF1 
PA2G4 
FGFRL1 
NCRNA00085 
NAIF1 
TUBA4A 
SNORA7B 
 
 
 
PAX1 
OR6C6 
LYPD5 
MIR573 
NBPF1 
MIR644 
ATP5S 
SDHA 
CARHSP1 
POU5F1P3 
PRSS53 
NTSR1 
NSMAF 
PODNL1 
DEFB109P1 
MTUS1 
GRID2IP 
PCDHA9 
SLC34A1 
XKR8 
CGB8 
IKZF3 
CYB5D1 
 
Cytoband 
 
 
 
3q21.3 
9q34.3 
1p31.1 
2p13.1 
12q13.2 
4p16.3 
19q13.41 
9q34.11 
2q35 
3q21.3 
 
 
 
20p11.22 
12q13.2 
19q13.31 
20q11.22 
1p36.13 
20q11.22 
14q21.3 
5p15.33 
16p13.2 
12p13.31 
16p11.2 
20q13.33 
8q12.1 
19p13.12 
8p23.1 
8p22 
7P22.1 
5q35.3 
5q35.3 
1p35.3 
19q13.33 
17q12 
17p13.1 
MAT-score  
 
 
 
2.11849 
2.20809 
2.19158 
2.15965 
2.1286 
2.30551 
2.18293 
2.13735 
2.15182 
2.11849 
 
 
 
-3.01632 
-2.23403 
-3.27096 
-2.28038 
-3.20013 
-2.31912 
-2.2307 
-2.28793 
-3.65721 
-3.52326 
-2.54622 
-2.21473 
-2.28793 
-2.23439 
-2.21249 
-2.39771 
-2.24916 
-2.48487 
-2.37638 
-2.7105 
-2.46624 
-2.27505 
-2.25635 
 
Transcript ID 
 
 
 
NR_002992 
NM_144653 
NM_058248 
NM_032673 
NM_006191 
NM_001004358 
NR_024330 
NM_197956 
NM_006000 
NR_002992 
 
 
 
NM_006192 
NM_001005493 
NM_001031749 
NR_030299 
NM_017940 
NR_030374 
NM_001003803 
NM_004168 
NM_014316 
NR_036440 
NM_001039503 
NM_002531 
NM_001144772 
NM_001146255 
NR_024044 
NM_020749 
NM_001145118 
NM_014005 
NM_003052 
NM_018053 
NM_033183 
NM_183228 
NM_144607 
Hypomethylated in HBeAg relative to Normal (Hypermethylated in Normal) 
 
Abbreviation: HBV - Hepatitis B virus, HBeAg – Hepatitis B e antigen, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
 
Hypermethylated in HBeAg relative to Normal (Hypomethylated in Normal) 
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Table 3.8: Methylation Profile of Gene Promoter CpG Islands in Cirrhotic HBV 
Compared to Non-Cirrhotic HBV Patients 
 
 
When comparing cirrhotic HBV patients with normal controls, cirrhotic HBV cases 
had 8 genes with promoter CpG islands hypermethylation (see Table 3.9). In normal 
controls, there were 16 genes with promoter CpG islands hypermethylation.  
 
 
 
 
 
 
 
 Distance to TSS 
 
 
 
-1 
-15 
-21 
-35 
-40 
-67 
 
  
 
-16 
-17 
-26 
-27 
-30 
-33 
-35 
-45 
-57 
-64 
-65 
-67 
-83 
-85 
-87 
-95 
-101 
-104 
-105 
 
 
P-value  
 
 
 
0.0029 
0.0013 
0.0011 
0.0046 
0.0052 
0.0016 
 
 
 
0.0012 
0.0008 
0.0008 
˂0.0001 
0.0089 
0.0098 
0.0054 
0.0035 
0.0007 
˂0.0001 
0.0026 
0.0002 
0.0004 
0.0015 
0.0046 
0.0065 
0.0015 
0.0062 
˂0.0001 
Gene Name 
 
 
 
Nucleophosmin/Nucleoplasmin 2 
Small nucleolar RNA C/D box 48 
Small Cajal body-specific RNA 10  
Sterile alpha motif and HD domain containing protein 1 
Laminin alpha 1 
Transmembrane protein 41A 
 
 
 
Preferentially expressed antigen in melanoma 
KIAA1542 
Transmembrane protein 9 
Cbl proto-oncogene E3 ubiquitin protein ligase C 
Chromosome 6 open reading frame 74 
Myosin 9 
Olfactory receptor, family 52, subfamily I, member 1 
Embryonic lethal abnormal vision Drosophila-like 2 
Ligand of numb-protein X 2 
Oligosaccharyltransferase 4 homolog 
Matrix extracellular phosphoglycoprotein 
NADH dehydrogenase ubiquinone 1, subcomplex unknown 1 
Guanylate cyclise 2C 
Hermopexin 
Coiled-coil domain containing protein 72 
MICAL-like protein 2 
Sphingosine-1-phosphate receptor 5 
Chromosome 6 open reading frame 46 
Potassium voltage gated channel, shaker-related subfamily member 3 
 
Gene Title 
 
 
 
NPM2 
SNORD48 
SCARNA10 
SAMHD1 
LAMA1 
TMEM41A 
 
 
 
PRAMEF20 
KIAA1524 
TMEM9 
CBLC 
C6orf174 
MYH9 
OR52R1 
ELAVL2 
LNX2 
OST4 
MEPE 
NDUFC1 
GUCY2C 
HPX 
CCDC72 
MICALL2 
S1PR5 
C9orf46 
KCNA3 
 
MAT-score  
 
 
 
2.87222 
3.14211 
3.18015 
2.75282 
2.70982 
3.06345 
 
 
 
-3.09943 
-3.19839 
-2.45359 
-4.02128 
-2.55635 
-2.4094 
-2.60874 
-2.73847 
-3.24346 
4.04884 
-2.82446 
-3.47922 
-2.6658 
-3.005 
-2.65857 
-2.54305 
-3.0063 
-2.43833 
-4.09363 
 
Transcript ID 
 
 
 
NM_182795 
NR_002745 
NR_004387 
NM_015474 
NM_005559 
NM_080652 
 
 
 
NM_001099852 
NM_020890 
NM_016456 
NM_001130852 
NM_001005177 
NM_002473 
NM_001005177 
NM_001171195 
NM_153371 
NM_001134693 
NM_001184694 
NM_002494 
NM_004963 
NM_000613 
NM_015933 
NM_182924 
NM_001166215 
NM_001012279 
NM_002232 
 
Cytoband 
 
 
 
8p21.3 
6p21.33 
12p13.31 
20q11.23 
18p11.23 
3q27.2 
 
 
 
1p36.21 
3q13.13 
1q32.1 
19q13.32 
6q22.33 
22q12.3 
11p15.4 
9p21.3 
13q12.2 
2p23.3 
4q22.1 
4q31.1 
12p12.3 
11p15.4 
3p21.31 
7p22.3 
19p13.2 
9p24.1 
1p13.3 
Hypermethylated in HBV with Cirrhosis relative to HBV without Cirrhosis (Hypomethylated in HBV without Cirrhosis 
 
 
Hypomethylated in HBV with Cirrhosis relative to HBV without Cirrhosis (Hypermethylated in HBV without Cirrhosis 
 
 
Abbreviation: HBV – Hepatitis B virus, MAT - Model-based analysis of tilling array, TSS -Transcription start site  
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Table 3.9: Methylation Profile of Gene Promoter CpG Islands in Cirrhotic HBV 
Patients Compared to Normal Controls 
 
 
HBV infected patients with hepatic inflammation had 5 genes hypermethylated 
within 100bp of the TSS in the core promoter region (see Table 3.10). The most 
methylated were NACC family member 2, BEN and BOP (POZ) domain containing 
(NACC2), uncharacterised gene (LOC285441), MicroRNA-527 (MIR527), defensin 
theta 1 pseudogene (DEFT1P) and nuclear apoptosis inducing factor 1 (NAIF1). In 
normal cases, there were 18 genes with hypermethylation of promoter region CpG 
islands.  
 
 
 
 
 
 
 Distance to TSS 
 
 
 
-12 
-29 
-28 
-33 
-36 
-55 
-60 
-84 
 
 
 
-6 
-6 
-7 
-9 
-10 
-21 
-27 
-29 
-31 
-32 
-63 
-76 
-86 
-87 
-89 
-103 
 
 
 
P-value  
 
 
 
0.0079 
0.0037 
0.0061 
0.0053 
0.0046 
0.0047 
0.0088 
0.0094 
 
 
 
0.0072 
0.0004 
0.0012 
0.0008 
0.0010 
0.0076 
0.0061 
0.0029 
0.0084 
˂0.0001 
0.0090 
0.0074 
0.0005 
0.0011 
0.0006 
˂0.0001 
Gene Name 
 
 
 
Thyroid hormone receptor associated protein 3 
Uncharacterised 
UBX domain protein 1 
Potassium inwardly- rectifying channel subfamily J, member 15 
Leucine rich repeat containing 28 
Defensin theta 1 pseudogene 
Tubulin alpha 4a 
Nuclear apoptosis inducing factor 1 
 
 
 
Olfactory receptor, family 5, subfamily AU, member 1 
Leukocyte receptor cluster member 1  
Paired box 1 
Placenta 8 
LY6/PLAUR domain containing 5 
MicroRNA-573 
Cbl proto-oncogene E3 ubiquitin protein ligase C 
Transmembrane protein 80 
Neutral sphingomyelinase activation associated factor 
DICTN1antisense RNA 1 
Asparagine-linked glycosylation 1-like pseudogene 
Transmembrane protein 25 
Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
MicroRNA-4267 
Scavenger receptor class B, member 2 
Coiled-coil domain containing 56 (pseudogene) 
 
Gene Title 
 
 
 
THRAP3 
LOC285441 
UBXN1 
KCNJ15 
LRRC28 
DEFT1P 
TUBA4A 
NAIF1 
 
 
 
OR5AU1 
LENG1 
PAX1 
PLAC8 
LYPD5 
MIR573 
CBLC 
TMEM80 
NSMAF 
LOC100189589 
LOC650368 
TMEM25 
IKBKB 
MIR4267 
SCARB2 
CCDC56 
 
 
Cytoband 
 
 
 
1p34.3 
4q35.2 
11q12.3 
21q22.13 
15q26.3 
8p23.1 
2q35 
9q34.11 
 
 
 
14q11.2 
19q13.42 
20p11.22 
4q21.22 
19q13.31 
4p15.2 
19q13.32 
11p15.5 
8q12.1 
2p13.1 
11p15.4 
11q23.3 
8p11.21 
2q13 
4q21.1 
17q21.31 
 
MAT-score  
 
 
 
2.27614 
2.44828 
2.34464 
2.3729 
2.40318 
2.39852 
2.25535 
2.24223 
 
 
 
-3.33412 
-3.33412 
-3.04332 
-3.17101 
-3.09667 
-2.38239 
-2.47331 
-2.73699 
-2.34636 
-5.06774 
-2.31751 
-2.39296 
-3.26291 
-3.07784 
-3.22882 
-3.91033 
 
 
Transcript ID 
 
 
 
NM_005119 
NM_033900 
NM_015853 
NM_170737 
NM_144598 
NR_036686.1 
NM_006000 
NM_197956 
 
 
 
NM_001004731 
NM_024316 
NM_006192 
NM_00113071 
NM_00103174 
NR_030299 
NM_012116 
NM_174940 
NM_00114477 
NR_024463 
NR_024248 
NM_001144034 
NM_001556 
NR_036225 
NM_001204255 
NM_001040431 
 
 
 
Hypermethylated in HBV with Cirrhosis relative to Normal (Hypomethylated in Normal) 
 
 
Abbreviation: HBV - Hepatitis B virus, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
 
Hypomethylated in HBV with Cirrhosis relative to Normal (Hypermethylated in Normal) 
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Table 3.10: Methylation Profile of Gene Promoter CpG Islands in HBV Patients 
with Inflammation Compared to Normal Controls 
 
 
 
 
 
 
 
 
 
 
 
 
HBV infected patients older than 40 years were compared to normal controls (see 
Table 3.11). Older HBV infected patients had 11 genes hypermethylated compared 
to normal controls. The most methylated includes coiled-coil domain containing 127 
(CCDC127), TBC1 domain family member 17 (TBC1D17), MicroRNA 527 
(MIR527), regulator of G protein signalling 14 (RGS14) and small nucleolar RNA, 
H/ACA box 52 (SNORA52).  There were 19 genes hypermethylated in Normal 
relative to HBV infected patients older than 40 years. 
 
 
 
 
 
 
 P-value  
 
 
 
0.0026 
0.0064 
0.0090 
0.0093 
0.0066 
 
 
 
0.0081 
0.0006 
0.0081 
0.0001 
0.0006 
0.0065 
0.0007 
0.0007 
0.0078 
0.0006 
0.0008 
0.0077 
0.0073 
0.0009 
0.0008 
0.0048 
0.0098 
˂0.0001 
Distance to TSS 
 
 
 
-25 
-28 
-64 
-84 
-92 
 
 
 
-7 
-10 
-29 
-35 
-40 
-42 
-44 
-55 
-63 
-67 
-73 
-80 
-83 
-85 
-89 
-96 
-97 
-103 
 
 
Gene Name 
 
 
 
NACC family member 2, BEN and BTP (POZ) domain containing 
MicroRNA-527 
Uncharacterised 
Nuclear apoptosis inducing factor 1 
Defensin theta 1 pseudogene 
 
 
 
Paired box 1 
LY6/PLAUR domain containing 5 
GTP binding protein 5 (putative) 
Breast cancer anti-oestrogen resistance 3 
N-acetyltransferase gene 
Hydroxyprostaglandin dehydrogenase 15 – (NAD) 
Polymerase (DNA directed) alpha 2 
Chorionic gonadotropin, beta polypeptide 8 
Neutral sphingomyelinase activation associated factor 
Hyaluronoglucosaminidase 3 
Gelsolin 
Chromobox homolog 8 
UBX domain protein 1 
Potassium inwardly- rectifying channel subfamily k, member 2 
Scavenger receptor class B, member 2 
RecQ protein-like DNA helicase Q1-like 
Protocadherin alpha 1 
Coiled-coil domain containing 56 
 
 
 
Gene Title 
 
 
 
NACC2 
MIR527 
LOC285441 
NAIF1 
DEFT1P 
 
 
 
PAX1 
LYPD5 
GTPBP5 
BCAR3 
NAT6 
HPGD 
POLA2 
CGB8 
NSMAF 
HYAL3 
GSN 
CBX8 
UBB 
KCNK2 
SCARB2 
RECQL 
PCDHA1 
CCDC56 
 
 
Cytoband 
 
 
 
9q34.3 
19q13.42 
4q35.2 
9q34.11 
8p23.1 
 
 
 
20p11.22 
19q13.31 
20q13.33 
1p22.1 
3p21.31 
4q34.1 
11q13.1 
19q13.33 
8q12.1 
3p21.31 
9q33.2 
17q25.3 
17p11.2 
1q41 
4q21.1 
12p12.1 
5q31.3 
17q21.31 
MAT-score  
 
 
 
2.7026 
2.45859 
2.36857 
2.363 
2.45859 
 
 
 
-2.33096 
-3.12202 
-2.32991 
-3.564 
-3.14107 
-3.14107 
-3.09335 
-3.06265 
-2.34125 
-3.14107 
-3.03573 
-2.34706 
-2.35959 
-3.01734 
-3.03112 
-2.4994 
-2.26522 
-3.67078 
 
Transcript ID 
 
 
 
NM_144653 
NR_030219 
NR_033900 
NM_197956 
NR_036686.1 
 
 
 
NM_006192 
NM_00103174 
NM_015666 
NM_003567 
NM_001200018 
NM_000860 
NM_002689 
NM_033183 
NM_001144772 
NM_001200029 
NM_001127665 
NM_020649 
NM_018955 
NM_001017424 
NM_005506 
NM_032941 
NM_031411 
NM_001040431 
 
 
Hypermethylated in HBV with Inflammation relative to Normal (Hypomethylated in Normal) 
 
 
Hypomethylated in HBV with Inflammation relative to Normal (Hypermethylated in Normal) 
 
 
Abbreviation: HBV - Hepatitis B virus, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
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Table 3.11: Methylation Profile of Gene Promoter CpG Islands in HBV Patients 
Older than 40 years Compared to Normal Controls 
   
Genes that were shown to have significant promoter region CpG island 
hypermethylation within 100bp upstream of TSS in HBV infected patients were 
summarised in Table 3.12. The major functional groups of these genes are related to 
cyclin dependent kinase, growth factors, regulation of hepatic metabolism, tumour 
suppressors, transcription regulators, splicing of mRNA, vitamin D receptor (VDR) 
binding, ubiquitination and pseudogenes. Most of these hypermethylated genes are 
involved in various signalling pathways including those of HBV infection with HCC 
calcium, TGF Beta, tuberculosis, cell adhesion, tight junction, mRNA surveillance, 
MAP kinase, cell cycle, viral carcinogenesis, PPAR gamma, type 2 diabetes mellitus, 
apoptosis and HTLV-1 infection (see Appendices 26.A – O).  
 
 
 
 
Hypermethylated in HBV Patients ˃ 40 years relative to Normal (Hypomethylated in Normal) 
 
 
Hypomethylated in HBV Patients ˃ 40 years relative to Normal (Hypermethylated in Normal) 
 
 
 
Abbreviation:  ˃ - Older than, HBV – Hepatitis B virus, MAT - Model-based analysis of tilling array, TSS - Transcription start site  
 
Distance to TSS 
 
  
 
-1 
-9 
-17 
-20 
-28 
-30 
-30 
-48 
-71 
-91 
-92 
 
 
-6 
-7 
-10 
-17 
-27 
-27 
-31 
-32 
-34 
-41 
-46 
-49 
-55 
-59 
-65 
-67 
-96 
-98 
-103 
 
 
 
 
Gene Name 
 
 
 
Coiled-coil domain containing 127 
Olfactory receptor family 8, subfamily B, member 4 
Transmembrane protein 95 
TBC1 domain family, member 17 
MicroRNA 527 
Fanconi anaemia complementation group E 
Regulator of G protein signalling 14 
Protein phosphatise 1 regulatory subunit 8 
Non-coding RNA protein 
Par-6 partitioning defective 6 homolog alpha (C.elegans) 
Small nucleolar RNA, H/ACA box 52 
 
 
 
Leukocyte receptor cluster member 1 
Paired box 1 
LY6/PlAUR domain containing 5 
MicroRNA 4267 
Cbl proto-oncogene E3 ubiquitin ligase C 
Abhydrolase domain containing 1  
MicroRNA 138-2  
Solute carrier, family 30 (zinc transporter), member 8 
Gelsolin 
Nucleolar complex associated 2 homolog  
Ubiquitin B  
Adaptor-related protein complex 2, beta 1 subunit 
Chorionic gonadotropin beta polypeptide 8 
Histatin 3 
Transmembrane protein 80 
DICTN1antisense RNA 1 
RecQ protein-like (DNA helicase Q1-like) 
Neutral sphingomyelinase activation associated factor 
Coiled-coil domain containing protein 
 
Gene Title 
 
 
 
CCDC127 
OR8B4 
THEM95 
TBC1D17 
MIR527 
FANCE 
RGS14 
PPP1R8 
NCRNA00085 
PARD6A 
SNORA52 
 
 
 
LENG1 
PAX1 
LYPD5 
MIR4267 
CBLC 
ABHD1 
MIR138-2 
SLC30A8 
GSN 
LOC401010 
UBB 
AP2B1 
CGB8 
HTN3 
TMEM80 
LOC100189589 
RECQL 
NSMAF 
CCDC56 
 
 
 
Cytoband 
 
 
 
5p15.33 
11q24.2 
17p13.1 
19q13.41 
19q13.42 
6p21.31 
5q35.3 
1p35.3 
19q13.41 
16q22.1 
11p15.5 
 
 
 
19q13.42 
20p11.22 
19q13.31 
2q13 
19q13.32 
2p23.3 
16q13 
8q24.11 
9q33.2 
2q21.1 
17p11.2 
17q12 
19q13.33 
4q13.3 
11p15.5 
2p13.1 
12p12.1 
8q12.1 
17q21.31 
 
 
MAT-score 
 
 
 
2.51712 
2.39954 
2.3663 
2.41936 
2.64899 
2.47682 
2.61364 
2.57335 
2.40713 
2.39208 
3.11802 
 
 
 
-3.15795 
-2.41437 
-3.35125 
-3.00631 
-2.54886 
-2.60717 
-2.49835 
-2.47766 
-3.02306 
-2.46938 
-3.15419 
-2.50097 
-3.2507 
-2.56456 
-2.79753 
-5.33245 
-2.51545 
-2.47126 
-5.33245 
 
 
Transcript ID 
 
 
 
NM_145265 
NM_001005196 
NM_198154 
NM_024682 
NR_030219 
NM_021922 
NM_006480 
NM_014110 
NR_024330 
NM_016948 
NR_002585 
 
 
 
NM_024316 
NM_006192 
NM_001031749 
NR_036225 
NM_012116 
NM_032604 
NR_029680 
NM_001172811 
NM_198252 
NR_002826 
NM_018955 
NM_001282 
NM_033183 
NM_000200 
NM_174940 
NR_024463 
NM_032941 
NM_001144772 
NM_001040431 
 
 
P-value  
 
 
 
0.0054 
0.0832 
0.0098 
0.0079 
0.0032 
0.0032 
0.0064 
0.0044 
0.0083 
0.0088 
0.0004 
 
 
 
0.0010 
0.0085 
0.0006 
0.0016 
0.0058 
0.0049 
0.0068 
0.0072 
0.0015 
0.0073 
0.0010 
0.0067 
0.0007 
0.0056 
0.0030 
˂0.0001 
0.0064 
0.0073 
0.0002 
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Table 3.12: Summary of Genes with Promoter Region CpG Island Hypermethylation 
and their Clinical Significance in HBV Infection 
 
 
 
 
 
Genes 
 
A.  Cyclin-Dependent Kinase 
CCND3 
PARD6A 
 
B. Growth Factors  
FGFRL1 
PARD6A 
 
C. Metabolism Regulators 
PTGR2 
TRPV5 
 
D. Tumor Suppressors 
GABPB2 
NACC2 
NAIF1 
PA2G4 
PARD6A 
PATE3 
PCGF1 
PTOV1 
PTGR2 
TBC1D17 
TUBA4A 
 
E. Transcription Regulators 
EXOSC3 
GABPB2 
RRNP3 
PA2G4 
PCGF1 
PTOV1 
 
F. Regulation of RNA Splicing 
EXOSC3 
SNORD48 
THRAP3 
 
G. Genes Encoding Ubiquitin Proteins 
LNX2 
PA2G4 
TRIP12 
UBXN1 
 
H. Vitamin D -Related Genes 
THRAP3 
TRPV5 
 
I. Pseudogenes 
RRNP3 
 
J.  Genes that interact with HIV Proteins 
THRAP3 
TUBA4A 
 
Physiological Functions  
 
 
Liver regeneration; Wound healing process  
Protein kinase C binding; Asymmetrical cell division  
 
 
Negatively regulate cell growth; Tissue regeneration; Healing 
Transforming growth factor β receptor signaling pathway 
 
 
Prostaglandin metabolism; Immune function 
Calcium and phosphorus metabolism 
 
 
Cell adhesion; Immune function 
Negatively regulates apoptosis 
Induction of cell apoptosis 
Cell proliferation; Cell cycle arrest 
Cell cycle arrest, proliferation and apoptosis 
Induces cell cycle arrest and apoptosis 
Cell cycle progression and proliferation 
Enhances cell Proliferation 
Cell proliferation and apoptosis 
Inhibits cell transformation and proliferation 
Regulates cell adhesion  
 
 
Ribosomal transcription 
Initiates transcription via RNA polymerase 1 
Initiates transcription via RNA polymerase II 
Negative regulation of transcription 
DNA transcription regulator 
DNA Replication and transcription regulator 
 
 
RNA and mRNA metabolic process 
snoRNA processing and binding 
Regulates mRNA processing 
 
 
E3 ubiquitin ligase activity 
Histone H2A monoubiquitination 
Histone H2A ubiquitination 
E3 ubiquitin ligase activity 
 
 
Vitamin D receptor binding 
Transport vitamin D-induced calcium ion  
 
 
Ribosomal transcription 
 
 
Interact with HIV-1 Protease and Gag Proteins 
Interact with HIV-1 Tat and Rev Proteins 
Related Diseases  
 
 
Liver fibrosis; HCC suppression 
Defects in Caenorhabditis elegans 
 
 
Liver fibrosis; HCC suppression 
Defects in Caenorhabditis elegans 
 
 
Autoimmune disease; Type 2 diabetes mellitus 
Rickets; Osteoporosis; Hyperparathyroidism 
 
 
Unknown 
Unknown 
Gastric cancer 
Cancer 
Metastatic carcinoma 
Glioma cells 
B-cell lymphoma 
Prostate and bladder malignancies 
Unknown 
Unknown 
Unknown 
 
 
Unknown 
Gastric cancer; inflammation 
Unknown 
Cancer 
B-cell lymphoma 
Prostate and bladder cancers 
 
 
Unknown  
Cancer 
Hyperthyroidism; Hypercalcemia 
 
 
Breast cancer 
Unknown 
Unknown 
Unknown 
 
 
Hyperthyroidism; Hypercalcemia 
Hyperparathyroidism 
 
 
Colorectal cancer 
 
 
HIV-1 
HIV-1 
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3.6  DISCUSSION 
Using the GeneChip
®
 Human Promoter 1.0R array (Affymetrix, Santa Clara, 
California), this study has investigated the presence of genome wide promoter CpG 
island methylation profiles in patients with chronic HBV infection.  
Systemic bias occurs in microarray work due to a number of various factors. These 
occur at sample preparation, hybridization and measurement of methylation or gene 
expression. Batch to batch variation in the array manufacturing will also introduce 
bias during sample analysis as will the day-to-day variation in laboratory conditions 
that will also cause variation in results based on the day of sample preparation and 
analysis.  
From the PCA done earlier, technical biological batch effects were found to be a big 
source of variation and resulted in some tissue samples clustered far from one 
another or hidden in technical batch effects (see Figure 3.8A). RMA applies quantile 
normalization, which is a technique that forces the distribution of the raw signal 
intensities of the microarray data to be the same in all the samples under analysis. 
This reduces the global differences being arrays but does not address the batch effect 
which needs to be addressed separately. After background correction and removal of 
batch effects through RMA, the clustering of the tissue samples became closer, easily 
identified and analysed (see Figure 3.8B). 
Epigenetic mechanisms are involved in various biological processes such as the 
transcriptional regulation of genes and virus related tumorigenesis. Although early 
research showed that altered DNA methylation could silence tumour suppressor 
genes, the effect has also been shown to affect a wide range of genes 
28 - 32
. Research 
continues to show that methylation of CpG island promoter regions is a key 
mechanism for gene silencing in many conditions 
28, 209
.   
This study demonstrated the presence of genome wide hypermethylation of promoter 
CpG island regions in patients with chronic HBV infection. The possible clinical 
implications of such gene hypermethylation in HBV related liver and human disease 
are discussed (Section 3.6.1 - 3.6.10). None of the gene promoter CpG islands 
methylated in the comparisons of HBV patients with HCC (see Table 3.5) and HCC 
with neighbouring tissues (see Table 3.5) were discussed since there were no 
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evidences that indicate that they may have relevant biological significance in the 
liver as far as HBV is concerned. It is also important to note that the HCC for 
patients used in this study was cryptogenic which means the underlying aetiology 
was obscure.   
 
3.6.1 CYCLIN-DEPENDENT KINASES 
The genes methylated in chronic HBV infection that are associated with cyclin-
dependent kinases were cyclin D3 (CCND3) and par-6-partitioning defective 6 
homolog alpha (PARD6A) (see Table 3.12.A). These genes are implicated in various 
cellular signalling pathways and angiogenesis, suggesting a role in tumorigenesis. 
They have been reported previously as key players in the establishment of liver 
inflammation, fibrosis and tumorigenesis 
38, 47, 48
.  
Protein kinases including cyclin-dependent kinases (CDK) are central regulators of 
the cell cycle. CDK-related protein kinases are regulated by cyclins, CDK inhibitors 
and phosphorylating proteins 
33, 34
.  
Regulation of protein kinases is an important step that facilitates hepatic regeneration 
after injury due to viral hepatitis infections, alcohol and drugs 
35 - 37
. Liver fibrosis 
results from a process of continuous and concurrent inflammation and healing in 
response to hepatocyte injury. It is accompanied by the activation of macrophage cell 
lines of Kupffer and other phagocytic cells, which line the liver sinusoids 
38
. In 
response to liver damage, Kupffer cells induce inflammatory actions, activation of 
hepatic stellate cells and accumulation of extracellular matrix that replaces damaged 
hepatocytes. Importantly, genes regulating hepatic inflammatory and fibrogenic 
actions trigger cell cycle activation, cell growth, apoptosis and liver regeneration 
38 - 
44
. Inactivation of these genes by DNA methylation may disrupt wound healing and 
liver regeneration processes, resulting in the excessive production of extracellular 
matrix and severe scarring leading to cirrhosis and liver cancer. 
 
Cyclin D3 (CCND3) Gene 
Cyclins are targets of oncogenic viruses and play a critical role in tumorigenesis by 
regulating the cell cycle through their interaction with CDK-inhibitors and CDK-
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related protein kinases 
45, 46
. They also interact with phosphorylating proteins such as 
retinoblastoma and p53, whose activities are required for cell cycle progression 
through the G2 phase and G1/S transition 
12, 47 - 49
.  
CCND3 protein encoded by CCND3 gene is a prominent example of cyclins that 
play an important role in liver regeneration and fibrosis. Through phosphorylation of 
tumor suppressors, CCND3 protein regulates the activities of cyclin-dependent 
protein kinases CDk4 and CDk6 
47 - 49
.  Activation of receptor tyrosine kinases is 
associated with active hepatic stellate cells (HSC) and accumulation of extracellular 
matrix (ECM) and therefore CCND3 gene is important in the regulation of hepatic 
inflammation and fibrosis 
45-49
.  In HBV-induced HCC, the CCND3 protein was 
reported to be negatively regulated by MiR-138 that acts as a tumour suppresser, 
leading to cell cycle arrest and HCC suppression 
234
.  In addition, high levels of 
CCND3 protein expression were observed in breast cancer and HBV-induced HCC 
with cirrhosis background 
45, 46
. This correlates with loss of cell cycle control and 
malignant phenotypes, implying that it has a significant role in tumour progression 
45, 
46, 49
.  In this study, there was only 1 HBV related HCC sample (see Table 3.2) and 
this would have limited the ability of the microarray analysis to show the presence of 
CCND3 gene promoter hypermethylation in the comparison of  HBV with HCC 
patients and HBV e antigen and normal controls (see Table 3.5 to 3.7). 
 
Par-6-Partitioning Defective 6 Homolog Alpha (PARD6A) 
PARD6A is a member of the PAR6 gene family. Mutations of PAR6 genes cause 
defects during the formation of Caenorhabditis elegans embryo by disrupting proper 
asymmetric partitioning of cytoplasm 
50- 52
. The PAR6B gene regulates the formation 
of tight-junctions that mediate cell to cell interaction required to maintain epithelial 
cell polarity and accurate asymmetric cell division processes in breast cancer cells 
(see Appendix 26.G) 
51, 53
.   
The PARD6A gene is involved in asymmetrical cell division that generates two 
daughter cells with different cell proliferation and polarization fates 
52
. It induces cell 
proliferation and polarization by activating atypical protein kinase C (PKC) and cell 
division cycle 42 (CDC42) signalling pathways 
53
. The activation of PKC is 
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mediated by calcium ions and diacylglycerol that are produced in the cell membrane 
during signal transduction of inositol phospholipids 
51
. HBx protein enhances 
diacylglycerol expression to activate the PKC signalling pathway which acts as an 
intracellular receptor for tumour suppressors and activators of oncogenes 
54, 55
.  
It is possible that methylation of the PARD6A-associated promoter CpG island is 
used to alter calcium signalling as part of the virus’ survival strategy. The PARD6A 
gene may also be an essential component in the biogenesis of epithelial cell tight 
junctions, implying that loss in the normal function of this gene may alter epithelial 
cell architecture and tissue remodelling leading to liver cancer. 
 
3.6.2 GROWTH FACTORS 
The CpG island promoter region of the FGFRL1 gene was hypermethylated in HBV 
e antigen positive patients (see Table 3.12.B). The FGFRL1 gene may be important 
in the development of inflammation and fibrosis through its involvement in the 
activation of extracellular signal-regulated protein kinases (ERK)/MAPK pathway 
(see Appendix 26.J) 
69, 70
. The methylation of FGFRL1 gene may disrupt 
ERK/MAPK pathway resulting in uncontrolled cell growth that could lead to 
malignancy.  
Growth factors such as FGFRL1 encoded by FGFRL1 gene, transforming growth 
factor beta (TGF-β), insulin-like growth factor (ILGF), epidermal growth factor 
receptor (EGFR) and tumour necrosis factor (TNF) stimulate cell growth, 
proliferation and apoptosis. These processes are involved in the development of 
hepatic steatosis, cirrhosis and HCC 
56 - 58, 63, 67, 68
. They control various stages of 
liver regeneration by regulating inflammation, wound healing and fibrosis 
59, 60
. They 
also control the cell cycle via the regulation of c-Myc proto-oncogene and Smad 
proteins that transduce extracellular signals from growth factor ligands to the nucleus 
where they regulate gene transcription.  
The disruption of growth factors TGF-β, ILGF, EGFR and TNF during HBV 
infection has been described in human hepatoma cell lines, transgenic mice and 
woodchucks, resulting in increased cell proliferation, apoptosis and premalignant 
alteration of hepatocytes 
61 - 68
. In HBV-related HCC, EGFR has been shown to be 
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targeted by HBx protein for cell growth 
65
.  In addition, HBx protein induces 
apoptosis by directing or sensitising the infected hepatocytes to growth factor related 
apoptotic pathways 
65 - 68
.  
 
Par-6-Partitioning Defective 6 Homolog Alpha (PARD6A) Gene 
The PARD6A gene regulates the signalling pathway of transforming growth factor 
beta (TGF-β) by activating Smad proteins and triggering the induction of epithelial-
to-mesenchymal transition (EMT)
 72, 73
. EMT is a potent regulator of hepatocytes 
migration, survival, inflammation and fibrosis, and contributes to the development of 
malignant invasion and metastasis ability 
71 - 74
. Upregulation of the TGF-β gene 
correlates with high levels of HBx protein in the livers of transgenic mice, suggesting 
that the PARD6A gene may be involved in the transactivation of HBx protein 
75
.  
 
3.6.3 METABOLIC REGULATORS   
Prostaglandin reductase 2 (PTGR2) and transient receptor potential cation channel 
subfamily v member 5 (TRPV5) genes were found to be hypermethylated in HBV 
patients (see Table 3.12.C). These genes are involved in lipid and glucose metabolic 
pathways. 
Abnormal regulation of hepatic metabolism is a recently described novel feature of 
HBV infection and HBV-related HCC 
76
. Disruption in the transcriptional activities 
of metabolic regulators could result in the accumulation of mutations leading to 
carcinogenesis 
80
. A common consequence of disruption of metabolism regulators by 
HBx protein in the liver is hyperglycemia. Hyperglycemia is characterised by 
excessive glucose levels in the blood and causes liver damage that can lead to the 
development of fibrosis, cirrhosis and HCC 
80, 81
.  
HBx protein disrupts metabolism by interfering with peroxisome proliferator-
activated receptor gamma (PPARγ) gene, RAR-β2, inducible nitric oxide synthase 
(iNOS) and SREBP resulting in hepatitis steatotis and hyperglycemia (see Appendix 
26.K) 
77 - 81
. This would lead to inflammation, cirrhosis and HCC overtime 
77
.  
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Prostaglandin Reductase 2 (PTGR2) Gene  
The PTGR2 gene encodes PTGR2 protein that controls hepatic lipid and glucose 
metabolism by suppressing the expression of PPARγ protein. PTGR2 protein 
catalyses NADPH-dependent reduction of 15-keto-prostaglandin E2 (PGE2) into 
13,14-dihydro-15-keto-PGE2. This catalysis suppresses PPARγ protein, a key 
negative regulator of hepatocyte proliferation, apoptosis, lipid and glucose 
metabolism 
80
. NADPH is a potent ROS inducer, suggesting that PTGR2 gene may 
be involved in the induction of apoptosis by HBx protein-upregulated ROS that 
establishes oxidative stress and hepatic injury
 81
.  
HBx protein transcriptionally activates PPARγ gene via ROS upregulation and 
increases the expression of lipogenic and gluconeogenic genes 
81
. These effects are 
associated with the activation of iNOS and JNK pathways resulting in significant 
elevation of lipid and glucose concentrations in the blood that can cause severe liver 
damage 
80, 81 
(see Appendix 26.M). Abnormal metabolism of lipids and glucose 
impairs liver function and causes insulin resistance in type 2 diabetes mellitus, which 
is often seen in HBV infection and predisposes to HCC development (see Appendix 
26.M) 
80
.  
Another outcome of PTGR2 hypermethylation is the disruption of the function of 
cylooxygenase-2. Cyclooxygenase-2 produces prostaglandins which are important in 
the development of tissue inflammation. It is highly expressed in most tumours 
including HBV-related HCC 
211
. In HBV-related HCC, cyclooxygenase-2 increases 
the expression of HBx protein which forms a complex with p53 protein in the 
cytoplasm and disrupts p53-mediated transcription and apoptosis by activating 
prostaglandin E2  
212
 .  
These findings suggest that the significant methylation of the PTGR2 gene promoter 
shown in this study may be one of the mechanisms utilised by HBx protein to take 
over control of p53-mediated apoptosis and transactivate the PPARγ gene to benefit 
viral survival. However, the adverse effects of this are abnormal lipid and glucose 
metabolism leading to the development of steatosis, hyperglycemia, inflammation 
and cirrhosis. 
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Transient Receptor Potential Cation Channel Subfamily V Member 5 (TRPV5) 
TRPV5 gene is a member of the transient receptor family and is a fundamental 
cofactor of calcium and phosphorus metabolism. It is regulated by the vitamin D 
receptor (VDR) which is activated by 1,25-dihydroxyvitamin D3 (vitamin D). 
Vitamin D induces the immune system by initiating cytokine production that 
regulates cell growth and proliferation 
82
. Low levels of vitamin D are seen in 
patients with liver failure and active tuberculosis as a result of impaired synthesis 
83 - 
86, 241
. Recent studies have shown a significant association between low serum levels 
of vitamin D and HBV viral loads in patients with chronic HBV infection 
83, 84
.  
The TRPV5 gene is an important regulator of calcium metabolism, suggesting that 
abnormal inactivation of TRPV5 protein expression by HBx protein-induced 
methylation may help to stimulate viral replication while affecting cell cycle 
progression, proliferation and differentiation
 87, 88
. Several studies suggest that HBx 
protein increases cytosolic calcium uptake and stimulates HBV replication via the 
activation of store operated calcium entry, AP-1 and tyrosine kinase transcription 
pathways which influence cell proliferation and apoptosis 
54, 87 - 92
. This effect may be 
achieved via the methylation of TRPV5 gene. 
 
3.6.4 TUMOUR SUPPRESSOR GENES 
The tumour suppressor gene GABPB2, NACC2, NAIF1, PA2G4, PATE, PCGF1, 
PARD6A, PTGR2, TBC1D17 and TUBA4A were hypermethylated in HBV patients 
(see Table 3.12.D). The NACC2 and NAIF1 genes are located in chromosome 9, 
which interestingly appeared to be highly methylated when HBV infected patients 
were compared to normal controls (see Figure 3.10B).. Hypermethylation of 
chromosome 9 in chronic HBV infection may be attributed to the know presence of a 
large amount of oncogenes and tumour suppressor genes located in this chromosome. 
These would render the, chromosome more vulnerable to HBV-induced DNA 
methylation
247
. In addition, it is not known whether or not HBV has preferential sites 
of viral integration, e.g. at sites of oncogenes and tumour suppressor genes, which 
would also make a chromosome with a high density of such genes more susceptible 
to HBV viral integration and therefore sustain more DNA hypermethylation as part 
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of the innate response to the presence of viral DNA in the genome.  
Tumour suppressor genes play a critical role in liver carcinogenesis. They maintain 
various cellular pathways that regulate cell-cycle, growth, proliferation and 
apoptosis. When disrupted, malignant transformation and ability to invade other 
tissues and metastasize occurs in the affected cells 
28 - 31 
. Inappropriate DNA 
hypermethylation is an important factor in driving abnormal inactivation or silencing 
in the expression of tumour suppressor genes 
56, 93 - 96
.  
 
GA Binding Protein Transcription Factor Beta Subunit 2 (GABPB2) Gene 
GABPB2 gene is a member of the GA binding proteins and has been described as one 
of E26 transforming sequence (ETS)-associated transcription factors 
97, 98
. ETS 
factors regulate the expression of cancer-related genes when targeted by cellular 
signalling pathways such as MAPK/ERK and JNK 
99
. They are key players in tissue 
remodelling, cell growth, differentiation, apoptosis and metastases. They regulate the 
immediate early response genes, suggesting that GABPB2 might be expressed at an 
early stage of infection 
100
. Since some ETS factors regulate the production of ROS, 
the GABPB2 gene may also be involved in ROS activities 
101
.  
GABPB2 gene modulates the expression of yes-associated protein (YAP) oncogene 
which inhibits ROS-induced oxidative stress and apoptosis via the activation of the 
JNK pathway. In HCC, loss of YAP results in G1/S cycle arrest and increased 
apoptosis that drives tumorigenesis 
102
. The expression of the YAP gene is also 
modulated by HBx protein via the activation of cAMP response element binding 
(CREB) to promote cellular growth in hepatoma cells expressing HBV-induced HCC 
103
. It is possible that during the course of HBV infection, the transcriptional activity 
of the GABPB2 gene is activated or silenced via HBx protein-induced aberrant 
methylation. This would alter the activities of CREB, c-Jun N-terminal kinase (JNK) 
and mitogen-activated protein kinases (MAPK)/ERK signalling pathways leading to 
apoptosis and compensatory hepatocyte proliferation. 
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NACC Family Member 2, BEN and BTB (POZ) Domain Containing (NACC2) 
Gene 
NACC2 is a novel gene. Little is known about the regulation and physiological 
relevance of this gene in viral infections and cancers. The NACC2 gene has been 
linked to the negative regulation of the mitochondrial intrinsic apoptotic signalling 
pathway, which may be disrupted by HBx protein to increase viral replication
 105
. 
The intrinsic signalling pathway is characterised by the release of the cytochrome C 
into the cytoplasm where it induces apoptosis by increasing caspase 3 activities 
104
. 
It is possible that in response to damage caused by HBV infection, the NACC2 gene 
controls apoptosis by regulating the intrinsic pathway via its interaction with p53 
transcriptional activator or cytosolic cytochrome C. A study by Lee et al
105
 showed 
an increase in the level of cytosolic cytochrome C in HeLa and HepG2 cells-
expressing HBx protein. Hypermethylation of the NACC2 promoter CpG island may 
be a mechanism by which the HBx protein causes the release of cytochrome C for 
apoptosis induction in infected hepatocytes.    
 
Nuclear Apoptosis Inducing Factor 1 (NAIF1) 
The NAIF1 gene, also known as Chromosome 9 open reading frame 90 (C9orf90), 
encodes the nuclear localised NAIF1 protein that is highly expressed in liver and 
gastric tissues 
106
. Expression of the NAIF1 protein in oesophageal carcinoma and 
gastric cancer cells regulates cell proliferation and apoptosis by activating caspases 
3, 8 and 9 pathways. Downregulation of NAIF1 protein expression was shown to 
induce cell cycle arrest (G0/G1) and apoptosis in gastric cancer cells 
106
. Since 
caspases 3 and 9 regulate apoptosis 
244
, methylation of promoter region CpG island 
in the NAIF1 gene may be another mechanism by which HBx protein alters caspases 
3 and 9 pathways leading to induction or inhibition of apoptosis that is associated 
with increased viral replication and cell survival.  
 
Par-6-Partitioning Defective 6 Homolog Alpha Gene 
The PARD6A gene induces the expression of the TGF-β gene, which displays its 
tumour suppressive role by inhibiting cell proliferation and inducing apoptosis in 
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cultured hepatocytes (see Appendix 26.B) 
107, 108
. Expression of the TGF-β protein in 
liver cells is associated with a highly invasive phenotype accompanied by recurrence 
of aggressive tumours and metastasis 
109
. HBx protein deregulates 
phosphatidylinositol 3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) 
pathways in order to inhibit the TGF-β induced apoptosis in hepatoma cells 110, 111. 
The ability of the PARD6A gene in regulating apoptosis might be HBx protein-
dependent and therefore may play a critical role in the pathogenesis HBV infection 
and development of HBV-induced HCC.  
 
Proliferation Associated 2G4 (PA2G4) Gene 
The PA2G4 gene encodes PA2G4 protein that is also known as V-erb-b2 
erythroblastic leukemia viral oncogene homolog 3 (ErbB3)-binding protein 1 (EBP1)
 
112
. The PA2G4 protein (EBP1) is known to inhibit the expression of E2F1 and 
androgen receptor-regulated genes such as prostate specific antigen by binding to and 
activating Sin3A-histone deacetylases (HDAC) 2 complex 
221, 222
. Sin3A-HDAC2 
complex repress the transcription of the targeted gene by binding to its promoter. 
Repression of E2F1 and AR mediated transcription inhibits proliferation and induces 
differentiation in human breast and prostate cancer cell lines 
114, 221 -223
. The 
downregulation of the PA2G4 protein in leukemia, breast, bladder and prostate 
cancer cells is associated with increased cell growth, proliferation, differentiation and 
tumour progression 
95
. 
The PA2G4 protein also interacts with the cytoplasmic domain of inactive tyrosine 
kinase ErbB3 protein 
112
. The ErbB3 protein is an active receptor of ligand heregulin 
that stimulates its tyrosine phosphorylation and enables it to dissociate and 
translocate to the nucleus 
224
. This induces intracellular adhesion molecule 1 
expression leading to cellular proliferation and differentiation 
225, 226
. Apart from 
ErbB3 protein, the ErbB3 gene also encodes an epidermal growth factor receptor 
(EGFR) which activates the PI3K-AKT and JNK-MAPK pathways, which are 
involved in DNA synthesis, cell proliferation and apoptosis. Their disruption will 
contribute to malignant transformation of liver cells 
113
.  
The PA2G4 protein is a cell cycle regulatory DNA-binding protein. It appears in the 
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nuclei from late G1 to early S phase and disappear late at G2, suggesting its 
important role on cell cycle progression 
227
. Mouse recombinant PA2G4 protein was 
shown to have an inhibitory effect on DNA replication in Xenopus egg extracted 
single stranded DNA template 
114
. Methylation and disruption of the PA2G4 gene in 
chronic HBV infection would result in inhibited apoptosis leading to uncontrolled 
cell growth, differentiation and abnormal DNA synthesis. 
 
Prostate and Testis Expressed 3 (PATE3) Gene 
The PATE3 gene encodes the ataxia telangiectasia mutated (ATM) gene and is 
abundantly expressed in the prostate and testis. Mutations in the ATM gene result in 
predisposition to infections, disrupts cell cycle arrest, DNA repair and apoptosis via 
phosphorylation of the p53, checkpoint kinase 2 (CHK2) and Histone 2A member X 
(H2AX) tumour suppressor genes 
115
. In human glioma cells, knockdown of the ATM 
mutated gene was shown to trigger DNA damage by increasing the level of ROS and 
altering radiation-induced apoptosis 
116, 117
.  
Methylation of the PATE3 gene during HBV infection may either inactivate or 
upregulate the level of mutated ATM gene, altering the cellular p53 and ROS 
signalling pathways which then worsen DNA damage caused by HBV infection. 
 
Polycomb Group Ring Finger 1 (PCGF1) Gene 
The PCGF1 gene is a mammalian homolog of the Drosophila polycomb genes that 
negatively regulates the cell cycle via the activation of B-cell CLL/lymphoma (Bcl)-
6 and p21 cyclin-dependent kinase inhibitor 
118
. The Polycomb genes typically 
modify histone tails by reversibly repressing the transcriptional activity of genes 
specific to cell fate thereby influencing hepatocyte transformation 
119
. The 
transcriptional repressive capability of the PCGF1 gene, its interaction with the Bcl-
6/p21 genes and association with enhanced cell cycle progression and proliferation 
suggests a possible role of the PCGF1 gene in tumorigenesis.  
The PCGF1 gene encodes a protein that contains the RING finger motif conserved 
with cysteine rich domain which is involved in the monoubiquitination and  
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degradation pathway of histone H2A protein 
118, 120
. The expression of the p21 gene 
depends on the p53 signalling pathway, suggesting that the PCGF1 gene may induce 
histone H2A monoubiquitination by disrupting the p53 signalling pathway. The 
PCGF1- induced monoubiquitination switches off the transcriptional elongation of 
RNA polymerase II and this suggests that it also has a role in gene transcription 
120
. 
Although there is no known direct association of the PCGF1 gene with HBV 
infection, alteration in the expression of encoded PCGF1 protein may be involved in 
carcinogenesis through abnormal ubiquitination and gene silencing.  
 
Prostate Cancer Overexpressed 1 (PTOV1) Gene 
The PTOV1 gene encodes a novel mitogenic protein that is expressed at a high level 
in malignancies 
122
. The PTOV1 protein acts as a tumour suppressor and potential 
marker for cancer progression due to its increased level of expression and enhanced 
cell proliferation in high-grade bladder and prostate cancers 
122
.  The PTOV1 protein 
shuttles dynamically from the cytoplasm into the nucleus to promote the entry into 
the S phase of the cell cycle. Insulin-like growth factor-1 (IGF1) is a known inducer 
of cell cycle S phase entry-related gene that upregulates the phosphorylation of 
retinoic acid-induced retinoblastoma contributing to G0/G1-S transition 
121
. IGF-1 
promotes cell cycle progression via activation of the PI3K and NF-кB signalling 
pathways that are regulated by ROS and implicated in the transactivation of HBx 
protein 
122
.   
In the lung cancer, the interaction of the PTOV1 gene with Zyxin, a nuclear-
translocated gene that regulates cell adhesion and motility occurs through the 
activation of transforming growth factor beta (TGF-β)/Smad3 46. The collaboration 
of the PTOV1 and Zyxin genes was shown to negatively regulate the retinoic acid 
promoter region by suppressing of retinoic acid receptor activities, leading to 
enhanced cell growth and proliferation 
123
. Though the underlying biological 
mechanisms related to the PTOV1 gene in HBV infection have not yet been 
elucidated, it is possible that promoter methylation of the PTOV1 gene serves as a 
key silencer of gene transcription that is important in the development of HBV 
related liver disease and HCC.  
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Prostaglandin Reductase 2 (PTGR2) Gene  
The PTGR2 gene is highly expressed in the liver and is required for activating the 
CREB pathway which is involved in liver regeneration and disrupted in malignancy
 
124
. CREB is a cellular transcription factor that binds to the cAMP response element 
(CRE) in the promoter regions of the target genes thereby limiting or inducing their 
transcription 
124
.  
The loss of PTGR2 protein expression in gastric cancer cells is associated with 
altered mitochondrial function that leads to increased ROS production and apoptosis 
125
. In addition, the ERK1/2 and caspase 3 pathways that usually co-operate with the 
CREB in producing ROS are activated and lead to gastric cancer progression 
accompanied by increased expression of the Bcl-2 protein 
126
. The Bcl-2 protein 
typically maintains induced mitochondrial oxygen consumption 
125
. 
Increased expression of the PPARγ ligand, a binding partner for CREB, has been 
shown to activate hepatic stellate cells leading to fibrosis associated with cell cycle 
arrest, growth and increased proliferation in tumour cells 
127, 128
. CREB is 
transactivated by HBx protein causing increased cell survival and is also activated by 
methyl groups thereby inhibiting gene transcription 
129, 131
. These findings suggest 
that the PTGR2 gene may be methylated and transcriptionally altered in HBV 
infection resulting in the activation of the CREB pathway to facilitate the survival of 
infected hepatocytes.  
 
TBC (tre-2/USP6, BUB2, cdc16) 1 Domain Family, Member 17 (TBC1D17) Gene 
The TBC1D17 gene encodes three protein domains including Ubiquitin specific 
protease 6 (USP6)/Tre-2 oncogene (tre-2), Budding uninhibited by Benzinidazole 2 
(BUB2) and Cell division cycle 16 (CDC16). The TBC1D17 gene regulates cell 
transformation, proliferation and cytokinesis by binding to the auxin response factors 
(ARF)-GTPase activating protein (ArfGAP)
 132
. This binding stimulates the 
transcriptional activities of NF-кB, mammalian target of rapamycin (mTOR) and 
Wnt/β-catenin signalling pathways required for liver regeneration 233.  
In HBV-induced HCC, there is upregulation of the mTOR signalling pathway by 
HBx protein via NF-кB pathway associated with inhibition of cell transformation and 
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proliferation 
133
. An mTOR-dependent signalling pathway leads to activation of 
hepatic stellate cells, which in turn activate leucine residues of hepatocyte growth 
factor, stimulating the production of hepatocyte growth factor 
245
. Hepatocyte growth 
factor is essential in tissue regeneration, angiogenesis and tumorigenesis due to its 
ability to stimulate mitogenesis, cell motility and matrix invasion. When abnormally 
regulated, hepatocyte growth factor may lead to tumorigenesis 
245
. Hypermethylation 
of TBC1D17 gene may disrupt mTOR and NF-кB signalling pathways and affect the 
physiological activities of hepatocyte growth factor, leading to increased cell 
proliferation and malignant transformation in the liver. 
 
Tubulin Alpha 4A (TUBA4A) Gene 
The TUBA4A gene is a microtubule associated oncogene that maintains the cell 
structure and is required for cell adhesion 
134
. The TUBA4A gene is a regulator of the 
Wnt/β-catenin pathway, which initiates transcription by binding to T-cell factor 
(TCF)/Lymphoid enhancing factor (LEF) transcription factors through its β-catenin 
binding region. The Wnt/β-catenin pathway regulates cell-cell adhesion and this may 
explain its association with the TUBA4A gene 
135
. Microtubule proteins often 
increase their stabilization by interacting with the APC tumour suppressor, which 
inhibits uncontrolled cell proliferation by suppressing the activity of Wnt/β-catenin 
pathway. Downregulation of the APC protein was shown to increase Wnt/β-catenin 
transcriptional activity in a mouse model, resulting in increased cell proliferation, 
deregulated protein metabolism, hepatomegaly and ultimately HCC development 
135
.  
The APC protein forms a complex with binding partners and destroys β-catenin via 
ubiquitin-independent degradation. This process is important to inhibit cell 
proliferation by repressing genes that induce cell division and growth from being 
switched on more than is necessary. The HBx protein competitively interacts with 
APC and displaces β-catenin from APC-mediated ubiquitination and degradation 136. 
This upregulates the Wnt/β-catenin signalling pathway causing uncontrolled cell 
growth that would favour the development of HCC. It is possible that the TUBA4A 
gene is upregulated via HBV-induced hypermethylation allowing HBx protein to 
alter the Wnt/β-catenin signalling pathway, disrupt ubiquitination and increase the 
risk of malignancy. 
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3.6.5 TRANSCRIPTION REGULATORS  
RNA polymerase 1 transcription factor homolog pseudogene 3 and GA binding 
protein transcription factor beta subunit 2 genes were hypermethylated in HBV 
infection and are transcriptional regulators (see Table 3.12.E). 
HBx protein may also contribute to liver tumorigenesis by deregulating RNA and 
DNA dependent transcription factors 
137, 138
. HBx protein binds to core promoter 
TATA binding proteins (TBPs) and TBP-associated factors (TAFs) that normally 
form the transcription factor II human (TFIIH) complex 
139 - 142
. The TBP and TFIIH 
complex are p53-dependent basal transcription factors and are required for normal 
transcription initiation, cell-cycle control, DNA excision and repair processes 
140, 143, 
148
.  
HBx protein disrupts the p53 pathway by binding to the carboxy terminus of TBP 
and TFIIH transcription factors 
140
. This leads to inhibition of DNA repair causing 
DNA damage and accumulation of mutations that activate tumour invasion and 
metastasis properties in cells 
141, 143, 153 - 155
.  
The TBP and TFIIH complex encodes the TATA box-binding protein-associated 
factor RNA polymerase I subunit B (TAF1B) protein and mutations in its gene is 
associated with colorectal cancer microsatellite instability, characterised by the 
presence of multiple copies of short tandem DNA repeat sequences 
149,152
. 
 
RNA Polymerase 1 Transcription Factor Homolog Pseudogene 3 (RRN3P3) Gene 
The RRN3P3 gene is transcribed by RNA polymerase 1, which is also involved in the 
synthesis of ribosomal RNA genes 
228
. Although there is not much information about 
this gene and human diseases including cancer, RRN3P3 gene may play a role in 
HBV infection as the HBx protein has been described as a novel virus transcriptional 
modulator of RNA polymerases and TFIIB
 228
.  HBx protein specifically binds to 
RNA polymerase II subunit B, which when highly expressed stimulates the 
transcription of HBx protein 
228
. Hypermethylation of RRN3P3 gene (see Table 
3.12.E) may be a strategy for viral infection to increase the transcription of HBx 
protein. 
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GA Binding Protein Transcription Factor Beta Subunit 2 (GABPB2) Gene 
GA binding protein (GABP) transcription factor activates genes required for DNA 
methylation and histone modification contributing to self-renewal, tissue 
regeneration and differentiation 
157 - 159
. GABP induces growth and antioxidant 
defence by activating Hippo pathway 
50
.  
GABPB2 transcription factor, encoded by GABPB2 gene, is a member of GABP 
family proteins. It contains ankyrin repeats in its promoter and regulates transcription 
by forming a tetrameric complex with the DNA-binding alpha subunits. It also has 
transcriptional activation domain (TAD) that mediates the initiation and elongation 
of RNA polymerase II transcription 
156
.  
Hypermethylation of the GABPB2 gene promoter CpG island may result in the 
silencing of GABPB2 gene expression. This could interfere with normal regulation 
and function of this gene leading to continuous hepatic damage, cirrhosis and HCC. 
 
3.6.6 REGULATION OF RNA SPLICING  
Microarray analysis revealed hypermethylation of CpG islands in the promoter 
regions of a number of the RNA processing-related genes that may be implicated in 
the transcriptional activities of the HBx protein (see Table 3.12.F).  
The DNA methylation machinery has been described in transposons and other DNA 
repeats where it alters the regulation of mRNA splicing, which is important for 
proper protein folding and mRNA production. In eukaryotes, mRNA sequences with 
introns and exons are transcribed from DNA. The pre-mRNA transcripts undergo 
post-translational modifications which excise introns from the sequence by splicing 
and joining the exons to form a contiguous coding sequence 
176
.  
Disruption of the mRNA splicing pattern often results in incomplete intron excision 
that leads to loss of protein expression or aberrant protein production. About 60% of 
disease-causing mutations are associated with abnormal mRNA splicing 
176
. 
Accumulation of abnormal or aberrant mRNA splicing has been identified mostly in 
cancerous cells and is rare in normal cells, suggesting that abnormal mRNA splicing 
contributes to tumorigenesis 
177
.  
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In HBV infection, the HBx protein activates transcription factors that stimulate the 
expression of RNA processing-related genes through its interaction with cis-acting 
elements 
178 - 180
. Regulation of RNA processing-related genes may play an important 
role in the pathogenesis of HBV infection.  
 
Exosome Component 3 (EXOSC3) Gene 
The EXOSC3 gene encodes the ribosomal RNA–processing protein 40 (Rrp40), 
which is characterised by having 5ꞌ to 3ꞌ exoribonucleolytic activity. The 5ꞌ to 3ꞌ 
exoribonucleolytic activity of Rrp40 facilitates the degradation of the EXOSC3 
protein. The cytoplasmic exosome complex is involved in the normal turnover and 
degradation of mRNA that has been tagged for degradation via nonsense-mediated 
RNA decay (see Appendix 26.H). This mRNA surveillance pathway is required for 
the elimination of mRNA transcripts that contain errors and have premature stop 
codons 
181
.  
Non-stop decay is another mRNA surveillance pathway and is required for the 
detection of mRNA molecules that lack stop codons and prevents them from being 
translated. It blocks the translation of such mRNA molecules by directing them 
towards the nuclear exosome complex for degradation (see Appendix 26.H) 
182
.  
Given these critical processes, it is evident that hypermethylation of the EXOSC3 
gene promoter CpG island may alter the transcriptional activities of Rrp40 leading to 
abnormal regulation of these critical pathways. Consequently, this may cause the 
accumulation of aberrant mRNA transcripts that, if translated, will either result in the 
loss of anticipated protein production or antimorphs which are dominant negative 
mutations that antagonise normal gene activity 
183
.  
 
Small Nucleolar RNA C/D Box 48 (SNORD48) Gene 
The SNORD48, also known as chromosome 6 open reading frame 48 (C6orf48) is a 
relatively newly described gene that belongs to a class of small nucleolar RNA 
(snoRNAs) molecules. The SnoRNA genes with C/D box motif play a part in the 
normal 2ꞌ-O-ribose methylation of rRNA, small nuclear RNA (snRNA) and transfer  
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RNA (tRNA). Induction of the snoRNA methylation by SNORD48 gene is important 
for stability, proper snoRNA processing and nucleolar localization 
184
. Such genes 
are frequently downregulated in cancer cells as they are located at the chromosomal 
fragile sites that are in close proximity to tumour suppressor genes 
185
.  
Chromosomal fragile sites in HBV infection have been described by Murakami et 
al
186
 who used by Alu-PCR based techniques to show that the HBV genome 
integrates at chromosomal fragile sites in human chromosomes. HBV genome 
integration at chromosomal fragile sites was shown to lead to chromosomal 
instability resulting in the accumulation of mutations and epigenetic alterations 
186
.  
Hypermethylation of the promoter regions of genes similar to the SNORD48 gene 
were also identified in this study and these include the small nucleolar RNA H/ACA 
box 52 (SNORA52) and small nucleolar RNA H/ACA box 7D (SNORA7D) genes (see 
Table 3.7 and 3.11).  
 
Small Nucleolar RNA H/ACA Box 52 (SNORA52) and Small Nucleolar RNA 
H/ACA Box 7D (SNORA7D) Gene  
Compared to the SNORD48 gene, the SNORA52 and SNORA7D genes have a 
H/ACA box motif that aids in guiding pseudouridylation which is the conversion of 
uridine to pseudouridine 
185
. Induction of pseudouridylation by ROS-related 
oxidative stress has been reported suggesting that the SNORD48 gene is involved in 
regulating apoptosis through the transactivation role of the HBx protein 
185
. It is 
possible that these genes are involved in the induction of ROS-related oxidative  
stress by the HBx protein.   
 
Thyroid Hormone Receptor Associated Protein 3 Gene 
Another mRNA splicing-related gene is the THRAP3 which is also a VDR-regulated 
gene. The THRAP3 gene is also known and reported as TRAP150 
187
. The THRAP3 
(TRAP150) gene regulates mRNA splicing and initiates thyroid hormone associated-
gene transcription via activation of cell signalling pathways that involve transcription 
and initiation factors. The THRAP3 gene (TRAP150) may exert its transcription 
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activating role by binding to the Transcription elongation factor 1 (TCERG1/CA150) 
188
. The TCERG1 gene contains two conserved F residues (FF) and WW domains 
that mediate protein-protein interaction. It uses these domains to interact with RNA 
polymerase II and the pre-mRNA splicing factor SF1 
188, 189
. There is no documented 
link between THRAP3 gene and liver disease. However, it is possible that HBx 
protein forms a complex with THRAP3 gene and disrupts protein-to-protein 
interactions between THRAP3 and transcription factors such as TCERG1. This 
would prevent the transcriptional transactivating properties of THRAP3 gene leading 
abnormal mRNA splicing that would influence the progression of liver disease.   
The TCERG1 gene is involved in the regulation of the HIV-1 Tat protein expression 
190
. Overexpression of TCERG1 protein is associated with significant reduction of 
Tat-dependent activation of HIV-1 Long terminal repeat (LTR) promoter and 
transcription initiation in vivo 
190
. This may explain the interaction of the THRAP3 
gene with HIV-1 activated proteins in human cell lines 
191
. In the presence of HBV 
and HIV coinfection, the potential interaction would result in the suppression of 
TCERG1 protein due to HBV related methylation. This would activate HIV-1 LTR 
promoter, leading to increased expression of Tat protein and enhanced viral 
replication. 
 
3.6.7 VITAMIN D RECEPTOR REGULATED GENES  
Hypermethylation of the promoter regions of the VDR-related genes transient 
receptor potential cation channel subfamily v member 5 (TRPV5) and thyroid 
hormone receptor associated protein 3 (THRAP3) were noted in patients with 
chronic HBV infection (see Table 3.12.G).  
Vitamin D receptor (VDR) is a ligand activated transcriptional regulator of calcium 
absorption 
163, 164
. It usually forms a heterodimer complex with retinoid x receptor to 
cause gene transcription 
229
. It also causes gene transcription by binding to 1,25-
dihydroxyvitamin D3 via vitamin-D responsive elements (VDRE) of VDR-targeted 
genes which stimulates cell-mediated immunity and may inhibit cell proliferation 
230 -
232
.  
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HBx protein stimulates viral replication and core viral particle assembly by 
increasing the mitochondrial calcium signals in HepG2 cells expressing HBx protein. 
This induces cell proliferation and favours tumorigenesis.  Recent studies show that 
the level of 25-hydroxyvitamin D is very low in the presence of chronic HBV 
infection, suggesting that vitamin D deficiency may play a role in enhancing viral 
replication 
83, 84
. The binding of vitamin D to the BH3 binding motif of Bcl-2 related 
proteins controls the production of various proteins involved in calcium transport and 
consumption 
54, 87, 168
. High calcium levels caused by the HBx protein control the 
cells and induce apoptosis via activation of transcription factors such as the Bcl-2 
and AP-1 proteins 
168, 169
. It is possible that hypermethylation of the VDR-related 
promoter genes is a key mechanism through which HBx protein binds to Bcl-2 
related proteins and modulates calcium signalling and increases the replication of 
HBV.    
VDR is a highly polymorphic and is implicated in various malignancies such as 
breast, colorectal and cervical cancer 
160
. Some studies have established an 
association between VDR polymorphisms and the outcome of HBV infection in an 
Asian population from China and Taiwan. This correlation is thought to influence the 
genetic susceptibility to HBV infection in these populations 
161, 162
.  
 
Transient Receptor Potential Cation Channel Subfamily V Member 5 Gene 
The TRPV5 gene is transcriptionally regulated by VDR and parathyroid hormone 
(PTH) via protein kinase A and C. Its main role is to maintain the serum level of 
calcium and phosphorus in the blood. It interacts with S100 calcium binding proteins 
and vitamin D-dependent protein containing EF-hand calcium binding motifs. 
Activation of the S100 proteins by vitamin D receptors regulates cell cycle 
progression, proliferation and differentiation 
170
. In response to low calcium, 
parathyroid gland secretes PTH to raise calcium levels in the blood by increasing 
renal calcium reabsorption 
171
.  
Mouse studies showed that the TRPV5 gene mediates renal calcium reabsorption and 
its downregulation suppresses this process 
172
. Loss or upregulation of the TRPV5 
gene expression from HBV-induced hypermethylation may result in the same 
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conditions associated with the VDR mutations and this may display a gateway 
mechanism for HBx protein to control the infected cells.  
 
Thyroid Hormone Receptor Associated Protein 3 (THRAP3) Gene 
The THRAP3 gene forms a thyroid hormone receptor-associated protein (TRAP) 
complex by interacting with thyroid and steroid receptors 
173
. This interaction 
facilitates ligand-dependent binding of TRAP factors to nuclear receptors that 
regulate cell cycle, growth and differentiation 
173
. The THRAP3 gene is involved in 
vitamin D receptor binding, suggesting that it may also be involved in the regulation 
of intracellular calcium uptake and utilisation. The cytochrome P450 (CYP) 
superfamily is a large group of enzymes abundantly expressed in the liver and 
involved in the metabolism of oxidative molecules by converting them into water-
soluble molecules for clearance 
173
.  
It has been shown that the VDR activates CYP family 27 subfamily B polypeptide 1 
(CYP27B1) protein that regulates 1,25-dihydroxyvitamin D3 and causes induction of 
cathelicidin and β-defensin antimicrobial peptides that act as innate immune defenses 
against infection 
174, 175
. Hormonal imbalance resulting from these events may result 
in reduced ability to mount effective innate immune responses against HBV 
infection, abnormal cell proliferation and apoptosis with an increased risk of 
malignancies 
171
. Alteration in the transcriptional activity of the THRAP3 gene via 
HBV-induced hypermethylation may negatively regulate VDR binding and may 
reduce cathelicidin and β-defensin induction by suppressing CYP24A1. This may 
also help to explain the low levels of vitamin D seen in Asian patients with HBV 
infection 
83
. 
 
3.6.8 GENES ENCODING UBIQUITIN PROTEINS 
In this study, HBV patients had hypermethylation of four genes that encode ubiquitin 
proteins. These were UBX domain protein 1 (UBXN1), ligand of Numb protein X 2 
(LNX2), PA2G4 and thyroid hormone receptor interactor 12 (TRIP12) genes (see 
Table 3.12H).  
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Most ubiquitin-regulated genes are tumour suppressor genes that are involved in the 
development of cancer by regulating signal transduction, cell cycle arrest and 
proliferation 
192
. Disruption of the normal ubiquitination activities of these genes 
may alter p53, Notch and Wnt cellular signalling pathways contributing to tumour 
initiation and progression 
193, 194
. Methylation of such genes is rare in normal tissue 
or epithelial cells but is frequently present in malignant cells, suggesting that they 
could potentially be used as tumour markers for the early detection of many 
malignancies including HCC 
195, 199
. 
The HBx protein binds ubiquitin proteins to protect itself from degradation 
201
. It is 
possible that the HBx protein disrupts the normal physiological functions of ubiquitin 
proteins to achieve its transactivation role leading to increased viral replication and 
protection against immune defence mechanism 
200, 201
. The reported mechanisms 
underlying the regulation of ubiquitin proteins and their physiological role in HBV or 
HBV-induced HCC are still not fully elucidated.  
 
UBX Domain Protein 1 (UBXN1) Gene 
The UBXN1 is a cellular receptor protein that interacts with the cell cycle regulator 
BRCA1-associated RING domain protein 1 (BARD1) heterodimer and regulates its 
activity in an ubiguitin-independent manner. This interaction triggers a critical block 
in the enzymatic functions of the BARD1 protein which involves E3 ubiquitin ligase 
activity. Elevated levels of UBXN1 are associated with a significant reduction of E3 
ubiquitin ligase activity. Many cases of ovarian and breast cancer have germline 
mutations of BRCA1 gene 
202
. Amplified in breast cancer 1 (AIB1) protein is highly 
expressed in human HBx protein positive HCC tissues, but rarely in HBx protein 
negative HCC tissues and this correlates with enhanced cell proliferation and HCC 
progression 
203
. Hypermethylation of the UBXN1 promoter CpG island during HBV 
infection may be another mechanism by which HBx protein causes gene 
transactivation.  
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Ligand of Numb protein X 2 (LNX2) Gene 
The LNX2 gene is a member of the Ligand of Numb protein X family proteins that 
are implicated in the development of the nervous system in Drosophila 
204
. The LNX2 
gene has PDZ-domain containing RING finger motif that acts as the E3 ubiquitin 
ligase which binds to phosphotyrosine domain of Numb and promotes its degradation 
via the ubiquitin-proteasome pathway
204
. The LNX proteins are the key regulators of 
cell fate decisions, differentiation and proliferation, suggesting their role in cancer
192
.  
In breast cancer, loss of LNX2-activated Numb protein activates of the oncogene 
Notch signalling pathway and suppresses p53 activity 
204
. Furthermore, 
overexpression of the LNX2 protein activates Notch signalling and ultimately Wnt/β-
catenin pathway in colorectal cancer 
204
. A recent study by Luo et al
205
 suggests that 
the HBx protein downregulates the NF-кB transcriptional factor by reducing the 
activity of the Notch signalling pathway and contributes to liver tumorigenesis. The 
p53, Wnt/β-catenin and NF-кB signalling pathways have been shown to be the 
central targets of HBx protein 
205
, suggesting that any alteration in either the LNX2 or 
Numb gene may also be important in HBV liver disease pathogenesis and cancer 
development. 
 
Proliferation Associated 2G4 (PA2G4) Gene 
Apart from being a tumour suppressor gene, the PA2G4 gene may be oncogenic in 
cells by interacting with human double minute-2 protein (HDM-2) via the ErbB3 
binding isoform 
206
. The HDM-2 protein is an E3 ubiquitin ligase that, when 
overexpressed, inhibits p53-mediated cell cycle arrest and apoptosis by suppressing 
the p53 signalling pathway 
207
. Given this data, hypermethylation of the PA2G4 
promoter CpG island in HBV infection cause the overexpression of PA2G4 protein, 
leading to uncontrolled cell differentiation and abnormal ubiquitination that develop 
into cancer.  
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Thyroid Hormone Receptor Interactor 12 (TRIP12) Gene 
The TRIP12 is an important ubiquitin gene and has a homologous to E6-AP carboxyl 
terminal - like domain that allows it to function as an E3 ubiquitin ligase that is 
required for DNA repair 
207
. The TRIP12 gene may play a critical role in liver 
disease and tumorigenesis as it is important in repairing and cleaving damaged DNA 
by recruiting histone 2A protein that mediates ubiquitination to the sites of damage 
207
.  
Abnormal transcriptional activity of the TRIP12 gene due to HBV induced 
methylation may either be associated with loss of the TRIP12 protein expression that 
will limit ubiquitination by histone 2A protein at the sites of DNA damage. This can 
also lead to overexpression of the TRIP12 protein that will increase the level of 
histone 2A protein production and lead to hyper-accumulation of ubiquitination. 
These events would ultimately cause mutations that can cause cancer 
207
. 
 
3.6.9 PSEUDOGENES 
Hypermethylation in the promoter CpG islands of pseudogenes such as RNA 
polymerase 1 transcription factor homolog pseudogene 3 (RRN3P3), coiled-coil 
domain containing 144B pseudogene (CCDC144B), defensin theta 1 pseudogene 
(DEFT1P), family with sequence similarity 106 member C pseudogene (FAM106C) 
and keratin 42 pseudogene (KRT42P) were identified in patients with chronic HBV 
infection (see Tables 3.4, 3.5 and 3.12.I).  
Pseudogenes have recently been defined as the newly discovered regulators of gene 
expression. They are ubiquitous and abundant in tumour tissues as compared to 
normal tissue, suggesting that they may have a role in the pathogenesis of human 
diseases and cancers 
144
. They resemble the structure and sequence of their parental 
genes, but have defects that make them produce abnormal mRNA sequences that 
encode non-functional proteins 
145, 146
. When transcribed, pseudogenes induce a 
series of genetic alterations such as loss of promoter sequences, frameshift mutations, 
deletions and insertions, giving them entirely different functions to their parental 
genes 
147
.  
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The clinical relevance of the hypermethylation of promoter CpG islands of RRN3P3, 
CCDC144B, DEFT1P, FAM106C, KRT42P pseudogenes may be the loss of normal 
gene expression as well as the abnormal activation of genes that could cause liver 
disease and malignancy. 
 
3.6.10 GENES THAT INTERACT WITH HIV-1 PROTEINS 
TUBA4A and THRAP3 are two genes that interact with human immunodeficiency 
virus type 1 (HIV-1) Gag, Rev and Tat proteins which were found to be 
hypermethylated (see Table 3.12.J). TUBA4A gene interacts with HIV-1 Gag and 
Protease proteins while THRAP3 gene interacts with Rev and Tat proteins 
190, 191, 213, 
216
.  
It is estimated that 5 - 10 % of chronic HBV infected individuals worldwide are co-
infected with HIV-1 
214, 215
. HIV-1 influences HBV pathogenesis and accelerates the 
risk of hepatic cirrhosis and HCC. The liver related mortality is 2 -3 times higher in 
HBV co-infected patients compared to those with HIV-1 monoinfection 
215
. The 
mechanisms underlying HBV and HIV-1 co-infection are still under investigation. 
 
Tubulin Alpha 4A Gene 
The TUBA4A gene interacts with the human immunodeficiency virus type 1 (HIV-1) 
Rev and transactivator of transcription (Tat) protein which is abundantly expressed in 
the liver 
213, 216
. The Tat protein enhances the carcinogenic effects of HBV in the 
liver of transgenic mice through its interaction with HBx protein. It appears that 
interaction of TUBA4A gene with HIV-1 proteins depolymerises microtubules that 
are formed by tubulins leading to the alteration of microtubules dynamics and 
activation of Bcl-2 mediated apoptosis. It is possible that HBx protein may disrupt 
Bcl-2 mediated apoptosis and other apoptotic related pathways such as MAPK and 
Wnt signalling pathways by methylating the gene promoter TUBA4A region (see 
Appendix 26.O) 
213
. 
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Thyroid Hormone Receptor Associated Protein 3 (THRAP3) Gene 
Overexpression of TCERG1 protein is associated with a significant reduction of Tat-
dependent activation of HIV-1 Long terminal repeat (LTR) promoter and 
transcription initiation in vivo 
190
. This may explain the interaction of the THRAP3 
gene with HIV-1 activated proteins in human cell lines 
191
. It is possible that the 
THRAP3 gene is expressed in the presence of high viral replication to inhibit viral  
DNA replication and core viral particle assembly by altering the transcriptional 
activity of the HBx protein. In return, HBV could trigger a self-defence mechanism 
by using HBx protein to inactivate the transcriptional activity of the THRAP3 protein 
via hypermethylation of its promoter and therefore silencing the THRAP3 gene. This 
disruption would also favour the replication of HIV-1, helping to explain the severity 
of HBV-HIV coinfection related liver disease. 
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3.7 CONCLUSIONS 
This study successfully demonstrates the presence of genome-wide promoter region 
CpG islands methylation in patients with chronic HBV infection. Hypermethylation 
of promoter CpG island regions of several genes was identified. These include 
cyclin-dependent kinases, growth factors, metabolic regulators, tumour suppressors, 
transcription regulators, RNA splicing regulators, ubiquitin related proteins, 
pseudogenes and VDR-regulated genes.  
Cyclin-dependent kinases, growth factors and some tumour suppressors such as 
CCND3, PARD6A, PA2G4, PTGR2 and TBCD17 genes are associated with cellular 
signalling pathways such as activation of transcription factors TGFβ, NF-kβ, CREB, 
ROS, MAPK and JNK whose targets are inflammation and fibrogenic related genes 
(see Sections 3.6.1, 3.6.2 and 3.6.4). This suggests that any alteration of their 
functions may result in HBV induced inflammation, fibrosis and cancer in the liver.  
An important role of HBV in calcium signalling pathway was suggested by vitamin 
D receptor (VDR)-regulated genes including THRAP3 and TRPV5 (see Section 
3.6.8), which regulates calcium homoeostasis. HBV related disruption of calcium 
signalling by methylation of VDR related genes has an influence on apoptosis, 
cancer and particularly viral replication.  
Alteration of  mRNA splicing in HBV infection was also suggested by the 
hypermethylation of the mRNA processing related genes EXOSC3, SNORD48, 
SNORA7D and SNORA52 (see Section 3.6.6), which are required for proper folding 
of mRNA and protein production. Their abnormal function could cause abnormal 
mRNA splicing and subsequently abnormal protein production and function. These 
abnormalities would disrupt normal liver function. 
Hypermethylation of genes encoding LNX2, UBXN1 and TRIP12 (see Section 
3.6.H) ubiquitin-related proteins, supports the evidence that HBV alter the 
proteasomal activity of infected cells to facilitate and enhance viral replication and 
survival 
236 - 240
.  
Many tumour suppressor genes were found to be hypermethylated (see Section 
3.6.4). The evidence links this to the action of HBx protein which would increase cell 
survival and the risk of cancer development.  
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None of the identified gene promoters have previously been investigated in chronic 
HBV infection and related HCC. However, their cellular binding partners are known 
to be activated by HBx protein, which appears to be the driving force behind HBV 
induced gene promoter methylation and the accompanying abnormal gene function. 
HBx protein is an important transcriptional transactivator protein that influences viral 
replication and cell survival by disrupting cellular signalling pathways 
96
. The 
hypermethylated gene promoters identified in the study are potential and known 
targets of HBx protein and their abnormal function would benefit the virus and its 
survival. 
Hypermethylation is typically associated with the downregulation of gene expression 
209 
and therefore it is most likely that hypermethylation of the identified genes leads 
to downregulation of gene expression. Further studies of the gene expression profile 
of these hypermethylated genes will broaden our understanding of some of the gene 
transcriptional changes that contribute to the development of HBV induced liver 
injury and cancer. In addition, any such new insights may contribute to the 
development of new treatments and early diagnostic tools for chronic HBV infection 
and related HCC in sub-Saharan Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
149 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
3.8 REFERENCES 
1. Bickle TA, Krüger DH. Biology of DNA restriction. Microbiol Rev 1993; 57(2): 
434-450. 
2.  Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A 
genomic sequencing protocol that yields a positive display of 5-methylcytosine 
residues in individual DNA strands. Proc Natl Acad Sci 1992; 89(5): 827-1831. 
3. Kuppuswamy MN, Hoffmann JW, Kasper CK, Spitzer SG, Groce SL, Bajaj SP. 
Single nucleotide primer extension to detect genetic diseases: experimental 
application to hemophilia B (factor IX) and cystic fibrosis genes. Proc Natl Acad 
Sci 1991; 88(4): 1143-1147. 
4. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. 
Methylation of the hMLH1 promoter correlates with lack of expression of 
hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor 
cell lines. Cancer Res 1997; 57(5): 808-811. 
5. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific 
PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of 
the National Academy of Sciences 1996; 93(18): 9821-9826. 
6. Hou P, Ji M, Ge C, Shen J, Li S, He N, et al. Detection of methylation of human 
p16Ink4a gene 5′‐CpG islands by electrochemical method coupled with 
linker‐PCR. Nucleic Acids Res 2003; 31(16): e92-e92. 
7.  Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA 
methylation analysis. BioTechniques 2010; 49(4): iii-xi. 
8. Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, 
Myklebost O, et al. Evaluation of high-resolution microarray platforms for 
genomic profiling of bone tumours. BMC Res Notes 2010; 3(1): 223-233. 
9. Hou P, Ji M, Li S, He N, Lu Z. High-throughput method for detecting DNA 
methylation. J Biochem Biophys Methods 2004; 60(2): 139-150. 
10. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade 
with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous 
cell carcinomas of the head and neck. Cancer Res 1999; 59(8): 1935-1940. 
150 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
11. Estécio MRH, Yan PS, Ibrahim AEK, Tellez CS, Shen L, Huang THM, et al. 
High-throughput methylation profiling by MCA coupled to CpG island 
microarray. Genome Res 2007; 17(10): 1529-1536. 
12. Zhao MS, Liang Q, Cheung KF, Kang W, Lung RWM, et al. Genome-Wide 
Identification of Epstein-Barr Virus–Driven Promoter Methylation Profiles of 
Human Genes in Gastric Cancer Cells. Cancer 2012: 1-9. 
13. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, 
et al. Genome-wide DNA methylation differences between late-onset 
Alzheimer's disease and cognitively normal controls in human frontal cortex. J 
Alzheimer's Dis 2012 Proc Natl Acad Sci; 29(3): 571-588. 
14. Bocker MT, Hellwig I, Breiling A, Eckstein V, Ho AD, Lyko F. Genome-wide 
promoter DNA methylation dynamics of human hematopoietic progenitor cells 
during differentiation and aging. Blood 2011; 117(19): e182-e189. 
15.  Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, Dallol A, et al. A genome-
wide screen identifies frequently methylated genes in haematological and 
epithelial cancers. Mol Cancer 2010; 9: 44-50. 
16. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, et al. 
Genome-wide screen of promoter methylation identifies novel markers in 
melanoma. Genome Res 2009; 19(8): 1462-1470. 
17. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of 
epidermal growth factor receptor signaling. Mol Sys Biol 2005; 1(1): 1-17. 
18. Johnson WE, Li W, Meyer CA, Gottardo R, Carroll JS, Brown M, et al. Model-
based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci 2006; 103(33): 
12457-12462. 
19. Taskesen E, Beekman R, De Ridder J, Wouters B, Peeters J, Touw I, et al. HAT: 
Hypergeometric Analysis of Tiling-arrays with application to promoter-
GeneChip data. BMC Bioinformatics 2010; 11(1): 275-283. 
20. Chung JY, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, 
et al. Factors in tissue handling and processing that impact RNA obtained from 
formalin-fixed, paraffin-embedded tissue. J Histochem 2008; 56(11): 1033-1042. 
151 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
21. Lin J, Kennedy SH, Svarovsky T, Rogers J, Kemnitz JW, Xu A, et al. High-
quality genomic DNA extraction from formalin-fixed and paraffin-embedded 
samples deparaffinized using mineral oil. Anal Biochem 2009; 395(2): 265-267. 
22. Tang W, David FB, Wilson MM, Barwick BG, Leyland-Jones BR, Bouzyk MM. 
DNA extraction from formalin-fixed, paraffin-embedded tissue. Cold Spring 
Harb Protoc; 2009(2): 5138-5143. 
23.  Huang WY, Sheehy TM, Moore LE, Hsing AW, Purdue MP. Simultaneous 
recovery of DNA and RNA from formalin-fixed paraffin-embedded tissue and 
application in epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2010; 
19(4): 973-977. 
24. Jacobs S, Thompson ER, Nannya Y, Yamamoto G, Pillai R, Ogawa S, et al. 
Genome-wide, high-resolution detection of copy number, loss of heterozygosity, 
and genotypes from formalin-fixed, paraffin-embedded tumor tissue using 
microarrays. Cancer Res 2007; 67(6): 2544-2551. 
25. Tuefferd M, De Bondt A, Van den Wyngaert I, Talloen W, Göhlmann H. 
Microarray profiling of DNA extracted from FFPE tissues using SNP 6.0 
Affymetrix platform. Formalin-Fixed Paraffin-Embedded Tissues: Springer 
2011: 147-160. 
26. Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, Carvalho 
B, et al. Genome‐wide copy number alterations detection in fresh frozen and 
matched FFPE samples using SNP 6.0 arrays. Gene Chromosome Canc 2008; 
47(11): 957-964. 
27. Huang THM, Perry MR, Laux DE. Methylation profiling of CpG islands in 
human breast cancer cells. Hum Mol Genet 1999; 8(3): 459-470. 
28. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. 
Aberrant CpG-island methylation has non-random and tumour-type–specific 
patterns. Nat Genet 2000; 24(2): 132-138. 
29. Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade 
astrocytomas. Brain Tumor Pathol 2000; 17(2):49-56. 
30. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat 
152 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
Rev Genet 2002; 3(6): 415-428. 
31. Gottlob K, Fulco M, Levrero M, Graessmann A. The hepatitis B virus HBx 
protein inhibits caspase 3 activity. J Biol Chem 1998; 273(50): 33347-33353.  
32. Miao J, Chen GG, Chun SY, Lai PS. Hepatitis B virus X protein induces 
apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett 
2006; 236(1): 115-124. 
33. Livneh E, Fishman DD. Linking Protein Kinase C to Cell‐Cycle Control. Eur J 
Biochem 1997; 248(1): 1-9. 
34. Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, 
cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent 
kinase inhibitors (CKIs). Oncogene 1995; 11(2): 211-219. 
35. Fausto N, Campbell JS, Riehle KL. Liver regeneration. Hepatology 2006; 
43(S1): S45-S53. 
36. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular 
response to tissue injury. J Biol Chem 2000; 275(4): 2247-2250. 
37. Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. Independent 
regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative 
stress in the liver. Proc Natl Acad Sci 1996; 93(23): 12908-12913. 
38. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 
1998; 29(5): 836-847. 
39. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. 
2001; 21(03): 397-416. 
40. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic 
fibrogenesis. J Gastroenterol Hepatol 2007; 22(s1): S79-S84. 
41. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani–Moghadam M, London RM, 
et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 
137(2): 713-723. 
42. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits 
hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo 
153 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
model of liver fibrosis. Gastroenterology 1999; 117(5): 1198-1204. 
43. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2):209-218. 
44. Jaeschke H. Cellular adhesion molecules: regulation and functional significance 
in the pathogenesis of liver diseases. Am J Physiol 1997; 36(3): G602-G611. 
45. Kim GJ, Sun W, Won NH, Park SH. Increased expression of cyclin D3 are 
involved in hepatocellular carcinoma. Mol Cell Toxicol 2008; 4(2): 93-99. 
46. Liu Y, Tong Z, Li T, Chen Q, Zhuo L, Li W, et al. Hepatitis B virus X protein 
stabilizes amplified in breast cancer 1 protein and cooperates with it to promote 
human hepatocellular carcinoma cell invasiveness. Hepatology 2012; 56(3): 
1015-1024. 
47.  Loachim E. Expression patterns of cyclins D1, E and cyclin‐dependent kinase 
inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other 
cell cycle regulators (pRb, p53 and Ki‐67 and PCNA) and clinicopathological 
features. Int J Clin Pract 2008; 62(11): 1736-1743. 
48. Hirabayashi H, Fujii Y, Sakaguchi M, Tanaka H, Yoon HE, Komoto Y, et al. 
p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 
gene in thymoma and thymic carcinoma. Int J cancer 1997; 73(5): 639-644. 
49. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 
expression in transitional cell carcinoma of the bladder: correlation with p53, 
waf1, pRb and Ki67. Br J Cancer 2001; 84(2): 270-275. 
50. Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, et al. The Ets Transcription Factor 
GABP Is a Component of the Hippo Pathway Essential for Growth and 
Antioxidant Defense. Cell Rep 2013; 3(5): 1663-1677. 
51. Cunliffe HE, Jiang Y, Fornace KM, Yang F, Meltzer PS. PAR6B is required for 
tight junction formation and activated PKCζ localization in breast cancer. Am J 
Cancer Res 2012; 2(5): 478 - 491. 
52. Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, et al. The polarity 
protein Par6 induces cell proliferation and is overexpressed in breast cancer. 
Cancer Res 2008; 68(20): 8201-8209. 
154 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
53. Munson C, Huisken J, Bit-Avragim N, Kuo T, Dong PD, Ober EA, et al. 
Regulation of neurocoel morphogenesis by Pard6γb. Dev Biol 2008; 324(1): 41-
54. 
54. Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in 
hepatitis B virus DNA replication. Science 2001; 294(5550): 2376-2378. 
55. Cong YS, Yao YL, Yang WM, Kuzhandaivelu N, Seto E. The hepatitis B virus 
X-associated protein, XAP3, is a protein kinase C-binding protein. J Biol Chem 
1997; 272(26): 16482-16489. 
56. Li W, Tan D, Zenali MJ, Brown RE. Constitutive activation of nuclear factor-
kappa B (NF-κB) signaling pathway in fibrolamellar hepatocellular carcinoma. 
Int J Clin Exp Path 2010; 3(3): 238-243. 
57. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 
2001; 411(6835): 342-348. 
58. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade 
with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous 
cell carcinomas of the head and neck. Cancer Res 1999; 59(8): 1935-1940. 
59. Daveau M, Scotte M, François A, Coulouarn C, Ros G, Tallet Y, et al. 
Hepatocyte growth factor, transforming growth factor α, and their receptors as 
combined markers of prognosis in hepatocellular carcinoma. Mol Carcinogen 
2003; 36(3): 130-141. 
60.  Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKβ couples hepatocyte 
death to cytokine-driven compensatory proliferation that promotes chemical 
hepatocarcinogenesis. Cell 2005; 121(7): 977-990. 
61. Radaeva S, Li Y, Hacker HJ, Burger V, Kopp-Schneider A, Bannasch P. 
Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, 
cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in 
preneoplastic hepatocellular lineages in woodchucks. J Hepatol 2000; 33(4): 580-
600. 
62. Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus 
transgenic mice. Hepatology 1994; 20(5): 1162-1172. 
155 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
63. Scharf JD, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann 
H. Characterization of the insulin-like growth factor axis in a human hepatoma 
cell line (PLC). Carcinogenesis 1998; 19(12): 2121-2128. 
64. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, et al. 
Insulin-like growth factor-I serum concentrations and patterns of insulin-like 
growth factor binding proteins in patients with chronic liver disease. J Hepatol 
1996; 25(5): 689-699. 
65. Chen YJ, Chien PH, Chen WS, Chien YF, Hsu YY, Wang LY, et al. Hepatitis B 
Virus-Encoded X Protein Downregulates EGFR Expression via Inducing 
MicroRNA-7 in Hepatocellular Carcinoma Cells. Evid Based Complement 
Alternat Med 2013: 1-10. 
66. Clippinger AJ, Gearhart TL, Bouchard MJ. Hepatitis B virus X protein modulates 
apoptosis in primary rat hepatocytes by regulating both NF-κB and the 
mitochondrial permeability transition pore. J Virol 2009; 83(10): 4718-4731. 
67. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic 
killing by tumor necrosis factor α. Proc Natl Acad Sci 1997; 94(16): 8744-8749. 
68. Wang WH, Grégori G, Hullinger RL, Andrisani OM. Sustained activation of p38 
mitogen-activated protein kinase and c-Jun N-terminal kinase pathways by 
hepatitis B virus X protein mediates apoptosis via induction of Fas/FasL and 
tumor necrosis factor (TNF) receptor 1/TNF-α expression. Mol Cell Biol 2004; 
24(23): 10352-10365. 
69. Steinberg F, Zhuang L, Beyeler M, Kälin RE, Mullis PE, Brändli AW, et al. The 
FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors 
(FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem 2010; 
285(3): 2193-2202. 
70. Silva PN, Altamentova SM, Kilkenny DM, Rocheleau JV. Fibroblast Growth 
Factor Receptor Like-1 (FGFRL1) Interacts with SHP-1 Phosphatase at Insulin 
Secretory Granules and Induces Beta-cell ERK1/2 Protein Activation. J Biol 
Chem 2013; 288(24): 17859-17870. 
71. Valdés F, Álvarez AM, Locascio A, Vega S, Herrera B, Fernández M, et al. The 
Epithelial Mesenchymal Transition Confers Resistance to the Apoptotic Effects 
156 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
of Transforming Growth Factor β in Fetal Rat Hepatocytes. Mol Cancer Res 
2002; 1(1): 68-78. 
72. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in 
homeostasis and cancer. Nat Rev Cancer 2003; 3(11): 807-820. 
73. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-β signaling to 
growth arrest, apoptosis, and epithelial–mesenchymal transition. Curr Opin Cell 
Biol 2009; 21(2): 166-176. 
74. Coulouarn C, Lefebvre G, Daveau R, Letellier F, Hiron M, Drouot L, et al. 
Genome‐wide response of the human Hep3B hepatoma cell to proinflammatory 
cytokines, from transcription to translation. Hepatology 2005; 42(4): 946-955 
75. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, et al. Regulation of 
transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X 
transactivator. Role in HBV pathogenesis. J Clin Invest 1996; 97(2): 388-395. 
76. Zhao J, Zhao Y, Wang H, Gu X, Ji J, et al. Association between metabolic 
abnormalities and HBV related hepatocellular carcinoma in Chinese: A cross-
section study HCC. Nutr J 2011; 10: 487-495. 
77. Jung JK, Park SH, Jang KL. Hepatitis B virus X protein overcomes the growth-
inhibitory potential of retinoic acid by downregulating retinoic acid receptor-β2 
expression via DNA methylation. J Gen Virol 2010; 91(2): 493-500. 
78. Majano PL, García-Monzón C, López-Cabrera M, Lara-Pezzi E, Fernández-Ruiz 
E, García-Iglesias C, et al. Inducible nitric oxide synthase expression in chronic 
viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 
1998; 101(7): 1343-1350. 
79. Park YH, Shin HJ, Kim SK, Kim JM, Kim JH, Bang D, et al. iNOS promotes 
HBx-induced hepatocellular carcinoma via upregulation of JNK activation. 
Biochem Biophys Res Commun 2013; 435: 244-249. 
80. Shin HJ, Park YH, Kim SU, Moon HB, Han YH, Lee CH, et al. Hepatitis B virus 
X protein regulates hepatic glucose homeostasis via activation of inducible nitric 
oxide synthase. J Biol Chem 2011; 286(34): 29872-29881. 
81. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B 
157 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 
and PPARγ. Gastroenterol 2007; 132(5): 1955-1967. 
82. Makishima M, Yamada S. Targeting the vitamin D receptor: advances in drug 
discovery. Nature 2005; 15(9): 1133-1145. 
83. Farnik H, Bojunga J, Berger A, Allwinn R, Waidmann O, Kronenberger B, et al. 
Low vitamin D serum concentration is associated with high levels of hepatitis B 
virus (HBV) replication in chronically infected patients. Hepatology 2013:1-23. 
84. Demir C, Demir M. Vitamin D levels in patients with chronic hepatitis B virus 
infection and naturally immunized individuals. H O A J 2013; 1: 1-4. 
85. Gao L, Tao Y, Zhang L, Jin Q. Vitamin D receptor genetic polymorphisms and 
tuberculosis: updated systematic review and meta-analysis [Review article]. The 
international journal of tuberculosis and lung disease 2010; 14(1): 15-23. 
86. Chocano‐Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. Nutr Rev 
2009; 67(5): 289-293. 
87. Choi Y, Gyoo Park S, Yoo JH, Jung G. Calcium ions affect the hepatitis B virus 
core assembly. Virology 2005; 332(1): 454-463. 
88. Chami M, Oulès B, Paterlini-Bréchot P. Cytobiological consequences of 
calcium-signaling alterations induced by human viral proteins. BBA-Mol Cell 
Res 2006; 1763(11): 1344-1362. 
89. Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by 
hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 
2006; 80(9): 4406-4414. 
90. Gearhart TL, Bouchard MJ. The hepatitis B virus X protein modulates hepatocyte 
proliferation pathways to stimulate viral replication. J Virol 2010; 84(6): 2675-
2686. 
91. Gearhart TL, Bouchard MJ. Replication of the hepatitis B virus requires a 
calcium-dependent HBx-induced G1 phase arrest of hepatocytes. Virology 2010; 
407(1): 14-25. 
92. Oh JC, Jeong DL, Kim IK, Oh SH. Activation of calcium signaling by hepatitis B 
virus-X protein in liver cells. Exp Mol Med 2003; 35(4): 301-309. 
158 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
93. Diao J, Khine AA, Sarangi F, Hsu E, Iorio C, Tibbles LA, et al. X protein of 
hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-
regulation of the SAPK/JNK pathway. J Biol Chem 2001; 276(11): 8328-8340. 
94. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-κB activity enhances 
chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 
activation. Proc Natl Acad Sci 2006; 103(28): 10544-10551. 
95. He HC, Ling XH, Zhu JG, Fu X, Han ZD, Liang YX, et al. Down-regulation of 
the ErbB3 binding protein 1 in human bladder cancer promotes tumor 
progression and cell proliferation. Mol Biol Rep 2013; 4: 1-7. 
96. Vivekanandan P, Daniel HDJ, Kannangai R, Martinez-Murillo F, Torbenson M. 
Hepatitis B virus replication induces methylation of both host and viral DNA. J 
Virol 2010; 84(9): 4321-4329. 
97. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into 
the specificity of ETS transcription factors. Annu Rev Biochem 2011; 80: 437-
471. 
98. Collins PJ, Kobayashi Y, Nguyen L. The ets-related transcription factor GABP 
directs bidirectional transcription. PLoS Genet 2007;3(11):e208-e213. 
99. Sementchenko VI, Watson DK. Ets target genes: past, present and future. 
Oncogene 2000; 19(55): 6533-6548. 
100. Buchwalter G, Gross C, Wasylyk B. Ets ternary complex transcription factors. 
Gene 2004; 324: 1-14. 
101. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Ets-1 is a critical 
transcriptional regulator of reactive oxygen species and p47phox gene 
expression in response to angiotensin II. Circ Res 2007; 101(10): 985-994. 
102. Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, et al. The Ets Transcription Factor 
GABP Is a Component of the Hippo Pathway Essential for Growth and 
Antioxidant Defense. Cell Rep 2013; 3(5): 1663-1677. 
103. Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, et al. Hepatitis B virus X 
protein modulates oncogene yes‐associated protein by CREB to promote growth 
of hepatoma cells. Hepatology 2012; 56(6): 2051-2059. 
159 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
104. Kuo CY, Wu CC, Hsu SL, Hwang GY. HBx inhibits the growth of CCL13-
HBX-stable cells via the GSK-3β/β-catenin cascade. Intervirology 2008; 51(2): 
130-136. 
105. Lee YI, Hwang JM, Im JH, Lee YI, Kim NS, Kim DG, et al. Human hepatitis B 
virus-X protein alters mitochondrial function and physiology in human liver 
cells. J Biol Chem 2004; 279(15): 15460-15471. 
106. Luo Q, Zhong JL, Zhao M, Ma YM, Liu J, Wang J, et al. Effects of NAIF1 on 
biological behavior of esophageal carcinoma cell line EC9706 by using pTet-off 
system. Chinese J Cell Mol Immunol 2011; 27(2): 162-165. 
107. Carr BI, Hayashi I, Branum EL, Moses HL. Inhibition of DNA synthesis in rat 
hepatocytes by platelet-derived type β transforming growth factor. Cancer Res 
1986; 46(5): 2330-2334. 
108. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch 
W, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver 
by transforming growth factor beta 1. Proc Natl Acad Sci 1992; 89(12): 5408-
5412. 
109. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor‐β gene 
expression signature in mouse hepatocytes predicts clinical outcome in human 
cancer. Hepatology 2008; 47(6): 2059-2067. 
110. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus X 
protein inhibits transforming growth factor-β-induced apoptosis through the 
activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 2000; 275(33): 
25858-25864. 
111. Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modulates hepatitis B virus-X 
protein induced survival signaling in Chang liver cells. Virus Res 2006; 122(1): 
53-60. 
112. Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, et al. 
Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this 
binding by heregulin. Br J Cancer 2000; 82(3): 683-689. 
113. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of 
160 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
epidermal growth factor receptor signaling. Mol Sys Biol 2005; 1(1):1-17. 
114. Izuta S, Kitahara M, Hamaguchi T. Regulation of eukaryotic DNA replication 
by proliferation associated protein, PA2G4, in vitro. Nature 2004; 48(1): 285-
286. 
115. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia 
telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad 
Sci 2000;97(19): 10389-10394. 
116. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, et al. 
Identification and characterization of a novel and specific inhibitor of the ataxia-
telangiectasia mutated kinase ATM. Cancer Res 2004;64(24): 9152-9159. 
117. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, et al. 
Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic 
leukaemia. Lancet 1999; 353(9146): 26-29. 
118. Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ. Polycomb group and 
SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to 
BCL6 targets. Mol Cell Biol 2006; 26(18): 6880-6889. 
119. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, 
development and cancer. Nat Rev Cancer 2006; 6(11): 846-856. 
120. Zhou W, Zhu P, Wang J, Pascual G, Ohgi KA, Lozach J, et al. Histone H2A 
monoubiquitination represses transcription by inhibiting RNA polymerase II 
transcriptional elongation. Mol Cell 2008; 29(1): 69-80. 
121. You H, Zheng H, Murray SA, Yu Q, Uchida T, Fan D, et al. IGF‐1 induces Pin1 
expression in promoting cell cycle S‐phase entry. J Cell Biochem 2002; 84(2): 
211-216. 
122. Ren M, Zhong X, Ma CY, Sun Y, Guan QB, Cui B, et al. Insulin-like growth 
factor-1 promotes cell cycle progression via upregulation of cyclin D1 
expression through the phosphatidylinositol 3-kinase/nuclear factor-κB signaling 
pathway in FRTL thyroid cells. Acta Pharmacol Sin 2008; 30(1): 113-119. 
123. Youn HS, Kim EJ, Um SJ. Zyxin cooperates with PTOV1 to confer retinoic 
acid resistance by repressing RAR activity. Cancer Lett 2013; 331(2): 192-199. 
161 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
124. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor 
activated by a diverse array of extracellular signals. Annu Rev Biochem 1999; 
68(1): 821-861. 
125. Chang EYC, Tsai SH, Shun CT, Hee SW, Chang YC, Tsai YC, et al. 
Prostaglandin reductase 2 modulates ROS-mediated cell death and tumour 
transformation. Am J Pathol 2012; 181(4): 1316-1326. 
126. Kelly EK, Wang L, Ivashkiv LB. Calcium-activated pathways and oxidative 
burst mediate zymosan-induced signaling and IL-10 production in human 
macrophages. J Immunol 2010; 184(10): 5545-5552. 
127. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, et al. 
PPAR [gamma] 2 gene Pro12Ala polymorphism may influence serum level of 
an adipocyte-derived protein, adiponectin, in the Japanese population. Metab 
Clin Exp 2002; 51(11): 1407-1409. 
128. Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, et al. Hepatitis B virus X 
protein modulates oncogene yes‐associated protein by CREB to promote growth 
of hepatoma cells. Hepatology 2012; 56(6): 2051-2059. 
129. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 
6(8): 597-610. 
130. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et 
al. DNA methylation patterns in hereditary human cancers mimic sporadic 
tumorigenesis. Hum Mol Genet 2001; 10(26): 3001-3007. 
131. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 
2000; 403(6765): 41-45. 
132. Reuckert C, Haucke V, et al. The oncogenic TBC domain protein USP6/TRE17 
regulates cell migration and cytokinesis. Biol Cell 2011; 104 (1): 22-33. 
133. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, et al. Hepatitis B virus 
X protein upregulates mTOR signaling through IKKβ to increase cell 
proliferation and VEGF production in hepatocellular carcinoma. PloS One 2012; 
7(7): e41931-e41931. 
134. Oellerich T, Oellerich MF, Engelke M, Münch S, Mohr S, Nimz M, et al. β2 
162 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
integrin–derived signals induce cell survival and proliferation of AML blasts by 
activating a Syk/STAT signaling axis. Blood 2013; 121(19): 3889-3899. 
135. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, et al. 
Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads 
to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004; 101(49): 17216-
17221. 
136. Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. Hepatitis B viral X protein 
interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-
catenin signaling. Cancer Lett 2011; 300(2): 162-172. 
137. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, et al. Hepatitis B virus X protein 
upregulates survivin expression in hepatoma tissues. J Med Virol 2005; 77(3): 
374-381. 
138. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the 
development of liver cancer. J Lab Clin Med 2006; 147(2): 58-66. 
139. Wang HD, Trivedi A, Johnson DL. Hepatitis B virus X protein induces RNA 
polymerase III-dependent gene transcription and increases cellular TATA-
binding protein by activating the Ras signaling pathway. Mol Cell Biol 1997; 
17(12): 6838-6846. 
140. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction 
of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 
response element-directed transactivation. J Virol 1995; 69(3): 1851-1859. 
141. Qadri I, Fatima K, AbdeL-Hafiz H. Hepatitis B virus X protein impedes the 
DNA repair via its association with transcription factor, TFIIH. BMC Microbiol 
2011; 11(1): 48-55. 
142. Haviv I, Shamay M, Doitsh G, Shaul Y. Hepatitis B virus pX targets TFIIB in 
transcription coactivation. Mol Cell Biol 1998; 18(3): 1562-1569. 
143. Li L, Zhang A, Cao X, Chen J, Xia Y, Zhao H, et al. General Transcription 
Factor IIB Overexpression and a Potential Link to Proliferation in Human 
Hepatocellular Carcinoma. Pathol Oncol Res 2012; 19: 1-9. 
144. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. 
163 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B 
virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130(3): 823-
837. 
145. Mattick JS, Taft RJ, Faulkner GJ. A global view of genomic information–
moving beyond the gene and the master regulator. Trends Genet 2010; 26(1): 
21-28. 
146. Harrison PM, Zheng D, Zhang Z, Carriero N, Gerstein M. Transcribed 
processed pseudogenes in the human genome: an intermediate form of expressed 
retrosequence lacking protein-coding ability. Nucleic Acids Res 2005; 33(8): 
2374-2383. 
147. Wu X, Hsu TC, Cao S, Lee JJ, Amos CI, Spitz MR. Deletion in poly (ADP-
ribose) polymerase pseudogene and lung cancer risk. Carcinogenesis 1998; 
19(1): 93-98. 
148. Smale ST, Kadonaga JT. The RNA polymerase II core promoter. Annu Rev 
Biochem 2003; 72(1): 449-479. 
149. Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, Garbe Y, et 
al. Serum antibodies against frameshift peptides in microsatellite unstable 
colorectal cancer patients with Lynch syndrome. Fam Cancer 2010; 9(2): 173-
179. 
150. Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent 
M, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite 
instability are correlated with the number and spectrum of frameshift mutations. 
Modern Pathol 2009; 22(9): 1186-1195. 
151. Yamaguchi T, Iijima T, Mori T, Takahashi K, Matsumoto H, Miyamoto H, et 
al. Accumulation profile of frameshift mutations during development and 
progression of colorectal cancer from patients with hereditary nonpolyposis 
colorectal cancer. Dis Colon Rectum 2006; 49(3): 399-406. 
152. Li LS, Kim NG, Kim SH, Park C, Kim H, Kang HJ, et al. Chromosomal 
imbalances in the colorectal carcinomas with microsatellite instability. Am J 
Pathol 2003; 163(4): 1429-1436. 
164 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
153. Lin Y, Nomura T, Cheong JH, Dorjsuren D, Iida K, Murakami S. Hepatitis B 
virus X protein is a transcriptional modulator that communicates with 
transcription factor IIB and the RNA polymerase II subunit 5. J Biol Chem 
1997; 272(11): 7132-7139. 
154. Gurtsevitch VE. Human oncogenic viruses: hepatitis B and hepatitis C viruses 
and their role in hepatocarcinogenesis. Biochemistry (Moscow) 2008; 73(5): 
504-513. 
155. Cheong JH, Yi MK, Lin Y, Murakami S. Human RPB5, a subunit shared by 
eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein 
and may play a role in X transactivation. EMBO J 1995; 14(1): 143 -152. 
156. Michaely P, Bennett V. The ANK repeat: a ubiquitous motif involved in 
macromolecular recognition. Trends Cell Biol 1992; 2(5): 127-129. 
157. Yu S, Cui K, Jothi R, Zhao DM, Jing X, Zhao K, et al. GABP controls a critical 
transcription regulatory module that is essential for maintenance and 
differentiation of hematopoietic stem/progenitor cells. Blood 2011; 117(7): 
2166-2178. 
158. Yang ZF, Drumea K, Cormier J, Wang J, Zhu X, Rosmarin AG. GABP 
transcription factor is required for myeloid differentiation, in part, through its 
control of Gfi-1 expression. Blood 2011; 118(8): 2243-2253. 
159. Wenz T. Mitochondria and PGC-1α in aging and age-associated diseases. J Agi 
Res 2011; 2011: 1-12. 
160. Egan JB, Thompson Pa, Ashbeck EL, Conti DV, Duggan D, Hibler E, et al. 
Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the 
likelihood of colon adenoma recurrence. Cancer Res 2010; 70(4): 1496-1504. 
161. Egan JB, Thompson PA, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, et al. 
Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D 
receptor FokI polymorphism collectively modulate β‐catenin activity in colon 
cancer cells. Mol Carcinog 2010; 49(4): 337-352. 
162. Li JH, Chen DM, Li Z, Liu Y, Gao JR, Zeng XJ, et al. Study on association 
between vitamin D receptor gene polymorphisms and the outcomes of HBV 
165 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
infection. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23(4): 402-405. 
163. Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, et al. Vitamin D 
receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B 
carriers in Taiwan. Genes Immun 2009; 11(1): 87-93. 
164. Li YC, Bolt MJG, Cao LP, Sitrin MD. Effects of vitamin D receptor 
inactivation on the expression of calbindins and calcium metabolism. Am J 
Physiol-Endocrinol Metab 2001; 281(3): E558-E564. 
165. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, 
vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003; 3(8):601-
614. 
166. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 
124(1): 1-6. 
167. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of 
apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 
1997; 275(5303): 1129-1132. 
168. Chittenden T, Harrington EA, O'Connor R, Remington C, Lutz RJ, Evan GI, et 
al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-
736. 
169. Geng X, Harry BL, Zhou Q, Skeen-Gaar RR, Ge X, Lee ES, et al. Hepatitis B 
virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2 
increase and cell death in Caenorhabditis elegans. Proc Natl Acad Sci 2012; 
109(45): 18465-18470. 
170. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the 
EF-hand type. BBA-Mol Cell Res 1999; 1450(3): 191-231. 
171. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the symdrome of 
hereditary 1,25-dihydroxyvitamin D resistant-rickets. Endocr Rev 1999; 20: 
156-188. 
172. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshiwara Y, et al. 
Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine 
hypoplasia and growth retardation after weaning. Nat Genet 1997;16: 391-396. 
166 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
173. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. 
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug 
Metab Disposition 2002; 30(8): 883-891. 
174. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial 
peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly 
up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J 2005; 
19(9): 1067-1077. 
175. Klotman ME, Chang TL. Defensins in an innate antiviral immunity. Nat Rev 
Immunol 2006; 6: 447-456. 
176. Philips AV, Cooper TA. RNA processing and human disease. CMLS 2000; 
57(2): 235-249. 
177. Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. 
Trends Genet 2002; 18(3): 123-127. 
178. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in 
inflammatory and autoimmune diseases. Cell Mol Immunol 2006; 3(4): 255-261. 
179. Fatima G, Mathan G, Kumar V. The HBx protein of hepatitis B virus regulates 
the expression, intracellular distribution and functions of ribosomal protein 
S27a. J Gen Virol 2012; 93(Pt 4): 706-715. 
180. Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus 
transactivator protein, HBx, associates with the components of TFIIH and 
stimulates the DNA helicase activity of TFIIH. Proc Natl Acad Sci 1996; 93(20): 
10578-10583. 
181. Baker KE, Parker R. Nonsense-mediated mRNA decay: terminating erroneous 
gene expression. Curr Opin Cell Biol 2004; 16(3): 293-299. 
182. Vasudevan S, Peltz SW, Wilusz CJ. Non‐stop decay—a new mRNA 
surveillance pathway. Bioessays 2002; 24(9): 785-788. 
183. Muller HJ. Further studies on the nature and causes of gene mutations. Nature 
1932; 1(21):3-255. 
184. Ge J, Liu H, Yu YT. Regulation of pre-mRNA splicing in Xenopus oocytes by 
targeted 2′-O-methylation. RNA 2010; 16(5): 1078-1085. 
167 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
185. Durkin SG, Glover TW. Chromosome fragile sites. Annu Rev Genet 2007; 41: 
169-192. 
186. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, et al. 
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV 
related hepatocellular carcinomas. Gut 2005; 54(8): 1162-1168. 
187. Lee KM, Hsu IW, Tarn WY. TRAP150 activates pre-mRNA splicing and 
promotes nuclear mRNA degradation. Nucleic Acids Res 2010; 38(10): 3340-
3350. 
188. Lin KT, Lu RM, Tarn WY. The WW domain-containing proteins interact with 
the early spliceosome and participate in pre-mRNA splicing in vivo. Mol Cell 
Biol 2004; 24(20): 9176-9185. 
189. Goldstrohm AC, Albrecht TR, Suñé C, Bedford MT, Garcia-Blanco MA. The 
transcription elongation factor CA150 interacts with RNA polymerase II and the 
pre-mRNA splicing factor SF1. Mol Cell Biol 2001; 21(22): 7617-7628. 
190. Suñé C, Hayashi T, Liu Y, Lane WS, Young RA, Garcia-Blanco MA. CA150, a 
nuclear protein associated with the RNA polymerase II holoenzyme, is involved 
in Tat-activated human immunodeficiency virus type 1 transcription. Mol Cell 
Biol 1997; 17(10): 6029-6039. 
191. Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, 
et al. Global landscape of HIV-human protein complexes. Nature 2011; 
481(7381): 365-370. 
192. Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, et al. The ubiquitin peptidase 
UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 
and is frequently silenced in breast cancer. PLoS One 2012; 7(1): e29783. 
193. Mani A, Gelmann E. The ubiquitin-proteasome pathway and its role in cancer. J 
Clin Oncol 2005; 23(21): 4776-4789. 
194. Orlowski RZ, Dees EC. Applying drugs that affect the ubiquitin-proteasome 
pathway to the therapy of breast cancer. Breast Cancer Res 2003; 5(1): 1-7. 
195. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, et al. A survey of 
methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J 
168 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
Cancer 2011; 128(6): 1393-1403. 
196. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, et al. The 
presence of aberrant DNA methylation in noncancerous esophageal mucosae in 
association with smoking history. Cancer 2009; 115(15): 3412-3426. 
197. Okochi‐Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi 
T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. 
Int J Cancer 2006; 119(6): 1338-1344. 
198. Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R. 
Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell 
carcinoma. J Transl Med 2009; 7(1): 90-99. 
199. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, et al. Epigenetic 
identification of ubiquitin carboxyl‐terminal hydrolase L1 as a functional tumor 
suppressor and biomarker for hepatocellular carcinoma and other digestive 
tumors. Hepatology 2008; 48(2): 508-518. 
200. Masucci MG. Epstein–Barr virus oncogenesis and the ubiquitin–proteasome 
system. Oncogene 2004; 23(11): 2107- 2115. 
201. Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X 
protein is both a substrate and a potential inhibitor of the proteasome complex. J 
Virol 1999; 73(9): 7231-7240. 
202. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348(23): 
2339-2347. 
203. Yonghong L, Zhangwei T, Tiang L, Qiang C, Luting, Z, Wengang L, et al. 
Hepatitis B virus X protein stabilizes amplified in breast cancer 1 and cooperates 
with it to promote human HCC cell invasiveness. Hepatology 2012; 56(3): 1015-
1024. 
204. Camps J, Pitt JJ, Emons G, Hummon AB, Case CM, Grade M, et al. Genetic 
amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin 
pathway in colorectal cancer. Cancer Res 2013; 73(6): 2003-2013. 
205. Luo J, Zhou H, Wang F, Xia X, Sun Q, Wang R, et al. The hepatitis B virus X 
protein downregulates NF-κB signaling pathways through decreasing the Notch 
169 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
signaling pathway in HBx-transformed L02 cells. Int J Oncol 2013; 42(5): 1636-
1643. 
206. Xia X, Cheng A, Lessor T, Zhang Y, Hamburger AW. Ebp1, an ErbB‐3 binding 
protein, interacts with Rb and affects Rb transcriptional regulation. J Cell 
Physiol 2001; 187(2): 209-217. 
207. Xia X, Lessor TJ, Zhang Y, Woodford N, Hamburger AW. Analysis of the 
expression pattern of Ebp1, an ErbB-3-binding protein. Biochem Biophys Res 
Commun 2001; 289(1): 240-244. 
208. Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant, C, Grofte M, et al. 
TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged 
chromosomes. Cell 2012; 150(4): 697-709. 
209. Kwon, Y. J., Lee, S. J., Koh, J. S., Kim, S. H., Lee, H. W., Kang, M. C, Bae JB, 
Kim YJ, Park JH. Genome-wide analysis of DNA methylation and the gene 
expression change in lung cancer. J Thorac Oncol 2012; 7(1): 20-33. 
210. Zhao C, Xianmin B. Promoter methylation of tumor related genes in gastric 
carcinoma. Mol Cancer Res 2012; 27: 1271-1282. 
211. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, et al. Metabolic factors and risk 
of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up 
study in Taiwan. Gastroenterelogy 2008; 135: 111-121. 
212. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, et al. Hepatitis B 
virus X protein and p53 tumour suppressor interactions in the modulation of 
apoptosis. Proc Natl Acad Sci USA 1997; 94: 14707-14712. 
213. Vogel CM, Boesecke C, Wasmuth JC, et al. HIV and hepatitis C co-infection. 
Dtsch Med Wochenschr 2010; 135: 1186-1191. 
214. Modi AA, Field JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9:25-39. 
215. Burnett RJ, Francois G, Kew MC, et al. Hepatitis B virus and human 
immunodeficiency virus co-infection in sub-Saharn Africa: A call for further 
investigation. Liv Internat 2005; 25: 201-213. 
216. Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical 
hepatocarcinogenesis by the HIV-1 tat gene. Armer J Pathol 2000; 157: 1081-
170 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
1089. 
217. Bickmore WA, Bird AP. Use of restriction endonucleases to detect and isolate 
genes from mammalian cells. Meth Enzymol 1992; 216: 224-244. 
218. GeneChip Human Promoter 1.0R Array. Accessed on 16 September 2013 at: 
http://www.affymetrix.com/estore/browse/products.jsp?productId=131461#1_1. 
219. Yuanxin Y, Chengcai A, Li L, Jiayu G, Guihong T, Zhangliang C. T-linker-
specific ligation PCR (T-linker PCR): an advanced PCR technique for 
chromosome walking or for isolation of tagged DNA ends. Nucleic Acid Res 
2003; 31(12): e68 – e78. 
220. Ishak K, Baptista A, Bianchi L, Callea F, DeGrooke J, Gudat F, et al. 
Histological grading of chronic hepatitis. J Hepatol 1995; 22: 696-699. 
221. Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML, et al. Repression of 
androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. 
Oncogene 2002; 21(36): 5609-5618. 
222. Zhang YX, Woodford N, Xia XM, Hamburger AW. Repression of E2F1 
mediated transcription by the ErbB3 binding protein EbP1 involves histone 
deacetylases. Nucleic Acid Res 2003; 10: 312168 – 312177. 
223. Lessor TJ, Yoo JY, Xia X, Woodford N, Hamburger AW. Ectopic expression of 
the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of 
human breast cancer cell lines. J Cell Physiol 2000; 15: 183321-183329. 
224. Carraway KL III, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, et 
al.. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994; 269: 
14303–14306 
225. Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, et al. 
Differentiation Factor (heregulin) induces expression of intercellular adhesion 
molecule 1: implications for mammary tumour. Cancer Res 1993; 53: 5251–
5261. 
226. Fedi P, Pierce JH, DiFiore PP and Kraus MH. Efficient coupling with 
phosphatidylinositol 3-kinase, but not phospholipase Cg or GTPase activating 
protein, distinguished erbB-3 signaling from that of other ErbB/EGFR family 
171 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
members. Mol Cell Biol 1994; 14: 492–500. 
227. Radomski N, Jong E. Molecular cloning a murine cDNA encoding novel 
protein, p38-2G4 a protein highly, which varies with cell cycle. Exp Cell Res 
1995; 220: 434 -445. 
228. Cheong JH, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by 
eukaryotic nuclear RNA polymerases, binds human hepatitis B virus x protein 
and may play a role in X transactivation. EMBO 1995; 14(1): 143 – 150. 
229. Mangelsdorf DJ, Thummel C, Beato M. The nuclear receptor superfamily: The 
second decade. Cell 1995; 83: 835–839. 
230. Tachi Y, Shimpuku H, Nosaka Y, Kawamura T, Shinohara M, Ueda M, et al. 
Vitamin D receptor gene polymorphism is associated with chronic periodontitis. 
Life Sci 2003; 73: 3313 – 3321. 
231. Zhang, D.E., Hetherington, C.J., Gonzalez, D.A., Chen, H.M., Tenen, D.G. 
Regulation of CD14 expression during monocytic differentiation induced with 1 
alpha, 25-dihydroxyvitamin D3. J Immunol 1994; 153 (7): 3276–3284. 
232. Rockett, K.A., Brookes, R., Udalova, I., Vidal, V., Hill, A.V., Kwiatkowski, D., 
1998. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses 
growth of Mycobacterium tuberculosis in a human macrophage-like cell line. 
Infect Immun 1998; 66 (11): 5314–5321. 
233. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells 
by TGF alpha and collagen type I is mediated by oxidative stress through c-myb 
expression. J Clin Invest 1995; 96: 2461–2468. 
234. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest 
by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012; 
33(5):1113-1120.  
235. Yamanaka T, Horikoshi Y, Suzuki A, et al. PAR-6 regulates aPKC activity in a 
novel way and mediates cell-cell contact-induced formation of the epithelial 
junctional complex. Genes Cell 2001; 6: 721–731.  
236. Keasler VV, Hodqson, AJ, Madden CR. Enhancement of hepatitis B virus 
replication by the regulatory X protein in vitro and in vivo. J Virol 2007; 81(6): 
172 
Chapter 3: Genome Wide Methylation Profile Investigation with Microarray 
2656-2662.  
237. Lucifora J, Arzberger S, Durantel, D, Belloni, L, Strubin, M, Levrero, M, et al. 
Hepatitis B virus X protein is essential to initiate and maintain virus replication 
after infection. J Hepatol 2011; 55(5): 996-1003. 
238. Tsuge M, Hiraga, N, Akiyama R, Tenaka, S, Matsushita M, Mitsui F, et al. HBx 
protein is indispensable for development of viraemia in human hepatocyte 
chimeric mice. J Gen Virol 2010; 91: 1854-1864. 
239. Xu Z, Yen TSB, Wu L, Madden CR, Tan W, et al. Enhancement of HBV 
replication by its X protein in transgenic mice. J Virol 2002; 76(5): 2579-2584. 
240. Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, et al., The transcriptional 
transactivation function of HBx protein is important for its augmentation role in 
hepatitis B virus replication. J Virol 2005; 79(9): 5548-5556. 
241. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a 
systemic review and meta-analysis. Int J Epidemiol 2008; 37(1): 113 - 119. 
242. Affymetrix Chromatin Immunoprecipitation Assay Protocol Manual. 
http://www.affymetrix.com/support/support_result.affx. Accessed March 2012. 
243. Library file, Hg 19/ GRCh37. Feb 2009 Version. 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/ Accessed September 
2012. 
244. Kim KH, Seong BL. Pro-apoptotic function of HBV X protein is mediated by 
interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 
2003; 22: 2104 - 2116. 
245. Tomiya T, Nishikawa T, Inoue Y, Ohtomo N, Ikeda H, Tejima K, et al. Leucine 
stimulates HGF production by hepatic stellate cells through mTOR pathway. 
Biochem Biophys Res Commun 2007; 358 (1): 176 – 180. 
246. Affymetrix U133_Plus_2_na24.hg19.-transcript.csv file. 
http://www.affymetrix.com/support_result.affx. Accessed September 2012.  
246. Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, et al. 
DNA sequence and analysis of human chromosome 9. Nature 2014; 429: 369 – 
374. 
173 
Chapter 4: Validation of Microarray Data Findings Using Bisulfite DNA Sequencing 
CHAPTER 4 
VALIDATION OF MICROARRAY DATA FINDINGS USING 
BISULFITE DNA SEQUENCING  
 
4. INTRODUCTION 
Bisulfite DNA sequencing was first introduced by Frommer et al
1
 as a genomic tool 
for mapping methylated cytosines in the early 1990s. This technique is considered to 
be the gold-standard for DNA methylation analysis at a single base-pair resolution. It 
involves sodium bisulfite conversion that differentiates non-methylated from 
methylated cytosines by converting methylated cytosines to uracils that appear as 
thymine in the bisulfite DNA converted sequence 
1, 2
.  
Other quantitative methylation techniques include combined bisulfite restriction 
analysis (COBRA), methylation-sensitive single nucleotide primer extension (MS-
SNuPE), MethylLight and methylation-specific PCR (MSP) and they also employ the 
same principle of modifying DNA with sodium bisulfite prior to PCR amplification 
3 
– 5, 12, 14, 15
. However, bisulfite DNA sequencing and MSP remains the most common 
used today in validating microarray data 
2
. The use of bisulfite DNA sequencing and 
MSP methylation analysis techniques in validating the methylation profiles of CpG 
islands is based on their high sensitivity and specificity, which enable one to analyse 
every CpG site in a target region. Although the experimental procedure is laborious 
and time consuming, these techniques also allow for the easy interpretation of data 
4, 
5
. 
In a study investigating methylation of CpG islands in the promoter regions of the B-
cell gene in Hodgkin lymphoma cell lines, bisulfite DNA sequencing was shown to 
be able to detect all methylated CpG sites 
6
. The use of bisulfite DNA sequencing in 
validating microarray data has shown high levels of sensitivity 
6 - 8
.  
 
 
174 
Chapter 4: Validation of Microarray Data Findings Using Bisulfite DNA Sequencing 
4.1 AIMS  
In this study, bisulfite DNA sequencing was used to: 
1. Validate the microarray CpG island methylation data findings using several 
selected genes in patients with chronic hepatitis B virus (HBV) infection. 
2. Validate the microarray CpG data findings using the highly methylated Cyclin D3 
gene in patients with chronic HBV infection and normal controls. 
3. Investigate the influence of HBV e antigen positivity on the degree of methylation 
of promoter region CpG islands of the Cyclin D3 gene. 
 
4.2 METHODS 
4.2.1  Sample Materials 
Genomic DNA extracted from the blood samples of HBV patients was used for 
bisulfite DNA sequencing analysis. Twenty-nine HBV samples were used to validate 
the presence of CpG island methylation in genes selected from the microarray data 
discussed in Chapter 3. For investigating the influence of HBV e antigen, 10 HBV e 
antigen positive, 10 HBV e antigen negative and 10 normal control samples were 
used. 
 
4.2.2  Isolation of DNA from Blood Samples 
Genomic DNA was extracted from blood using the Wizard® Genomic DNA 
Purification Kit (Promega Corporation, Madison, WI, USA, Appendix 16) according 
to the manufacturer’s protocol (see Appendix 17). The quality of the DNA samples 
was assessed using the Nanodrop ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific, USA). 
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4.2.3 Designing of Bisulfite DNA Sequencing Primers 
The genes were randomly chosen to validate the microarray methylation data were 
cyclin D3 (CCND3), exosome component 3 (EXOSC3), fibroblast growth factor 
receptor-like-1 (FGFRL1), GA binding protein transcription factor beta subunit 2 
(GABPB2), NACC family member 2, BEN and BTP (POZ) domain containing 
(NACC2), proliferation associated 2G4 (PA2G4), TBC1 domain family member 17 
(TBC1D17), thyroid hormone receptor associated protein 3 (THRAP3), tubulin 
alpha 4a (TUBA4A), transient receptor potential cation channel subfamily v member 
5 (TRPV5) and UBX domain protein 1 (UBXN1). These genes were amongst those 
that showed higher methylation rates in chronic HBV infected patients when 
compared to normal, autoimmune hepatitis (AIH) or hepatocellular carcinoma 
(HCC) cases on the microarray data analysis (see Chapter 3, Tables 3.3-3.10). 
The primer design algorithm used is outlined in Figure 4.1. Using the transcript start 
and stop information obtained from the microarray data analysis using Partek 
Genomic Suite, the sequence of the targeted gene promoter regions were downloaded 
from Ensembl hg19 assembly 
35
. The primers used to target the regions were 
designed using Applied Biosystem Methyl Primer Express Software
®
 v1.0 
36, 37
. This 
software and CpG Island Searcher
® 38 
calculates the density of CpG dinucleotides 
and determines the presence of CpG islands. If the targeted region has no CpG 
island, the programme can design primers that will amplify the entire region of 
interest.  
For optimal primer function (see Figure 4.1), a number of parameters were taken 
into consideration when designing the primers. These were that the length of the 
primers is between 18 and 27 bp to ensure specificity, primers have an annealing 
temperature of between 56 and 64 °C and that the length of the PCR products was 
kept short to less than 450bp to ensure maximum yield. 
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Figure 4.1: Primer Design Algorithm. 
Gene promoter sequences were downloaded from Ensembl hg 19 assembly 
35
. Tandem Repeat 
Finder
39
 and DFAM
40, 41
 were used to screen for the presence of Alu repeats in the targeted region of 
interest. Applied Biosystem Methyl Primer Express Software
®
 v1.0 
36, 37  
was used to design the 
primers.  
 
The Tandem Repeat Finder
® 39
 and DFAM
®
 software 
40, 41
 were used to determine 
the presence of repetitive DNA sequences or Alu repeats in the sequence of the 
targeted promoter region and ensure that the primers were not designed within such 
region. The characteristics of the primers used for the bisulfite DNA sequencing 
work are outlined in Table 4.1. 
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Table 4.1: Promoter Region Primers used for Bisulfite DNA Sequencing Work 
 
Abbreviations: CCND3 – Cyclin D3, EXOSC3 – Exosome component 3, FRFRL1 – Fibroblast growth factor receptor-like 1, GABPB2 – GA binding 
protein transcription factor beta subunit 2, NACC2 - NACC family  member 2, BEN and BTP (POZ) domain containing,  PA2G4 – Proliferation 
associated 2 G4, PCR – Polymerase chain reaction, TBC1D17 – TBC1 domain  family member 17, THRAP3 – Thyroid receptor associated protein 3, 
TUBA4A –Tubulin alpha 4A, TRPV5 – Transient receptor potential cation channel subfamily v member 5,  UBXN1 – UBX domain protein 1. 
Name of Gene 
 
 
CCND3 
 
 
EXOSC3 
 
 
FGFRL1 
 
 
GABPB2 
 
 
NACC2 
 
 
PA2G4 
 
 
TBC1D17 
 
 
THRAP3 
 
 
TUBA4A 
 
 
TRPV5 
 
 
UBXN1 
 
Primer Sequences 
 
 
Forward: 5ꞌ-TTTGAGATGGAGTTTTTTTTTG-3ꞌ 
Reverse: 5'-AATCCCAACACTTTAAAAAACC-3' 
 
Forward: 5' GGGATTTTTGGAAGTTGAGTAG 3' 
Reverse: 5' AAAAAAATCCCATAAACCCAC 3' 
 
Forward: 5' GTGTTTYGAGAGTTGAGGATT 3' 
Reverse: 5' TCCCTACRAAACTTTATCAACTC 3' 
 
Forward: 5' TGTTAGGAGATYGAGATTATTTTA 3' 
Reverse: 5' CCTAATAAACACATTTTTCCAAT 3'    
 
Forward: 5' GGAGGGTTTTTAGTGGGG 3' 
Reverse: 5' AACTCTCCCRAACTTAACRAAT 3' 
 
Forward: 5' TGTTTTTGAATTTATTATTTTAGAAAA 3' 
Reverse: 5' TCCTCCRAAACTAAAAAAACA 3' 
 
Forward: 5' TAGTATTTTTTGTTTYGGTTTG 3' 
Reverse: 5' AAAACCAAAAAAATACCATTTT 3' 
 
Forward: 5' TTTTAAAATGGTGGGGGTAG 3' 
Reverse: 5' TAAACCCRCTACCTCCTAAA 3' 
 
Forward: 5' AGATGTAGGGTGTTGTGGTAG 3' 
Reverse: 5' CTATACAATTCTAAATCCTCRACC 3' 
 
Forward: 5' TTTTAATTTGTGAAATTGGGGT 3' 
Reverse: 5' TCATTCCTAAAAAAAATCCCAA 3' 
 
Forward: 5' TGGGAATAGGGAGGTAATTTAT 3' 
Reverse: 5' CAAAAATCCCTTTAACAATCAA 3' 
 
  
 
 
 
Annealing 
Temperature (°C) 
 
60 
 
 
60 
 
 
60 
 
 
57 
 
 
61 
 
 
57 
 
 
57 
 
 
60 
 
 
58 
 
 
61 
 
 
59 
PCR 
Product Size 
 
260 
 
 
381 
 
 
398 
 
 
335 
 
 
256 
 
 
288 
 
 
303 
 
 
257 
 
 
295 
 
 
421 
 
 
281 
CpG 
Percentage 
 
33 
 
 
36 
 
 
68 
 
 
33 
 
 
57 
 
 
21 
 
 
31 
 
 
42 
 
 
42 
 
 
29 
 
 
30 
 
Position of CpG 
 Islands 
 
42016711- 42017283 
 
 
37785152 - 37785873 
 
 
1005016 - 1005705 
 
 
151042422 -151043032 
 
 
138987157 - 138987769 
 
 
56497246 - 56498050 
 
 
50380045 - 50380662 
 
 
220118699 - 220119322 
 
 
142630888 - 142631689 
 
 
142630888 - 142631689 
 
 
62246556 - 62247149 
 
 
 
 
 
4.2.4 Bisulfite Conversion of Genomic DNA 
Bisulfite conversion was done using the methods developed by Frommer et al
1
, 
Clarke et al
2
, and recently modified by Zhang et al
42
.  The recent modification 
includes a digestion step prior to DNA conversion which reduces the DNA into 
smaller fragments and facilitates strand separation. BamHI restriction endonuclease 
(details in Appendix 16) was used to digest 2µg of genomic DNA by cutting 
GꞌGATTꞌC sites outside the region targeted by the primers. Following this, the 
digested DNA was subjected to sodium bisulfite treatment using EZ DNA 
Methylation Gold kit
®
 (Zymo Research, Netherlands, Appendix 16) following the 
manufacturer’s instructions. Briefly, 20µl of digested DNA was mixed with bisulfite 
mix and incubated at 80°C for 10 minutes and 53°C for up to 16 hours in a thermal 
cycler to complete bisulfite DNA conversion. In this reaction, sodium bisulfite 
converts unmethylated cytosine residues to uracils in single stranded DNA and leaves 
methylated cytosine residues unaffected (see Figure 4.2). The protocols for 
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restriction digestion and bisulfite conversion of DNA are described in Appendices 18 
and 19. 
 
Figure 4.2: Bisulfite Conversion of Genomic DNA (Adapted from Clarke et al
2
).  
After denaturation, the DNA is treated with sodium bisulfite which leaves methylated cytosines 
unaffected and converts unmethylated ones into uracils that appear as thymines in the DNA sequence. 
Abbreviations: C - Cytosine, Met - Methylated, PCR - Polymerase chain reaction, T - Thymine, U - 
Uracil.  
 
After bisulfite conversion, 1µl of converted products was run on 1.2% agarose gel. 
After gel electrophoresis, the gel was chilled at 4°C for 15 minutes before viewing 
under ultraviolet light. Using the primers listed in Table 4.1, bisulfite converted 
DNA was used for PCR amplification (see Appendix 20). Longer denaturation steps 
were incorporated in the PCR conditions to prevent the formation of secondary 
structures that usually form during bisulfite DNA conversion
42
. The PCR 
components included HotStar Taq polymerase
®
 (Qiagen, USA) to prevent 
polymerization at room temperature. After PCR amplification, the products were 
checked on 1.2% agarose gel and purified using the QIAquick Gel Extraction Kit
®
 
(Qiagen, USA, Appendix 16) following the manufacturer’s instructions (see 
Appendix 21). This purification step removes primer-dimers, deoxynucleotide 
triphosphates (dNTPs), Taq polymerase and salts from PCR reactions that would 
otherwise interfere with the subsequent cloning process. 
 
4.2.5 Cloning of Amplified Bisulfite Converted DNA into the Vector 
The purified PCR products were cloned into a pGEM
®
-T Easy Vector using the 
pGEM
®
-T Easy Vector System II (Promega, USA, see Figure 4.3). The pGEM
®
-T 
Easy Vector has a single 3ꞌ-terminal thymidine that overhangs at both ends at the 
cloning site, ensuring highly efficient insertions of PCR products.  
179 
Chapter 4: Validation of Microarray Data Findings Using Bisulfite DNA Sequencing 
 
Figure 4.3: Sequence Map and Multi-Cloning Site of pGEM
®
-T Easy Vector Map. 
A pGEM
®
-T Easy Vector is a linearised vector of 3015bp derived from pGEM
®
-5ZF (+) vector 
(GenBank Accession Number X65308).  It encodes phage T7 and SP6 promoter RNA polymerases 
at the multiple-cloning sites within the lacZ gene encoding β-galactosidase. These promoter RNA 
polymerases synthesise RNA from the inserted DNA in the 5ꞌ to 3ꞌ direction and are important in 
blue/white recombinant selection. 
 
The pGEM
®
-T Easy Vector also has the ampR gene that confers resistance to 
ampicillin during bacterial growth. It also encodes phage T7 and SP6 promoter RNA 
polymerases at the multiple-cloning sites within the lacZ gene encoding β-
galactosidase that catalyse the hydrolysis of the lactose analog X-gal.  
The promoter RNA polymerases synthesise RNA from the inserted DNA in the 5ꞌ to 
3ꞌ direction and are important in blue/white recombinant selection. X-gal is an inert 
chromogenic substrate for β-gal. It is colorless and turns blue in the presence of β-gal 
and is therefore used as a visual marker for non-recombinant colonies. When an insert 
is cloned into the vector, β-galactosidase is destroyed and is unable to cleave X-gal 
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hence the clone appears white. White colonies indicate the presence of PCR inserts 
and blue colonies represent clones with no PCR inserts.  
The ligation was carried out using the T4 DNA ligation system (Promega, USA, 
Appendix 16) according to the manufacturer’s protocol (see Appendix 22). Ligation 
reactions were prepared using a 3:1 molar ratio of the insert to the vector. After an 
overnight incubation for high efficiency ligation, the reactions were transformed into 
JM109 competent cells (Promega, USA, see Appendix 23). Cells transformed with 
ligation reactions were plated on 2xYT agar plates supplemented with 100µl/ml 
ampicillin (Sigma Aldrich, USA), 200µg/ml isopropyl-β-D-1-thiogalactopyranoside 
(IPTG, Sigma Aldrich) and 100µg/ml X-gal (Sigma Aldrich, USA).  
 
4.2.6 Screening of Positive Clones with Vector Plus Insert 
Promoter primers which include the pUC/M13, SP6 and T7 enclosing the cloned 
inserts were used in colony PCR to identify positive clones with vector and inserts. 
The multiple cloning region of the pGEM
®
-T Easy vector is flanked by a number of 
restriction sites for restriction endonucleases that can be used to release the inserts in 
a single digestion with NotI, BstZI and EcoRI enzymes. 
Positive selection of clones with vector plus inserts was carried out using the blue or 
white color screening. At least and up to 15 white clones were picked and suspended 
in 20µl deionised water and then 5µl of the recovered supernatant was used as a 
template in a PCR reaction set (see Appendix 24). A portion of the PCR reaction 
was run on 1.5% agarose gel. PCR products from these positive clones were purified 
(see Appendix 21) and sent for sequencing.  
 
4.2.7 Sequencing of Positive Clones with Vector Plus Insert 
The purified PCR product of 5ng/µl was sent for sequencing using Dye Terminator 
DNA Sequencer at the Central Sequencing Facility at the University of Stellenbosch, 
South Africa. The sequencing was performed with 1pmol/µl of both M13 forward (-
20) 5ꞌ- GTA AAA CGA CGG CCA GT-3ꞌ and M13 reverse (-27) 5ꞌ- CAG GAA 
ACA GCT ATG AC-3ꞌ primers (Whitehead Scientific, SA, see Appendix 25.A). 
181 
Chapter 4: Validation of Microarray Data Findings Using Bisulfite DNA Sequencing 
DNA sequencing was done using the BigDye Terminator V3.1 sequencing kit
®
 
(Applied Biosystem) following manufacture’s protocol with slight modifications.  
 
4.3 STATISTICAL METHODS AND DATA ANALYSIS 
The sequencing results were extracted in FASTA format using a trace file viewer like 
Chromas 
43
. BioEdit Sequence Alignment Editor was used to create ClustalW 
multiple alignment of the gene promoter region sequence downloaded from Ensembl 
hg 19 assembly 
35
 and the bisulfite converted sequence of positive clones.  
The demographic and clinical data of the study patients was analysed using STATA 
13 (College Station, Texas, USA, see Appendix 25.C). Categorical binary data were 
summarised as counts and percentages, and categorical ordinal data as median and 
inter-quantile values. Ordinal numerical data was summarised as median and inter-
quantile values and continuous numerical data as means and standard deviations.  
The investigation of possible associations between independent categorical variables 
was performed using the Pearson Chi-Squared test and Fisher’s exact test where 
appropriate. A two-sided P-value of ˂ 0.05 was considered significant. 
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4.4 RESULTS 
4.4.1  Visualising Successful Bisulfite DNA Conversion 
Figure 4.4 shows an agarose gel analysis of bisulfite converted DNA products. 
Initially, only the DNA ladder bands are observed and with no DNA products visible. 
After chilling the gel on ice, the successfully bisulfite converted DNA products 
appear as a smear between 100 and 1500 bp (see Figure 4.4B, Lanes 2 - 12). All 
samples were successfully converted. 
 
Figure 4.4: Agarose Gel Analysis of DNA Products after Bisulfite Treatment. 
2µg of DNA was treated with sodium bisulfite, converted using EZ DNA Methylation Kit and then 
2µl from eluted bisulfite converted DNA was run on 1.5% agarose gel containing ethidium bromide. 
A gel picture was taken immediately after electrophoresis (A, before chilling) and another after 
chilling at 4°C for 10 minutes (B, after chilling).  
Lane 1: 100bp DNA ladder, Lane 2: BC_ 522, Lane 3: BC_ 496, Lane 4: BC_ 505, Lane 5: BC_ 
496, Lane 6: BC_ 428, Lane 7: BC_ 428, Lane 8: BC_ 499, Lane 9: BC_ 444, Lane 10: BC_ 594, 
Lane 11: BC_ 505, Lane 12: BC_ 493 
Abbreviations: bp - Base pairs, BC - Bisulfite converted, DNA - Deoxyribonucleic acid. 
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4.4.2 Analysis of PCR Amplified Bisulfite Converted Genomic DNA 
Agarose gel analysis to confirm successful PCR amplification of bisulfite converted 
DNA products is shown in Figure 4.5.  The PCR products produced expected 
amplicons ranging from 256 - 500 bp depending on the gene promoter primer used is 
listed in Table 4.1 (see Figure 4.5, Lanes 2 – 12). Products in Lane 4 (CCND3) and 
7 (TUBA4A) appeared as more than one band including the expected correct bands 
of 260 and 295 bp respectively (see Figure 4.5, Lane 4 and 7) 
 
 
Figure 4.5: Gel Analysis of PCR Amplified Bisulfite Converted DNA. 
300ng of bisulfite converted double stranded DNA was amplified using primers specific to eleven 
different human promoter gene region CpG islands. About 2µl of the PCR products was run on 1.5% 
agarose gel.  
Lane 1: 100bp DNA ladder, Lane 2: BC_NACC2_522, Lane 3: BC_THRAP3_496, Lane 4: 
BC_CCND3_505, Lane 5: BC_UBXN1_496, Lane 6: BC_PA2G4_428, Lane 7: BC_TUBA4A_428, 
Lane 8: BC_TBC1D17_499, Lane 9: BC_GABPB2_444, Lane 10: BC_EXOSC3_594, Lane 11: 
BC_FGFRL1_505, Lane 12: BC_TRPV5_493.  
Abbreviations: bp - Base pairs, BC - Bisulfite converted, DNA - Deoxyribonucleic acid, CCND3 - 
Cyclin D3, EXOSC3 - Exosome component 3, FGFRL1 - Fibroblast growth factor receptor-like 1, 
GABPB2 - GA binding protein transcription factor beta subunit 2, NACC2 - NACC family member 2 
gene promoter, PA2G4 - Proliferation associated 2G4, THRAP3 - Thyroid hormone receptor 
associated protein 1, TBC1DF17 - TBC 1 domain family member 17, TRPV5 - Transient receptor 
potential cation channel subfamily v member 5, TUBA4A - Tubulin 4a, UBXN1 - UBX domain 
protein 1. 
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4.4.3 Screening of Positive Clones with Vector Plus Insert by Colony PCR 
Subcloning of the PCR products obtained after amplification of bisulfite converted 
DNA into pGEM T-Easy vector for methylation profile analysis was successful. 
Figure 4.6 shows the PCR products amplified from positive clones with correct 
inserts and these produced expected amplicons ranging from 400 – 600 bp depending 
on the gene promoter primer product size (see Table 4.1), thus confirming successful 
cloning of the insert into the vector. 
 
 
Figure 4.6: Agarose Gel Analysis of Cloned Bisulfite Converted PCR Products into 
pGEM
®
 T-Easy Vector. 
White colonies were picked and resuspended in 20µl of deionised water and centrifuged briefly to 
obtain a supernatant. 5µl of the supernatant was used as a template in a 50µl PCR reaction following 
which PCR product was run on 1.5% agarose gel.  
Lane 1: 100bp DNA ladder, Lane 2: CLN_NACC2_522, Lane 3: CLN_THRAP3_496, Lane 4: 
CLN_CCND3_505, Lane 5: CLN_UBXN1_496, Lane 6: CLN_PA2G4_428, Lane 7: 
CLN_TUBA4A_428, Lane 8: CLN_TBC1D17_499, Lane 9: CLN_GABPB2_444, Lane 10: 
CLN_EXOSC3_594, Lane 11: CLN_FGFRL1_505, Lane 12: CLN_TRPV5_493. 
Abbreviations: bp - Base pairs, CLN – Colony, DNA - Deoxyribonucleic acid, CCND3 - Cyclin D3, 
EXOSC3 - Exosome component 3, FGFRL1 - Fibroblast growth factor receptor-like 1, GABPB2 - 
GA binding protein transcription factor beta subunit 2, NACC2 - NACC family member 2 gene 
promoter, PA2G4 - Proliferation associated 2G4, THRAP3 - Thyroid hormone receptor associated 
protein 1, TBC1DF17 - TBC 1 domain family member 17, TRPV5 - Transient receptor potential 
cation channel subfamily v member 5, TUBA4A - Tubulin 4A, UBXN1 - UBX domain protein 1. 
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4.4.4 Methylation Pattern of the Gene Promoter CpG Island Regions of Selected 
Candidate Genes 
The methylation profile data of the genes used for validation are summarised in 
Table 4.2. The selected sequence of the CCND3 promoter CpG islands shows that all 
of the cytosines detected across the selected sequence were methylated (see Table 
4.2). In contrast, none of the cytosines in the promoter regions of GABPB2 and 
PA2G4 genes were methylated and only 1(0.2%) was methylated in EXOSC3 gene 
(see Table 4.2).  
 
Table 4.2: The DNA Methylation Profiles of the Gene Promoter CpG Sequences 
used for Validation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Gene 
 
 
CCND3 
EXOSC3 
FGFRL1 
GABPB2 
NACC2 
PA2G4 
TBC1D17 
THRAP3 
TUBA4A 
TRPV5 
UBXN1 
 
Cloning 
 
 
Successful 
Successful 
Successful 
Successful 
Successful 
Successful 
Unsuccessful 
Successful 
Successful 
Unsuccessful 
Unsuccessful 
 
Sequence 
Alignment 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
 
Methylated 
Cytosine (N, %) 
 
19 (100) 
1(0.2) 
2 (3.1) 
0 
2 (5.6) 
0 
- 
1 (4.8) 
2 (18) 
- 
- 
 
Bisulfite 
Converted (N, %) 
 
0 
6 (98.9) 
65 (96.9) 
1 (100) 
36 (94.4) 
14 (100) 
- 
21 (95.2) 
11 (82) 
- 
- 
 
Age 
(years) 
 
26 
18 
26 
22 
48 
33 
33 
36 
33 
17 
36 
Viral DNA 
Log10 
 
8.2 
4.1 
8.2 
8.3 
8.2 
2.1 
1.3 
3.0 
2.6 
1.8 
3.4 
eAg 
 
 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
ALT 
 
 
271 
33 
271 
25 
118 
12 
22 
21 
12 
23 
21 
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Figure 4.7 shows the DNA methylation profile of a selected section of the bisulfite-
sequenced clone of the CCND3 gene promoter CpG island region. The ClustalW 
multiple alignment and chromatograph shows no conversion of any cytosine to 
thymine, indicating that the sequence of the CCND3 gene promoter CpG island was 
completely methylated.  
 
Figure 4.7: Methylation Profile of a Selected Section of CCND3 Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, CCND3 - Cyclin D3, CpG - Cytosine-
phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - Original sequence from Ensembl. 
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A selected section of the sequence alignment for the FGFRL1 promoter CpG island 
is shown in Figure 4.8. The ClustalW multiple alignment of the Ensembl derived 
original sequence and bisulfite converted sequences starts from base 107 and end in 
base 505 of the FGFRL1 promoter CpG island. Only 2 out of the 67 CpG sites across 
the FGFRL1 promoter CpG island were methylated. All the other unmethylated 
cytosines are converted to thymines indicating complete bisulfite conversion. 
 
 
Figure 4.8: Methylation Profiles of a Selected Section of FGFRL1 Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, FGFRL1 – Fibroblast growth factor receptor 
like-1, CpG - Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, OS – Original sequence 
from Ensembl. 
 
188 
Chapter 4: Validation of Microarray Data Findings Using Bisulfite DNA Sequencing 
The ClustalW multiple alignment of the original and bisulfite converted sequences 
starts from base 136 and ends in base 392 of the NACC2 promoter (see Figure 4.9). 
The NACC2 promoter exhibited 2 methylated cytosines out of 38 cytosines of the 
promoter CpG sites (see Figure 4.9).  
 
Figure 4.9: Methylation Profile of a Selected Section of NACC2 Promoter CpG Sites 
Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations:  BCS - Bisulfite converted sequence, NACC2 – NACC family member 2 BEN and 
BTP (POZ) domain containing, CpG - Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, 
OS – Original sequence from Ensembl. 
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The ClustalW multiple alignment of the original and bisulfite converted sequences 
starts from base 160 and ends in base 360 of the PA2G4 gene promoter (see Figure 
4.10). All the cytosines in the selected section of the PA2G4 promoter region are 
unmethylated and converted to thymines (see Figure 4.10).  
 
 
Figure 4.10: Methylation Profile of a Selected Section of PA2G4 Promoter CpG 
Sites Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, PA2G4 – Proliferation associated 2G4, CpG - 
Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - Original sequence from Ensembl. 
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The ClustalW multiple alignment of the original and bisulfite converted sequences 
starts from base 111 and ends in base 366 of the THRAP3 gene promoter CpG island 
(see Figure 4.11). The ClustalW multiple alignment of the original sequence for 
THRAP3 gene promoter exhibited methylation of 1 of the 22 cytosines in the selected 
section of the CpG island in this gene promoter illustrated here (see Figure 4.11).  
 
 
Figure 4.11: Methylation Profile of a Selected Section of THRAP3 Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, THRAP3 – Thyroid hormone receptor 
associated protein 3, CpG - Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - 
Original sequence from Ensembl. 
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The ClustalW multiple alignment of the original and bisulfite converted sequences 
starts from base 160 and ends in base 300 of the TUBA4A gene promoter CpG island 
(see Figure 4.12). There were 2 methylated cytosines in the selected section of the 
aligned sequence of the clone with TUBA4A gene promoter CpG island.   
 
 
Figure 4.12: Methylation Profile of a Selected Section of TUBA4A Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, TUBA4a – Tubulin 4a, CpG - Cytosine-
phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - Original sequence from Ensembl. 
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The ClustalW multiple alignment of the Ensembl derived original and bisulfite 
converted sequences starts from base 267 and ends in base 354 of the GABPB2 
promoter CpG island (see Figure 4.13). Only one CpG site was observed on the 
selected region of sequence alignment and the cytosine on this site was converted to 
thymine and is therefore not methylated (see Figure 4.13).  
 
 
Figure 4.13: Methylation Profile of a Selected Section of GABPB2 Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations: BCS - Bisulfite converted sequence, GABPB2 – GA binding protein transcription 
factor beta subunit 2, CpG - Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - 
Original sequence from Ensembl. 
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The ClustalW multiple alignment of the original and bisulfite converted sequences 
starts from base 193 and ends in base 449 of the EXOSC3 gene promoter CpG island 
(see Figure 4.14). The EXOSC3 gene promoter CpG island exhibited 7 CpG sites on 
the selected section of aligned region (see Figure 4.14). Only 1 cytosine of the CpG 
sites was methylated and the rest were converted to thymines.    
 
 
Figure 4.14: Methylation Profile of a Selected Section of EXOSC3 Promoter CpG 
Island Using Bisulfite DNA Sequencing.  
Clones with vector plus insert were PCR amplified and sequenced with M13 reverse primer. 
Methylation profile analysis was performed using trace file viewer like Chromas and sequence 
alignment of original and bisulfite converted sequences was done with ClustalW multiple alignment in 
BioEdit Sequence Alignment Editor. After bisulfite conversion, methylated cytosines remain 
unaffected and unmethylated cytosines are converted to uracils that appear as thymines in the DNA 
sequence.  
Abbreviations:  BCS - Bisulfite converted sequence, EXOSC3 – Exosome component 3, CpG - 
Cytosine-phosphate-Guanine, DNA - Deoxyribonucleic acid, OS - Original sequence from Ensembl. 
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4.4.5 Methylation Profile of Cyclin D3 in HBV e Antigen Positive and Negative 
Patients 
The profile of the cohort used to investigate the highly methylated CCND3 gene is 
outlined in Table 4.3. There was equal proportion of HBV e antigen positive, 
negative and normal controls. Bisulfite DNA sequencing analysis was unsuccessful 
in 30% HBV e antigen positive, 50% HBV e antigen negative and 70% normal 
control DNA samples (see Figure 4.3).  
 
Table 4.3: Profile of Patient Cohort Used to Investigate CCND3 Gene   
 Experimental Data 
 
 
 
Bisulfite Conversion and Amplified by PCR 
Cloned into the Vector 
Successful in Sequencing and Used for Analysis   
Sample Cohort 
(Number = 30) 
 
Number (%) 
30 (100) 
18 (60) 
15 (50) 
HBVeAg Positive 
(Number = 10) 
 
Number (%) 
10 (100) 
8 (80) 
7 (70) 
HBVeAg Negative 
(Number = 10) 
 
Number (%) 
10 (100) 
7 (60) 
5 (50) 
Negative Controls 
(Number = 10) 
 
Number (%) 
10 (100) 
3 (30) 
3 (30) 
Abbreviations: % - Percentage, HBVeAg – Hepatitis B virus e antigen, PCR – Polymerase chain reaction 
 
 
The ClustalW multiple alignment of bisulfite converted sequences of clones with 
CCND3 gene promoter CpG islands of normal controls, HBeAg positive and 
negative patients is shown in Figure 4.15. Cytosine methylation is present only in 
HBV patients and all the cytosines in the normal control sequences were converted to 
thymines, indicating the absence of methylation at those sites (see Figure 4.15). 
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Figure 4.15: Methylation Profile in a Selected Section of the CCND3 Promoter 
Region in HBV Patients and Controls.  
Single clone with vector plus insert was PCR amplified and sequenced with M13 reverse primer. For 
each CpG site, CHBV, HBV and Normal sera were compared using ClustalW multiple aligned 
sequences generated in BioEdit Sequence Alignment Editor.  
Abbreviations: CCND3 Ensembl - Cyclin D3 sequence derived from Ensembl,  CHBV – HBV e 
antigen positive, CpG - Cytosine-phosphate-Guanine, HBV – HBV e antigen negative. 
 
In the successfully cloned and sequenced samples, most of the patients were male 11 
(78.6%) and young with a median age of 22.3 yrs (see Table 4.4). There was no 
gender (p = 0.5) or age difference (p = 0.7) between the HBV e antigen positive and 
negative groups. The HBV e antigen positive group had significantly higher HBV 
DNA levels (p = 0.02) and CCND3 gene promoter methylation (p = 0.001) compared 
to the HBV e antigen negative group. The HBV e antigen positive group had higher 
ALT levels (p = 0.09) and INR levels (p = 0.09) but these did not reach significance 
levels. 
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Table 4.4: Demographic and Methylation Profile of the CCND3 Gene Promoter in 
HBV Infected Cohort 
  
 
 
 
 
 
 
 
When the cohort was analysed by the different HBV genotypes, there was no 
difference in the gender profile (p = 0.6), age at diagnosis (p = 0.3), alpha fetoprotein 
levels (p = 0.65) and ALT levels (p = 0.4) between HBV genotypes A and D infected 
patients (see Table 4.5). Genotype D patients had significantly higher HBV DNA 
levels (p = 0.006) and CCND3 gene promoter methylation (p = 0.005) compared to 
genotype A patients. Genotype D had higher INR levels (p = 0.07) but this did not 
reach statistical significance. 
 
Table 4.5: Cohorts HBV Genotype and CCND3 Gene Promoter Methylation Profiles 
 
 
 
 
 
 
 
 
 
 
 
Male Gender  
 
 
Age (years) 
Log10 HBV DNA 
Methylation %  
 
αFP (u/L) 
Albumin (35 – 50 g/L) 
ALT (0 – 40 u/L) 
INR (˂ 1.2) 
Platelets (150 – 400 x 109 L) 
Genotype A 
 
(Number, %) 
6 (75) 
 
(Median, IQR) 
20.3 (18.5 - 33.6) 
5.2 (4.6 - 5.2) 
40 (30 - 80) 
 
2.5 (1.7 - 3.1) 
44.5 (11 - 45.5) 
36 (24 - 146.5) 
0.98 (0.92 - 1.05) 
239.5 (219 - 303) 
 
Genotype D 
 
(Number, %) 
5 (83.3) 
 
(Median, IQR) 
25.3 (23.3 - 44.4) 
8.3 (8.2 -8.5) 
80 (80 - 80) 
 
2.7 (2.4 – 3.5) 
45 (43 - 49) 
60.5 (37 - 108) 
1.19 (1.03 - 1.35) 
24.4 (204 - 254) 
P Value 
 
 
0.6 
 
 
0.3 
0.006 
0.005 
 
0.65 
0.36 
0.4 
0.07 
0.79 
Abbreviations: % - Percentage, αFP – Alpha Fetoprotein, ALT – Alanine aminotransferase, INR – 
International normalised ratio, IQR - Inter -quantile range, HBV - Hepatitis B virus  
  
 
 
 
Male Gender  
 
 
Age (years) 
HBV DNA Log10 
Methylation %  
 
α FP (u/L) 
Albumin (35 – 50 g/L) 
ALT (0 – 40 u/L) 
INR (˂ 1.2) 
Platelets (150 – 400 x 109 L) 
HBV eAg Negative 
N = 6 
 
(Number, %) 
5 (71.53) 
 
(Median, IQR) 
21.1 (18.4 - 44.8) 
5.15 (3.9 -16.9) 
40 (20 - 40) 
 
2.5 (1.3 – 2.8)  
45 (40 - 46) 
32 (21 – 45) 
0.96 (0.9 – 1.1) 
237 (212 – 244) 
 
HBV eAg Positive 
N = 8 
 
(Number, %) 
6 (85.71) 
 
(Median, IQR) 
24.7 (18.8 - 44.4) 
8.3 (8.2 -8.5) 
80 (80 - 80) 
 
3 (2.4 – 4.6) 
42 (44 - 49) 
67 (37 - 271) 
1.1 (1 - 1.35) 
254 (204 - 400) 
 
P Value 
 
 
 
0.5 
 
 
0.7 
0.022 
0.001 
 
0.19 
0.65 
0.09 
0.09 
0.57 
 
Abbreviations: % - Percentage, αFP – Alpha Fetoprotein, ALT – Alanine aminotransferase, INR – International normalised 
ratio, IQR - Inter -quantile range, HBVeAg - Hepatitis B virus e antigen  
All 
N = 13 
 
(Number, %) 
11 (78.6) 
 
(Median, IQR) 
22.3 (18.8 - 44.4) 
8.2 (5.2 -8.3) 
50 (40 - 80) 
 
2.5 (2.1 – 3.3)  
44.5 (42 - 46) 
42.5 (27 – 108) 
1.02 (0.9 – 1.1) 
239 (212 – 254) 
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4.5 DISCUSSION 
The main aim of this study was to validate the methylation profiles of promoter CpG 
islands of selected genes identified in the microarray data analysis. The promoter 
regions of interest were those of CCND3, EXOSC3, FGFRL1, PA2G4, GABPB2, 
NACC2, TBC1D17, TUBA4A, THRAP3, TRPV5 and UBXN1 genes. Using bisulfite 
DNA conversion, cloning of amplified converted DNA and sequencing, every 
cytosine methylated in the target sequence of the selected gene promoter regions was 
successfully identified (see Figures 4.7 - 4.15), confirming the presence of DNA 
methylation in chronic HBV infected patients. In addition, the highly methylated 
CCND3 gene was further investigated in HBV infected patients and normal controls 
(see Figure 4.15) 
 
4.5.1 Visualizing Successful Bisulfite DNA Conversion 
The chilling effect method first discovered and described by Ruga et al
10
 was used to 
visualize successful bisulfite conversion of DNA in an agarose gel prior to PCR 
amplification and cloning into the vector (see Figure 4.4B). As bisulfite converted 
DNA is single stranded, it is impossible to view it in an agarose gel with ethidium 
bromide because the complementarily of bases is lost and the two strands are too far 
apart than in normal double stranded DNA that allows intercalation of the ethidium 
bromide 
10
.   
Dropping the temperature through chilling allows single stranded DNA to fold back 
onto itself and retain a local base pairing allowing intercalation of the ethidium 
bromide and therefore visualization under ultraviolet 
10
.  Knowledge of this effect 
allows one to visualize successfully converted DNA samples prior to PCR 
amplification and cloning into the vector. 
 
4.5.2 Validation of Methylation Profiles Obtained Through Microarray Data 
Analysis   
Eleven promoter regions of CCND3, EXOSC3, FGFRL1, PA2G4, GABPB2, NACC2, 
TBC1D17, TUBA4A, THRAP3, TRPV5 and UBXN1 genes were selected to give a 
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representation of genes in each of the functional groups of cyclin-dependent kinase, 
growth factors, tumour suppressors, transcriptional factors, vitamin D receptor 
binding, mRNA splicing and metabolic regulators that were identified in the 
microarray analysis (see Chapter 3, Tables 3.12) 
16 - 24
. 
The ClustalW multiple sequence alignment comparing the gene promoter sequences 
downloaded from Ensembl hg19 assembly 
35
  and DNA sequences amplified from 
positive colonies harbouring clones with CCND3, EXOSC3, FGFRL1, NACC2, 
TUBA4A and THRAP3 genes showed the presence of methylation, confirming the 
methylation data from microarray analysis.  
The methylation rate of cytosine bases varied from 0 to 100 % between different 
genes (see Table 4.2). The targeted sequences of FGFRL1, NACC2, THRAP3, 
TUBA4A and EXOSC3 showed CpG site methylation rates of 3 – 18 % (see Table 
4.2). Lower rates of methylation in the promoter regions of these genes may be 
related to the stage of disease progression and function of the genes. Alternatively, 
different primers targeting other areas of the promoter could have found higher rates 
of methylation in the same patients. Although some of these genes may be 
methylated early in the stage of disease, methylation may accumulate as the liver 
disease progresses and could therefore become higher in the advanced liver disease 
47
. This needs further investigation in older patients or cirrhotic patients using 
different bisulfite sequencing primers.  
Higher methylation rates may be influenced by the duration of infection, virus 
genotype, viral load and environmental factors such as aflatoxins, drugs, chronic 
smoking and alcohol consumption which can also induce methylation 
15, 28 -34 
. In this 
study, the CCND3 gene promoter region analysed was found to be heavily 
methylated (see Table 4.2).  The DNA used for the bisulfite DNA sequence analysis 
in the validation cohort of CCND3 gene was obtained from a young patient with a 
high ALT and HBV viral load (see Table 4.2). In the CCND3 gene validation cohort, 
methylation was associated with HBV e antigen positive status, viral load and 
genotype (see Table 4.4). These observations are supported by several studies which 
show that HBV genotype A infected patients, viral loads of greater than 1 x 10
4
 
copies per ml and HBV e antigen positive status are associated with increased 
methylation and a high risk of malignant transformation of hepatocytes 
30, 33, 43 - 45
.   
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The type of HBV insert being methylated could be another risk factor for increased 
methylation in CCND3 gene validation cohort as it may be possible that HBV x, core 
or surface antigens insert differently into the genome and therefore stimulate 
different host immune responses 
46
. This hypothesis would find support from the 
recent work of Tseng et al study which shows that the risk of developing HCC is 
high in patients with raised levels of HBV surface antigen, even in the presence of 
low HBV DNA levels 
58
.  This finding could be a reflection of high HBV surface 
antigen levels causing higher levels of HBV surface integration into the human 
genome resulting in higher rate of malignant transformation 
59 -
 
61
. Therefore, the 
higher methylation levels of CCND3 (see Table 4.2) and other genes identified in 
HBV infected patients compared to normal controls in this study (see Chapter 3, 
Table 3.3) may be due to genomic instability caused by HBV inserts into the genome 
of surface antigen 
62
.     
Although bisulfite DNA conversion for the promoters of TRPV5, UBXN1 and 
TBC1D17 genes was successful, there were no positive clones with a correct insert in 
the vector. Similar data was obtained with some of CCND3 gene validation cohort 
(see Table 4.3). One possible reason for this failure is that ultraviolet light 
overexposure of the DNA on the agarose gel prevented successful ligation. On 
ultraviolet light overexposure, pyrimidine dimmers may form 
48
. These can prevent 
ligation of DNA extracted from ultraviolet exposed gel. This can be avoided by 
limiting the time of ultraviolet light exposure using a glass plate between the gel and 
ultraviolet source. Another possibility is that, although, the PCR fragment may be 
successfully inserted into the vector, it fails to disrupt the lacZ gene, resulting in a 
higher number of blue colonies. This can be caused by low activity of DNA ligase 
and buffer due to multiple freeze-thaw cycles. This can be addressed by making use-
single aliquots of DNA ligase and buffer, and using a fresh aliquot with every 
ligation 
48
. It is also possible that the successful inserts were from DNA fragments 
that were not the targeted sequence. This can be addressed by ensuring that there are 
no other undesired bands in the PCR product before ligation 
49
 
The PA2G4 and GABPB2 gene promoter regions exhibited no methylation and all 
the cytosines in the CpG sites of these regions were converted to thymines, further 
validating successful bisulfite conversion. The absence of DNA methylation in the 
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promoter regions of PA2G4 and GABPB2 genes may be due to the fact that the 
selected patient happened not to have methylation in these genes. Another 
explanation could be due to a possible lower rate of methylation in blood when 
compared to liver tissue, which as a replication site for HBV may exhibit more 
methylation 
63
. It is also possible that the selected region have no methylated sites 
and this can be addressed by using different set of primers to target the entire 
promoter region. Patients may also not have HBV related methylation due to having 
a short period of infection and therefore not have accumulated much methylation. 
There could also be patient specific factors that could delay or prevent methylation 
such as the absence of cigarette smoking or no use of drugs that could facilitate 
methylation in the presence of HBV infection. Viral related factors would also be 
important. These could be the viral genotype, level of viral replication and the type 
of inserts in the genome such as HBV surface antigen compared to HBV x antigen 
that could affect the innate immune response and hence the activation of methylation 
(see Chapter 1, Section 1.4.3). These genes need to be studied further with a larger 
cohort, patients with different viral loads and genotypes.  
There was no methylation observed in the core promoter regions within 100bp 
upstream of the TSS in chromosomes X and Y (see Chapter 3, Figures 3.9 and 
3.10).  A possible explanation for this finding could be that these chromosomes are 
protected by the normal epigenetic silencing that occurs during embryogenesis as is 
seen with X chromosome inactivation and may therefore and remain relatively 
inactive and protected from further methylation throughout the lifetime of the cell 
64 - 
66
 (see Chapter 1, Section 2.2.2). 
 
4.5.3 Methylation of CCND3 Gene Promoter Region Compared by HBV e 
Antigen Status  
In the study cohort, normal cases had no methylation and HBV e antigen positive 
cases were significantly more methylated. This methylation difference was 
associated with genotype D and a high viral load (see Table 4.4), suggesting that the 
higher methylation rate of the CCND3 gene promoter is strongly associated with 
HBV e antigen positive status. The HBV e antigen positive patients were also 
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significantly associated with higher viral DNA load and genotype D while age at 
analysis had no influence (see Table 4.4).  
The high methylation rate of the CCND3 gene promoter region in this study suggests 
that the CCND3 gene could be important in the pathogenesis of liver disease in 
chronic HBV infection. The CCND3 gene is a cyclin-dependent kinase gene that is 
important in liver regeneration and wound healing processes and has been linked to 
the development of liver fibrosis and HCC
 22, 26
. The abnormal function of the 
CCND3 gene promoter due to methylation would disrupt normal cellular signalling 
with effects on cell growth, differentiation, proliferation and apoptosis. Such changes 
would promote the clonal expansion of mutant hepatocytes, increase hepatic 
inflammation and fibrosis 
26, 27
.  
The association with HBV e antigen positivity could be a reflection of the high viral 
DNA load thereby confirming the known HBV viral physiology of high replication 
in HBV e antigen positive patients 
33
. The association of high methylation rates with 
viral replication is significant in that the risk of cirrhosis and liver cancer is strongly 
correlated with viral replication 
33
.  
Notably, genotype D cases had significantly higher HBV DNA levels and CCND3 
gene promoter methylation compared to genotype A cases (see Table 4.5). This can 
be explained by clinical differences of HBV genotypes which have been previously 
reported in respect to their influence in HCC and response to chronic HBV treatment 
50 - 53
. Sustained biochemical remission and clearance of HBV DNA or HBV surface 
antigen was found to be frequent in HBV genotype A than D which is associated 
with more severe liver disease 
50
. Moreover, genotype D was found to be frequent in 
HCC patients below 40 years of age 
51
, suggesting that it could be more damaging to 
the liver.   In terms of therapy, the response to interferon was found to be 
significantly higher in genotype A than D chronic HBV infected patients, and in 
patients with lower levels of HBV DNA and higher levels of ALT 
52 -  58
.  Given this 
evidence, it is interesting to suggest that high DNA methylation rates may have an 
influence on the ability to respond to anti-HBV treatment. The level of DNA 
methylation and the HBV genotype could possibly predict the response to antiviral 
therapy and if so be used to individualise therapy by type and duration.       
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4.6 CONCLUSION 
This study has confirmed the microarray findings that patients with chronic HBV 
infection have significantly methylated gene promoter CpG islands compared to 
other patient groups.  
In patients with chronic HBV infection, methylation was significantly associated 
with the HBV viral load, HBV e antigen positive status and genotype D. Some genes 
were highly methylated and this could relate to their importance in liver disease in 
the presence of chronic HBV infection. In particular, the CCND3 gene was highly 
methylated and its potential disruption could explain the development of hepatic 
inflammation, fibrosis and malignant transformation.  
These mechanisms require further investigation to investigate the link between liver 
disease and DNA methylation caused by viral or environmental factors such as 
duration of infection, virus genotype, viral load, insertion of HBV antigens, drugs, 
aflatoxins, chronic smoking and alcohol consumption.  
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
5.  INTRODUCTION 
Hepatitis B virus (HBV) is one of the most prevalent infections in humans and 
important cause of acute and chronic hepatitis
 1, 2, 126
. Long term inflammatory 
changes due to chronic hepatitis cause hepatocyte injury and the release of reactive 
oxygen species and Kupffer cells activation 
3, 4
. These produce proinflammatory and 
fibrogenic cytokines resulting in the recruitment of immune cells 
4
. The Kupffer cells 
also activate hepatic stellate cells which produce extracellular matrix proteins and 
cytokines 
5, 10
. Repeating cycles of this activation and inflammation leads to cirrhosis 
characterised by regenerative nodules and irreversible fibrosis 
6 – 8, 126, 127
.  
The ability of the virus to cause liver injury is associated with genetic changes that 
affect both viral and host DNA leading to mutations that predispose to liver injury 
and possible cancer 
9, 10
.  These events link chronic HBV infection with 
hepatocellular carcinoma (HCC). HCC is the sixth most common cancer in the world 
with highest incidence rates being in Asia and sub-Saharan Africa 
11, 12
.  More than 
80% of HCC cases arise in chronic HBV infection, strongly suggesting that HBV is 
an important contributor to the development of tumour 
11 - 14
.   
Possible mechanisms by which HBV infection causes HCC have been described and 
these include HBV DNA integration, epigenetic changes and aberrant transcriptional 
activities of HBx protein 
11, 15, 16, 24, 25
 (see Figure 5.1). Nearly 90% of HBV-related 
HCC cases show evidence of HBV integration into the host genome 
11
. This is 
associated with genetic changes such as genomic instability, deletions and 
chromosomal translocations in the host cells, which may lead to accumulation of 
mutations and epigenetic changes with a malignant phenotype 
16
. Several 
contributing environmental and viral factors such as chronic tobacco smoking, 
alcohol consumption, aflatoxins, HBV e antigen positive status, high viral load and 
HBV genotype have been identified in HBV-related HCC cases and are associated 
with many epigenetic changes 
17 - 23
. 
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Figure 5.1: Proposed Model in which HBV Induced Genetic Alterations Contributes 
to Liver Disease. 
Hepatitis B virus related hepatocellular carcinoma is a multi-step processes that cause hepatocyte 
transformation due to HBV integration into cellular DNA, epigenetic changes and transcriptional 
activities by hepatitis B x protein. 
Abbreviations: DNA – Deoxyribonucleic acid, HBV – Hepatitis B virus, HB eAg – Hepatitis B virus 
e antigen, HBs – Hepatitis B virus surface antigen, HBx – Hepatitis B virus x gene. 
 
5.1 DNA METHYLATION AND LIVER DISEASE 
Abnormal hypermethylation of various cellular genes including host tumour 
suppressors has been described in various cancers and is associated with silencing of 
genes critical for preventing malignant transformation 
25
. Gene expression has been 
reported in HBV infection where the DNA methylation machinery is induced as a 
host defence mechanism to suppress viral genes 
25
. This correlates with loss of 
normal activity in genes important for wound-healing and immune processes. 
Disruption of these processes will interfere with normal cell proliferation, apoptosis 
and potentiates the ability to metastasize in abnormal cells as seen in chronic liver 
disease and malignant transformation
 26 - 28
.  
HBV DNA integrates into the cellular DNA in liver tissue of patients with chronic 
HBV infection and HCC 
11
. Following HBV infection, DNA methyltransferases  
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(DNMTs) methylate any HBV DNA integrated into the human genome. This novel 
epigenetic mechanism enables the suppression of HBV antigens, leading to reduced 
viral replication 
29, 30
. HBV is thought to induce DNA methylation via HBx protein, 
which modulates cellular signalling pathways by activating DNMT 1 and 3 to benefit 
the virus. Activation of DNMT 1 and 3 inappropriately methylates host cellular 
genes including tumour suppressor genes whose disruption causes transformation of 
hepatocytes and hepatic malignancy 
24, 25, 29, 30, 32
.  
A large group of cancer-related genes are hypermethylated in chronic HBV infection 
and HCC cases, and some of these were described in the literature review (see 
Chapter 1, Section 1.4.3). These genes include p16
INK4A
, E-cadherin, tumour 
promoter insulin-like growth factor binding 3 (IGJBP-3), retinoic acid receptor beta-
2 (RAR-β2), glutathione-S-transferase P1 (GSTP1), deleted in lung and oesophageal 
cancer 1 (DLEC1) and caveolin-1 genes 
32 - 37
. Hypermethylation of these genes 
correlates with loss of gene expression and insensitivity of malignant cells to 
apoptotic stimuli that leads to development tumour and progression 
32 – 30
.    
 
5.2 HYPOTHESIS AND STUDY OUTLINE 
The published literature reviewed in Chapter 1 Section 4.3.3 shows that that the 
methylation of integrated viral DNA into the host genome is associated with the 
transcriptional alteration and silencing of host genes that include tumour suppressor 
genes critical for the development of liver cancer 
30
.  
It was hypothesised that HBV DNA methylation may result in unintended and 
inappropriate methylation of adjacent host DNA. If the methylation occurred in CpG 
islands within gene promoter regions, this could alter the transcriptional activation of 
genes resulting in biological changes that are responsible for the clinical 
manifestations of liver disease and cancer development in chronic HBV infection.  
To test this hypothesis, the presence of genome-wide methylation of promoter CpG 
islands in patients with chronic HBV infection was investigated using Human 
Promoter 1.0R array
®
 (see Chapter 3). The microarray data showed the presence of 
genome-wide promoter region hypermethylation. This finding was validated using 
bisulfite DNA sequencing in patients with chronic HBV infection (see Chapter 4). 
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5.3 HBV INDUCED HEPATIC INFLAMMATION AND FIBROSIS  
Hepatic stellate cells and the extracellular matrix are key sources of growth factors 
such as fibroblast growth factors (FGF), epidermal growth factors (EGF), tumour 
necrosis factor alpha (TNFα), platelet-derived growth factor (PDGF) and 
transforming growth factor beta (TGFβ). These growth factors control cell 
proliferation, differentiation and remodelling of the extracellular matrix 
38 - 41
. 
Hepatic stellate cell activation is associated with the upregulation of cellular 
signalling pathways activated via transcription factors such as TGFβ, nuclear factor-
kappa B (NF-кB) and mitogen-activated protein kinases (MAPK) whose targets are 
inflammation and fibrogenic related genes 
39, 48, 50, 51, 53
. Changes in the activity of 
growth factors and their pathways can disrupt liver regeneration processes, resulting 
in the production of extracellular matrix, scarring, cirrhosis and liver cancer 
38
.  
 
5.3.1 Transforming Growth Factor Beta Signalling Pathway 
The FGFRL1 gene was significantly methylated in HBV e antigen positive cases (see 
Table 3.7), PARD6A gene in cirrhotic HBV cases (see Table 3.4) and PTOV1 gene 
in HBV compared to autoimmune hepatitis patients (see Table 3.5). In the validation 
work, the  FGFRL1 gene had low levels of methylation in chronic HBV infected 
patients (see Table 4.2).  
The association of these genes with liver disease would be via their influence on the 
TGFβ signalling pathway. The TGFβ signalling pathway facilitates hepatic 
regeneration and wound healing processes. Alteration of these genes could mediate 
the mitogenic effects of TGFβ protein by increasing its fibrogenic actions in hepatic 
stellate cells 
43, 48, 49. TGFβ protein activates the MAPK pathway and Smad proteins 
which regulate the epithelial-to-mesenchymal cell transition, tumour invasion and 
metastasis, suggesting that these genes may have a significant role in tumour 
development and progression in chronic HBV infection 
42, 57, 58
. 
In breast cancer cells, PAR6B gene regulates the formation of tight-junctions that 
mediate cell-to-cell interactions required to maintain epithelial cell polarity and 
accurate asymmetric cell division processes 
44, 45
.  Therefore, the PARD6A gene 
appears to be the essential component in the biogenesis of epithelial cell tight 
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junctions, suggesting that loss of its normal function may alter epithelial cell 
architecture, tissue remodelling and facilitate malignant transformation. In this study, 
PARD6A is hypermethylated in HBV infection (see Chapter 3 Table 3.3), especially 
in patients older than 40 years compared to normal patients (see Chapter 3 Table 
3.11).  
 
5.3.2 MAPK/PKC Signalling Pathways 
In this study, the CCND3 gene was highly methylated in HBV infection (see 
Chapter 3, Table 3.3) and in the validation experiments, this was significantly 
associated with an increased HBV viral load, and HBV e antigen positive status and 
genotype D (see Chapter 3, Tables 4.4 and 4.5)  
The CCND3 gene can be linked to liver disease through its ability to stimulate 
inflammation and fibrosis through retinoblastoma and MAPK/phosphatidylinositol 3 
kinase (PI3K) signalling pathways 
46
. MAPK in cooperation with protein kinase C 
(PKC) induces the transcription of cyclin, CDK 4 and 6 via the activation of 
transcription factors RAS, AP-1 and Myc which are recruited by PDGF growth 
factor. PDGF growth factor induces proliferation which when highly expressed, 
causes cell injury and fibrosis 
46, 54, 55
. High level of CCND3 gene expression is 
present in HCC occurring in cirrhotic livers and breast cancer tissues, implying that it 
has a significant role in the development of these cancers 
46, 47
.  
PA2G4 protein interacts with ErbB3 protein which is associated with the epidermal 
growth factor receptor (EGFR). EGFR forms heterodimers with other EGF and then 
stimulates the intracellular tyrosine kinase activity that activates the PI3K-AKT and 
c-Jun N-terminal kinase (JNK)-MAPK pathways 
50
. These are involved in DNA 
synthesis, cell proliferation and apoptosis, and their disruption will contribute to liver 
fibrosis and malignant transformation of cells 
50
. In this study, the PA2G4 gene 
which encodes PA2G4 protein was methylated in HBV patients who are HBV e 
antigen positive compared to normal controls (see Chapter 3, Table 3.7). 
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 5.3.3 NF-КB Signalling Pathway 
In this study, the TBC1D17 gene was methylated in HBV patients who are older than 
40 years compared to normal individuals (see Chapter 3, Table 3.11). It can be 
linked to liver disease through the NF-кB and mammalian target of rapamycin 
(mTOR) signalling pathways. It stimulates the activity of NF-кB and mTOR 
signalling pathways by binding to the auxin response factors (ARF)-GTPase 
activating protein (ArfGAP).  
Activation of mTOR/NF-кB signalling pathways marks the activation of hepatic 
stellate cells and leads to regulation of tumour necrosis factor alpha (TNFα) protein 
51, 53, 59, 60
. Increased expression of TNFα protein leads to the activation of 
transcription factors activating protein-1 and JNK. This in turn activates matrix 
metalloproteinase, cytokines and chemokines such as fibronectin and neutrophills 
which protect hepatocytes from increased ROS-mediated damage through c-myb 
expression 
48, 50, 52
. It is possible that the TBC1D17 gene has a protective role in the 
liver, and is involved in wound healing and liver regeneration processes 
59, 60
. Any 
alteration in the transcriptional activities of this gene could disrupt the mTOR/NF-кB 
signalling pathway and lead to liver damage and fibrosis. 
 
   
5.4 HEPATITIS B VIRAL INFECTION AND MALIGNANCY 
The data obtained in this study highlights hypermethylation of CpG islands located 
in the promoter regions of various genes involved in a wide range of cellular 
signalling pathways, which when inappropriately regulated, will favour malignant 
transformation of hepatocytes and lead to liver cancer (see Chapter 3, Table 3.12).  
 
 5.4.1 Cell Cycle and Apoptosis  
The CCND3 and PTGR2 genes were hypermethylated in all HBV infected cases 
compared to normal controls (see Chapter 3, Tables 3.3), PARD6A gene in cirrhotic 
HBV cases (see Chapter 3, Table 3.4), NACC2 in HBV e antigen positive patients 
with inflammation (see Chapter 3, Tables 3.7 and 3.10) and NAIF1 in HBV e 
antigen positive patients with inflammation and cirrhosis (see Chapter 3, Tables 
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3.7, 3.9 and 3.10). In the validation experiments, the CCND3 gene was highly 
methylated while the NACC2 gene had low level of methylation in HBV e antigen 
positive patients (see Chapter 3, Table 4.2).  
Hypermethylation of the identified genes reveal an important way in which HBV 
may inappropriately induce or inhibit apoptosis for viral replication and cell survival 
through the activation of HBx protein (see Chapter 1, Section 4.3.2). The 
association of these genes with HBV and liver disease may be through the activation 
of p53, cyclooxygenase-2, inducible nitric oxide synthase (iNOS), NF-кB, ROS, 
JNK, caspases 3 and 9 signalling pathways (see Appendix 26.N). These pathways 
regulate apoptosis and induction of antiviral immunity, and are critically important 
for hepatic inflammation, regeneration, fibrosis and HCC 
61 -66
. Disruption of the 
normal activities of these pathways by HBx protein inhibits apoptosis leading to 
uncontrolled cell growth and proliferation favouring hepatocarcinogenesis 
63, 64
.  
It is not surprising that some of the genes identified in this study are concurrently 
involved in regulating the cell cycle, proliferation and apoptosis as these processes 
are connected
 67
. An intimate link between apoptotic and proliferative pathways has 
been demonstrated previously in several in vivo studies
 68, 69
. These studies showed 
that in a large population of proliferating cells, some cells will be undergoing 
apoptosis and uncontrolled cell proliferation is more frequently associated with cell 
cycle arrest and increased or inhibited apoptosis 
67 - 69
.  
Further research is necessary to better understand the role these genes may play in 
apoptosis and proliferation through the influence of HBx protein. Such studies could 
result in the development of therapies that inhibit HBx protein mediated activities. 
 
5.4.2 Calcium Signalling Pathway 
Microarray data analysis revealed hypermethylation of vitamin D receptor regulated 
genes TRPV5 and THRAP3. The TRPV5 gene was hypermethylated in HBV 
compared to AIH patients (see Chapter 3, Table 3.4) while THRAP3 was 
hypermethylated in HBV cirrhotic patients (see Chapter 3, Table 3.9). These genes 
can be linked to liver disease through their association with the vitamin D receptor 
which plays an important role in the calcium cellular signalling pathway. The TRPV5 
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and THRAP3 genes are epithelial calcium channels that maintain the balance of 
extracellular calcium by regulating 1,25-dihydroxyvitamin D3 which is the active 
form of vitamin D
78
.  
HBV infection alters cytosolic calcium signalling (see Appendix 26.A) as an ideal 
strategy to change the intracellular environment favouring viral propagation, capsids 
assembly and cell survival 
70, 71, 74, 76
. The regulation of calcium signalling is 
mediated by HBx protein through the activation of transcription factor AP-1 and 
modulation of Pyk2 and Src kinases hepatocyte proliferation pathways for survival 
72, 
73
. Elevated levels of calcium signalling caused by HBx protein is required to 
stimulate store operated calcium (SOC), which is the entry of extracellular calcium 
76
. SOC stimulates viral replication by inhibiting antiviral immunity and deregulating 
Pyk2/Src signalling pathways. This inappropriately regulates apoptosis and 
proliferation contributing to HBV pathogenesis and tumorigenesis 
72 - 77
. 
 
5.4.3 Alteration of mRNA Splicing  
In this study, hypermethylation of RNA processing related genes RRN3P3, GABPB2, 
EXOSC3 and SNORD48 was identified in HBV infected patients, particularly those 
with liver cirrhosis (see Chapter 3, Tables 3.3, 3.4 and 3.7).  The RRN3P3, 
GABPB2, EXOSC3 and SNORD48 genes are required for the proper folding of RNA 
and production of protein while preventing the translation of erroneous mRNA 
transcripts that lack or contain premature stop codons through their degradation 
81 , 82
. 
They also initiate RNA elongation and transcription by binding to the core promoter 
region through RNA polymerase I and transcriptional activation domain (TAD) 
78, 79
. 
The relationship between these genes and HBV infection has not been investigated 
before. These genes could be linked to HBV infection through the transcriptional 
activities of HBx protein that are known to affect the mRNA surveillance pathway 
(see Appendix 26.H).  
HBx protein can alter RNA splicing by binding and transactivating transcription 
factors through interaction with cis-acting elements such as RNA polymerase I and 
TAD binding domains (see Chapter 3, Section 3.6.6) 
80 - 84
. HBx protein induced 
hypermethylation of RRN3P3, GABPB2, EXOSC3 and SNORD48 genes could cause 
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incorrect mRNA splicing and loss of protein expression or aberrant protein 
production, leading to severe liver disease 
83, 84
.  
 
5.4.4 Protein Ubiquitination 
This study has identified hypermethylation of genes encoding LNX2, UBXN1 and 
TRIP12 ubiquitin-related proteins in HBV infection (see Tables 3.3, 3.4 and 3.9). 
The link of LNX2, UBXN1 and TRIP12 proteins with liver disease appears to be 
through the ubiquitination and protein degradation pathways activated by HBx 
protein via the p53, Wnt and Notch signalling pathways 
86, 93
. Disruption of 
ubiquitination and proteosomal degradation pathways by HBx protein may be 
required for viral evasion of the host immune defences as has been shown in Epstein-
Barr viral infection 
91
. LNX2, UBXN1 and TRIP12 ubiquitin-related proteins have 
unique domains that function as E3 ubiquitin ligases which induces ubiquitination 
and proteosomal degradation 
92
. They are involved in the regulation of DNA repair, 
cell cycle, proliferation and apoptosis, which explains the possible role in causing 
cancers 
87 - 90
.  
HBx protein alters the proteosomal activity of infected cells to facilitate viral entry as 
well as enhancing viral replication and survival 
91- 93
. It protects itself from cellular 
degradation by manipulating and mimicking the transcriptional activity of ubiquitin-
related proteins 
92, 93
. It uses protein-to-protein interaction to bind to and activate 
ubiquitin related genes 
92
. This changes ubiquitin ligase functions and inhibits protein 
degradation and apoptosis, contributing to malignant transformation in the liver 
87 - 90
.  
Gene deletion mutations and methylation of ubiquitin-related genes or proteins have 
been observed in malignancies including HCC and are associated with loss of protein 
expression and normal function 
87 - 90
. It is evident that they could potentially be used 
as tumour markers for the early detection of many malignancies including HCC. 
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5.4.5 Suppression of Tumour Suppressor Genes  
In this study, a large group of tumour suppressor genes GABPB2, NACC2, NAIF1, 
PA2G4, PARD6A, PATE 3, PCGF1, PTOV1, PTGR2, TUBA4A and TBC1D17 are 
hypermethylated in HBV infected liver tissues (see Chapter 3, Table 3.12). 
GABPB2, PTGR2, PA2G4, PARD6A, TBC1D17, NAIF1, NACC2, PCGF1 and 
TUBA4A genes were particularly hypermethylated in those who were HBV e antigen 
positive, had cirrhosis or significant hepatic inflammation or older than 40 years (see 
Chapter 3, Tables 3.3, 3.7, 3.9 - 3.11). The PTOV1gene was hypermethylated in 
HBV patients when compared to AIH patients (see Chapter 3, Table 3.4) and 
PATE1 gene in HCC cases (see Chapter 3, Table 3.5). In the validation 
experiments, PA2G4 and GABPB2 genes were unmethylated while NACC2 and 
TUBA4A genes had a low level of methylation in patients who were HBV e antigen 
negativ (see Chapter 3, Table 4.2).  
These genes can be connected to liver disease through the activation of CREB, 
Wnt/β-catenin, MAPK/ERK and mTOR cellular signalling pathways 94, 95. These 
pathways are key targets for HBx protein. They are important regulators of cell 
growth or proliferation and often perturbed in liver carcinogenesis 
94
. They initiate 
transcription by binding to CREB, APC, P1-3k, ROS, NF-кB, EBP1, ETS and 
ArfGab cellular transcriptional elements on the promoter regions of the downstream 
target genes
 94 - 103
. HBV-induced hypermethylation of these genes via HBx protein 
could inhibit this binding and suppress transcription of genes critical for preventing 
tumorigenesis. In addition, loss of expression of tumour suppressor genes due to 
DNA methylation is a critical step in the development of malignancy in HBV 
infection. 
 
5.5 CLINICAL CORRELATION OF HBV WITH METABOLISM 
PTGR2 and TRPV5 genes were highly methylated in HBV cases compared to normal 
controls or AIH patients (see Chapter 3, Table 3.3). The association of these genes 
with liver disease will be through their involvement in hepatic metabolism via 
PPARγ and calcium signalling pathways which are important in regulating 
hepatocyte proliferation and apoptosis (see Appendices 26.A and 26.L). PTGR2 and 
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TRPV5 genes regulate the metabolism of lipids, glucose and calcium 
78, 106
. 
Disruption of these processes due to HBV induced methylation could cause 
hyperglycemia and fatty liver that will impair liver function 
106, 107
 (see Chapter 3, 
Table 3.12). In addition, this could disrupt type 2 diabetes mellitus signalling 
pathways causing insulin resistance which is often seen in chronic HBV infection 
and predisposes to HCC development 
108, 109 
(see Chapter 3, Section 3.6.3 and 
Appendix 26.M).  
Involvement of PTGR2 gene in liver disease could also be through the disruption of 
COX-2. COX-2 is an enzyme that produces prostaglandins including PTGR2 protein 
and is essential for inflammation 
108
. This enzyme is highly expressed in most 
tumours including HBV-related HCC in which it increases the expression of HBx 
protein which disrupts p53 mediated transcription and apoptosis by activating 
prostaglandin E2 
108, 109
. 
 
5.6 ASSOCIATION OF HBV AND HIV INFECTION 
This study revealed hypermethylation of TUBA4A and THRAP3 genes (see Tables 
3.4 and 3.9) which interact with HIV- 1 proteins. TUBA4A gene interacts with HIV-1 
Protease and Gag proteins 
111
. This interaction enhances the carcinogenic effect of 
HBx protein by disrupting microtubules formation and interferes with Bcl-2 
mediated apoptosis 
111
.   
THRAP3 protein interacts with Rev and Tat proteins
 110
. The effect of HBV 
methylation on THRAP3 gene is to increase viral replication by altering calcium 
signalling pathway and this accelerates the progression of fibrosis and cirrhosis and 
HCC 
112 - 114
.  
HBV and HIV co-infection would therefore increase viral replication of both viruses 
through the activation of Bcl-2, MAPK and Wnt signalling pathways in a 
collaborative manner (see Appendix 26.O). These possible interactions require 
further investigation. 
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5.7  A UNIFYING HYPOTHESIS BASED ON THE LITERATURE 
AND THESIS RESEARCH FINDINGS 
The study findings of extensive genome-wide promoter region hypermethylation in 
chronic HBV infected patients and the involvement of various genes whose function 
can be directly linked to liver disease significantly validate the study hypothesis. The 
inappropriate methylation could alter the transcriptional activation of genes resulting 
in biological changes that are responsible for the clinical manifestation of liver 
disease and tumour development 
115 - 117
. The methylation of genes identified in this 
study can result in the alteration of multiple cellular processes and pathways which 
are known to cause liver inflammation, fibrosis, cirrhosis and cancer (see Figure 
5.2).  
 
Figure 5.2: An Integrated Review of the Identified Genes and their Possible Role in 
Causing Liver Disease. 
Multiple cellular processes and key genes or proteins are altered by HBV induced methylation and 
this could cause abnormalities that favour and maintain viral replication and lead to liver 
inflammation, fibrosis, cirrhosis and possible cancer.  
 
HBV encodes a transcriptional activator and oncogenic protein HBx, which appears 
to be the main driving force behind the epigenetic alterations seen in HBV infection 
118
. Abnormalities caused by the transcriptional activities of HBx protein could have 
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significant detrimental effects such as the suppression of antiviral immune responses 
and the development of pro-inflammatory responses and fibrosis. By being localised 
in the cytoplasm, nucleus and mitochondria of HBV infected hepatocytes, it appears 
that HBx protein manages to exploit the entire body of cellular signalling pathways 
for viral survival and propagation.
 
HBx protein may achieve its transcriptional 
transactivation action by either interacting with key genes or altering their related 
cellular signalling pathways or by hijacking their binding partners and taking over 
their roles 
119 -125
. These detrimental effects would connect HBV infection to 
malignant transformation by inducing uncontrolled cell growth, proliferation and 
disrupting apoptosis. 
Although the underlying mechanisms are still unclear, processes such as cell cycle 
progression, calcium homeostasis, hepatic metabolism, protein ubiquitination, RNA 
splicing and vitamin D receptor regulation are key mechanisms that HBx protein 
alters to favour viral replication and cell survival (see Sections 5.4.1 - 5.4.2). 
Hypermethylation of a large group of tumour suppressor genes was identified in this 
study (see Section 5.4.2). Hypermethylation correlates with loss of gene expression 
in tumour suppressor genes as discussed in Chapter 1, Section 1.4.3. This could 
cause genetic instability, hepatocyte transformation and tumour development. 
The results of the validation study on the methylation profiles of CCND3 gene (see 
Chapter 4, Section 4.4.5) in HBV e antigen positive patients supports the hypothesis 
that increased methylation is associated with host and viral factors.  
Further studies are needed to investigate the relationship between host factors and 
HBV characteristics with the severity of HBV induced DNA methylation and liver 
disease. 
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5.8  STUDY LIMITATIONS 
This study had some limitations and difficulties that needed to be addressed in terms 
of study efficiency, costs and practicality. 
 
a)  Choice of Normal Controls  
The choice of a “normal” control in microarray studies of humans is difficult as there 
are many causes of DNA methylation other than viral infections. Some are 
cumulative with age due to exposure to environmental factors such as cigarette 
smoking, alcohol and other toxins. Some studies are addressing this by using 
placental derived DNA at birth which would theoretically have pre-environmental 
exposure DNA damage and methylation 
104
. In this study, liver derived DNA was 
used for microarray work. Patients who had been biopsied for the investigation of 
abnormal liver tests that had resolved completely and had no evidence of HBV, 
HCV, HIV, AIH or other causes of chronic liver disease were used as normal 
controls relative to chronic HBV infected cases.   
To address this difficulty, a study that will investigate the presence of DNA 
methylation using DNA from cord blood lymphocytes is being set-up 
104
. This will 
provide local reference DNA methylation profiles from neonatal DNA prior to 
environmental exposures and viral infections as has been suggested in recent studies 
104
.  
 
b) Sample Size 
For reasons study efficiency and costs of microarray work, the sample size used was 
pragmatic. The ratio of control to study cases used was 1:9, which was 2 controls to 
18 HBV infected cases. This was adequate as sample size calculations had shown 
that a ratio of 1:4 would be adequate for this study. In the validation cohort for 
CCND3 gene, the analysed sample size was limited by the success of positive colony 
screening and sequencing as at times more than 30 colonies may be needed before a 
successful insertion occurs 
128
. The use of cheaper techniques that do not require the 
cloning step such as Methyl Profiler DNA methylation PCR array will be considered. 
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c) Gene Expression Data  
Gene expression work which would have helped in further validation of the 
microarray data analysis was not done in this study due to costs. This work will be 
done in planned future work. 
 
5.9  FUTURE WORK 
Hypermethylation of key cellular genes identified in this study could disrupt various 
important processes and cellular signalling pathways that could alter hepatocyte 
physiology. This could contribute to mechanisms that connect HBV infection to the 
development of liver injury and HCC and therefore warrants further investigations.  
 
a) Gene Expression Work 
Tumour suppressor genes silencing and alteration in the cell cycle and hepatic 
metabolism due to DNA methylation are important in developing HBV related liver 
disease features such as fibrosis, cirrhosis and HCC. Methylation of GABPB2, 
CCND3, NACC2, NAIF1, PA2G4, PARD6A, PATE 3, PCGF1, PTOV1, PTGR2, 
TUBA4A and TBC1D17 could result in loss of gene expression leading to liver 
disease. Therefore, further bisulfite DNA sequencing and gene expression studies 
using either microarray or real-time PCR are required to investigate the expression 
status of these hypermethylated genes. 
 
b) Pathway Analysis Work 
Cellular protein ubiquitination and hepatic metabolism involving calcium signalling 
pathway are important targets used by HBx protein to modulate transcription, 
proliferation and apoptosis, and benefit the virus. TRPV5, THRAP3, LNX2, UBXN1 
and TRIP12 genes act as tumour suppressor genes or oncogenes, whilst in some 
circumstances may be targets for therapy. Methylation of these genes suggests their 
critical role in the development of cancer and studies investigating their role in 
ubiquitination and other pathways will be important as they may provide diagnostics 
tools and treatment possibilities.  
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Such studies will increase our understanding of some of the gene transcriptional 
changes that occur in HBV infection and provide new insights in the development of 
chronic HBV infection related liver disease. 
 
c) HBV Integration into the Host Genome Work 
Recent studies have now confirmed the strong correlation between high levels of 
HBV surface antigen and the risk of HCC 
59 -
 
61
. This correlation is most likely to be 
due to an increased rate of viral surface antigen integration into the host genome 
which could result in higher rates of genomic DNA methylation, more gene damage 
and a higher risk for hepatic inflammation, fibrosis, cirrhosis and malignant 
transformation in these patients (see Chapter 4, Section 4.5.2).  In view of these 
findings, new studies are needed that will investigate the association between HBV 
surface antigen levels and integration into the human genome with associated DNA 
methylation. These will give insight into how best to use HBV surface antigen levels 
in future treatment algorithms that should seek to reduce the risk of HCC as a 
treatment outcome. 
 
d) Comparison of Blood and Liver Tissue Methylation Profile Work 
Although the blood DNA is reliable in investigating DNA methylation profiles in 
patients with viral hepatitis, it is less sensitive as compared to liver tissue
 134
. HBV 
replicates in the liver, suggesting that liver tissue could harbour a more representative 
methylation profile. More studies are needed to investigate whether the differences in 
methylation within the same patient are significantly different between blood and 
liver tissue derived samples. 
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5.10  CONCLUSIONS 
The thesis findings provide new insights into the possible mechanisms by which 
chronic HBV infection of hepatocytes alters the cellular signalling machinery though 
DNA methylation, causing chronic liver disease and HBV associated liver cancer 
(see Figure 5.1). Understanding the molecular mechanisms through which the 
function of the genes shown to be differentially hypermethylated in this study may 
help in identifying possible new targets that could be used for the early diagnosis of 
HBV related liver complications as well as develop new therapies.  
In summary, this study has successfully identified the presence of DNA 
hypermethylation in a cohort of HBV infected patients. The DNA methylation 
changes were confirmed using bisulfite DNA sequencing. Higher rates of 
methylation appear to be associated with an increased HBV viral load, genotype D 
with some genes being more hypermethylated than others, particularly the gene 
CCND3. Although the mechanisms through which particular genes are affected by 
HBV associated hypermethylation are not as at present entirely understood, they 
could be related to factors such as the HBV e antigen status, HBV surface antigen 
levels, the type of HBV viral insertions and a high HBV viral load 
49, 50, 129
.  
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1. Reagents 
Products Catalog No Local Supplier Sources 
Absolute Ethanol E7023 Sigma, SA Sigma, USA 
95% Ethanol  E7148 Sigma, SA Sigma, USA 
TRI Reagent T9424 Sigma, SA Sigma, USA 
1-Bromo-3-chloropropane  B9673 Sigma, SA Sigma, USA 
Isopropanol  (2-propanol) 19516 Sigma, SA Sigma, USA 
Methanol  H410 Microsep, SA Romil, USA 
Sodium phosphate  S3264 Sigma, SA Sigma, USA 
Sodium hydroxide 221465 Sigma, SA Sigma, USA 
Trisodium citrate C8532 Sigma, SA Sigma, USA 
SDS L3771 Sigma, SA Sigma, USA 
RNA Zap R2020 Sigma, SA Sigma, USA 
Diethylpyrocarbonate D5758 Sigma, SA Sigma, USA 
EDTA BB100935V Merck, SA Merck, Africa 
1% SDS  L4522 Sigma, SA Sigma, USA 
Guanidine  hydrochloride G3272 Sigma, SA Sigma, USA 
 
2. Equipment 
 
 
 
 
 
Products Catalog No Local Supplier Sources 
1.5ml Eppendorf tubes 071015-247 Lasec, SA Axygen Scientific, USA 
20µl, 200μl and 1000μl  tips 94300120 Lasec, SA Axygen Scientific, USA 
Microcentrifuge L0027161 Lasec, SA Axygen Scientific, USA 
Pippetman P1000, P200, P20 F123602 - Gilson Medical Electronics, France 
Heating Block MH-4-6638 - Fried Electric, Israel 
Nanodrop Spectrophotometer  ND-1000 Promega, SA ThermoScientific NanoDrop  
Super-Mixer 220V Vortex  #288181 - Scientific Industries, USA 
VM-1000 Votex Mixer SI-100 - Aron Laboratory Instruments, Taiwan 
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PROTOCOLS 
Homogenisation and Phase Separation 
1. Homogenise liver tissues in 1ml of TRI Reagent solution with danca 
     homogenizer.  
2. Allow the samples to stand for 5 minutes at room temperature.  
3. For phase separation, add 100µl of 1-Bromo-3-chloropropane in the homogenised 
tissue, cover the sample tightly and shake vigorously for 15 seconds.  
4. Incubate the sample for 2 -15 minutes at room temperature.  
5. Centrifuge the resulting mixture at 12000 x g for 15 minutes at 4°C.  
      Note: Centrifugation separates the mixture into 3 phases: a red organic phase 
containing protein, an interphase containing DNA and a colourless upper aqueous 
phase containing RNA.  
6. Transfer the aqueous phase into separate fresh tube for RNA extraction.  
7. Store the interphase and organic phase at 4°C for subsequent isolation of the DNA 
and proteins. 
 
RNA Extraction 
1. Add 500µl of 2-propanol per into an aqueous phase sample obtained above.  
2. Incubate the sample at room temperature for 5 - 10 minutes. Centrifuge at 12000 x g 
for 10 minutes at 4 °C. Note: The RNA precipitation will form a pellet on the side 
and bottom of the tube.  
3. Discard the supernatant and wash the RNA pellet with 1000µl of 75% ethanol. 
4. Vortex the sample and centrifuge at 7500 x g for 5 minutes at 4 °C.  
5. If the RNA pellets float, repeat the wash step with 75% ethanol and centrifuge at 
12000 x g and briefly dry the RNA pellet for 30 minutes by air-drying.  
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     Note: Do not let the RNA pellet dry completely, as this will greatly decrease its   
     solubility.  
6. Add 100µl of DEPC-treated water to the RNA pellet and mix by repeated pipetting 
with a micropipette until dissolved.  
7. Measure the absorbance with Nanodrop. 
8. Store RNA samples in aliquots at -80°C. 
 
DNA Extraction 
1. Wash the DNA pellet obtained above twice in 0.1M trisodium citrate, 10% ethanol 
solution.  
     Note: During each wash, allow the DNA pellet to stand at room temperature with    
     occasional mixing for at least 30 minutes.  
2. Centrifuge at 2000 x g for 5 minutes at 4 °C.  
3. Resuspend the DNA pellet in 1.5ml of 75% ethanol and incubate the sample for 20 
minutes at room temperature. Note: Do not to reduce the time samples remain in the 
washing solution. Thirty minutes is the absolute minimum time for efficient removal 
of phenol from the DNA.  
4. Air-dry the DNA pellet for 30 minutes and dissolve in 100µl of 8 mM sodium 
hydroxide, pH 8 with repeated slow pipetting with a micropipette.  
5. Centrifuge at 12000 x g for 10 minutes to remove any insoluble material and    
transfer the supernatant to a fresh eppendorf tube. 
6. The purity ant integrity of DNA samples were measured with Nanodrop.  
7. Store the DNA samples at -80°C in aliquots.  
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Protein Isolation 
1. Precipitate protein from the phenol-ethanol supernatant obtained in above with 1.5ml 
of 2-propanol.  
2. Incubate the sample at room temperature for at least 10 minutes and centrifuge at  
     12000 x g for 10 minutes at 4 °C.  
3.  Discard the supernatant and wash pellet 3 times in 2ml of 0.3M guanidine 
hydrochloride with 95% ethanol solution. 
4.  During each wash, incubate the samples in wash solution for 20 minutes at room  
     temperature and centrifuge at 7500 x g for 5 minutes at 4 °C.  
5.  After the 3 washes, add 2ml of 100% ethanol and vortex the protein pellet.  
6.  Incubate the pellet at room temperature for 20 minutes. Centrifuge at 7500 x g for  
     5 minutes at 4 °C.  
7.  Air-dry the protein pellet and dissolve in 1% SDS.  
8.  Remove any insoluble material by centrifugation at 10000 x g for 10 minutes at    
     4°C and transfer the supernatant to a new tube.  
9.  Store the protein in aliquots at –80°C. 
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APPENDIX 2:  
DNA Extraction from FFPE Tissues  
 
1. Commercial Kits. 
Products Catalog No Local Supplier Sources 
AllPrep DNA/RNA FFPE Kit 80234 Whitehead Scientific, SA Qiagen, USA 
 
2. Reagents. 
Products Catalog No Local Supplier Sources 
Absolute ethanol E7023 Whitehead Scientific, SA Sigma, USA 
Heptane 28471 Merck, SA Merck, Victoria 
Isopropanol  (2-propanol) 19516 Sigma, SA Sigma, USA 
Methanol   Sigma, SA Sigma, USA 
 
3. Equipment. 
 
 
 
 
 
Products Catalog No Local Supplier Sources 
1.5ml Eppendorf tubes 071015-247 Lasec, SA Axygen Scientific, USA 
20µl, 200μl and 1000μl  tips 94300120 Lasec, SA Axygen Scientific, USA 
Microcentrifuge L0027161 Lasec, SA Axygen Scientific, USA 
Pippetman P1000, P200, P20 F123602 - Gilson Medical Electronics, France 
Heating Block MH-4-6638 - Fried Electric, Israel 
Nanodrop Spectrophotometer  ND-1000 Promega, SA ThermoScientific NanoDrop  
Super-Mixer 220V Vortex  #288181 - Scientific Industries, USA 
VM-1000 Votex Mixer SI-100 - Aron Laboratory Instruments, Taiwan 
1.5ml Eppendorf tubes 071015-247 Lasec, SA Axygen Scientific, USA 
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PROTOCOL 
1. Trim excess paraffin off the samples microtome using a clean scalpel and make sure  
     to use fresh clean scalpel for each sample. 
2. Cut sections of 20μm thick and put them in 1.5ml Safe-Lock micro centrifuge tubes.  
3. Immerse the sections in 500μl heptane and then incubate for 10 minutes at room 
    temperature. 
4. Add 25μl methanol and centrifuge for 2 minutes at 9000 x g after, vortexing for 10  
    seconds. 
5. Discard all the supernatant and add 1ml absolute ethanol to the pellets. 
6. Vortex the mixture and centrifuge at full speed for 2 minutes. 
7. Remove all the ethanol without disturbing the pellets. 
8. Leave the lid of the eppendorf tubes open and incubate at room temperature until all  
    the ethanol has evaporated. 
9. Resuspend the pellets by adding 150μl Buffer PKD and flick the tubes with a finger to  
    loosen the pellets.  
10. Add 10μl proteinase K, mix by vortexing and then incubate at 56°C for 15 minutes. 
11. Cool the samples on ice for 3 minutes and centrifuge for 15 minutes at 14000 x g. 
12. Carefully transfer the RNA- containing supernatants into a new eppendorf tubes and 
keep this for RNA purification. 
13. Resuspend the DNA-containing pellets in 180μl Buffer ATL, add 40μl proteinase K, 
and mix by vortexing. 
14. Incubate at 56°C for overnight and further incubate at 90°C for another 2 hours. 
15. Briefly centrifuge the micro-centrifuge tubes to remove drops from the inside the 
lids. 
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16. Mix 200μl Buffer AL and 200μl absolute ethanol in separate eppendorf tubes and 
mix thoroughly by vortexing.  
17. Add 400μl of the mixture to the sample and mix thoroughly again by vortexing. 
18. Transfer the entire sample to a QIAamp MinElute spin columns placed in a 2ml 
collection tubes.  
19. Centrifuge the samples for 1 minute at 13000 x g and discard the collection tubes  
with the flow-through. 
20. Place the QIAamp MinElute spin columns in a new 2ml collection tubes.  
21. Add 700μl Buffer AW1 to the spin columns and centrifuge for 15 seconds at 13000 
x g to wash the spin column membranes and then discard the flow-through. 
22. Add 700μl Buffer AW2 to the QIAampMinElute spin columns. 
23. Centrifuge for 15 seconds at 13000 x g and then discard the flow-through. 
24. Add 700μl absolute ethanol to the QIAamp MinElute spin columns and centrifuge 
for 15 seconds at 13000 x g. 
25. Discard the collection tubes with the flow-through and place the QIAamp MinElute 
spin columns in a new 2ml collection tubes.  
26. Open the lids of the spin columns and centrifuge at full speed for 5 minutes and then 
discard the collection tubes with the flow-through.  
27. Place the QIAamp MinElute spin columns in a new 1.5ml collection tubes and add 
60μl Buffer ATE directly to the spin column membranes. 
28. Close the lids gently and incubate for 1 minute at room temperature for the pellets to 
become completely dissolved. 
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APPENDIX 3: 
Kits, Products, Equipment and Consumable for DNA Microarray 
Work 
 
1. Commercial kit. 
Product Catalogue Number Supplier 
QIAquick PCR Purification Kit 28104 Qiagen, USA 
 
2. Enzymes and Ladders.  
Product Catalogue Number Supplier 
100bp Ladder  New England Biolabs MA 
BstUI (comes with 100x BSA and 10x NEBuffer) #R0518S New England Biolabs MA 
HhaI (comes with 100x BSA and 10x NEBuffer) #R0139L New England Biolabs MA 
Human Apurinic/Apyrimidinic Endonuclease I (APE 1, comes 
with10X APE 1 Reaction Buffer) 
78454 Affymetrix, USA 
MseI (comes with 100x BSA and 10x NEBuffer) #R0525S New England Biolabs MA 
T4-DNA ligase (10X T4 DNA Ligase Buffer with 10mM ATP) #M0202S New England Biolabs MA 
Tag DNA Polymerase (10X Standard Tag Reaction Buffer) #M0273L New England Biolabs MA 
Terminal DeoxynucleotidylTransferase(TdT), Recombinant 
(comes with 5X TdT Reaction Buffer) 
72033 Affymetrix, USA 
Uracil-DNA Glycosylase 71960 Affymetrix, USA 
 
3. Washing buffers and other reagents.  
Product Catalogue Number Supplier 
Array Holding Buffer 901248 Affymetrix, USA 
Control oligonucleotide B2 900301 Affymetrix, USA 
DMSO 901244 Affymetrix, USA 
DNA Labeling Reagent, DLR (Biotin-11-dXTP Analog) 79015 Affymetrix, USA 
50Mm MgCl2 #B0510A New England Biolabs, MA 
Pre-Hybridization Mix 901242 Affymetrix, USA 
2X Hybridization Mix 901243 Affymetrix, USA 
Stain Cocktail 1 901246 Affymetrix, USA 
Stain Cocktail 2 901247 Affymetrix, USA 
Wash Buffer A 900721 Affymetrix, USA 
Wash Buffer B 900722 Affymetrix, USA 
Array Holding Buffer 901248 Affymetrix, USA 
 
 
248 
Appendix 3: Kits, Products, Equipment and Consumables for DNA Microarray Work 
4. Laboratory equipment. 
Product Catalogue Number Supplier 
Agarose Gel Electrophoresis Apparatus 161-3000 Bio-Rad, California, US 
Eppendorf Centrifuge 5415R  54260000018 Eppendorf, Life Science 250 
C1000TM Thermal Cycler 184-1000 Bio-Rad, California, US 
Dry Bath Incubator MD-01N-110 Ms Major Science, Taiwan 
GeneChipRFluidics Station 450 P/N 00-0079 Affymetrix, USA 
GeneChipR Hybridization Oven 645 P/N 8001318 Affymetrix, USA 
GeneChipRProbe Array (Human  Promoter 1.0R array) 900775 Affymetrix, USA 
GeneChipRScanner 3000 (7G) P/N 00-00212 Affymetrix, USA 
Molecular Imager (R) Gel DocTM XR+ with image LabTM 
Software 
170-8195 Bio-Rad, California, US 
Vapo.Protect Mastercycler 950021209 Eppendorf, Germany 
Water Bath 6032012 Thermocon, India 
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APPENDIX 4:  
Restriction Digest of DNA with MseI Enzyme 
 
Table 1: Components in the Reaction/s 
 
Components Volume for 1 reaction 
10X NEBuffer 4 4 μl 
100X BSA 0.4 μl 
MseI Enzyme 1 μl 
DNA 1.5 μg 
Deionized water up to a total volume of 40 μl 
 
PROTOCOL 
1. Use 1.5μg of extracted DNA for restriction digest. 
2. Set up a reaction in a total volume of 40μl as shown in Table 1. 
3. Mix well and spin down for few seconds. 
4. Incubate the reaction on a heating block set at 37°C for 2 hours. 
5. Load 2μl of digested product/s on 1.5% of agarose gel. 
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APPENDIX 5:  
Purification of DNA Using Qiaquick PCR Purification Kit 
 
PROTOCOL 
1. Add 5 volume of Buffer PB to 1 volume of digested product/s and mix well. 
2. Transfer the mixture into MinElute spin columns provided in the kit. 
3. Centrifuge at 13000 rpm for 1 minute. 
4. Discard the flow-through. 
5. Wash the columns with 750μl of Buffer PE. 
6. Centrifuge at 13000 rpm for 1 minute and discard the flow-through. 
7. Centrifuge at the same speed for another 1 minute. 
8. Transfer the MinElute Spin Columns into  new eppendorf tubes and add 32μl of     
elution buffer to the centre of the columns. 
9. Incubate for 1 minute at room temperature. 
10. Elute purified DNA by centrifuging at 13000 rpm for 1 minute. 
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APPENDIX 6:  
Annealing of Universal Linkers 
 
Table 1: Components in the Annealing Reaction 
 
 
  
 
PROTOCOL 
1. Prepare the universal linkers in a total volume of 200μl. 
2. Set up the reaction as shown in Table 1. 
3. Anneal the universal linkers in C1000TM Thermal Cycler (Bio-rad, California, USA) 
under 95°C for 5 minutes, 70°C for 2 minutes and 52°C for 10 minutes. 
4. Cool at 4°C for at least 30 minutes. 
 
 
 
 
 
 
 
 
 
 
 
Component Volume for 1 reaction 
10X Standard Tag Buffer 20 μl 
H-12 80 μl 
H-24 80 μl 
Deionized water 20 μl 
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APPENDIX 7:  
Ligation of DNA with Universal Linkers 
  
Table 1: Components in the Ligation Reaction/s 
Component Volume for 1 reaction 
10X T4 DNA Ligase Buffer 4 μl 
H-12/H-24 Annealed Linkers 4 μl 
T4 DNA Ligase 1 μl 
Purified DNA 30 μl 
Deionized water 5 μl 
 
PROTOCOL  
1. Set-up ligation mix as shown in Table 1. 
2. Incubate the reaction in the water bath at 16°C for overnight. 
3. Inactivate the T4 DNA ligase by incubating at 65°C for 10 minutes. 
4. Run 2μl of ligated product/s on 2% agarose gel. 
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APPENDIX 8:  
PCR Amplification of Ligated Products  
 
Table 1: Components in the PCR Reaction/s 
Component Volume for 1 reaction Final Concentration 
10X Standard Tag Buffer 5μl 1X 
10 mMdNTP + dUTP mix 2μl 200µM 
10 μM *Primer B (H-24) 1.2μl 0.2µM 
5 U/μl Tag Polymerase 1μl 1.25U/50µl 
Ligated Product 10 μl - 
Deionized water 30.8μl _ 
Total 50 μl _ 
      *Primer B: 5ꞌ-GTTTCCCAGTCACGGTC-3ꞌ 
 
PROTOCOL 
1. Set-up PCR reactions as shown in Table1. 
2. PCR cycle conditions: 72°C for 3 minutes, initial denaturing at 95°C for 3 minutes, 
30 cycles of [further denaturing at 95°C for 30 seconds, annealing at 62°C for 
1minute, elongation at 72°C for 2 minutes], 1 cycle at 72°C for 10 minutes and hold 
at 4°C. 
3. Run 2μl of PCR products on 2% agarose gel. 
4. Purify the PCR products using Qiagen PCR purification Kit as described in Appendix 5. 
5. Use the purified PCR product/s for restriction digest in Appendix 9. 
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APPENDIX 9:  
Restriction Digestion of PCR Products with BstuI and HhaI Enzymes 
  
 Table 1: Components in the Reaction/s 
Components Volume for 1 reaction 
10X NEBuffer 4 4μl 
100X BSA 0.4μl 
BstU I enzyme 1 μl 
Hha I enzyme 1 μl 
Purified PCR-amplified DNA 30 μl 
Deionized water 3.6μl 
 
PROTOCOL  
1. Set up digestion reaction in a total volume of 40μl as shown in Table 1. 
2. Mix well and spin down the contents in the reaction/s. 
3. Place the reaction/s in C1000TM Thermal Cycler (Bio-rad, California, USA) under the 
following cycling conditions: 37°C for 1 hour and 60°C for another 1 hour. 
4. Load 2 μl of digested product/s on 1.5% of agarose gel. 
5. Purify the digested product/s using Qiagen PCR Purification Kit as described in 
Appendix 5. 
6. Use 10ul of purified product/s for PCR amplification as described earlier in 
Appendix 8. 
7. Purify the amplified PCR product/s again as described in Appendix 5. 
8. Use the purified PCR product/s for fragmentation protocol in Appendix 10. 
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APPENDIX 10: 
Fragmentation of PCR Amplified and Purified DNA Target/s 
      
Table 1: Components in the Reaction/s 
Component Volume for 1 reaction 
Amplified dsDNA 7.5 μg 
Deionized water Up to 32.2 μl 
10X APE I Reaction buffer 4.8μl 
Uracil-DNA Glycosylase (2U/μL) 4μl 
Human Apurinic/Apyrimidinic Endonuclease I (10 U/μl) 7μl 
Total 48μl 
 
PROTOCOL  
1. Set-up Fragmentation mix as shown in Table 1. 
2. Mix well and spin down the mixture. 
3. Incubate the reaction/s at: 37°C for 60 minutes, 93°C for 2 minutes and 4°C for at 
least 2 minutes. 
4. Run 2μl of PCR products on 4% agarose gel and use the rest of the products/s for 
labelling protocol in Appendix 11. 
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APPENDIX 11:  
Labelling of Fragmented Double Stranded DNA Target/s 
 
Table 1: Components in the Reaction/s  
Components Volume for 1 reaction 
Fragmented dsDNA 45μl 
5X Terminal DeoxynucleotidylTransferase (TdT), Recombinant Reaction Buffer 12μl 
Terminal DeoxynucleotidylTransferase (TdT), Recombinant  (30 U/μl) 2μl 
DNA-Labelling Reagent (10mM) 1μl 
Total 60μl 
 
PROTOCOL  
1. Set-up labelling mix as shown in Table 1. 
2. Mix well and spin down the mixture. 
3. Incubate the reaction/s at 37°C for 60 minutes, 70°C for 10 minutes and 4°C for at 
least 2 minutes. 
4. Use the product/s for hybridization protocol in Appendix 12. 
 
 
  
 257 
Appendix 12: Hybridization of Labelled Double Stranded DNA Target/s 
 
APPENDIX 12:  
Hybridization of Labelled Double Stranded DNA Target/s 
     
Table 1: Components in the reaction/s  
Components Volume for 1 reaction (μl) 
Labelled dsDNA target 60μl 
Control Oligonucleotides B2 3.3μl 
2X Hybridization Mix 100μl 
DMSO 14.0μl 
Nuclease Free water 22.7μl 
Total 200μl 
 
PROTOCOL 
1. Set-up hybridization mix as shown in Table 1. 
2. Flick-mix the reaction/s and spin down the mixture. 
3. Incubate the reaction/s at 99°C for 5 minutes and 45°C for 5 minutes. 
4. Centrifuge at 14000 rpm for 1 minute. 
5. Inject 200μl hybridization cocktail into the GeneChip® Human Promoter 1.0R probe 
arrays. 
6. Hybridize the probe arrays for 16 hours in 45°C GeneChipR Hybridization Oven 645 
set at 60 rpm. (Note: Hybridization oven must be switched on and set at the required 
conditions at least 30 minutes before use). 
7. After hybridization, transfer the hybridization mixture from probe arrays into fresh 
tubes and store at -80°C for future use. 
8. Inject in 200μl of Array Holding Buffer into the probe arrays. 
9. Use the probe arrays for washing and staining protocol in Appendix 14, after 
priming protocol in Appendix 13. 
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 APPENDIX 13:  
Registration of Probe Arrays and Preparation of GeneChip
®
 Fluidics 
Station 450/250 Protocol 
 
PROTOCOL 
Step 1: Registering of Probe Arrays  
1. Prior to washing and staining, the arrays were first registered in Affymetrix GeneChip®  
    Command Console (AGCC) that operates GeneChip
®
 Fluidics Station 450/250. 
Step 2: Preparation of the Fluidics Station  
1. Switch on the GeneChip® Fluidics Station 450 that is operated using AGCC  
    connected on the computer. 
2. Click AGCC Fluidics Control icon in the AGCC Launcher and then click on   
Master/Station controls. 
3. Select Probe Array Type (e.g. Human Promoter 1.0 R array). 
Step 3: Priming the Fluidics Station  
1. This step is done only when the fluidics station is first started or when wash solutions 
are changed. It is important to ensure that the lines of the GeneChip
®
 Fluidics Station 
450 are filled with correct buffers and that the GeneChip
®
 Fluidics Station 450 is ready 
for running the staining and washing protocol. 
 Table 1: Washing Buffers for Priming Protocol 
Buffers Volume 
Wash Buffer A 300ml 
Wash Buffer B 300ml 
Deionised water 300ml 
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2. Fill the intake buffer reservoirs on the right side of the instrument with deionised water, 
appropriate Wash A and Wash B solutions in the order set in Table 1. 
3. Empty the waste bottle reservoir and fill the water reservoir with deionised water. 
4. Place 3 empty 1.5ml microcentrifuge vials into stain holder position 1, 2 and 3. 
5. Press the washblock lever into the engaged or closed position and push the needle lever into the 
down position. 
6. Select Protocol .e.g. Prime _450 maintenance protocol and from the AGCC Fluidics  
Control. 
7. Select Station ID and this will allow selection of the number of modules to use e.g. if 4 arrays 
are processed, all 4 modules must be selected by clicking Run All Modules on Current 
Station or by clicking Run All Modules on Current Station button.  
8. When the priming protocol is complete, the LCD window displays the message Ejects &    
     Inspects cartridge. 
9. Continue with staining and washing protocol of probe arrays in Appendix 14. 
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APPENDIX 14:  
Staining and Washing of the Probe Arrays using GeneChip
®
 Fluidics 
Station 450/250  
 
Table 1: Preparation of Staining Reaction/s 
Reagents  Volume Eppendorf Tubes 
Stain Cocktail 1 (Light sensitive, so need to be covered with foil) 600μl 1 
Stain Cocktail 2 600μl 2 
Array holding buffer 800μl 3 
 
PROTOCOL  
1. Gently tap the bottles of reagents to mix well before use. 
2. Aliquot each staining reagents and Array Holding Buffer into individual l.5ml eppendorf 
tubes as shown in Table 1.  
3. Spin down all vials to remove the bubbles. 
4. Check on the GeneChip® Fluidics Station 450/250 whether the priming protocol 
from Appendix 13 is complete. If it is complete, the LCD window will display the 
message Ejects & Inspects cartridge. 
5. Insert the appropriate probe array into the designated module of the GeneChip® 
Fluidics Station 450 while the cartridge lever is in the down or eject position.  
6. Make sure the wash solutions and water reservoirs contain enough liquid for the run 
to complete and that the waste bottle has enough room to collect waste from the 
running protocol. 
7. Remove three 1.5ml microcentrifuge vials put into stain holder position 1, 2 and 3 during 
priming protocol.  
8. Follow the instructions on the LCD window of the GeneChip® Fluidics Station 450 by  
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placing the three microcentrifuge vials with reagents aliquots as shown in Table 1 
into the sample holders 1, 2, and 3 on the fluidics station. 
a) Place one vial containing 600μl Stain Cocktail 1 containing SAPE Stain Solution 
in sample holder 1. 
b) Place one vial containing 600μl Stain Cocktail 2 containing Antibody Solution in 
sample holder 2. 
c) Place one vial containing 800μl of Array Holding Buffer in sample holder 3. 
9. Press down the needle lever to snap needles into position and start the run. 
10. The run begins and the Fluidics Station dialog box at the workstation terminal and 
       the LCD window will display the status of the washing and staining as the protocol 
      progresses. 
11. When the protocol is complete, the LCD window displays the message Ejects & 
Inspects cartridge. 
12. Remove the probe arrays from the GeneChip® Fluidics Station 450 modules by first 
pressing down the cartridge lever to the eject position and continue with scanning 
protocol in Appendix 15.  
13. If there are no more samples to wash and stain, shut down the fluidics station by 
performing the Shutdown Protocol as follows: 
a) Place the Wash A and Wash B lines into deionized water. 
b) Place empty 1.5ml microfuge tubes in the stain holders. 
c) Run the Shutdown_450 Protocol.  
14. When the shutdown protocol is complete, the LCD display will indicate that 
GeneChip
®
 Fluidics Station 450 is no longer primed. Turn off the GeneChip
®
 Fluidics 
Station 450/250 using the toggle switch on the lower left side of the machine. 
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APPENDIX 15:  
Scanning of the Probe Arrays Protocol 
 
PROTOCOL 
1. Turn on GeneChip® Scanner 3000 (7G) 30 minutes before use. This instrument was 
operated by GeneChip
®
 operating software version 1.4. 
a) Soon after turned on, both the yellow and green lights of the scanner will be 
switched on and the scanner will enter the laser warm-up state. After about 10 
minutes, the green light will turn off and the yellow light will remain on.  
b) Wait 10 minutes for the laser to stabilize. When the green light turns on, the 
scanner is ready to scan an array. 
2. Check if there are bubbles in the probe arrays before scanning. 
a) If there are no bubbles, proceed to scanning protocol in the GeneChip® Scanner 
3000 (7G). 
b) If you see bubbles in the probe arrays, pipette in and out the Array Holding 
Buffer until the bubbles are disappeared and then proceed to scanning protocol. 
3. On the AGCC control scan, click Start button. 
4. On the scanner dialog box, select the Sample Name of the array you wish to scan 
from Sample File Name drop-down list. 
5. After selected the Sample Name, click Start in the start scanner dialog box to start 
the run. After clicking Start the scanner dialog box will appear, and the scanner door 
will open with the chip transport mechanisms rises to accept the probe array.  
6. Gently clean access fluid from around the septa of probe array with soft cloth and 
load the probe array in the chip transport mechanism and click OK in the scanner 
dialog box to start scanning process.  
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7. After scanning process is complete, AGCC will save the image data, generates 
“.CEL” files and ejects the probe array. If no more probe array to scan, shut down 
the AGCC control scanner and switch off the scanner. 
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APPENDIX 16:  
Commercial Kits, Reagents and other Consumables Used For Isolation 
of DNA from Blood and Bisulfite Sequencing Work 
 
1. Commercial Kits 
Product Catalogue Number Local Supplier Supplier 
EZ DNA Methylation-GoldTM Kit D5006 Ingaba Biotec, SA Zymo Research, Germany 
pGEM-T Easy Vector  System II [comes 
with a vector, JM109 Cells, T4 DNA Ligase 
and Buffer] 
A1380 Whitehead Scientific, SA Promega, USA 
QIAquick Gel Extraction Kit 28704 Whitehead Scientific, SA Qiagen, USA 
Wizard® Genomic DNA Purification Kit  1125 Anatech Promega, USA 
  
2. Restriction Enzymes and Primers 
Product Catalogue Number Local Supplier Supplier 
100bp Ladder  Ingaba Biotec, SA New England Biolabs MA 
BamHI  FastDigest Enzyme, comes with 
10X FastDigest and FastDigest Green 
Buffers 
FD0054 Ingaba Biotec, SA Thermo Scientific, USA 
250U HotStarTaq DNA Polymerase, 
comes with PCR buffer, 2Q solution and 
25mM Magnesium Chloride (MgCl2) 
203203 Whitehead Scientific, SA Qiagen, USA 
pUC/M13 Forward Primer #Q5601 Whitehead Scientific, SA Promega, Madison, USA 
pUC/M13 Reverse Primer #Q5421 Whitehead Scientific, SA Promega, Madison, USA 
Primers for Bisulfite DNA Sequencing  - Whitehead Scientific, SA Promega, Madison, USA 
 
3. Preparation of Buffers  
Buffer Composition 
EDTA 0.1M EDTA, deionised water, Autoclave 
TBE (10X) 0.9M Tris base, 0.09M Boric Acid and 0.02M  Ethylenediaminetetraacetic acid (EDTA)[ pH 8.0] 
Tris buffer 1M Tris Base and  deionised water  [pH 8.0], Autoclave 
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4. Bacterial Culture Additives 
Product Catalogue Number Local Supplier Supplier 
-Bromo-4-chloro-3-indolyl b-D-galactopyranoside (X-gal) 72035 Sigma, SA Sigma, USA 
Ampicillin Sodium Crystaline A9518 Sigma, SA Sigma, USA 
Isopropyl B-D Thiogalactopyranoside Diox (IPTG) 16758 Sigma, SA Sigma, USA 
5-Bromo-4-chloro-3-indolyl b-D-galactopyranoside (X-gal) 72035 Sigma, SA Sigma, USA 
Ampicillin Sodium Crystaline A9518 Sigma, SA Sigma, USA 
 
5. Equipment 
 
 
6. Chemicals and other Laboratory Consumables 
Product Catalogue Number Local Supplier Supplier 
Agar A7002 Sigma, SA Sigma, USA 
Deoxynucleotide Triphosphate Set DNTP100 Sigma, SA Sigma, USA 
Sodium Chloride S9888 Sigma, SA Sigma, USA 
Tryptone T9410 Sigma, SA Sigma, USA 
Yeast Extract 70161 Sigma, SA Sigma, USA 
 
Products Catalogue Number Local Supplier Sources 
0.2ml and 0.5 ml PCR tubes 93400150 Lasec, SA Axygen Scientific, USA 
1.5ml Eppendorf tubes 071015-247 Lasec, SA Axygen Scientific, USA 
20µl, 200μl and 1000μl  tips 94300120 Lasec, SA Axygen Scientific, USA 
Microcentrifuge L0027161 Lasec, SA Axygen Scientific, USA 
C1000TM Thermal Cycler 184-1000 - Bio-Rad, California, US 
Pippetman P1000, P200, P20 F123602 - Gilson Medical Electronics, 
France 
90mm Petri Dish, Single Vent 90032 Whitehead Scientific, SA Qiagen, USA 
10µl Inoculating Loop, Hard, 
Dark Blue 
SL10H Whitehead Scientific, SA Qiagen, USA 
Heating Block MH-4-6638 - Fried Electric, Israel 
Nanodrop ND-1000 UV-Vis 
Spectrophotometer  
844-0020xx Promega, SA ThermoScientific, USA 
Super-Mixer 220V Vortex  #288181 - Scientific Industries, USA 
VM-1000 Votex Mixer SI-100 - Aron Laboratory Instruments, 
Taiwan 
Water Bath SMC ETech - Thermocon 
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APPENDIX 17:  
Isolation of Genomic DNA from Blood Samples Using Wizard
®
 
Genomic DNA Purification Kit 
 
PROTOCOL 
1. To 2.5ml blood sample, add 7.5ml of Cell Lysis Solution in a sterile 15ml centrifuge 
tubes. 
2. Gently invert the tubes 5-6 times to mix thoroughly and incubate the mixture at room 
temperature for 10 minutes to lyse the red blood cells. Invert intermittently during 
the incubation at least 2-3 times. 
3. Centrifuge at 2000 x g for 10 minutes at room temperature. 
4. Decant and remove as much supernatant as possible without disturbing the visible 
white pellet (Note: If the blood has been frozen, repeat the above steps until the 
pellet is nearly white. There may be some loss of DNA in frozen samples. If the 
pellet appears to contain only red blood cells, add an additional aliquot of Cell Lysis 
Solution and repeat above steps). 
5. Vortex the tubes vigorously for 10-15 seconds to re-suspend the white blood cells. 
The white blood cells need to be re-suspended to obtain efficient cell lysis. 
6. Add 2.5ml of Nuclei Lysis Solution, pipet the solution 5-6 times to lyse white blood 
cells. The solution should become very viscous. (If clumps are visible after mixing, 
incubate the solution at 37°C until the clumps are disrupted. If clumps are still visible 
after 1hr, add 3ml of additional Nuclei Lysis Solution and repeat the incubation). 
7. Optional: Add RNase A to a final concentration of 20g/ml, to the nuclear lysate 
and mix the samples by inverting the tubes 25 times. Incubate the mixture at 37°C 
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Genomic DNA Purification Kit 
 
 
for 15 minutes and then cool to room temperature. 
8. Add 825l of Protein Precipitation Solution to the nuclear lysate and vortex for 10-
20 seconds vigorously. Small protein clumps may be visible after vortexing. (If 
additional Nuclei Lysis Solution was used in Step 6 above, additional 825l of 
Protein Precipitation Solution should be used). 
9. Centrifuge at 2 000 x g for 10 minutes at room temperature. A dark brown protein 
pellet should be visible. 
10. Transfer the supernatants to a 15ml centrifuge tubes containing 2.5ml of isopropanol 
at room temperature. 
11. Gently mix the solution by inversion until the white thread-like strands of DNA form 
a visible mass. 
12. Centrifuge at 2 000 x g for 1minute at room temperature. The DNA should be visible 
as a small white pellet. 
13. Decant the supernatants and add 10ml of room temperature 70% ethanol to the DNA. 
Gently invert the tubes several times to wash the DNA pellet and the sides of the 
tube. Repeat the centrifugation step at 2 000 x g for 1 minute at room temperature. 
14. Carefully aspirate the ethanol to avoid aspirating the DNA pellet into the pipette. 
Air-dry the DNA pellet for 10-15 minutes. 
15. Add 207.5l of DNA Rehydration Solution to the tubes and re-hydrate the DNA by 
incubating at 65°C for 1 hour. Alternatively, re-hydrate the DNA by incubating the 
solution overnight at room temperature or at 4°C. 
16. Store the DNA in aliquots at 2-8°C. 
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APPENDIX 18: 
Restriction digests of Genomic DNA with BamHI Enzyme 
 
Table 1: Components in the Reaction/s 
Components Volume for 1 reaction 
10X FastDigest Buffer 3μl 
BamHI FastDigest Enzyme 1μl 
Patient genomic DNA 2μg 
Deionised water Up to a total volume of  30μl 
 
PROTOCOL  
1. Pipette 2μg of genomic DNA in 0.2ml PCR tube. 
2. Set up the reaction/s in a total volume of 30μl as shown in Table 1. 
3. Mix well and spin down the reactions for few seconds. 
4. Incubate the reactions on a water bath at 37°C for 15 minutes. 
5. Inactivate the enzyme at 80°C for 5 minutes. 
6. Load 10μl of digested product/s on 1.2% of agarose gel. 
7. Use 20μl for bisulfite DNA conversion in Appendix 19. 
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APPENDIX 19:  
Bisulfite Conversion of Digested DNA using EZ DNA Methylation-
Gold
TM
 Kit 
 
PROTOCOL 
1. Prepare CT conversion reagent by adding 300μl of M-Dilution Buffer, 50μl M-
Dissolving Buffer into CT conversion reagent tube provided in the kit. 
2. Add 130μl of CT conversion reagent into 20μl of the BamHI digested genomic DNA 
recovered in Appendix 18. 
3. Perform the following temperature steps: 98°C for 10 minutes, 50°C for 16 hours, 
4°C for 10 minutes. 
4. Add 150μl of CT converted DNA into Zymo-SpinTM IC Column with 600μl of M-
Binding Buffer and mix by inverting several times with the cap closed. 
5. Centrifuge at 14000 x g for 30 seconds and discard the flow-through.  
6. Add 100μl of M-Wash buffer with 100% ethanol to the column and centrifuge again 
at the same conditions. 
7. Add 200μl of M-Desulphonation Buffer to the column and incubate at room 
temperature for 20 minutes with frequent mixing by vortexing. 
8. Add 200μl of M-Wash buffer with 100% ethanol to the column and centrifuge as 
previously described. Repeat this step one more time. 
9. Throw the tube with flow-through and place the Zymo-SpinTM IC Column into a new 
1.5ml eppendorf tube. 
10. Elute the converted DNA by spinning at 14000 x g for 30 seconds. 
11. Use 150ng of bisulfite converted DNA for PCR amplification in Appendix 20. 
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APPEDNDIX 20:  
 
PCR Amplification of Bisulfite Converted DNA 
 
Table 1: PCR Components for Bisulfite Converted DNA 
Components Volume for 1 reaction Final Concentration 
10X PCR Tag Buffer 5μl 1X 
10mM dNTP  1μl 200µM 
10μM Forward Primer 2.5μl 0.5µM 
10μM Forward Primer 2.5μl 0.5µM 
250U HotStar Taq Polymerase 0.25μl 2.5U/ reaction 
Bisulfite converted DNA 150ng 150ng 
Deionized water Up to 50μl _ 
Total 50μl _ 
 
PROTOCOL 
1. Set-up the PCR reactions as shown in Table 1. 
2. PCR cycle conditions: 1 cycle of initial denaturation of 95°C for 15 minutes, 5 cycles 
of [denaturing at 94°C for 45 seconds, annealing at a temperature predicted by primer 
designer software for 45 seconds, elongation at 72°C for 90 seconds], 5 cycles of 
[denaturing at 94°C for 45 seconds, annealing at 5°C less temperature predicted by 
primer designer software for 45 seconds, elongation at 72°C for 90 seconds], 35 
cycles of [denaturing at 94°C for 45 seconds, annealing at a primer-specific annealing 
temperature for 45 seconds, elongation at 72°C for 90 seconds], 1 cycle of final 
extension at 72°C for 5 minutes and hold at 4°C. 
3. Run 5μl of the PCR product/s on 1.2% agarose gel. 
4. Excise the product/s from gel and weigh the excised product/s. 
5. Purify the excised product/s using QIAquick Gel Extraction Kit as described in 
Appendix 21. 
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APPEDNDIX 21:  
Purification of Excised Gel Product/s using QIAquick Gel Extraction 
Kit 
 
PROTOCOL 
1. Add 5 volume of Buffer PB to 1 volume of amplified PCR or excised gel product/s 
and mix well.  
2. Transfer the reaction mixtures into MinElute spin columns provided in the kit. 
3. Centrifuge at 13000 rpm for 1 minute. 
4. Discard the flow-through. 
5. Wash the columns with 750μl of Buffer PE with 100% ethanol. 
6. Centrifuge at 13000 rpm for 1 minute, discard the flow-through and further centrifuge 
at the same speed for another 1 minute. 
7. Transfer the MinElute Spin Columns into new eppendorf tubes and add 32μl of 
elution buffer  
      to the centre of the columns. Incubate for 1 minute at room temperature. 
8. Elute the purified DNA by centrifuging at 13000 rpm for 1 minute. 
9. Use the purified product/s for ligation in Appendix 22. 
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APPENDIX 22: 
Cloning of Purified DNA into pGEM-T
®
 Easy Vector System II 
     
Table 1: Components for Ligation Reaction/s 
Component Standard Reaction Positive Control Background Control 
2X Rapid Ligation Buffer, T4 DNA ligase 5μl 5μl 5μl 
pGEM-T Easy vector (50ng) 1μl 1μl 1μl 
Purified DNA 3μl - - 
Control Insert - 2μl - 
T4 DNA Ligase 1 μl 1μl 1μl 
Nuclease-free water to a final volume of 10μl 10μl 10μl 
 
PROTOCOL 
1. Determine the amount of insert DNA required using Biomath calculator sourced at 
www.promega.com/biomath. 
2. Centrifuge pGEM-T® Easy vector and insert DNA tubes to collect the contents at the  
bottom of the tubes in 0.5ml PCR tubes.  
3. Shake the 2X rapid Ligation buffer vigorously before each use. 
4. Set ligation reactions as described in Table 1. 
5. Mix the reactions by pipetting and incubate overnight at 4°C. 
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APPEDNDIX 23: 
Preparation of Media, Plates and Transformation of Ligated Products 
 
Table 1: Preparation of Buffers and Bacterial Culture Media used in this Study 
Buffer Composition 
Ampicillin [100µg/ml] 0.2 g Ampicillin  in 10ml deionised water, filter sterilize and store  the aliquots at -20°C 
EDTA 0.1M EDTA, deionised water, Autoclave 
IPTG [238.3µg/ml] 0.238g IPTG in 10ml deionised water, filter sterilize and store the aliquots at -20°C 
TBE (10X) 0.9M Tris base, 0.09M Boric Acid and 0.02M  Ethylenediaminetetraacetic acid (EDTA)[ pH 8.0] 
Tris buffer 1M Tris Base and  deionised water  [pH 8.0], Autoclave 
2xYT medium 1% Tryptone, 0.5% Yeast Extract, 1% Sodium Chloride  [pH7.0], Autoclave 
2xYT Agar  1% Tryptone, 0.5% Yeast Extract, 1% Sodium Chloride  and 3% Agar, Autoclave 
X-gal [200µg/ml] 0.2g X-gal in 10ml dimethyl sulfoxide (DMSO), filter sterilize, cover with aluminium foil and 
store  the aliquots at -20°C 
 
 
PROTOCOL 
1. For each ligation reaction, prepare two 2xYT agar plates as described in Table 1.  
2. Supplement the agar with 100μg/ml ampicillin, 100μg/ml X-gal and 200μg/ml IPTG. 
3. Remove J109 competent cells out of the freezer and thaw on ice for 5 minutes. 
4. Add 10µl of ligated products into 1.5ml eppendorf tubes on ice. 
5. Carefully transfer 50µl of cells into the tube with ligated products and mix gently by 
flicking the tube with a finger. Use 100μl cells for determination of transformation 
efficiency 
6. Incubate on ice for 20 minutes. 
7. Heat-shock the cells for 50 seconds at 42°C in water bath. 
8. Immediately put the cells on ice for 2 minutes to recover. 
9. Add 940µl of 2xYT media to the cell transformed with ligated products. 
10. Shake at 37°C for 1.5 hours. 
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11. Spread 100µl of cells transformed with ligated products onto 2xYT plates with X-
gal, IPTG and ampicillin.  
12. Centrifuge the remaining cells at 1000 x g for 10 minutes, resuspend the pellet in 
200μl of 2xYT medium and plate 100μl for higher number of colonies. 
13. For transformation efficiency, perform 1:10 dilution with 2xYT and plate 100μl. 
14. Incubate the plates up to 24 hours at 37°C. 
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APPENDIX 24: 
Screening Positive Clones with Vector and Inserts Using Colony PCR 
 
Table 1: Components in the Reaction/s for Colony PCR  
Components Volume for 1 reaction Final Concentration 
10X PCR  Go Tag Buffer 5μl 1X 
10mM dNTP  2μl 200µM 
10μM *Forward Primer 1μl 0.2µM 
10μM *Reverse Primer 1μl 0.2µM 
250U HotStar Taq Polymerase 1.25μl 1.25U/50µl 
Colony Supernatant 3μl _ 
Deionized water 36.8μl _ 
Total 50μl _ 
          *pUC/M13 Forward Primer: 5ꞌ-GTTTTCCCAGTCACGAC-3ꞌ 
          * pUC/M13 Reverse Primer: 5ꞌ-CAGGAAACAGCTATGAC-3ꞌ 
 
 
PROTOCOL 
1. The selection of colony is based on blue/white screening method. Clones with no     
PCR products usually produce blue colonies and with PCR products produce white 
colonies.  
2. Pick up 5 white colonies from plate/s plated with cells transformed with each ligated 
reaction. 
3. Resuspend the colonies individually into 10μl of deionised water and heat at 95°C 
for 5 minutes. 
4. Centrifuge at 10000 x g for 1 minute and keep the supernatant. 
5. Set-up PCR mix as shown in Table 1. 
6. PCR cycle conditions: 1 cycle of denaturing at 95°C for 2 minutes, 35 cycles of 
[denaturing at 95°C for 1 minute, annealing at 55°C for 1 minute, extension at 72°C 
for 1 minute], 1 cycle of 72°C for 5 minutes and hold at 4°C. 
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7. Run 5μl of PCR product/s on 1.2% agarose gel. 
8. Purify the PCR product/s using Qiagen Gel Extraction Kit as described in Appendix 
21. 
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APPENDIX 25:  
DNA Sequencing of Colony PCR Products and Data Analysis 
 
PROTOCOL 
A.  DNA Sequencing 
1. Sent positive colony PCR products of about 8ng/µl each for sequencing in the 
Central Sequencing Facility at the University of Stellenbosch, South Africa.  
2. Use of BigDye Terminator V3.1 sequencing kit® (Applied Biosystem) for DNA 
sequencing following manufacture’s protocol with slight modifications.  
3. Sequence the DNA using 1pmol/µl of both M13 forward (-20) 5ꞌ- GTA AAA CGA 
CGG CCA GT-3ꞌ and M13 reverse (-27) 5ꞌ- CAG GAA ACA GCT ATG AC-3ꞌ 
primers (Whitehead Scientific, SA). 
4. After sequencing, extract sequencing results in FASTA format using a trace file 
viewer like Chromas
1
.  
 
B. Sequence Alignment 
1. Use of BioEdit Sequence Alignment Editor to create ClustalW multiple alignment of 
the gene promoter region sequence downloaded from Ensembl
2
 and the bisulfite 
converted sequence of positive clones.  
 
C. Analysis of Demographic and Clinical Data 
1. Analyse the demographic and clinical data of the study patients using STATA 13 
(College Station, Texas, USA).  
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2. Summarize categorical binary data as counts and percentages and categorical ordinal 
as median and inter-quantile values.  
3. Summarize ordinal numerical data as median and inter-quantile values and 
continuous numerical data as means and standard deviations.  
4. Performed Pearson Chi-Squared test and Fisher’s exact test to investigate possible 
association between independent categorical variables.  
 
 
REFERENCES 
1. Trace file viewer like Chromas. http://www.technnelysium.com.au. Assessed at April 
2013. 
2. Ensembl Genome Browser. http://www.ensembl.org/index.html. Accessed April 
2013. 
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Partek Genomic Suite software was used to investigate the biological significance of 
genes in each microarray analysis group using the GO terms. Some of these 
pathways are outlined below as: 
A. HBV Infection and HCC Calcium Signalling Pathway 
B. HBV Infection and TGF Beta Pathway 
C. HBV Infection and TB Pathway 
D. HBV Infection and Cancer Pathway 
E. HBV Infection and Cell Adhesion Pathway 
F. HBV Infection Pathway 
G. HBV Infection and Tight Junction Pathway 
H. HBV Infection and mRNA Surveillance Pathway 
I. HBV Infection and MAP Kinase Pathway 
J. HBV Infection and the Cell Cycle Pathway 
K. HBV Infection and Viral Carcinogenesis Pathway 
L. HBV Infection and PPAR Gamma Signalling Pathway 
M. HBV Infection and Type 2 Diabetes Mellitus Signalling Pathway 
N. HBV Infection and Apoptosis Pathway 
O. HBV Infection and HTLV-1 Infection Pathway
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A. HBV Infection and HCC Calcium Signalling Pathway 
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B. HBV Infection and TGF Beta Pathway 
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C. HBV Infection and Tuberculosis Pathway
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D. HBV Infection and Cancer Pathway
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E. HBV Infection and Cell Adhesion Pathway 
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F. HBV Infection Pathway
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G. HBV Infection and Tight Junction Pathway 
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H. HBV Infection and mRNA Surveillance Pathway 
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I. HBV Infection and MAP Kinase Pathway 
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J. HBV Infection and the Cell Cycle Pathway
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K. HBV Infection and Viral Carcinogenesis Pathway 
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L. HBV Infection and PPAR Gamma Signalling Pathway 
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M. HBV Infection and Type 2 Diabetes Mellitus Signalling Pathway 
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N. HBV Infection And Apoptosis Pathway 
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O. HBV Infection and HTLV-1 Infection Pathway 
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